As filed with the Securities and Exchange Commission on
September 26, 2005
Registration No. 333-126626
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 5 to
Form S-1
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
GENOMIC HEALTH, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
8071
|
|
77-0552594
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Primary Standard Industrial
Classification Code Number)
|
|
(I.R.S. Employer
Identification No.)
|
301 Penobscot Drive
Redwood City, CA 94063
(650) 556-9300
(Address, including zip code, and telephone number, including
area code, of registrants principal executive offices)
Randal W. Scott, Ph.D.
Chief Executive Officer
Genomic Health, Inc.
301 Penobscot Drive
Redwood City, CA 94063
(650) 556-9300
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copies to:
|
|
|
|
|
Stanton D. Wong
Justin D. Hovey
Pillsbury Winthrop Shaw Pittman LLP
P.O. Box 7880
San Francisco, CA 94120
(415) 983-1000
(415) 983-1200 facsimile
|
|
Gabriella A. Lombardi
Pillsbury Winthrop Shaw Pittman LLP
2475 Hanover Street
Palo Alto, CA 94304
(650) 233-4500
(650) 233-4545 facsimile
|
|
William H. Hinman, Jr.
Simpson Thacher & Bartlett LLP
3330 Hillview Avenue
Palo Alto, CA 94304
(650) 251-5000
(650) 251-5002 facsimile
|
Approximate date of commencement of proposed sale to the
public:
As soon as practicable after this Registration
Statement becomes effective.
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act of 1933, check the
following
box.
o
If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act,
please check the following box and list the Securities Act
registration statement number of the earlier effective
registration statement for the same
offering.
o
If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering.
o
If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering.
o
If delivery of the prospectus is expected to be made pursuant to
Rule 434, please check the following
box.
o
The Registrant hereby amends this Registration Statement on
such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be
changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is
effective. This prospectus is not an offer to sell these
securities and it is not soliciting any offer to buy these
securities in any state where the offer or sale is not
permitted.
|
Subject to
completion, dated September 26, 2005
5,016,722 Shares
Common Stock
This is an initial public offering of shares of common stock by
Genomic Health, Inc. We are offering 5,016,722 shares of
our common stock. No public market currently exists for our
common stock.
We anticipate the initial public offering price will be between
$12.00 and $14.00 per share.
We expect our common stock to be quoted on the Nasdaq National
Market under the symbol GHDX.
This investment involves risk. See Risk
Factors beginning on page 7.
|
|
|
|
|
|
|
|
|
|
|
Per Share
|
|
|
Total
|
|
|
|
|
|
|
|
|
Initial Public Offering Price
|
|
$
|
|
|
|
$
|
|
|
Underwriting Discount
|
|
$
|
|
|
|
$
|
|
|
Proceeds to Genomic Health, Inc. (before expenses)
|
|
$
|
|
|
|
$
|
|
|
We have granted the underwriters a 30-day option to purchase up
to an additional 752,508 shares from us on the same terms
and conditions as set forth above if the underwriters sell more
than 5,016,722 shares of common stock in this offering.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The underwriters expect to deliver the shares on or
about ,
2005.
Joint Book-Running
Managers
|
|
Piper Jaffray
|
Thomas Weisel Partners LLC
|
JMP
Securities
,
2005
individualized
treatment decision physician orders test sample tracking pathology review RNA processing
automated multi-gene analysis quantitative readout patient report
reimbursement support
|
TABLE OF CONTENTS
You should rely only on the information contained in this
prospectus. We have not, and the underwriters have not,
authorized any person to provide you with different information.
This prospectus is not an offer to sell, nor is it an offer to
buy, these securities in any state where the offer or sale is
not permitted. The information in this prospectus is complete
and accurate as of the date on the front cover, but the
information may have changed since that date.
Without limitation to the other restrictions referred to herein,
this communication is directed only at (i) persons outside
the United Kingdom; (ii) persons having professional
experience in matters relating to investments who fall within
the definition of investment professionals in
Article 19(5) of the Financial Services and Markets Act
2000 (Financial Promotion) Order 2005; or (iii) high net
worth bodies corporate, unincorporated associations and
partnerships and trustees of high value trusts as described in
Article 49(2) of the Financial Services and Markets Act
2000 (Financial Promotion) Order 2005. Without limitation to the
other restrictions referred to herein, any investment or
investment activity to which this communication relates is
available only to, and will be engaged in only with, the persons
referred to in (i)-(iii) above, and persons within the United
Kingdom who receive this communication (other than persons who
fall within (ii) or (iii) above) should not rely or
act upon this communication.
Until ,
all dealers that effect transactions in these securities,
whether or not participating in this offering, may be required
to deliver a prospectus. This is in addition to the
dealers obligation to deliver a prospectus when acting as
underwriters and with respect to their unsold allotments or
subscriptions.
PROSPECTUS SUMMARY
The items in the following summary are described in more
detail later in this prospectus. This summary provides an
overview of selected information and does not contain all of the
information you should consider. Therefore, you should also read
the more detailed information set out in this prospectus,
including the consolidated financial statements and related
notes appearing elsewhere in this prospectus, before investing
in our common stock. References in this prospectus to
we, us and our refer to
Genomic Health, Inc. unless the context requires otherwise.
GENOMIC HEALTH, INC.
Our Business
We are a life science company focused on the development and
commercialization of genomic-based clinical diagnostic tests for
cancer that allow physicians and patients to make individualized
treatment decisions. In January 2004, we launched our first test
under the brand name Onco
type
DX for early stage breast
cancer patients. We believe that Onco
type
DX is the first
genomic test that has clinical evidence supporting its ability
to predict the likelihood of cancer recurrence, the likelihood
of patient survival within 10 years of diagnosis and the
likelihood of chemotherapy benefit. Our first commercial test is
focused on patients with early stage, node negative, or N-,
estrogen receptor positive, or ER+, breast cancer who will be
treated with hormonal therapy. Approximately half of the 230,000
patients expected to be diagnosed with breast cancer in the
United States in 2005 are predicted to be early stage cancer
patients that are N-, ER+, and it is customarily recommended
that those patients be treated with hormonal therapy.
Many of the diagnostic factors currently used in connection with
early stage breast cancer are subjective. We believe these
factors have limited capability to predict future cancer
recurrence. Under current treatment regimens, a large percentage
of early stage breast cancer patients receive chemotherapy.
According to a National Surgical Adjuvant Breast and Bowel
Project, or NSABP, study published in 2004, the overall survival
at 12 years in early stage breast cancer patients using
only the hormonal therapy tamoxifen was approximately 83% and
the overall survival using tamoxifen hormonal therapy and
chemotherapy was 87%. Therefore, the incremental survival
benefit of chemotherapy in this study was only 4%. We believe
that the use of Onco
type
DX can provide a deeper
understanding of each patients breast cancer and therefore
should result in better informed and more appropriate treatment
decisions. Onco
type
DX is commercially available at a
list price of $3,460 through our laboratory located in Redwood
City, California, which is accredited under the Clinical
Laboratory Improvement Amendments of 1988 and by the College of
American Pathologists. In 2004, over 500 tests were ordered by
treating physicians. In December 2004, our validation study was
published in
The New England Journal of Medicine
and the
results of additional clinical trials were presented at the San
Antonio Breast Cancer Conference. In the six months ended
June 30, 2005, over 3,000 tests were ordered by treating
physicians. As of June 30, 2005, Onco
type
DX has
been ordered by over 1,400 physicians throughout the United
States.
We developed Onco
type
DX using a multi-step approach,
conducting clinical studies on tumor specimens from more than
2,600 breast cancer patients. Our technology provides
quantitative gene expression information for each patients
tumor, which we refer to as an oncotype. When an oncotype is
correlated with known clinical outcomes, it can be useful in
predicting the likelihood of an individual patients tumor
behavior. In breast cancer, we developed our gene panel by
narrowing the field of the approximately 25,000 human genes down
to 250 cancer-related genes through review of existing research
literature and computer analysis of genomic databases. We
evaluated the 250 genes in three independent clinical studies to
identify a 21-gene panel whose composite gene expression profile
can be represented by a single quantitative score, which we call
a Recurrence Score. The higher the Recurrence Score, the more
aggressive the tumor and the more likely it is to recur. The
lower the Recurrence Score, the less aggressive the tumor and
the less likely it is to recur. Moreover, we have demonstrated
that the Recurrence Score also correlates with chemotherapy
benefit, and we are undertaking further studies to support this
finding.
1
Onco
type
DX has been clinically validated for N-, ER+,
tamoxifen-treated breast cancer patients by two large
independent studies. The first study, conducted with the NSABP
and published in
The New England Journal of Medicine
in
December 2004, demonstrated that the Recurrence Score quantifies
the likelihood of cancer recurrence in early stage breast cancer
patients receiving tamoxifen therapy. Patients in a pre-defined
low Recurrence Score group were more than four times less likely
to have a recurrence of breast cancer than patients in a
pre-defined high Recurrence Score group (p-value<0.001, or
p<0.001). A p-value indicates the probability that the
result obtained in a statistical test is due to chance rather
than a true relationship between measures. A small p-value,
generally less than 0.05, or p<0.05, indicates that it is
very unlikely that the results were due to chance. The second
study, conducted with Northern California Kaiser Permanente in a
community hospital setting and reported at the San Antonio
Breast Cancer Conference in December 2004, demonstrated that the
Recurrence Score correlates with breast cancer survival at
10 years. The likelihood of breast cancer survival at
10 years was more than five fold higher for patients in the
pre-defined low Recurrence Score group when compared to patients
in the pre-defined high Recurrence Score group (p<0.003). An
additional study, which was conducted with the NSABP,
demonstrated that the Recurrence Score predicts the likelihood
of chemotherapy benefit. This study was reported at the San
Antonio Breast Cancer Conference in December 2004 and further
detailed results were presented at the annual meeting of the
American Society of Clinical Oncology in May 2005.
We are using the clinical development platform that we created
in connection with Onco
type
DX to build a product
pipeline. Our products under research and development include a
second generation product in N-, ER+ breast cancer, as well as
tests that can be utilized in N+ breast cancer patients and
tests that can be used to predict responsiveness to other
current treatments such as specific types of chemotherapies. We
are also conducting research on colon, prostate, renal cell and
lung cancers and melanoma. Over 550,000 treatment decisions are
expected to be made in the United States in 2005 for patients
diagnosed with early stages of breast cancer and these cancers.
In addition, we plan to develop additional tests in
collaboration with pharmaceutical partners for targeted
therapies. For example, in July 2005 we signed a
collaborative agreement with Bristol-Myers Squibb Company and
ImClone Systems Incorporated to develop a genomic test to
predict the likelihood of response to Erbitux in colorectal
carcinoma. Erbitux is a targeted therapy currently approved for
the treatment of metastatic colorectal carcinoma.
Revenues for clinical laboratory testing services may come from
several sources, including commercial third-party payors, such
as insurance companies and health maintenance organizations,
government payors, such as Medicare and Medicaid, and patients.
As a relatively new test, Onco
type
DX may be considered
investigational by payors and not covered under their
reimbursement policies. Upon commercialization of Onco
type
DX, we began working with third-party payors to establish
reimbursement coverage policies. Currently, several regional
payors, including Harvard Pilgrim Health Care, Inc. and Highmark
Blue Cross Blue Shield, have issued policies supporting
reimbursement for our test. In addition, Kaiser Foundation
Health Plan, Inc. has entered into a national clinical
laboratory services agreement to reimburse us for
Onco
type
DX tests performed for their patients. Where
policies are not in place, we pursue case-by-case reimbursement.
Through this process, as of June 30, 2005, over 180 payors
had reimbursed one or more Onco
type
DX tests.
Our selling and marketing strategy targets the oncology
community, primarily medical and surgical oncologists. Our
direct sales approach focuses on the clinical and economic
benefits of Onco
type
DX and the scientific validation
supporting our product. Our field staff has significant clinical
oncology selling and marketing experience from leading
biopharmaceutical, pharmaceutical and specialty reference
laboratory companies, and we promote our product through
marketing channels commonly used by the biopharmaceutical and
pharmaceutical industries, such as sponsored continuing medical
education, medical meeting participation and broad-based
publication of our scientific and economic data.
Our Solution
We believe that physicians and patients are currently making
crucial and expensive treatment decisions based on inadequate
and often subjective information with limited understanding of
the molecular profile of a
2
patients tumor. Our strategy is to identify treatment
decisions that can benefit from, and be guided by, each
patients individual genomic information.
Our genomic-based diagnostic approach correlates gene expression
information to clinical outcomes and provides information
designed to improve treatment decisions for cancer patients. We
have optimized methods and processes for screening hundreds of
genes at a time using minimal amounts of chemically preserved
tissue embedded in blocks of paraffin wax. This technology
allows us to analyze archived samples of tissue, retained by
hospitals for most cancer patients, to correlate gene expression
with known clinical outcomes. Once we have established and
validated a test, we can then analyze a patients tumor and
correlate the result to known clinical outcomes. As a result,
each tumors gene expression can be quantified and
correlated with responsiveness to therapy or the likelihood of
tumor recurrence or progression. This information ultimately
allows the physician and patient to choose a course of treatment
that is individualized for each patient.
Our solution fits within current clinical practice and
therapeutic protocols, facilitating product adoption. We analyze
tissues as they are currently handled, processed and stored by
clinical pathology laboratories. Once a patient is diagnosed
with breast cancer and a physician orders Onco
type
DX,
the pathology lab provides us with the tumor block or thin
sections from the biopsy specimen utilized for the diagnosis.
Because the specimens are chemically preserved and embedded in
paraffin wax, they require no special handling and can be sent
by overnight mail to our laboratory in California. We typically
analyze the tissue and deliver our results to the treating
physician within 10 to 14 days of receipt of the tissue
sample. This is within the crucial decision window after the
tumor has been surgically removed and before the patient and the
treating physician discuss additional treatment options.
We believe our solution provides information that has the
following benefits:
|
|
|
Improved Quality of Treatment Decisions
. We believe
our approach to genomic-based cancer analysis improves the
quality of cancer treatment decisions by providing an
individualized analysis of each patients tumor that is
correlated to clinical outcome. Our approach represents a
substantial departure from existing approaches to treatment,
which often use subjective, anatomic and qualitative factors to
determine treatments. Onco
type
DX has been shown in
clinical studies to classify many patients into recurrence risk
categories different from classifications based on current
guidelines. Thus, our solution enables patients and physicians
to make more informed decisions about treatment risk-benefit
and, consequently, design an individualized treatment plan.
|
|
|
Improved Economics of Cancer Care
. We believe that
improving the quality of treatment decisions can result in
significant economic benefits. In early stage breast cancer, our
data shows that many patients are misclassified as high or low
risk under existing treatment guidelines. Many low risk patients
misclassified as high risk receive toxic and expensive
chemotherapy treatment regimens. Chemotherapy may cost in excess
of $20,000, as compared to Onco
type
DXs list price
of $3,460. On the other hand, some high risk patients
misclassified as low risk are not provided chemotherapy
treatment, possibly necessitating future treatment costing up to
$50,000 or more if the cancer recurs.
|
Risks Associated With Our Business
Our business is subject to numerous risks, as more fully
described in the section entitled Risk Factors
immediately following this prospectus summary. We may be unable,
for many reasons, including those that are beyond our control,
to implement our current business strategy. Those reasons could
include failure to obtain reimbursement for Onco
type
DX
from a sufficient number of third-party payors, regulation of
our test by the U.S. Food and Drug Administration, failure
to maintain and to protect our intellectual property assets, and
inability to maintain current collaborations or enter into new
collaborations with organizations in the cancer field.
We currently have only one product, which was first
commercialized in January 2004. We have incurred
$80.5 million in cumulative net losses from our inception
in 2000, and we expect losses to continue for the foreseeable
future. Our net loss for the six months ended June 30, 2005
was $15.7 million, and for the year ended December 31,
2004, was $25.0 million.
3
We do not anticipate commercializing another product for at
least several years, if at all. All of our product candidates
other than those for breast cancer are in the clinical research
phase. We are unable to predict the extent of future losses or
when we will become profitable, if at all. Even if we succeed in
developing and commercializing another product, we may never
generate sufficient product revenues to achieve and then sustain
profitability.
Private Share Sale to Incyte Corporation
Concurrent with the closing of this offering, we expect to
exercise a put right and cause Incyte Corporation to purchase
from us in a private sale $5.0 million of our common stock
at a price per share equal to the initial public offering price.
Assuming an initial public offering price of $13.00 per share,
Incyte would purchase from us 384,615 shares of our common stock
if we exercise our put right.
CORPORATE INFORMATION
We were incorporated in Delaware in August 2000. Our principal
executive offices are located at 301 Penobscot Drive, Redwood
City, California 94063, and our telephone number is
(650) 556-9300. Our website is
www.genomichealth.com
. Information on our website is not
a part of this prospectus.
The Genomic Health logo and Onco
type
are our registered
trademarks. We have applied to register our trademarks,
Onco
type
DX and Recurrence Score, with the
U.S. Patent and Trademark Office. All other trademarks,
trade names and service marks appearing in this prospectus are
the property of their respective holders.
4
The Offering
|
|
|
Common stock offered by us
|
|
5,016,722 shares
|
Common stock to be outstanding after this offering
|
|
24,335,381 shares
|
Estimated initial public offering price per share
|
|
$12.00 to $14.00
|
Use of proceeds
|
|
We intend to use the net proceeds for general corporate
purposes, including working capital and capital expenditures.
See Use of Proceeds.
|
Proposed Nasdaq symbol
|
|
GHDX
|
Unless otherwise stated, all information in this prospectus
assumes:
|
|
|
|
|
a 1-for-3 reverse split of our common stock;
|
|
|
|
the automatic conversion of every three shares of our
convertible preferred stock into one share of common stock upon
the closing of this offering;
|
|
|
|
our distribution of 736,142 shares of our common stock as a
dividend to our stockholders prior to the date of this offering
and a proportional adjustment to options outstanding as of the
dividend distribution date to increase the aggregate number of
shares subject to exercise thereunder by
55,068 shares; and
|
|
|
|
no exercise of the over-allotment option granted to the
underwriters.
|
The number of shares of common stock to be outstanding
immediately after this offering:
|
|
|
|
|
includes 18,197,987 shares of common stock outstanding as
of August 31, 2005;
|
|
|
|
includes 736,142 shares of common stock issuable to our
stockholders of record prior to the date of this offering, less
an aggregate of 85 shares for which cash will be paid in
lieu of fractional interests, in connection with the stock
dividend described above that we expect to make upon the closing
of this offering;
|
|
|
|
includes 384,615 shares that we expect to issue in a private
sale to Incyte Corporation in connection with our exercise of a
put right described elsewhere in this prospectus, assuming an
initial public offering price of $13.00 per share;
|
|
|
|
excludes 1,416,206 shares of common stock issuable upon the
exercise of stock options outstanding as of August 31,
2005, at a weighted average exercise price of $1.91 per
share; and
|
|
|
|
excludes 5,000,000 shares of common stock available for
future issuance under our stock option plans following the date
of this offering.
|
Several of our significant existing stockholders, including
funds affiliated with Julian C. Baker, Felix J. Baker and
Integral Capital Partners VI, L.P. or their affiliates, have
indicated an interest in purchasing up to an aggregate of
500,000 shares of our common stock in this offering, less any
shares sold to our employees pursuant to our directed share
program. However, because indications of interest are not
binding upon us or the prospective purchasers, these
stockholders may not acquire any shares in this offering.
5
SUMMARY CONSOLIDATED FINANCIAL DATA
The following table presents our summary consolidated historical
financial information. You should read this information together
with the consolidated financial statements and related notes and
the information under Managements Discussion and
Analysis of Financial Condition and Results of Operations
included elsewhere in this prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
Six Months Ended
|
|
|
|
August 22, 2000
|
|
|
Year Ended December 31,
|
|
|
June 30,
|
|
|
|
(inception) to
|
|
|
|
|
|
|
|
|
|
Dec. 31, 2000
|
|
|
2001
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
Consolidated Statements of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenues
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
227
|
|
|
$
|
33
|
|
|
$
|
1,585
|
|
|
Contract revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125
|
|
|
|
100
|
|
|
|
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125
|
|
|
|
327
|
|
|
|
33
|
|
|
|
1,685
|
|
Operating expenses(1):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,828
|
|
|
|
931
|
|
|
|
2,874
|
|
|
Research and development
|
|
|
169
|
|
|
|
11,080
|
|
|
|
7,053
|
|
|
|
9,069
|
|
|
|
10,040
|
|
|
|
5,182
|
|
|
|
4,630
|
|
|
Selling and marketing
|
|
|
|
|
|
|
117
|
|
|
|
754
|
|
|
|
2,805
|
|
|
|
9,856
|
|
|
|
4,449
|
|
|
|
7,415
|
|
|
General and administrative
|
|
|
566
|
|
|
|
2,844
|
|
|
|
3,753
|
|
|
|
3,686
|
|
|
|
3,869
|
|
|
|
1,832
|
|
|
|
2,787
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
735
|
|
|
|
14,041
|
|
|
|
11,560
|
|
|
|
15,560
|
|
|
|
25,593
|
|
|
|
12,394
|
|
|
|
17,706
|
|
Interest and other income (expense), net
|
|
|
|
|
|
|
1,267
|
|
|
|
492
|
|
|
|
185
|
|
|
|
271
|
|
|
|
98
|
|
|
|
322
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(735
|
)
|
|
$
|
(12,774
|
)
|
|
$
|
(11,068
|
)
|
|
$
|
(15,250
|
)
|
|
$
|
(24,995
|
)
|
|
$
|
(12,263
|
)
|
|
$
|
(15,699
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(10.10
|
)
|
|
$
|
(20.14
|
)
|
|
$
|
(11.95
|
)
|
|
$
|
(12.43
|
)
|
|
$
|
(14.38
|
)
|
|
$
|
(7.26
|
)
|
|
$
|
(8.28
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing basic and diluted net loss per share
|
|
|
72,777
|
|
|
|
634,415
|
|
|
|
925,814
|
|
|
|
1,226,444
|
|
|
|
1,737,652
|
|
|
|
1,687,964
|
|
|
|
1,895,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Includes non-cash charges for stock-based compensation expense
of $191,000, $9,000 and $509,000 for the year ended
December 31, 2004 and the six months ended June 30,
2004 and 2005, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of June 30, 2005
|
|
|
|
|
|
|
|
|
|
Pro Forma
|
|
|
|
Actual
|
|
|
Pro Forma
|
|
|
As Adjusted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
|
(Unaudited)
|
|
Consolidated Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
25,231
|
|
|
$
|
25,231
|
|
|
$
|
88,855
|
|
Working capital
|
|
|
23,306
|
|
|
|
23,306
|
|
|
|
86,930
|
|
Total assets
|
|
|
30,832
|
|
|
|
30,832
|
|
|
|
94,456
|
|
Capital leases, long-term
|
|
|
2,483
|
|
|
|
2,483
|
|
|
|
2,483
|
|
Convertible preferred stock
|
|
|
103,212
|
|
|
|
|
|
|
|
|
|
Total stockholders equity (deficit)
|
|
|
(79,228
|
)
|
|
|
23,984
|
|
|
|
87,608
|
|
The preceding table presents a summary of our unaudited
consolidated balance sheet data as of June 30, 2005:
|
|
|
|
|
on an actual basis;
|
|
|
|
on a pro forma basis to give effect to the automatic conversion
of all outstanding shares of our convertible preferred stock
into common stock upon the closing of this offering; and
|
|
|
|
on a pro forma as adjusted basis to give effect to the sale of
5,016,722 shares of our common stock in this offering at an
assumed initial public offering price of $13.00 per share,
after deducting the estimated underwriting discount and
estimated offering expenses payable by us, and the sale of
384,615 shares of common stock to Incyte Corporation for
cash proceeds of $5.0 million in connection with our
expected exercise of a put right, at a purchase price equal to
the assumed initial public offering price of $13.00 per
share.
|
6
RISK FACTORS
You should carefully consider the risks described below
before making a decision to buy our common stock. The risks and
uncertainties described below are not the only ones we face. If
any of the following risks actually occur, our business,
financial condition and results of operations could be harmed.
In that case, the trading price of our common stock could
decline and you might lose all or part of your investment in our
common stock. You should also refer to the other information set
forth in this prospectus, including our consolidated financial
statements and the related notes. Additional risks and
uncertainties not presently known to us or that we currently
deem immaterial may also impair our business operations.
RISKS RELATED TO OUR COMPANY
We are an early stage company with a history of losses,
and we expect to incur net losses for the foreseeable
future.
We have incurred substantial net losses since our inception. For
the years ended December 31, 2002, 2003 and 2004 and the
six months ended June 30, 2005, we had a net loss of
$11.1 million, $15.3 million, $25.0 million and
$15.7 million, respectively. From our inception in August
2000 through June 30, 2005, we had an accumulated deficit
of approximately $80.5 million. To date, we have generated
only minimal revenues, and we may never achieve revenues
sufficient to offset expenses. We expect to devote substantially
all of our resources to continue commercializing our existing
product, Onco
type
DX, and to develop future products.
We expect to incur additional losses this year and in future
years, and we may never achieve profitability. In addition, we
have only recently begun to commercialize Onco
type
DX and
do not expect our losses to be substantially mitigated by
revenues from Onco
type
DX or future products, if any, for
a number of years.
We expect to continue to incur significant research and
development expenses, which may make it difficult for us to
achieve profitability.
In recent years, we have incurred significant costs in
connection with the development of Onco
type
DX. Our
research and development expenses were $7.1 million,
$9.1 million and $10.0 million for the years ended
December 31, 2002, 2003 and 2004, respectively, and
$4.6 million for the six months ended June 30, 2005.
We expect our research and development expense levels to remain
high for the foreseeable future as we seek to enhance our
existing product and develop new products. As a result, we will
need to generate significant revenues in order to achieve
profitability. Our failure to achieve profitability in the
future could cause the market price of our common stock to
decline.
If third-party payors, including managed care
organizations and Medicare, do not provide reimbursement for
Oncotype DX, its commercial success could be compromised.
Onco
type
DX has a list price of $3,460. Physicians and
patients may decide not to order Onco
type
DX unless
third-party payors, such as managed care organizations, Medicare
and Medicaid, pay a substantial portion of the tests
price. There is significant uncertainty concerning third-party
reimbursement of any test incorporating new technology,
including Onco
type
DX. From commercialization of
Onco
type
DX in January 2004 through June 30, 2005,
approximately 90% of our revenues derived from the sale of
Onco
type
DX have been paid by third-party payors.
Reimbursement by a third-party payor may depend on a number of
factors, including a payors determination that tests using
our technologies are:
|
|
|
|
|
not experimental or investigational,
|
|
|
|
medically necessary,
|
|
|
|
appropriate for the specific patient,
|
|
|
|
cost-effective, and
|
|
|
|
supported by peer-reviewed publications.
|
7
Since each payor makes its own decision as to whether to
establish a policy to reimburse for a test, seeking these
approvals is a time-consuming and costly process. To date, we
have secured policy-level reimbursement approval only from a
limited number of third-party payors and have not secured any
such approval from Medicare or any state Medicaid program. We
cannot assure you that coverage for Onco
type
DX will be
provided in the future by any third-party payors.
In early 2005, the Medical Advisory Panel of the Blue Cross and
Blue Shield Associations Technology Evaluation Center, or
BCBSA, a technology assessment group, concluded that the
existing clinical data in support of Onco
type
DX did not
meet the panels technology criteria for clinical
effectiveness and appropriateness. This assessment is provided
for informational purposes to members of BCBSA and can be used
by third-party payors and health care providers such as Blue
Cross and Blue Shield, which provide healthcare coverage for
nearly one-third of all Americans, as grounds to deny coverage
for Onco
type
DX.
In addition, in December 2004, the Northern California Medicare
contractor with responsibility for processing and paying claims
submitted by us announced that it would not provide coverage for
Onco
type
DX for Medicare beneficiaries. It also indicated
that there could be some questions concerning whether the
hospital must bill Medicare or we can bill Medicare directly.
Finally, it questioned which Medicare contractor has
jurisdiction to determine coverage for Medicare claims for our
test. Any determination that our test constitutes a hospital
service as opposed to an outpatient procedure could result in
lower payment rates in the event reimbursement is provided.
Insurers, including managed care organizations, as well as
government payors, such as Medicare, have increased their
efforts to control the cost, utilization and delivery of health
care services. From time to time, Congress has considered and
implemented changes in the Medicare fee schedules in conjunction
with budgetary legislation. Further reductions of reimbursement
for Medicare services may be implemented from time to time.
Reductions in the reimbursement rates of other third-party
payors have occurred and may occur in the future. These measures
have resulted in reduced prices, added costs and decreased test
utilization for the clinical laboratory industry. If we are
unable to obtain reimbursement approval from private payors and
Medicare and Medicaid programs for Onco
type
DX, or if the
amount reimbursed is inadequate, our ability to generate
revenues from Onco
type
DX could be limited.
If the U.S. Food and Drug Administration, or FDA, were to
begin regulating our products, we could be forced to stop sales
of Oncotype DX, we could experience significant delays in
commercializing any future products, or we could incur
substantial costs and time delays associated with meeting
requirements for premarket approval.
Clinical laboratory services like Onco
type
DX are
regulated under the Clinical Laboratory Improvement Amendments
of 1988, or CLIA, as administered through the Center for
Medicare/ Medicaid Services, as well as by applicable state
laws. Diagnostic kits that are sold and distributed as products
through interstate commerce are regulated as medical devices by
the FDA. Clinical laboratory tests that are developed and
validated by a laboratory for its own use are called home brew
tests. Most home brew tests currently are not subject to FDA
regulation, although reagents or software provided by third
parties and used to perform home brew tests may be subject to
regulation. We believe that Onco
type
DX is not a
diagnostic kit and also believe that it is a home brew test. As
a result, we believe Onco
type
DX is not subject to
regulation under current FDA policies. The container we provide
for collection and transport of tumor samples from a pathology
laboratory to our laboratory is a medical device subject to FDA
regulation but is currently exempt from premarket review by the
FDA.
In December 2004, the FDA, through the Office of In Vitro
Diagnostic Devices, or OIVD, initiated a dialogue with us
regarding the regulatory status of Onco
type
DX. We
subsequently engaged in informal communications with the FDA
regarding the status of our test. In early 2005, OIVD indicated
that the FDA is considering whether our test may be subject to
premarket review. We have not heard from the FDA since this
communication. We cannot provide any assurance that the FDA will
agree with our view on whether Onco
type
DX is subject to
regulation or that FDA regulation, including review by the FDA
before marketing, will not be required in the future for
Onco
type
DX.
8
If review by the FDA before marketing is required, we might have
to stop selling our test until a review is completed and
approval or clearance to market is obtained. In this case, the
regulatory approval process could involve, among other things,
successfully completing additional clinical trials and
submitting a premarket clearance notice or filing a premarket
approval application with the FDA. There is no assurance that
the FDA would clear or approve our test. Ongoing compliance with
FDA regulations would increase the cost, time and complexity of
conducting our business. In addition, should any of the clinical
laboratory device reagents, software or the tumor sample
container used in or for our home brew test be affected by
future regulatory actions, we could experience increased costs
of testing or delays and limitations or unavailability of the
reagents or software necessary to perform testing. If we are
unable to obtain the reagents necessary to perform our test at
all or on commercially reasonable terms, we would need to revise
Onco
type
DX so that it would not require those reagents.
Even if we were able to revise Onco
type
DX so that it
would not require those reagents, we would then be required to
re-validate our test before using it, which would be
time-consuming and expensive.
If we were required to conduct additional clinical trials
prior to marketing our products, those trials could lead to
delays or failure to obtain necessary regulatory approvals and
harm our ability to become profitable.
If the FDA decides to regulate our tests, it would require
extensive premarket clinical testing prior to submitting a
regulatory application for commercial sales. If we are required
to conduct premarket clinical trials, whether using
prospectively acquired samples or archival samples, delays in
the commencement or completion of clinical testing could
significantly increase our product development costs and delay
product commercialization. Many of the factors that may cause or
lead to a delay in the commencement or completion of clinical
trials may also ultimately lead to delay or denial of regulatory
approval. The commencement of clinical trials may be delayed due
to insufficient patient enrollment, which is a function of many
factors, including the size of the patient population, the
nature of the protocol, the proximity of patients to clinical
sites and the eligibility criteria for the clinical trial. We
may find it necessary to engage contract research organizations
to perform data collection and analysis and other aspects of our
clinical trials, which might increase the cost and complexity of
our trials. We may also depend on clinical investigators,
medical institutions and contract research organizations to
perform the trials properly. If these parties do not
successfully carry out their contractual duties or obligations
or meet expected deadlines, or if the quality, completeness or
accuracy of the clinical data they obtain is compromised due to
the failure to adhere to our clinical protocols or for other
reasons, our clinical trials may have to be extended, delayed or
terminated. Many of these factors would be beyond our control.
We may not be able to enter into replacement arrangements
without undue delays or considerable expenditures. If there are
delays in testing or approvals as a result of the failure to
perform by third parties, our research and development costs
would increase, and we may not be able to obtain regulatory
approval for our products. In addition, we may not be able to
establish or maintain relationships with these parties on
favorable terms, if at all. Each of these outcomes would harm
our ability to market our product, or to become profitable.
Complying with numerous regulations pertaining to our
business is an expensive and time-consuming process, and any
failure to comply could result in substantial penalties.
We are subject to CLIA, a federal law that regulates clinical
laboratories that perform testing on specimens derived from
humans for the purpose of providing information for the
diagnosis, prevention or treatment of disease. CLIA is intended
to ensure the quality and reliability of clinical laboratories
in the United States by mandating specific standards in the
areas of personnel qualifications, administration, participation
in proficiency testing, patient test management, quality
control, quality assurance and inspections. We have a current
certificate of accreditation under CLIA to perform testing. To
renew this certificate, we are subject to survey and inspection
every two years, and we expect that we will be inspected within
the next nine months. Moreover, CLIA inspectors may make random
inspections of our laboratory.
We are also required to maintain a license to conduct testing in
California. California laws establish standards for day-to-day
operation of our clinical laboratory, including the training and
skills required of personnel and
9
quality control. Moreover, several states require that we hold
licenses to test specimens from patients residing in those
states. Other states have similar requirements or may adopt
similar requirements in the future. Finally, we may be subject
to regulation in foreign jurisdictions as we seek to expand
international distribution of our test.
If we were to lose our CLIA accreditation or California license,
whether as a result of a revocation, suspension or limitation,
we would no longer be able to sell Onco
type
DX, which
would limit our revenues and harm our business. If we were to
lose our license in other states where we are required to hold
licenses, we would not be able to test specimens from those
states.
We are subject to other regulation by both the federal
government and the states in which we conduct our business,
including:
|
|
|
|
|
Medicare billing and payment regulations applicable to clinical
laboratories;
|
|
|
|
the federal Medicare and Medicaid Anti-kickback Law, and state
anti-kickback prohibitions;
|
|
|
|
the federal physician self-referral prohibition commonly known
as the Stark Law and the state equivalents;
|
|
|
|
the federal Health Insurance Portability and Accountability Act
of 1996;
|
|
|
|
the Medicare civil money penalty and exclusion
requirements; and
|
|
|
|
the federal civil and criminal False Claims Act.
|
The risk of our being found in violation of these laws and
regulations is increased by the fact that many of them have not
been fully interpreted by the regulatory authorities or the
courts, and their provisions are open to a variety of
interpretations. Any action brought against us for violation of
these laws or regulations, even if we successfully defend
against it, could cause us to incur significant legal expenses
and divert our managements attention from the operation of
our business. If our operations are found to be in violation of
any of these laws and regulations, we may be subject to any
applicable penalty associated with the violation, including
civil and criminal penalties, damages, fines, we could be
required to refund payments received by us, and we could be
required to curtail or cease our operations. Any of the
foregoing consequences could seriously harm our business and our
financial results.
Our financial results depend on sales of one product,
Oncotype DX, and we will need to generate sufficient revenues
from this and other products to run our business.
For the foreseeable future, we expect to derive substantially
all of our revenues from sales of one product, Onco
type
DX. We have only been selling this test since January 2004.
We are in the early stages of research and development for other
products that we may offer as well as for enhancements to our
existing product. We are not currently able to estimate when we
may be able to commercialize products for other cancers or
whether we will be successful in doing so. If we are unable to
increase sales of Onco
type
DX or to successfully develop
and commercialize other products or product enhancements, our
revenues and our ability to achieve profitability would be
impaired, and the market price of our common stock could decline.
We may experience limits on our revenues if only a small
number of physicians decide to adopt our test.
If medical practitioners do not order Onco
type
DX or any
future tests developed by us, we will likely not be able to
create demand for our products in sufficient volume for us to
become profitable. To generate demand, we will need to continue
to make oncologists, surgeons and pathologists aware of the
benefits of Onco
type
DX, and any products we may develop
in the future, through published papers, presentations at
scientific conferences and one-on-one education by our sales
force. In addition, we will need to demonstrate our ability to
obtain adequate reimbursement coverage from third-party payors.
Existing guidelines and practices regarding the treatment of
breast cancer recommend that chemotherapy be considered in most
cases, including many cases in which our test may indicate,
based on our clinical trial results, that chemotherapy is of
little or no benefit. Accordingly, physicians may be reluctant
to order a test that may suggest recommending against
chemotherapy in treating breast cancer where current guidelines
10
recommend consideration of such treatment. Moreover, our test
provides quantitative information not currently provided by
pathologists and it is performed at our facility rather than by
the pathologist in a local laboratory, so pathologists may be
reluctant to order or support our test. These facts may make it
difficult for us to convince medical practitioners to order
Onco
type
DX for their patients, which could limit our
ability to generate revenues and our ability to achieve
profitability.
We may experience limits on our revenues if only a small
number of patients decide to use our test.
Some patients may decide not to order our test due to its list
price of $3,460, part or all of which may be payable directly by
the patient if the applicable payor denies reimbursement in full
or in part. Even if medical practitioners recommend that their
patients use our test, patients may still decide not to use
Onco
type
DX, either because they do not want to be made
aware of the likelihood of recurrence or they wish to pursue a
particular course of therapy regardless of test results. If only
a small portion of the patient population decides to use our
test, we will experience limits on our revenues and our ability
to achieve profitability.
If we are unable to develop products to keep pace with
rapid medical and scientific change, our operating results and
competitive position would be harmed.
In recent years, there have been numerous advances in
technologies relating to the diagnosis and treatment of cancer.
For example, new hormonal therapies such as aromatase inhibitors
are viewed by physicians as promising therapies for breast
cancer with more tolerable side effects than those associated
with tamoxifen, the hormonal therapy commonly used today in
treatment. For advanced cancer, new chemotherapeutic strategies
are being developed that may increase survival time and reduce
toxic side effects. These advances require us continuously to
develop new products and enhance existing products to keep pace
with evolving standards of care. Our test could become obsolete
unless we continually innovate and expand our product to
demonstrate recurrence and treatment benefit in patients treated
with new therapies. New treatment therapies typically have only
a few years of clinical data associated with them, which limits
our ability to perform clinical studies and correlate sets of
genes to a new treatments effectiveness. If we are unable
to demonstrate the applicability of our tests to new treatments,
then sales of our tests could decline, which would harm our
revenues.
Our rights to use technologies licensed from third parties
are not within our control, and we may not be able to sell our
products if we lose our existing rights or cannot obtain new
rights on reasonable terms.
We license from third parties technology necessary to develop
our products. For example, we license technology from Roche
Molecular Systems, Inc. that we use to analyze genes for
possible inclusion in our tests and that we use in our
laboratory to conduct our tests. In return for the use of a
third partys technology, we may agree to pay the licensor
royalties based on sales of our products. Royalties are a
component of cost of product revenues and impact the margin on
our tests. We may need to license other technology to
commercialize future products. Our business may suffer if these
licenses terminate, if the licensors fail to abide by the terms
of the license or fail to prevent infringement by third parties,
if the licensed patents or other rights are found to be invalid
or if we are unable to enter into necessary licenses on
acceptable terms.
Our competitive position depends on maintaining
intellectual property protection.
Our ability to compete and to achieve and maintain profitability
depends on our ability to protect our proprietary discoveries
and technologies. We currently rely on a combination of patent
applications, copyrights, trademarks, trade secret laws and
confidentiality agreements, material data transfer agreements,
license agreements and invention assignment agreements to
protect our intellectual property rights. We also rely upon
unpatented know-how and continuing technological innovation to
develop and maintain our competitive position.
We do not have any issued patents. Our pending patent
applications may not result in issued patents, and we cannot
assure you that any patents that might ultimately be issued by
the U.S. Patent and Trademark Office will protect our
technology. Any patents that may be issued to us might be
challenged by third parties as being invalid or unenforceable,
or third parties may independently develop similar or competing
technology
11
that avoids our patents. We cannot be certain that the steps we
have taken will prevent the misappropriation and use of our
intellectual property, particularly in foreign countries where
the laws may not protect our proprietary rights as fully as in
the United States.
We may face intellectual property infringement claims that
could be time-consuming and costly to defend and could result in
our loss of significant rights and the assessment of treble
damages.
From time to time, we may receive notices of claims of
infringement, misappropriation or misuse of other parties
proprietary rights. Some of these claims may lead to litigation.
We cannot assure you that we will prevail in these actions, or
that other actions alleging misappropriation or misuse by us of
third-party trade secrets, infringement by us of third-party
patents and trademarks or the validity of our patents, will not
be asserted or prosecuted against us. We may also initiate
claims to defend our intellectual property. Intellectual
property litigation, regardless of outcome, is expensive and
time-consuming, could divert managements attention from
our business and have a material negative effect on our
business, operating results or financial condition. If there is
a successful claim of infringement against us, we may be
required to pay substantial damages (including treble damages if
we were to be found to have willfully infringed a third
partys patent) to the party claiming infringement, develop
non-infringing technology, stop selling our test or using
technology that contains the allegedly infringing intellectual
property or enter into royalty or license agreements that may
not be available on acceptable or commercially practical terms,
if at all. Our failure to develop non-infringing technologies or
license the proprietary rights on a timely basis could harm our
business. In addition, revising our test to include the
non-infringing technologies would require us to re-validate our
test, which would be costly and time consuming. Also, we may be
unaware of pending patent applications that relate to our test.
Parties making infringement claims on future issued patents may
be able to obtain an injunction that would prevent us from
selling our test or using technology that contains the allegedly
infringing intellectual property, which could harm our business.
One of the genes in the Onco
type
DX 21-gene panel may be
the subject of a patent, the rights of which are exclusively
licensed by a subsidiary of Pfizer Inc. We have initiated
discussions with Pfizer regarding a license of the patent but
have not reached an agreement. If we are not able to negotiate a
license on acceptable terms, and if our test is determined to
infringe this patent, then we may be forced to develop an
alternate method for performing our test. Revising our test may
take more than a year and may require that we spend considerable
amounts of money to develop a non-infringing gene panel and to
validate our findings through a clinical study or studies. We
may be forced to pay Pfizer royalties, damages and costs, or we
may be prevented from selling our test altogether, which would
greatly damage our business and operating results. Also, we are
aware of other patents owned by Pfizer that relate to another
gene in the Onco
type
DX 21-gene panel and are currently
investigating whether any of the claims warrant a license. In
addition, there are a number of patents and patent applications
that may constitute prior art in the field of genomic-based
diagnostics. We may be required to pay royalties, damages and
costs to firms who own the rights to these patents, or we might
be restricted from using any of the inventions claimed in those
patents.
If we are unable to compete successfully, we may be unable
to increase or sustain our revenues or achieve
profitability.
Our principal competition comes from existing diagnostic methods
used by pathologists and oncologists. These methods have been
used for many years and are therefore difficult to change or
supplement. In addition, companies offering capital equipment
and kits or reagents to local pathology laboratories represent
another source of potential competition. These kits are used
directly by the pathologist, which facilitates adoption more
readily than tests like Onco
type
DX that are performed
outside the pathology laboratory. In addition, few diagnostic
methods are as expensive as Onco
type
DX.
We also face competition from companies, such as Agendia B.V.,
that offer products or have conducted research to profile gene
expression in breast cancer using fresh or frozen tissue.
Commercial laboratories with strong distribution networks for
diagnostic tests, such as Genzyme Corporation, Laboratory
Corporation of America Holdings and Quest Diagnostics
Incorporated, may become competitors. Other potential
competitors include companies that develop diagnostic tests such
as Bayer Healthcare LLC, Celera Genomics, a business
12
segment of Applera Corporation, Roche Diagnostics, a division of
F. Hoffmann-La Roche Ltd, and Veridex LLC, a
Johnson & Johnson company, as well as academic and
research institutions.
Many of our present and potential competitors have widespread
brand recognition and substantially greater financial and
technical resources and development, production and marketing
capabilities than we do. Others may develop lower-priced, less
complex tests that could be viewed by physicians and payors as
functionally equivalent to our test, which could force us to
lower the list price of our test and impact our operating
margins and our ability to achieve profitability. If we are
unable to compete successfully against current or future
competitors, we may be unable to increase market acceptance for
and sales of our test, which could prevent us from increasing or
sustaining our revenues or achieving or sustaining profitability
and could cause the market price of our common stock to decline.
Our research and development efforts will be hindered if
we are not able to contract with third parties for access to
archival tissue samples.
Under standard clinical practice in the United States, tumor
biopsies removed from patients are chemically preserved and
embedded in paraffin wax and stored. Our clinical development
relies on our ability to secure access to these archived tumor
biopsy samples, as well as information pertaining to their
associated clinical outcomes. Others have demonstrated their
ability to study archival samples and often compete with us for
access. Additionally, the process of negotiating access to
archived samples is lengthy since it typically involves numerous
parties and approval levels to resolve complex issues such as
usage rights, institutional review board approval, privacy
rights, publication rights, intellectual property ownership and
research parameters. If we are not able to negotiate access to
archival tumor tissue samples with hospitals and collaborators,
or if other laboratories or our competitors secure access to
these samples before us, our ability to research, develop and
commercialize future products will be limited or delayed.
If we cannot maintain our current clinical collaborations
and enter into new collaborations, our product development could
be delayed.
We rely on and expect to continue to rely on clinical
collaborators to perform a substantial portion of our clinical
trial functions. If any of our collaborators were to breach or
terminate its agreement with us or otherwise fail to conduct its
collaborative activities successfully and in a timely manner,
the research, development or commercialization of the products
contemplated by the collaboration could be delayed or
terminated. If any of our collaboration agreements is
terminated, or if we are unable to renew those collaborations on
acceptable terms, we would be required to seek alternative
collaborations. We may not be able to negotiate additional
collaborations on acceptable terms, if at all, and these
collaborations may not be successful.
In the past, we have entered into clinical trial collaborations
with highly regarded organizations in the cancer field,
including the National Surgical Adjuvant Breast and Bowel
Project, or NSABP, and Northern California Kaiser Permanente.
Our success in the future depends in part on our ability to
enter into agreements with other leading cancer organizations.
This can be difficult due to internal and external constraints
placed on these organizations. Some organizations may limit the
number of collaborations they have with any one company so as to
not be perceived as biased or conflicted. Organizations may also
have insufficient administrative and related infrastructure to
enable collaborations with many companies at once, which can
extend the time it takes to develop, negotiate and implement a
collaboration. Additionally, organizations often insist on
retaining the rights to publish the clinical data resulting from
the collaboration. The publication of clinical data in
peer-reviewed journals is a crucial step in commercializing and
obtaining reimbursement for a test such as ours, and our
inability to control when, if ever, results are published may
delay or limit our ability to derive sufficient revenues from
any product that may result from a collaboration.
From time to time we expect to engage in discussions with
potential clinical collaborators which may or may not lead to
collaborations. For example we have held discussions with the
National Cancer Institute regarding conducting a large clinical
study utilizing Onco
type
DX. However, we cannot guarantee
that any discussions will result in clinical collaborations or
that any clinical studies which may result will be enrolled or
completed in a reasonable time frame or with successful
outcomes. Once news of discussions regarding
13
possible collaborations are known in the medical community,
regardless of whether the news is accurate, failure to announce
a collaborative agreement or the entitys announcement of a
collaboration with an entity other than us may result in adverse
speculation about us, our product or our technology, resulting
in harm to our reputation and our business.
New product development involves a lengthy and complex
process, and we may be unable to commercialize any of the
products we are currently developing.
We have multiple products under development and devote
considerable resources to research and development. For example,
we are currently conducting research on the application of our
technology to predict recurrence and the therapeutic benefit of
chemotherapy in colon, prostate, renal cell and lung cancers and
melanoma. There can be no assurance that our technologies will
be capable of reliably predicting the recurrence of cancers,
beyond breast cancer, with the sensitivity and specificity
necessary to be clinically and commercially useful for the
treatment of other cancers, or that we can develop those
technologies at all. In addition, before we can develop
diagnostic tests for new cancers and commercialize any new
products, we will need to:
|
|
|
|
|
conduct substantial research and development;
|
|
|
|
conduct validation studies;
|
|
|
|
expend significant funds; and
|
|
|
|
develop and scale-up our laboratory processes.
|
This process involves a high degree of risk and takes several
years. Our product development efforts may fail for many
reasons, including:
|
|
|
|
|
failure of the product at the research or development stage;
|
|
|
|
difficulty in accessing archival tissue samples, especially
tissue samples with known clinical results; or
|
|
|
|
lack of clinical validation data to support the effectiveness of
the product.
|
Few research and development projects result in commercial
products, and success in early clinical trials often is not
replicated in later studies. At any point, we may abandon
development of a product candidate or we may be required to
expend considerable resources repeating clinical trials, which
would adversely impact the timing for generating potential
revenues from those product candidates. In addition, as we
develop products, we will have to make significant investments
in product development, marketing and selling resources. If a
clinical validation study fails to demonstrate the prospectively
defined endpoints of the study, we would likely abandon the
development of the product or product feature that was the
subject of the clinical trial, which could harm our business.
The loss of key members of our senior management team or
our inability to retain highly skilled scientists, clinicians
and salespeople could adversely affect our business.
Our success depends largely on the skills, experience and
performance of key members of our executive management team. The
efforts of each of these persons will be critical to us as we
continue to develop our technologies and testing processes and
as we attempt to transition to a company with more than one
commercialized product. If we were to lose one or more of these
key employees, we may experience difficulties in competing
effectively, developing our technologies and implementing our
business strategies.
Our research and development programs and commercial laboratory
operations depend on our ability to attract and retain highly
skilled scientists and technicians, including geneticists,
licensed laboratory technicians, chemists and engineers. We may
not be able to attract or retain qualified scientists and
technicians in the future due to the intense competition for
qualified personnel among life science businesses, particularly
in the San Francisco Bay Area. We also face competition from
universities and public and private research institutions in
recruiting and retaining highly qualified scientific personnel.
In addition, our success depends on our ability to attract and
retain salespeople with extensive experience in oncology and
close relationships with medical oncologists, surgeons,
pathologists and other hospital personnel. We may have
14
difficulties locating, recruiting or retaining qualified
salespeople, which could cause a delay or decline in the rate of
adoption of our products. If we are not able to attract and
retain the necessary personnel to accomplish our business
objectives, we may experience constraints that will adversely
affect our ability to support our discovery, development and
sales programs.
All of our employees are at-will employees, which means that
either we or the employee may terminate their employment at any
time. We maintain key-person life insurance only on Randal
Scott, our Chief Executive Officer, Joffre Baker, our Chief
Scientific Officer, and Steven Shak, our Chief Medical Officer.
We may discontinue this insurance in the future, it may not
continue to be available on commercially reasonable terms or, if
continued, it may prove inadequate to compensate us for the loss
of these individuals services.
If our sole laboratory facility becomes inoperable, we
will be unable to perform our tests and our business will be
harmed.
We do not have redundant laboratory facilities. We perform all
of our diagnostic services in our laboratory located in Redwood
City, California. Redwood City is situated on or near earthquake
fault lines. Our facility and the equipment we use to perform
our tests would be costly to replace and could require
substantial lead time to repair or replace. The facility may be
harmed or rendered inoperable by natural or man-made disasters,
including earthquakes, flooding and power outages, which may
render it difficult or impossible for us to perform our tests
for some period of time. The inability to perform our tests may
result in the loss of customers or harm our reputation, and we
may be unable to regain those customers in the future. Although
we possess insurance for damage to our property and the
disruption of our business, this insurance may not be sufficient
to cover all of our potential losses and may not continue to be
available to us on acceptable terms, or at all.
In order to rely on a third party to perform our tests, we could
only use another facility with established state licensure and
CLIA accreditation under the scope of which Onco
type
DX
could be performed following validation and other required
procedures. We cannot assure you that we would be able to find
another CLIA-certified facility willing to adopt Onco
type
DX and comply with the required procedures, or that this
laboratory would be willing to perform the tests for us on
commercially reasonable terms. In order to establish a redundant
laboratory facility, we would have to spend considerable time
and money securing adequate space, constructing the facility,
recruiting and training employees, and establishing the
additional operational and administrative infrastructure
necessary to support a second facility. Additionally, any new
clinical laboratory facility opened by us would be subject to
certification under CLIA and licensed by several states,
including California and New York, which can take a significant
amount of time and result in delays in our ability to begin
operations.
Changes in healthcare policy could subject us to
additional regulatory requirements that may interrupt
commercialization of Oncotype DX and increase our costs.
Healthcare policy has been a subject of extensive discussion in
the executive and legislative branches of the federal and many
state governments. We developed our commercialization strategy
for Onco
type
DX based on existing healthcare
policies. Changes in healthcare policy, such as the creation of
broad limits for diagnostic products in general or requirements
that Medicare patients pay for portions of tests or services
received, could substantially interrupt the sales of Onco
type
DX, increase costs and divert managements attention.
For example, in 1993, the U.S. Congress passed federal
self-referral prohibitions commonly known as the Stark Law,
significantly restricting, regulating and changing healthcare
companies relationships with physicians. We cannot predict
what changes, if any, will be proposed or adopted or the effect
that such proposals or adoption may have on our business,
financial condition and results of operations.
We rely on a sole supplier for some of our laboratory
instruments and may not be able to find replacements in the
event our sole supplier no longer supplies that
equipment.
We rely solely on Applied Biosystems, a division of Applera
Corporation, to supply some of the laboratory equipment on which
we perform our tests. We periodically forecast our needs for
laboratory
15
equipment and enter into standard purchase orders with Applied
Biosystems based on these forecasts. We believe that there are
relatively few equipment manufacturers other than Applied
Biosystems that are currently capable of supplying the equipment
necessary for Onco
type
DX. Even if we were to identify
other suppliers, there can be no assurance that we will be able
to enter into agreements with such suppliers on a timely basis
on acceptable terms, if at all. If we should encounter delays or
difficulties in securing from Applied Biosystems the quality and
quantity of equipment we require for Onco
type
DX, we may
need to reconfigure our test process, which would result in
delays in commercialization or an interruption in sales. If any
of these events occur, our business and operating results could
be harmed. Additionally, if Applied Biosystems deems us to have
become uncreditworthy, it has the right to require alternative
payment terms from us, including payment in advance. We are also
required to indemnify Applied Biosystems against any damages
caused by any legal action or proceeding brought by a third
party against Applied Biosystems for damages caused by our
failure to obtain required approval with any regulatory agency.
If we are unable to support demand for our products, our
business may suffer.
Since we only began the commercialization of Onco
type
DX
in January 2004, we have limited experience in processing our
test and even more limited experience in processing large
volumes of tests. If demand for Onco
type
DX increases, we
will be required to implement increases in scale and related
processing, customer service, billing and systems process
improvements, and to expand our internal quality assurance
program to support testing on a larger scale. We will also need
additional certified laboratory scientists and other scientific
and technical personnel to process our tests. We cannot assure
you that any increases in scale, related improvements and
quality assurance will be successfully implemented or that
appropriate personnel will be available. Failure to implement
necessary procedures or to hire the necessary personnel could
result in higher cost of processing or an inability to meet
market demand. Since we have limited experience handling large
volumes of Onco
type
DX tests, there can be no
assurance that we will be able to perform tests on a timely
basis at a level consistent with demand. If we encounter
difficulty meeting market demand for Onco
type
DX, our
reputation could be harmed and our future prospects and our
business could suffer.
We may be unable to manage our future growth effectively,
which would make it difficult to execute our business
strategy.
Future growth will impose significant added responsibilities on
management, including the need to identify, recruit, train and
integrate additional employees. In addition, rapid and
significant growth will place strain on our administrative and
operational infrastructure, including customer service and our
clinical laboratory. Our ability to manage our operations and
growth will require us to continue to improve our operational,
financial and management controls, reporting systems and
procedures. If we are unable to manage our growth effectively,
it may be difficult for us to execute our business strategy.
If we were sued for product liability, we could face
substantial liabilities that exceed our resources.
The marketing, sale and use of our test could lead to the filing
of product liability claims if someone were to allege that our
product failed to perform as it was designed. We may also be
subject to liability for errors in the information we provide to
customers or for a misunderstanding of, or inappropriate
reliance upon, the information we provide. A product liability
claim could result in substantial damages and be costly and time
consuming for us to defend. Although we believe that our
existing product liability insurance is adequate, we cannot
assure you that our insurance would fully protect us from the
financial impact of defending against product liability claims.
Any product liability claim brought against us, with or without
merit, could increase our insurance rates or prevent us from
securing insurance coverage in the future. Additionally, any
product liability lawsuit could cause injury to our reputation,
result in the recall of our products, or cause current
collaborators to terminate existing agreements and potential
collaborators to seek other partners, any of which could impact
our results of operations.
16
If we use biological and hazardous materials in a manner
that causes injury, we could be liable for damages.
Our activities currently require the controlled use of
potentially harmful biological materials, hazardous materials
and chemicals and may in the future require the use of
radioactive compounds. We cannot eliminate the risk of
accidental contamination or injury to employees or third parties
from the use, storage, handling or disposal of these materials.
In the event of contamination or injury, we could be held liable
for any resulting damages, and any liability could exceed our
resources or any applicable insurance coverage we may have.
Additionally, we are subject on an ongoing basis to federal,
state and local laws and regulations governing the use, storage,
handling and disposal of these materials and specified waste
products. The cost of compliance with these laws and regulations
might be significant and could negatively affect our operating
results.
Our dependence on distributors for foreign sales of
Oncotype DX could limit or prevent us from selling our products
in foreign markets and from realizing long-term international
revenue growth.
International sales as a percentage of net revenues are expected
to remain minimal in the near term as we focus our efforts on
the sale of Onco
type
DX in the United States. We
currently depend on one third-party distributor to sell
Onco
type
DX in Israel. Over the long term, we intend to
grow our business internationally, and to do so we will need to
attract additional distributors to expand the territories in
which we sell Onco
type
DX. Distributors may not commit
the necessary resources to market and sell Onco
type
DX to
the level of our expectations. If current or future distributors
do not perform adequately, or we are unable to locate
distributors in particular geographic areas, we may not realize
long-term international revenue growth.
We may acquire other businesses or form joint ventures
that could harm our operating results, dilute your ownership of
us, increase our debt or cause us to incur significant
expense.
As part of our business strategy, we may pursue acquisitions of
complementary businesses and assets, as well as technology
licensing arrangements. We also may pursue strategic alliances
that leverage our core technology and industry experience to
expand our product offerings or distribution. We have no
experience with respect to acquiring other companies and limited
experience with respect to the formation of collaborations,
strategic alliances and joint ventures. If we make any
acquisitions, we may not be able to integrate these acquisitions
successfully into our existing business, and we could assume
unknown or contingent liabilities. Any future acquisitions by us
also could result in significant write-offs or the incurrence of
debt and contingent liabilities, any of which could harm our
operating results. Integration of an acquired company also may
require management resources that otherwise would be available
for ongoing development of our existing business. We may not
identify or complete these transactions in a timely manner, on a
cost-effective basis, or at all, and we may not realize the
anticipated benefits of any acquisition, technology license,
strategic alliance or joint venture.
To finance any acquisitions, we may choose to issue shares of
our common stock as consideration, which would dilute your
interest in us. If the price of our common stock is low or
volatile, we may not be able to acquire other companies for
stock. Alternatively, it may be necessary for us to raise
additional funds for acquisitions through public or private
financings. Additional funds may not be available on terms that
are favorable to us, or at all.
17
Our inability to raise additional capital on acceptable
terms in the future may limit our ability to develop and
commercialize new products and technologies.
We expect capital outlays and operating expenditures to increase
over the next several years as we expand our infrastructure,
commercial operations and research and development activities.
Specifically, we may need to raise additional capital to, among
other things:
|
|
|
|
|
sustain commercialization of our initial product or enhancements
to that product;
|
|
|
|
increasing our selling and marketing efforts to drive market
adoption and address competitive developments;
|
|
|
|
expand our clinical laboratory operations;
|
|
|
|
expand our technologies into other areas of cancer;
|
|
|
|
fund our clinical validation study activities;
|
|
|
|
expand our research and development activities;
|
|
|
|
acquire or license technologies; and
|
|
|
|
finance capital expenditures and our general and administrative
expenses.
|
Our present and future funding requirements will depend on many
factors, including:
|
|
|
|
|
the level of research and development investment required to
maintain and improve our technology position;
|
|
|
|
costs of filing, prosecuting, defending and enforcing patent
claims and other intellectual property rights;
|
|
|
|
our need or decision to acquire or license complementary
technologies or acquire complementary businesses;
|
|
|
|
changes in product development plans needed to address any
difficulties in commercialization;
|
|
|
|
competing technological and market developments; and
|
|
|
|
changes in regulatory policies or laws that affect our
operations.
|
If we raise additional funds by issuing equity securities,
dilution to our stockholders could result. Any equity securities
issued also may provide for rights, preferences or privileges
senior to those of holders of our common stock. If we raise
additional funds by issuing debt securities, these debt
securities would have rights, preferences and privileges senior
to those of holders of our common stock, and the terms of the
debt securities issued could impose significant restrictions on
our operations. If we raise additional funds through
collaborations and licensing arrangements, we might be required
to relinquish significant rights to our technologies or
products, or grant licenses on terms that are not favorable to
us. If adequate funds are not available, we may have to scale
back our operations or limit our research and development
activities.
We must implement additional and expensive finance and
accounting systems, procedures and controls as we grow our
business and organization and to satisfy new reporting
requirements, which will increase our costs and require
additional management resources.
As a public reporting company, we will be required to comply
with the Sarbanes-Oxley Act of 2002 and the related rules and
regulations of the Securities and Exchange Commission, including
expanded disclosures and accelerated reporting requirements and
more complex accounting rules. Compliance with Section 404
of the Sarbanes-Oxley Act and other requirements will increase
our costs and require additional management resources. We
recently have been upgrading our finance and accounting systems,
procedures and controls and will need to continue to implement
additional finance and accounting systems, procedures and
controls as we grow our business and organization and to satisfy
new reporting requirements. If we are unable to complete the
required Section 404 assessment as to the adequacy of our
internal control over financial reporting, if we
18
fail to maintain or implement adequate controls, or if our
independent registered public accounting firm is unable to
provide us with an unqualified report as to the effectiveness of
our internal control over financial reporting as of the date of
our first Form 10-K for which compliance is required, our
ability to obtain additional financing could be impaired. In
addition, investors could lose confidence in the reliability of
our internal control over financial reporting and in the
accuracy of our periodic reports filed under the Exchange Act. A
lack of investor confidence in the reliability and accuracy of
our public reporting could cause our stock price to decline.
RISKS RELATED TO OUR COMMON STOCK
Our operating results may fluctuate, which could cause our
stock price to decrease.
Fluctuations in our operating results may lead to fluctuations,
including declines, in our share price. Our operating results
and our share price may fluctuate from period to period due to a
variety of factors, including:
|
|
|
|
|
demand by physicians and patients for Onco
type
DX;
|
|
|
|
reimbursement decisions by third-party payors and announcements
of those decisions;
|
|
|
|
clinical trial results and publication of results in
peer-reviewed journals or the presentation at medical
conferences;
|
|
|
|
the inclusion or exclusion of our products in large clinical
trials conducted by others;
|
|
|
|
new or less expensive products and services or new technology
introduced or offered by our competitors or us;
|
|
|
|
the level of our development activity conducted for new
products, and our success in commercializing these developments;
|
|
|
|
the level of our spending on Onco
type
DX
commercialization efforts, licensing and acquisition
initiatives, clinical trials, and internal research and
development;
|
|
|
|
changes in the regulatory environment, including any
announcement from the FDA regarding its decisions in regulating
our activities;
|
|
|
|
the impact of seasonality on our business;
|
|
|
|
changes in recommendations of securities analysts or lack of
analyst coverage;
|
|
|
|
failure to meet analyst expectations regarding our operating
results;
|
|
|
|
additions or departures of key personnel; and
|
|
|
|
general market conditions.
|
Variations in the timing of our future revenues and expenses
could also cause significant fluctuations in our operating
results from period to period and may result in unanticipated
earning shortfalls or losses. In addition, the Nasdaq National
Market in general, and the market for life science companies in
particular, have experienced significant price and volume
fluctuations that have often been unrelated or disproportionate
to the operating performance of those companies.
If an active, liquid trading market for our common stock
does not develop, you may not be able to sell your shares
quickly or at or above the initial offering price.
Prior to this offering, there has not been a public market for
our common stock. An active and liquid trading market for our
common stock may not develop or be sustained following this
offering. You may not be able to sell your shares quickly or at
or above the initial offering price if trading in our stock is
not active. The initial public offering price may not be
indicative of prices that will prevail in the trading market. See
19
Underwriting for more information regarding the
factors that will be considered in determining the initial
public offering price.
Purchasers in this offering will experience immediate and
substantial dilution in the book value of their
investment.
The initial public offering price of our common stock is
substantially higher than the pro forma net tangible book value
per share of our common stock immediately after this offering.
In other words, you are paying a price per share that
substantially exceeds the value of our assets after subtracting
our liabilities. Based on an assumed initial public offering
price of $13.00 per share and the pro forma net tangible book
value of our common stock at June 30, 2005, your shares
will be worth $9.39 less per share than you will pay in the
offering. Further, investors participating in this offering will
contribute approximately 37.4% of the total amount invested by
stockholders since our inception but will only own approximately
20.7% of the total shares outstanding immediately after this
offering. The exercise of outstanding options will result in
further dilution of your investment. In addition, if we raise
funds by issuing additional shares, the newly issued shares will
further dilute your ownership interest.
We may allocate net proceeds from this offering in ways
with which you may not agree.
Our management will have broad discretion in using the proceeds
from this offering and may use the proceeds in ways with which
you may disagree. Because we are not required to allocate the
net proceeds from this offering to any specific investment or
transaction, you cannot determine at this time the value or
propriety of our application of the proceeds. Moreover, you will
not have the opportunity to evaluate the economic, financial or
other information on which we base our decisions on how to use
our proceeds. We may use the proceeds for corporate purposes
that do not immediately enhance our prospects for the future or
increase the value of your investment. As a result, you and
other stockholders may not agree with our decisions.
Future sales of shares by our stockholders could cause the
market price of our common stock to drop significantly, even if
our business is doing well.
After this offering, we will have outstanding
24,335,381 shares of common stock based on the number of
shares outstanding at August 31, 2005. This includes the
5,016,722 shares we are selling in this offering, which may
be resold in the public market immediately, other than any
shares sold to participants in our directed share program, which
are subject to a 180-day lockup. The remaining
19,318,659 shares will become available for resale in the
public market as shown in the chart below.
|
|
|
|
|
Number of Restricted
|
|
|
Shares/% of Total Shares
|
|
|
Outstanding Following
|
|
|
Offering
|
|
Date of Availability for Resale into the Public Market
|
|
|
|
|
3,560,462/14.6%
|
|
|
180 days (subject to extension in specified circumstances)
after the date of this prospectus due to the release of the
lock-up agreement these stockholders have with the underwriters
|
|
15,758,197/64.8%
|
|
|
At some point after 180 days (subject to extension in
specified circumstances) after the date of this prospectus,
subject to vesting requirements and the requirements of Rule 144
(subject, in some cases, to volume limitations), Rule 144(k) or
Rule 701
|
At any time and without public notice, the underwriters may in
their sole discretion release all or some of the securities
subject to the lock-up agreements. As restrictions on resale
end, the market price of our stock could drop significantly if
the holders of those shares sell them or are perceived by the
market as intending to sell them. In addition, six months after
this offering, the holders of 17,579,758 shares of common
stock issued upon the conversion of our preferred stock may
require us to file a registration statement covering those
shares, which may also cause our stock price to decline. These
declines in our stock price could occur even if our business is
otherwise doing well.
20
If our principal stockholders, executive officers and
directors choose to act together, they may be able to control
our management and operations, which may prevent us from taking
actions that may be favorable to you.
Our executive officers, directors and principal stockholders,
and entities affiliated with them, will beneficially own in the
aggregate approximately 46.1% of our common stock following this
offering. To the extent our existing stockholders purchase
additional shares, in this offering or otherwise, this ownership
concentration would increase. This significant concentration of
share ownership may adversely affect the trading price of our
common stock because investors often perceive disadvantages in
owning stock in companies with controlling stockholders. These
stockholders, acting together, will have the ability to exert
substantial influence over all matters requiring approval by our
stockholders, including the election and removal of directors
and any proposed merger, consolidation or sale of all or
substantially all of our assets. In addition, they could dictate
the management of our business and affairs. This concentration
of ownership could have the effect of delaying, deferring or
preventing a change in control of us or impeding a merger or
consolidation, takeover or other business combination that could
be favorable to you.
We do not expect to pay dividends in the foreseeable
future. As a result, you must rely on stock appreciation for any
return on your investment.
We do not anticipate paying cash dividends on our common stock
in the foreseeable future. Any payment of cash dividends will
also depend on our financial condition, results of operations,
capital requirements and other factors and will be at the
discretion of our board of directors. Accordingly, you will have
to rely on capital appreciation, if any, to earn a return on
your investment in our common stock. Furthermore, we may in the
future become subject to contractual restrictions on, or
prohibitions against, the payment of dividends.
Anti-takeover provisions in our charter, bylaws and
Delaware law may make it difficult for you to change our
management and may also make a takeover difficult.
Our corporate documents and Delaware law contain provisions that
limit the ability of stockholders to change our management and
may also enable our management to resist a takeover. These
provisions include limitations on persons authorized to call a
special meeting of stockholders and advance notice procedures
required for stockholders to make nominations of candidates for
election as directors or to bring matters before an annual
meeting of stockholders. These provisions might discourage,
delay or prevent a change of control or in our management. These
provisions could also discourage proxy contests and make it more
difficult for you and other stockholders to elect directors and
cause us to take other corporate actions. In addition, the
existence of these provisions, together with Delaware law, might
hinder or delay an attempted takeover other than through
negotiations with our board of directors.
21
INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements that involve
risks and uncertainties. The forward-looking statements are
contained principally in the sections entitled Prospectus
Summary, Risk Factors, Managements
Discussion and Analysis of Financial Condition and Results of
Operations and Business. These statements
involve known and unknown risks, uncertainties and other factors
that may cause our actual results, performance or achievements
to be materially different from any future results, performances
or achievements expressed or implied by the forward-looking
statements. Forward-looking statements include, but are not
limited to, statements about:
|
|
|
|
|
our expectation that, for the foreseeable future, substantially
all of our revenues will be derived from Onco
type
DX;
|
|
|
|
our expectation that our research and development expense levels
will remain high as we seek to enhance Onco
type
DX and
develop new products;
|
|
|
|
our dependence on collaborative relationships;
|
|
|
|
our compliance with federal, state and foreign regulatory
requirements;
|
|
|
|
the regulation of Onco
type
DX by the FDA;
|
|
|
|
our plans to pursue reimbursement on a case-by-case basis;
|
|
|
|
our ability, and expectations as to the amount of time it will
take, to achieve successful reimbursement from third-party
payors, such as insurance companies and health maintenance
organizations, and government insurance programs, such as
Medicare and Medicaid;
|
|
|
|
increases in patient and physician demand resulting from our
direct sales approach;
|
|
|
|
plans for enhancements of our existing test, Onco
type
DX,
to address different patient populations of breast cancer;
|
|
|
|
plans for future products addressing multiple cancers, including
colon, prostate, renal cell and lung cancers and melanoma;
|
|
|
|
the outcome or success of clinical trials;
|
|
|
|
the ability of genomics to change the diagnosis and treatment of
diseases such as cancer and thereby provide significant economic
benefits to the healthcare system;
|
|
|
|
the capacity of our laboratory to process tests;
|
|
|
|
the ability of our technology to screen increasing numbers of
genes in tissue samples;
|
|
|
|
our intellectual property and our strategies regarding filing
additional patent applications to strengthen our intellectual
property rights;
|
|
|
|
our expected stock-based compensation expense in future periods;
|
|
|
|
our anticipated cash needs and our estimates regarding our
capital requirements and our needs for additional
financing; and
|
|
|
|
anticipated trends and challenges in our business and the
markets in which we operate.
|
In some cases, you can identify forward-looking statements by
terms such as may, might,
will, objective, intend,
should, could, can,
would, expect, believe,
estimate, predict,
potential, plan, or the negative of
these terms, and similar expressions intended to identify
forward-
22
looking statements. These statements reflect our current views
with respect to future events and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking
statements. We discuss many of these risks in this prospectus in
greater detail under the heading Risk Factors. Also,
these forward-looking statements represent our estimates and
assumptions only as of the date of this prospectus. Unless
required by U.S. federal securities laws, we do not intend
to update any of these forward-looking statements to reflect
circumstances or events that occur after the statement is made.
You should read this prospectus and the documents that we
reference in this prospectus and have filed as exhibits to the
registration statement, of which this prospectus is a part,
completely and with the understanding that our actual future
results may be materially different from what we expect. We
qualify all of our forward-looking statements by these
cautionary statements.
This prospectus contains statistical data that we obtained from
reports generated by the American Cancer Society and by DaVinci
Oncology Specialists, a division of The Mattson Jack Group, Inc.
These reports generally indicate that they have obtained their
information from sources believed to be reliable but do not
guarantee the accuracy and completeness of their information.
Although we believe that the reports are reliable, we have not
independently verified their data.
23
USE OF PROCEEDS
We expect that the net proceeds we will receive from the sale of
the shares of common stock offered by us will be approximately
$58.6 million, based on an assumed initial public offering
price of $13.00 per share, after deducting the estimated
underwriting discount and estimated offering expenses payable by
us. If the underwriters exercise their over-allotment option in
full, we expect that our net proceeds will be approximately
$67.7 million. We also expect to receive $5.0 million
from our private sale of common stock to Incyte Corporation.
We currently expect to use our net proceeds from this offering
as follows:
|
|
|
|
|
approximately $25.0 million to build our commercial capabilities
in selling and marketing related to Onco
type
DX;
|
|
|
|
approximately $20.0 million to fund research and development
programs for Onco
type
DX and in a variety of cancers;
|
|
|
|
approximately $8.0 million for capital expenditures to expand
facilities and laboratory operations capacity and for
information systems infrastructure; and
|
|
|
|
the balance for working capital and other general corporate
purposes.
|
As of the date of this prospectus, we cannot predict with
certainty all of the particular uses for the proceeds of this
offering or the amounts that we will actually spend on the uses
set forth above. The amount and timing of actual expenditures
may vary significantly depending upon a number of factors, such
as the progress of our product development, regulatory
requirements, commercialization efforts, the amount of cash used
by operations and progress in reimbursement. Accordingly, our
management will have significant flexibility in applying the net
proceeds of this offering. A portion of the net proceeds may
also be used to acquire or invest in complementary businesses,
technologies, services or products. We have no current plans,
agreements or commitments with respect to any such acquisition
or investment, and we are not currently engaged in any
negotiations with respect to any such transaction.
Pending use of the net proceeds as described above, we intend to
invest the net proceeds of this offering in short-term,
interest-bearing, investment-grade securities.
DIVIDEND POLICY
We have never declared or paid any cash dividends on our capital
stock, and we do not currently intend to pay any cash dividends
on our common stock in the foreseeable future. We expect to
retain future earnings, if any, to fund the development and
growth of our business. Our board of directors will determine
future cash dividends, if any.
On September 8, 2005, our board of directors declared a
conditional dividend of 791,210 shares of our common stock,
which will be distributed upon the closing of this offering on a
pro rata basis to all of our stockholders of record as of the
date of this prospectus only if the initial public offering
price of our common stock is $11.40 or greater. This conditional
dividend will not be distributed if the initial public offering
price of our common stock is lower than $11.40. Our outstanding
stock options will be proportionately adjusted in the event this
conditional stock dividend is distributed. Based on our
outstanding stock options as of August 31, 2005, we would
issue approximately 736,142 shares pursuant to this dividend,
less an aggregate of 85 shares for which cash will be paid
in lieu of fractional interests, and the number of shares
underlying outstanding stock options would be increased by
approximately 55,068 shares. The sum of the total number of
shares issuable pursuant to the conditional dividend and the
additional shares issuable upon exercise of our outstanding
stock options as a result of the proportionate adjustments will
equal 791,210 shares. See Description of Capital
Stock Preferred Stock.
24
CAPITALIZATION
The following table describes our cash, cash equivalents and
capitalization as of June 30, 2005:
|
|
|
|
|
on an actual basis;
|
|
|
|
on a pro forma basis to give effect to the automatic conversion
of all outstanding shares of our convertible preferred stock
into common stock upon the closing of this offering, and to give
effect to the issuance of 791,210 shares of common stock
pursuant to the conditional dividend; and
|
|
|
|
on a pro forma as adjusted basis to give effect to the sale of
5,016,722 shares of common stock in this offering at an
assumed initial public offering price of $13.00 per share,
after deducting the estimated underwriting discount and
estimated offering expenses payable by us, the sale of
384,615 shares of common stock to Incyte Corporation for
cash proceeds of $5.0 million in connection with our
expected exercise of a put right, at a purchase price equal to
the assumed initial public offering price of $13.00 per
share.
|
You should read this table together with Managements
Discussion and Analysis of Financial Condition and Results of
Operations and our consolidated financial statements and
the related notes appearing elsewhere in this prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2005
|
|
|
|
|
|
|
|
|
|
Pro Forma
|
|
|
|
Actual
|
|
|
Pro Forma
|
|
|
As Adjusted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands, except share and per
|
|
|
|
share data)
|
|
|
|
(Unaudited)
|
|
Cash and cash equivalents
|
|
$
|
25,231
|
|
|
$
|
25,231
|
|
|
$
|
88,855
|
|
|
|
|
|
|
|
|
|
|
|
Capital leases, long-term
|
|
|
2,483
|
|
|
|
2,483
|
|
|
|
2,483
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock, $0.0001 par value, issuable in
series; 101,216,958 shares authorized,
48,480,819 shares issued and outstanding, actual; aggregate
liquidation preference of $103,599 at June 30, 2005;
5,000,000 shares authorized, no shares issued or
outstanding, pro forma; 5,000,000 shares authorized, no
shares issued or outstanding, pro forma as adjusted
|
|
|
103,212
|
|
|
|
|
|
|
|
|
|
Stockholders equity (deficit):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, $0.0001 par value; 105,000,000 shares
authorized, 1,932,921 shares issued and outstanding,
actual; 100,000,000 shares authorized,
18,884,404 shares issued and outstanding, pro forma;
100,000,000 shares authorized, 24,285,741 shares
issued and outstanding, pro forma as adjusted
|
|
|
1
|
|
|
|
2
|
|
|
|
2
|
|
|
Additional paid-in capital
|
|
|
5,085
|
|
|
|
108,296
|
|
|
|
171,920
|
|
|
Deferred stock-based compensation
|
|
|
(3,793
|
)
|
|
|
(3,793
|
)
|
|
|
(3,793
|
)
|
|
Accumulated deficit
|
|
|
(80,521
|
)
|
|
|
(80,521
|
)
|
|
|
(80,521
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity (deficit)
|
|
|
(79,228
|
)
|
|
|
23,984
|
|
|
|
87,608
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
26,467
|
|
|
$
|
26,467
|
|
|
$
|
90,091
|
|
|
|
|
|
|
|
|
|
|
|
The actual, pro forma and pro forma as adjusted information set
forth in the table:
|
|
|
|
|
excludes 1,424,393 shares of common stock issuable upon the
exercise of stock options outstanding as of June 30, 2005,
at a weighted average exercise price of $1.86 per share; and
|
|
|
|
excludes 5,000,000 shares of common stock available for
future issuance under our stock option plans following the date
of this offering.
|
25
DILUTION
Our pro forma net tangible book value as of June 30, 2005
was $24.0 million, or $1.27 per share of common stock.
Pro forma net tangible book value per share represents the
amount of our pro forma total tangible assets less total
liabilities, divided by the pro forma number of shares of common
stock outstanding, assuming the conversion of all shares of
convertible preferred stock outstanding as of June 30, 2005
into shares of our common stock and the issuance of
791,210 shares of common stock pursuant to the conditional
dividend. Pro forma net tangible book value dilution per share
represents the difference between the amount per share paid by
purchasers of shares of common stock in this offering and the
pro forma net tangible book value per share of common stock
immediately after completion of this offering on a pro forma as
adjusted basis. After giving effect to the sale of the
5,016,722 shares of common stock by us at an assumed
initial public offering price of $13.00 per share, and
after deducting the estimated underwriting discount and
estimated offering expenses payable by us, and our sale of
384,615 shares of common stock to Incyte Corporation for
cash proceeds of $5.0 million in connection with our
expected exercise of a put right, at a price per share
equal to the assumed initial public offering price, our pro
forma net tangible book value as of June 30, 2005 would
have been $87.6 million, or $3.61 per share of common
stock. This represents an immediate increase in net tangible
book value of $2.34 per share of common stock to existing
common stockholders and an immediate dilution in pro forma net
tangible book value of $9.39 per share to new investors
purchasing shares of common stock in this offering. The
following table illustrates this per share dilution:
|
|
|
|
|
|
|
|
|
|
Assumed initial public offering price per share
|
|
|
|
|
|
$
|
13.00
|
|
|
Pro forma net tangible book value per share at June 30, 2005
|
|
$
|
1.27
|
|
|
|
|
|
|
Increase in pro forma net tangible book value per share
attributable to new investors and the new investment by Incyte.
|
|
|
2.34
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma net tangible book value per share after this offering
|
|
|
|
|
|
|
3.61
|
|
|
|
|
|
|
|
|
Dilution in pro forma net tangible book value per share to new
investors
|
|
|
|
|
|
$
|
9.39
|
|
|
|
|
|
|
|
|
The following table summarizes as of June 30, 2005, on the
pro forma basis described above, the number of shares of common
stock purchased from us, the total consideration paid and the
average price per share paid by existing and new investors
purchasing shares of common stock in this offering, before
deducting the estimated underwriting discount and estimated
offering expenses.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Purchased
|
|
|
Total Consideration
|
|
|
|
|
|
|
|
|
|
|
|
Average Price
|
|
|
|
Number
|
|
|
Percent
|
|
|
Amount
|
|
|
Percent
|
|
|
Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Existing stockholders
|
|
|
18,819,233
|
|
|
|
77.7
|
%
|
|
$
|
104,027,660
|
|
|
|
59.7
|
%
|
|
$
|
5.53
|
|
New investors in this offering
|
|
|
5,016,722
|
|
|
|
20.7
|
|
|
|
65,217,386
|
|
|
|
37.4
|
|
|
|
13.00
|
|
New investment by Incyte
|
|
|
384,615
|
|
|
|
1.6
|
|
|
|
4,999,995
|
|
|
|
2.9
|
|
|
|
13.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
24,220,570
|
|
|
|
100.0
|
%
|
|
$
|
174,245,041
|
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The table above assumes no exercise of any outstanding stock
options. As of June 30, 2005, there were
1,424,393 shares of common stock issuable upon exercise of
outstanding stock options at a weighted average exercise price
of $1.86 per share, and there were 5,000,000 shares of
common stock available for future issuance under our stock
option plans following the date of this offering. To the extent
that any of these options are exercised, there will be further
dilution to new investors.
26
SELECTED CONSOLIDATED FINANCIAL DATA
The following selected consolidated financial data should be
read together with Managements Discussion and
Analysis of Financial Condition and Results of Operations
and our consolidated financial statements and related notes
included elsewhere in this prospectus. The selected consolidated
balance sheet data at December 31, 2003 and 2004 and the
selected consolidated statements of operations data for each
year ended December 31, 2002, 2003 and 2004 have been
derived from our audited consolidated financial statements that
are included elsewhere in this prospectus. The selected
consolidated balance sheet data at December 31, 2000, 2001
and 2002 and the selected consolidated statements of operations
data for the period from August 22, 2000 (inception) to
December 31, 2000 and for the year ended December 31,
2001 have been derived from our audited consolidated financial
statements not included in this prospectus. The selected
consolidated balance sheet data at June 30, 2005 and the
selected consolidated statements of operations data for the six
months ended June 30, 2004 and 2005 are derived from our
unaudited consolidated financial statements included in this
prospectus. The unaudited consolidated financial statements
include, in the opinion of management, all adjustments that
management considers necessary for the fair presentation of the
financial information set forth in those statements. Historical
results are not necessarily indicative of the results to be
expected in the future.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
Six Months Ended
|
|
|
|
August 22, 2000
|
|
|
Year Ended December 31,
|
|
|
June 30,
|
|
|
|
(inception) to
|
|
|
|
|
|
|
|
|
|
Dec. 31, 2000
|
|
|
2001
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands, except share and per share data)
|
|
|
|
|
|
(Unaudited)
|
|
Consolidated Statements of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenues
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
227
|
|
|
$
|
33
|
|
|
$
|
1,585
|
|
|
Contract revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125
|
|
|
|
100
|
|
|
|
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125
|
|
|
|
327
|
|
|
|
33
|
|
|
|
1,685
|
|
Operating expenses(1):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,828
|
|
|
|
931
|
|
|
|
2,874
|
|
|
Research and development
|
|
|
169
|
|
|
|
11,080
|
|
|
|
7,053
|
|
|
|
9,069
|
|
|
|
10,040
|
|
|
|
5,182
|
|
|
|
4,630
|
|
|
Selling and marketing
|
|
|
|
|
|
|
117
|
|
|
|
754
|
|
|
|
2,805
|
|
|
|
9,856
|
|
|
|
4,449
|
|
|
|
7,415
|
|
|
General and administrative
|
|
|
566
|
|
|
|
2,844
|
|
|
|
3,753
|
|
|
|
3,686
|
|
|
|
3,869
|
|
|
|
1,832
|
|
|
|
2,787
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
735
|
|
|
|
14,041
|
|
|
|
11,560
|
|
|
|
15,560
|
|
|
|
25,593
|
|
|
|
12,394
|
|
|
|
17,706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(735
|
)
|
|
|
(14,041
|
)
|
|
|
(11,560
|
)
|
|
|
(15,435
|
)
|
|
|
(25,266
|
)
|
|
|
(12,361
|
)
|
|
|
(16,021
|
)
|
Interest and other income (expense), net
|
|
|
|
|
|
|
1,267
|
|
|
|
492
|
|
|
|
185
|
|
|
|
271
|
|
|
|
98
|
|
|
|
322
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(735
|
)
|
|
$
|
(12,774
|
)
|
|
$
|
(11,068
|
)
|
|
$
|
(15,250
|
)
|
|
$
|
(24,995
|
)
|
|
$
|
(12,263
|
)
|
|
$
|
(15,699
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(10.10
|
)
|
|
$
|
(20.14
|
)
|
|
$
|
(11.95
|
)
|
|
$
|
(12.43
|
)
|
|
$
|
(14.38
|
)
|
|
$
|
(7.26
|
)
|
|
$
|
(8.28
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing basic and diluted net loss per share
|
|
|
72,777
|
|
|
|
634,415
|
|
|
|
925,814
|
|
|
|
1,226,444
|
|
|
|
1,737,652
|
|
|
|
1,687,964
|
|
|
|
1,895,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Includes non-cash charges for stock-based compensation expense
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
Six Months Ended
|
|
|
|
August 22, 2000
|
|
Year Ended December 31,
|
|
|
June 30,
|
|
|
|
(inception) to
|
|
|
|
|
|
|
|
|
Dec. 31, 2000
|
|
2001
|
|
2002
|
|
2003
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
|
|
|
(Unaudited)
|
|
Cost of product revenues
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
5
|
|
|
$
|
1
|
|
|
$
|
21
|
|
Research and development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42
|
|
|
|
6
|
|
|
|
166
|
|
Selling and marketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38
|
|
|
|
1
|
|
|
|
210
|
|
General and administrative
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
106
|
|
|
|
1
|
|
|
|
112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
191
|
|
|
$
|
9
|
|
|
$
|
509
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31,
|
|
|
|
|
|
|
|
|
At June 30,
|
|
|
|
2000
|
|
|
2001
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
|
|
|
(Unaudited)
|
|
Consolidated Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
7,503
|
|
|
$
|
28,678
|
|
|
$
|
25,318
|
|
|
$
|
11,062
|
|
|
$
|
38,275
|
|
|
$
|
25,231
|
|
Working capital
|
|
|
7,173
|
|
|
|
26,724
|
|
|
|
25,165
|
|
|
|
10,046
|
|
|
|
36,771
|
|
|
|
23,306
|
|
Total assets
|
|
|
7,617
|
|
|
|
30,408
|
|
|
|
27,376
|
|
|
|
13,096
|
|
|
|
41,538
|
|
|
|
30,832
|
|
Capital leases, short-term
|
|
|
|
|
|
|
|
|
|
|
163
|
|
|
|
161
|
|
|
|
|
|
|
|
777
|
|
Capital leases, long-term
|
|
|
|
|
|
|
|
|
|
|
150
|
|
|
|
|
|
|
|
|
|
|
|
2,483
|
|
Convertible preferred stock
|
|
|
7,917
|
|
|
|
41,783
|
|
|
|
51,073
|
|
|
|
51,064
|
|
|
|
103,212
|
|
|
|
103,212
|
|
Accumulated deficit
|
|
|
(735
|
)
|
|
|
(13,509
|
)
|
|
|
(24,577
|
)
|
|
|
(39,827
|
)
|
|
|
(64,822
|
)
|
|
|
(80,521
|
)
|
Total stockholders equity (deficit)
|
|
|
(731
|
)
|
|
|
(13,482
|
)
|
|
|
(24,502
|
)
|
|
|
(39,547
|
)
|
|
|
(64,154
|
)
|
|
|
(79,228
|
)
|
28
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION
AND RESULTS OF OPERATIONS
The following discussion of our financial condition and
results of operations should be read together with our
consolidated financial statements and related notes included
elsewhere in this prospectus. This discussion contains
forward-looking statements based upon current expectations that
involve risks, uncertainties and assumptions. Our actual results
may differ materially from those anticipated in these
forward-looking statements as a result of various factors,
including those set forth under Risk Factors,
Information Regarding Forward-looking Statements and
elsewhere in this prospectus.
Business Overview
We are a life science company focused on the development and
commercialization of genomic-based clinical diagnostic tests for
cancer that allow physicians and patients to make individualized
treatment decisions. Our first test, Onco
type
DX, is
used for early stage breast cancer patients to predict the
likelihood of cancer recurrence, the likelihood of patient
survival within 10 years of diagnosis and the likelihood of
chemotherapy benefit. All tumor samples are sent to our
laboratory in Redwood City, California for analysis. Upon
generation and delivery of a Recurrence Score report to the
physician, we generally bill third-party payors for
Onco
type
DX. As of June 30, 2005,
Onco
type
DX has been ordered by over
1,400 physicians throughout the United States. The list
price of our test is $3,460.
We launched Onco
type
DX in January 2004 and
initially made sales to a select number of physicians in a few
markets in the United States through a small direct sales force.
Late in 2004 and continuing into 2005, we have experienced a
significant increase in demand for Onco
type
DX. In
the year ended December 31, 2004 and the six months ended
June 30, 2005, 500 and 3,000 tests, respectively, were
ordered by treating physicians. We believe this increase in
demand resulted from the publication of our validation study in
The New England Journal of Medicine
and the presentation
of an additional study at the San Antonio Breast Cancer
Symposium, both of which occurred in December 2004. However,
this increased demand for our product is not necessarily
indicative of future growth rates, and we cannot assure you that
this level of increased demand can be sustained. Moreover, we
believe that each year we may experience decreased demand for
our tests in the summer months of July and August, which may be
attributed to physicians, surgeons and patients scheduling
vacations during this time. As of June 30, 2005, our
laboratory had the capacity to process up to 2,500 tests per
quarter, and our current expansion plan contemplates that we
will have capacity to process up to 4,000 tests per quarter by
the end of 2005.
We believe the key factors that will drive broader adoption of
Onco
type
DX will be acceptance by healthcare
providers of its clinical benefits, demonstration of the
cost-effectiveness of using our test, expanded reimbursement by
third-party payors, expansion of our sales force and increased
marketing efforts. Reimbursement of Onco
type
DX by
third-party payors is essential to our commercial success. In
general, clinical laboratory testing services, when covered, are
paid under various methodologies, including prospective payment
systems and fee schedules. Reimbursement from payors depends
upon whether a service is covered under the patients
policy and if payment practices for the service have been
established. As a relatively new test, Onco
type
DX
may be considered investigational by payors and not covered
under current reimbursement policies. Until we reach agreement
with an insurer on contract terms or establish a policy for
payment of Onco
type
DX, we expect to recognize
revenue on a cash basis.
Upon commercialization of Onco
type
DX, we began
working with third-party payors to establish reimbursement
coverage policies. As of August 2005, several regional payors,
including Harvard Pilgrim Health Care, Inc. and Highmark Blue
Cross Blue Shield, had issued policies supporting reimbursement
for our test. In addition, Kaiser Foundation Health Plan, Inc.
has entered into a national clinical laboratory services
agreement to reimburse us for Onco
type
DX tests performed
for their patients. Where policies are not in place, we pursue
case-by-case reimbursement. We believe that as much as 20% of
our future revenues may be derived from tests billed to
Medicare. We are working with many payors, including Medicare,
to establish policy-level reimbursement which, if in place, will
allow us to recognize revenues upon submitting an invoice. We do
not expect to recognize the majority of revenues in this manner
until 2007, at the earliest.
29
Since our inception, we have generated significant net losses.
As of June 30, 2005, we had an accumulated deficit of
$80.5 million. We incurred net losses of
$11.1 million, $15.3 million and $25.0 million in
the years ended December 31, 2002, 2003 and 2004,
respectively, and $15.7 million in the six months ended
June 30, 2005. We expect our net losses to continue for at
least the next several years. We anticipate that a substantial
portion of our capital resources and efforts will be focused on
research and development, both to develop additional tests for
breast cancer and to develop products for other cancers, scale
up our commercial organization, and other general corporate
purposes. Our financial results will be limited by a number of
factors, including establishment of coverage policies by
third-party insurers and government payors, our ability in the
short term to collect from payors often requiring a case-by-case
manual appeals process, and our ability to recognize revenues
other than from cash collections on tests billed until such time
as reimbursement policies or contracts are in effect. Until we
receive routine reimbursement and are able to record revenues as
tests are processed and reports delivered, we are likely to
continue reporting net losses.
Financial Operations Overview
We derive our revenues from product sales and contract research
arrangements and operate in one industry segment. Our product
revenues are derived solely from the sale of
Onco
type
DX. Payors are generally billed upon
generation and delivery of a Recurrence Score report to the
physician. Product revenues are recorded on a cash basis unless
a contract or policy is in place with the payor at the time of
billing and collectibility is reasonably assured. All product
revenues recognized to date reflect cash collections. Contract
revenues are derived from studies conducted with
biopharmaceutical and pharmaceutical companies and are recorded
on an accrual basis upon completion of the contractual
obligation.
Cost of product revenues represents the cost of materials,
direct labor, costs associated with processing tissue samples
including histopathology, anatomical pathology, paraffin
extraction, reverse transcription polymerase chain reaction, or
RT-PCR, and quality control analyses, license fees and delivery
charges necessary to render an individualized test result. Costs
associated with performing our test are recorded as tests are
processed. On the other hand, license fees are recorded at the
time product revenues are recognized or in accordance with other
contractual obligations. License fees represent a significant
component of our cost of product revenues and are expected to
remain so for the foreseeable future.
|
|
|
Research and Development Expenses
|
Research and development expenses from our inception in August
2000 through December 31, 2003 were $27.4 million, and
substantially all of these expenses were focused on the research
and development of Onco
type
DX, which we launched in
January 2004. During this time, Onco
type
DX was the only
product under development. Research and development expenses
represent costs incurred both to develop our technology and to
carry out our clinical studies to validate our multi-gene tests.
Most of the costs incurred prior to 2003 were to develop our
technology. During the years ended December 31, 2003 and
2004 and the six months ended June 30, 2005:
|
|
|
|
|
costs incurred for salaries and benefits were $4.2 million,
$4.7 million and $2.7 million;
|
|
|
|
costs paid to third party clinical collaborators, including
contract services, were $890,000, $1.8 million and $34,000;
|
|
|
|
costs allocated to overhead and facilities were
$1.3 million, $990,000 and $679,000;
|
|
|
|
depreciation costs for equipment were $576,000, $413,000 and
$181,000;
|
|
|
|
costs for materials to conduct gene assays in clinical research
and development studies were $918,000, $964,000 and $639,000;
|
|
|
|
license and technology rights were $991,000, $1.0 million
and $328,000; and
|
|
|
|
all other costs were $167,000, $143,000 and $72,000.
|
We charge all research and development expenses to operations as
they are incurred. All potential future product programs outside
of breast cancer are in the clinical research phase, and the
earliest we expect
30
another cancer program to reach the development stage is 2006.
However, the expected time frame that a product related to one
of these other cancers can be brought to market is uncertain
given the technical challenges and clinical variables that exist
between different types of cancers.
We do not record or maintain information regarding costs
incurred in research and development on a program or project
specific basis. Our research and development staff and
associated infrastructure resources are deployed across several
programs. Many of our costs are thus not attributable to
individual programs. We believe that allocating costs on the
basis of time incurred by our employees does not accurately
reflect the actual costs of a project.
As a result of the uncertainties discussed above, we are unable
to determine the duration and completion costs of our research
and development programs or when, if ever, and to what extent we
will receive cash inflows from the commercialization and sale of
a product.
|
|
|
Selling and Marketing Expenses
|
Our selling and marketing expenses consist primarily of
personnel costs and education and promotional expenses
associated with Onco
type
DX. These expenses include
the costs of educating physicians, laboratory personnel and
other healthcare professionals regarding our genomic
technologies, how our Onco
type
DX test was developed
and validated and the value of the quantitative information that
Onco
type
DX provides. Selling and marketing expenses
also include the costs of sponsoring continuing medical
education, medical meeting participation and dissemination of
our scientific and economic publications related to
Onco
type
DX.
|
|
|
General and Administrative Expenses
|
Our general and administrative expenses consist primarily of
personnel related costs, legal costs, including intellectual
property, accounting costs and other professional and
administrative costs.
Critical Accounting Policies and Significant Judgments and
Estimates
This discussion and analysis of our financial condition and
results of operations is based on our consolidated financial
statements, which have been prepared in accordance with
U.S. generally accepted accounting principles. The
preparation of these financial statements requires management to
make estimates and judgments that affect the reported amounts of
assets, liabilities and expenses and the disclosure of
contingent assets and liabilities at the date of the financial
statements, as well as revenues and expenses during the
reporting periods. We evaluate our estimates and judgments on an
ongoing basis. We base our estimates on historical experience
and on various other factors we believe are reasonable under the
circumstances, the results of which form the basis for making
judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Actual results
could therefore differ materially from those estimates under
different assumptions or conditions.
Our significant accounting policies are described in Note 1
to our consolidated financial statements included elsewhere in
this prospectus. We believe the following critical accounting
policies reflect our more significant estimates and assumptions
used in the preparation of our financial statements.
We have generated limited revenues since our inception. Product
revenues for our first product, Onco
type
DX, were
minimal from the commercial launch in January 2004 through
June 30, 2005, and were recognized on a cash basis. To
date, we have recognized all of our product revenues on a cash
basis because we have limited collection experience and a
limited number of contracts. In accordance with our policy,
revenues for tests performed will be recognized on an accrual
basis when the related costs are incurred, provided there is a
contract or coverage policy in place and the following criteria
are met:
|
|
|
|
|
persuasive evidence that an arrangement exists;
|
|
|
|
delivery has occurred or services rendered;
|
|
|
|
the fee is fixed and determinable; and
|
|
|
|
collectibility is reasonably assured.
|
Determination of the last two criteria will be based on
managements judgments regarding the nature of the fee
charged for products or services delivered and the
collectibility of those fees.
31
We generally bill third-party payors for Onco
type
DX
upon generation and delivery of a Recurrence Score report to the
physician. As such, we take assignment of benefits and the risk
of collection with the third-party payor. We usually bill the
patient directly for amounts owed after multiple requests for
payment have been denied or only partially paid by the insurance
carrier. As a relatively new test, Onco
type
DX may
be considered investigational by payors and not covered under
their reimbursement policies. Consequently, we pursue
case-by-case reimbursement where policies are not in place or
payment history has not been established.
Contract revenues are derived from studies conducted with
biopharmaceutical and pharmaceutical companies and are
recognized on a contract specific basis. Under certain
contracts, our input, measured in terms of full-time equivalent
level of effort or running a set of assays through our
laboratory under a contractual protocol, triggers payment
obligations and revenues are recognized as costs are incurred or
assays are processed. Certain contracts have payment obligations
that are triggered as milestones are complete, such as
completion of a successful set of experiments. In these cases,
revenues are recognized when the milestones are achieved.
|
|
|
Deferred Stock-based Compensation Expense
|
Stock-based compensation expense, which is a non-cash charge,
results from stock option grants at exercise prices that, for
financial reporting purposes, are deemed to be below the fair
value of the underlying common stock. We recognize stock-based
compensation expense on a straight-line basis over the vesting
period of the underlying option, which is generally four years.
The amount of stock-based compensation expense expected to be
amortized in future periods may decrease if unvested options for
which deferred stock-based compensation expense has been
recorded are subsequently cancelled or may increase if future
option grants are made with exercise prices below the deemed
fair value of the common stock on the date of measurement.
During the period from January 1, 2004 through
June 30, 2005, we granted options to employees to purchase
a total of 1,066,565 shares of common stock at exercise
prices ranging from $1.38 per share to $3.30 per share. We did
not obtain contemporaneous valuations from an independent
valuation specialist in connection with these grants. Instead,
we relied on our board of directors, the members of which we
believe have extensive experience in the life science industry
and a majority of which is comprised of non-employee directors,
to determine a reasonable estimate of the then-current value of
our common stock. Given the absence of an active market for our
common stock and resulting lack of liquidity in 2004 and the six
months ended June 30, 2005, our board of directors
determined the estimated fair value of our common stock on the
date of grant based on several factors, including the sales
prices and liquidation preferences of our preferred stock,
progress and milestones achieved in our business, our financial
condition, equity market conditions, trading ranges of
comparable public companies and the likelihood of achieving a
liquidity event such as an initial public offering or a sale of
the company given prevailing market conditions.
In connection with our proposed initial public offering, we have
reassessed the fair value of our common stock. In determining
the reassessed fair value per share of the common stock as of
each grant date, the factors identified in the preceding
paragraph were taken into account. We also considered other
material factors and business developments, including the
following:
|
|
|
|
|
we commercially launched Onco
type
DX in January 2004;
|
|
|
|
we conducted studies in 2004 with the NSABP to test additional
attributes of Onco
type
DX;
|
|
|
|
in the summer of 2004 and later in September 2004, the results
of these studies demonstrated that Onco
type
DX predicts
the likelihood of breast cancer recurrence and chemotherapy
benefit;
|
|
|
|
in October 2004,
The New England Journal of Medicine
accepted our validation study for publication and published
an online version of the results in December 2004;
|
|
|
|
the results of several of our studies were presented at the
annual San Antonio Breast Cancer Conference in December 2004;
|
|
|
|
in December 2004, the FDA, through the Office of In Vitro
Diagnostic Devices, initiated a dialogue with us regarding the
regulatory status of Onco
type
DX;
|
32
|
|
|
|
|
in December 2004, the local Medicare contractor in Northern
California indicated that it would not provide coverage for
Onco
type
DX;
|
|
|
|
in early 2005, the Medical Advisory Panel of the Blue Cross and
Blue Shield Association concluded that Onco
type
DX did
not meet the panels technology criteria for clinical
effectiveness and appropriateness;
|
|
|
|
beginning in early 2005, we began entering into contracts or
establishing policies with third-party payors to reimburse us
for our tests;
|
|
|
|
in the first quarter of 2005, our board of directors authorized
us to initiate the process of preparing for an initial public
offering; and
|
|
|
|
the market for new public offerings made by life science
companies in 2005 and the six months ended June 30, 2005
was highly volatile.
|
In reassessing the value of our common stock, we used a
straight-line approach because we determined that no single
event supported incremental movement in underlying value.
Further, we believe this approach is consistent with valuation
methodologies applied by other similar life science companies
pursuing an initial public offering. Based upon the reassessment
process, we determined that the reassessed fair value of the
options granted from January 1, 2004 through June 30,
2005 ranged from $1.95 to $11.25 per share. Accordingly,
deferred stock-based compensation of $3.6 million was
recorded during the year ended December 31, 2004 and
$846,000 was recorded during the six months ended June 30,
2005 in accordance with Accounting Principles Board, or APB,
Opinion No. 25. The deferred stock-based compensation will
be amortized on a straight-line basis over the vesting period of
the related awards, which is generally four years. For the year
ended December 31, 2004, we recorded employee stock-based
compensation expense of $191,000, $5,000 of which was allocated
to cost of product revenues and $186,000 of which was allocated
to other operating expenses. We expect deferred stock-based
compensation expense under APB Opinion No. 25 to be
$372,000, $1.1 million, $1.1 million and
$1.0 million for the last four months of 2005 and for the
years ending December 31, 2006, 2007 and 2008 (and
thereafter), respectively, before consideration of the impact of
the recent changes in accounting pronouncements for stock
options.
The information regarding net loss as required by Statement of
Financial Accounting Standards, or SFAS, No. 123, presented
in Note 1 to our consolidated financial statements, has
been determined as if we had accounted for our employee stock
options under the fair value method. The resulting effect on net
loss pursuant to SFAS No. 123 is not likely to be
representative of the effects on net loss pursuant to
SFAS No. 123 in future years, since future years are
likely to include additional grants and the impact of future
years vesting.
|
|
|
Clinical Collaborator Costs
|
We enter into collaboration and clinical trial agreements with
clinical collaborators and record these costs as research and
development expenses. We record accruals for estimated study
costs comprised of work performed by our collaborators under
contract terms. All clinical collaborators enter into agreements
with us which specify work content and payment terms.
In addition to costs for research and development, under one of
our collaboration agreements, we make annual payments resulting
from the commercial launch of Onco
type
DX. These
payments are recorded in cost of product revenues as a license
payment. Expense is recorded ratably over the year in which the
relevant payment is made. However, either party may terminate
the agreement upon 30 days prior written notice. If
this collaborative arrangement were not cancelable, a liability
for the entire stream of remaining payments of $2.5 million
would be recorded, payments would be made annually and expense
would be recognized ratably through 2011.
Results of Operations
|
|
|
Six Months Ended June 30, 2005 and 2004
|
Revenues.
Revenues were $1.7 million for the six
months ended June 30, 2005, as compared to $33,000 for the
comparable period in 2004. All revenues in 2004 were product
revenues from our first product, Onco
type
DX, which was
launched in January 2004. During 2005, product revenues were $1.6
33
million and contract revenues were $100,000. First cash
collections for Onco
type
DX were received during the
second quarter of 2004. These revenues were recognized upon cash
receipt.
Cost of Product Revenues.
For the six months ended
June 30, 2005, cost of product revenues was
$2.9 million, consisting of tissue sample processing costs
of $2.6 million for tests performed during the period and
license fees of $292,000. For the six months ended June 30,
2004, cost of product revenues was $931,000, consisting of
tissue sample processing costs of $571,000 and license fees of
$360,000. All costs for tissue sample processing were recorded
in the period in which the test was processed, regardless of
whether revenue was recognized with respect to that test.
Recorded costs for Onco
type
DX include direct material
costs, direct labor costs, equipment costs and other
infrastructure costs. License fees were recorded in cost of
product revenues for contractual obligations and royalties due
on product revenues. The decrease in license fees resulted from
non-recurring payments owing due to the commercialization of our
test in January 2004. Costs of product revenues will increase as
an absolute number as the volume of tests processed increases.
Research and Development Expenses.
Research and
development expenses were $4.6 million for the six months
ended June 30, 2005, a decrease from $5.2 million for
the comparable period of 2004. This decrease is a result of
spending $1.1 million less on clinical programs in 2005 as
compared to 2004 and a $192,000 reduction in license agreement
costs. These decreases were partially offset by higher personnel
costs in research and development of $521,000 and increases in
laboratory supplies of $163,000. We expect research and
development expenses to increase as we work to develop
additional tests for breast cancer and for other cancers.
Selling and Marketing Expenses.
Selling and marketing
expenses increased to $7.4 million for the six months ended
June 30, 2005, from $4.4 million for the comparable
period in 2004. The increase was due in part to personnel costs
of $1.8 million and travel and entertainment costs of
$532,000 associated with the growth of the commercial field
sales team compared to limited spending in this area in the
first half of 2004 when Onco
type
DX was launched.
Additionally, promotional spending for Onco
type
DX was
$505,000 higher for the six months ended June 30, 2005 than
for the comparable period in 2004. We expect selling and
marketing expenses to increase as a result of continued growth
in our sales infrastructure to support growth in our product
revenues and billings and as we incur a full year of costs for
the field sales personnel hired in late 2004 and as we hire
additional sales personnel.
General and Administrative Expenses.
General and
administrative expenses totaled $2.8 million for the six
months ended June 30, 2005, as compared to
$1.8 million for the comparable period in 2004. This
increase was due in part to increases in personnel costs of
$596,000, legal costs of $157,000 and billing and collections
costs of $160,000. We expect general and administrative expenses
to increase after this offering as a result of the need to hire
additional administrative personnel and due to higher legal,
accounting and related expenses associated with being a public
company.
Interest Income and Other Income/ Expense.
Interest
income was $393,000 for the six months ended June 30, 2005,
compared with $121,000 in the comparable period in 2004. This
increase was due to higher average cash balances from preferred
stock financings and higher interest rates during the six months
ended June 30, 2005. Other income during the six months
ended June 30, 2005 was $1,000 as compared to $20,000 of
expense in the comparable period of 2004.
Interest Expense.
Interest expense was $72,000 in the six
months ended June 30, 2005, compared with $3,000 in the
comparable period in 2004. The increase resulted from the
initiation of an equipment financing line established in March
2005 under which draws have been made and interest expense has
been incurred. No such arrangement existed in the prior year
period. We expect interest expense to increase as we make
interest payments on borrowings under our equipment loan and
make further draws throughout the remainder of 2005.
|
|
|
Years Ended December 31, 2004 and 2003
|
Revenues.
Revenues were $327,000 for the year ended
December 31, 2004, as compared to $125,000 for the
comparable period in 2003. Product revenues for the year ended
December 31, 2004 were $227,000, as
34
compared to zero in the comparable period in 2003. Product
revenues were all recognized upon cash receipt. Contract
revenues were $100,000 for the year ended December 31,
2004, down from $125,000 in the comparable period in 2003.
Contract revenues in both periods were for studies assessing our
gene expression technology.
Cost of Product Revenues.
For the year ended
December 31, 2004, cost of product revenues was
$1.8 million, consisting of tissue sample processing costs
of $1.3 million related to the launch of
Onco
type
DX and license fees of $477,000. During the
year ended December 31, 2004, we recorded costs for
Onco
type
DX that included direct material costs,
direct labor costs, equipment costs and other infrastructure
costs. All costs recorded for tissue sample processing in that
year represent the cost of all the tests processed regardless of
whether revenue was recognized with respect to that test.
License fees were recorded in cost of product revenues for
contractual obligations and royalties due on product revenues.
No cost of product revenues were recorded in the year ended
December 31, 2003 because we had not commercialized
Onco
type
DX.
Research and Development Expenses.
Research and
development expenses increased to $10.0 million for the
year ended December 31, 2004, from $9.1 million for
the comparable period in 2003. The increase in research and
development expenses is primarily due to $944,000 in increased
costs for clinical development programs studying distant
survival and chemotherapy benefits in early stage breast cancer
patients and increased personnel costs of $476,000, partially
offset by a decrease of $518,000 in facilities, depreciation and
other general expenses.
Selling and Marketing Expenses.
Selling and
marketing expenses increased to $9.9 million for the year
ended December 31, 2004, from $2.8 million for the
comparable period in 2003. The $7.1 million increase
primarily reflects an increase of $2.6 million for higher
promotional, education and tradeshow expenses, an increase of
$2.8 million in personnel related costs, mostly to
establish a domestic field sales organization, and $831,000 in
higher travel expenses associated with field sales personnel, as
well as costs of $405,000 for patient advocacy programs. For the
year ended December 31, 2003, selling and marketing
expenses were primarily for personnel related costs and market
research.
General and Administrative Expenses.
General and
administrative expenses of $3.9 million for the year ended
December 31, 2004 were slightly higher than the
$3.7 million for the comparable period in 2003. The
increase in general and administrative expenses reflects an
increase of $352,000 in recruiting and relocation costs, an
increase of $250,000 in legal costs and miscellaneous increases
in personnel and consulting related costs. These higher costs
are offset in part by a $493,000 decrease in costs related to
information technology support.
Interest Income and Other Income/Expense.
Interest
income was $295,000 for the year ended December 31, 2004,
compared with $199,000 in the comparable period in 2003. This
$96,000 increase was due to higher average cash balances from
preferred stock financings and higher interest rates during the
year ended December 31, 2004. Other expense was $20,000 for
the year ended December 31, 2004, and was zero for the
comparable period in 2003.
Interest Expense.
Interest expense is comprised of
the interest on deferral of contractual payments under a
collaboration agreement. Interest expense decreased to $4,000
for the year ended December 31, 2004, from $14,000 in the
comparable period in 2003 due to completing payments under the
payment schedule. The final payment under this agreement was
made in October 2004.
|
|
|
Years Ended December 31, 2003 and 2002
|
Revenues.
Contract revenues of $125,000 were
recorded for the year ended December 31, 2003, related to
two studies assessing our gene expression technology, both of
which were completed in 2003. There were no revenues for the
year ended December 31, 2002.
Research and Development Expenses.
Research and
development expenses were $9.1 million for the year ended
December 31, 2003, up from $7.1 million for the
comparable period in 2002. The increase of $2.0 million was
primarily due to $850,000 of higher personnel related costs, an
increase in the general
35
overhead allocation to our research and development department
of $755,000 and $699,000 in higher costs associated with our
clinical development programs. These increases in 2003 were
partially offset by a reduction of $496,000 in payments to
clinical collaborators.
Selling and Marketing Expenses.
Selling and
marketing expenses were $2.8 million for the year ended
December 31, 2003, up from $754,000 for the comparable
period in 2002. The increase of $2.0 million reflects
primarily increased costs of $1.0 million for market
research, promotion and tradeshow costs in preparation for the
January 2004 launch of Onco
type
DX and other patient
advocacy programs and increases of $742,000 in personnel related
costs as we began to establish our domestic field sales
organization. Selling and marketing expenses for the year ended
December 31, 2002, were primarily related to personnel,
consulting and market research services.
General and Administrative Expenses.
General and
administrative expenses decreased to $3.7 million for the
year ended December 31, 2003, from $3.8 million for
the comparable period in 2002.
Interest Income.
Interest income decreased to
$199,000 for the year ended December 31, 2003, from
$502,000 for the comparable period in 2002. This decrease was
due to significantly lower average cash and investment balances
as well as lower interest rates in calendar year 2003 as
compared to calendar year 2002.
Interest Expense.
Interest expense was $14,000 for
the year ended December 31, 2003, as compared to $13,000
for the year ended December 31, 2002. All interest expense
amounts related to deferred contractual payments under a
collaboration agreement.
Liquidity and Capital Resources
Since our inception in August 2000, we have incurred significant
losses and, as of June 30, 2005, we had an accumulated
deficit of approximately $80.5 million. We have not yet
achieved profitability and anticipate that we will continue to
incur net losses for the foreseeable future. We expect that our
research and development, selling and marketing and general and
administrative expenses will continue to grow and, as a result,
we will need to generate significant product revenues to achieve
profitability. We may never achieve profitability.
Since our inception, substantially all of our operations have
been financed through the sale of our preferred stock. Through
June 30, 2005, we had received net proceeds of
$103.2 million from the sale of preferred stock and
$425,000 from the issuance of common stock to employees,
consultants and directors in connection with the exercise of
stock options. We also financed our operations, purchases of
equipment and leasehold improvements through loans. As of
December 31, 2004, we had cash and cash equivalents of
$38.3 million and no debt, and, at June 30, 2005, we
had cash and cash equivalents of $25.2 million and debt
under our equipment loan of $3.3 million. As a result of
the issuance of our series E preferred stock, it will be
necessary to record a charge relating to the beneficial
conversion feature, or BCF, of our series E preferred stock
in the event the initial public offering price of our common
stock is less than $11.40 per share. We currently estimate the
BCF charge, if recorded, would be approximately $803,000. If the
charge is recorded, it would increase the net loss attributable
to common stockholders and the net loss per share attributable
to common stockholders, but will have no impact on cash and cash
equivalents, total stockholders equity (deficit) or
net loss in the period in which the initial public offering is
completed.
As of June 30, 2005, we had $25.2 million in cash and
cash equivalents, compared to $38.3 million at
December 31, 2004. This decrease was due primarily to cash
used in operating activities of $14.8 million, initial
public offering costs of $1.1 million and purchases of property
and equipment of $1.6 million, offset partially by proceeds
from our equipment loan of $3.3 million and the issuance of
common stock of $58,000.
Net cash used in operating activities was $14.8 million for
the six months ended June 30, 2005, compared to
$11.4 million for the six months ended June 30, 2004.
The increase in cash used of $3.4 million
36
was primarily due to an increase in selling and marketing
expenses of $3.0 million and higher lab processing costs of
$1.9 million, offset by cash collected from customers of
$1.6 million.
Net cash used in operating activities was $23.1 million,
$13.5 million and $12.3 million for the years ended
December 31, 2004, 2003 and 2002, respectively. Net cash
used in operating activities for these periods consisted
primarily of our net loss, partially offset by depreciation of
property and equipment.
Net cash used in investing activities was $1.6 million for
the six months ended June 30, 2005, compared to $797,000
for the six months ended June 30, 2004. This cash was used
to acquire property and equipment and for leasehold improvements.
Net cash used in investing activities was $1.8 million,
$739,000 and $631,000 for the years ended December 31,
2004, 2003 and 2002, respectively. Our investing activities for
these periods consisted primarily of purchases of property and
equipment. We expect amounts used in investing activities to
increase in 2005 and beyond as we expand research and
development activities and capacity in our commercial laboratory.
Net cash provided by financing activities during the six months
ended June 30, 2005 was $3.3 million, compared to
$29.9 million for the six months ended June 30, 2004.
Substantially all amounts in the 2004 period represented
proceeds from our sale of series E preferred stock. Amounts
in the six months ended June 30, 2005 consisted of proceeds
from our equipment loan of $3.3 million and the issuance of
$58,000 of common stock.
Net cash provided by financing activities was
$52.1 million, $27,000 and $9.6 million for the years
ended December 31, 2004, 2003 and 2002, respectively.
Financing activities consisted primarily of the sale of our
preferred stock for the years ended December 31, 2002 and
2004 and the sale of our common stock in the year ended
December 31, 2003.
Contractual
Obligations
As of December 31, 2004, we had the following contractual
commitments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period
|
|
|
|
|
|
|
|
More
|
|
|
|
|
Less than
|
|
|
|
|
than 5
|
Contractual Obligations
|
|
Total
|
|
|
1 Year
|
|
|
1-3 Years
|
|
|
3-5 Years
|
|
Years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
Operating lease obligations
|
|
$
|
944
|
|
|
$
|
813
|
|
|
$
|
131
|
|
|
$
|
|
|
|
$
|
|
|
In addition to the above, we are required to make a series of
annual payments under one of our collaboration agreements
beginning on the date that we commercially launched Onco
type
DX. The initial payment of $150,000 was made in January
2004. For a period of seven years on each anniversary of this
first payment, we are required to make additional payments in
increasing amounts. A payment of $150,000 was made in 2005. We
are required to make additional payments of $300,000 in each of
2006 and 2007, and $475,000 in each of 2008 through 2011.
However, either party may terminate the agreement upon 30
days prior written notice.
In March 2005, we entered into an arrangement to finance the
acquisition of laboratory equipment, computer hardware and
software, leasehold improvements and office equipment. In
connection with this arrangement, we granted the lender a
security interest in the assets purchased with the borrowed
amounts. We cannot prepay any amounts owed until 2006, at which
point we can prepay all, but not part, of the amounts owing
under the arrangement so long as we also pay a 6% premium on the
remaining payments. This premium is reduced to 5% in 2007 and 4%
in 2008. As of August 31, 2005, borrowings under this
arrangement were $3.7 million at an annual interest rate of
10.23%, 10.30%, 10.49%, 10.56% or 10.65%, depending on the
applicable note. As of August 31, 2005, we are required to
make payments under this arrangement of $417,000 in 2005,
$1.3 million in 2006, $1.3 million in 2007,
$1.1 million in 2008 and $275,000 in 2009. We expect to
request to borrow additional amounts under this arrangement.
We currently sublease approximately 25,000 square feet of
laboratory and office space under a sublease that expires in
February 2006. In September 2005, we entered into a lease
directly with the facility owner that
37
has a term of six years. When our existing sublease expires in
February 2006, the new lease will apply to the existing 25,000
square feet of laboratory and office space we currently occupy.
Under the new lease, we also lease approximately 23,000 square
feet of additional space which we expect to first occupy in
March 2006. If we first occupy space under this new lease in
March 2006, we will be required to make aggregate rent payments
of $460,000 in 2006, $730,000 in 2007, $753,000 in 2008,
$779,000 in 2009, $799,000 in 2010, $827,000 in 2011 and
$139,000 in 2012.
Operating
Capital and Capital Expenditure Requirements
We expect to continue to incur substantial operating losses in
the future and to make capital expenditures to keep pace with
the expansion of our research and development programs and to
scale up our commercial operations, which we expect to fund in
part with the proceeds of this offering. It may take several
years to move any one of a number of product candidates in
clinical research through the development phase and validation
phase to commercialization. We expect that the remainder of the
net proceeds and our existing cash and cash equivalents will be
used to fund working capital and for capital expenditures and
other general corporate purposes, such as licensing technology
rights, partnering arrangements for the processing of tests
outside the United States or reduction of debt obligations. A
portion of the net proceeds may also be used to acquire or
invest in complementary businesses, technologies, services or
products. We have no current plans, agreements or commitments
with respect to any such acquisition or investment, and we are
not currently engaged in any negotiations with respect to any
such transaction.
The amount and timing of actual expenditures may vary
significantly depending upon a number of factors, such as the
progress of our product development, regulatory requirements,
commercialization efforts, the amount of cash used by operations
and progress in reimbursement. We expect that we will receive
limited payments for Onco
type
DX test billings in the
foreseeable future. As reimbursement contracts with third-party
payors are put into place, we expect an increase in the number
and level of payments received for Onco
type
DX test
billings.
We currently anticipate that our cash and cash equivalents,
together with proceeds from this offering, collections for
Onco
type
DX and amounts available under our equipment
credit facility, will be sufficient to fund our operations for
at least the next 12 months. We cannot be certain that any
of our reimbursement contract programs or development of future
products will be successful or that we will be able to raise
sufficient additional funds to see these programs through to a
successful result.
Our future funding requirements will depend on many factors,
including the following:
|
|
|
|
|
the rate of progress in establishing reimbursement arrangements
with third-party payors;
|
|
|
|
the cost of expanding our commercial and laboratory operations,
including our selling and marketing efforts;
|
|
|
|
the rate of progress and cost of research and development
activities associated with expansion of Onco
type
DX
products for breast cancer;
|
|
|
|
the rate of progress and cost of research and development
activities associated with products in the research phase
focused on cancer, other than breast cancer;
|
|
|
|
the cost of acquiring or achieving access to tissue samples and
technologies;
|
|
|
|
the costs of filing, prosecuting, defending and enforcing any
patent claims and other intellectual property rights;
|
|
|
|
the effect of competing technological and market developments;
|
|
|
|
the cost and delays in product development as a result of any
changes in regulatory oversight applicable to our
products; and
|
|
|
|
the economic and other terms and timing of any collaborations,
licensing or other arrangements into which we may enter.
|
38
Until we can generate a sufficient amount of product revenues to
finance our cash requirements, which we may never do, we expect
to finance future cash needs primarily through public or private
equity offerings, debt financings, borrowings or strategic
collaborations. The issuance of equity securities may result in
dilution to stockholders. We do not know whether additional
funding will be available on acceptable terms, or at all. If we
are not able to secure additional funding when needed, we may
have to delay, reduce the scope of or eliminate one or more
research and development programs or selling and marketing
initiatives. In addition, we may have to work with a partner on
one or more of our product development programs or market
development programs, which would lower the economic value of
those programs to our company.
Income Taxes
Since inception, we have incurred operating losses and,
accordingly, have not recorded a provision for income taxes for
any of the periods presented. As of December 31, 2004, we
had net operating loss carryforwards for federal and state
income tax purposes of $60.2 million and
$57.8 million, respectively. We also had federal and state
research and development tax credit carryforwards of $855,000
and $569,000, respectively. If not utilized, the federal net
operating loss and tax credit carryforwards will expire
beginning in 2021. Utilization of net operating loss and credit
carryforwards may be subject to a substantial annual limitation
due to restrictions contained in the Internal Revenue Code that
are applicable if we experience an ownership change
that may occur, for example, as a result of this offering being
aggregated with certain other sales of our stock before or after
this offering. If not utilized, the state net operating loss
carryforward will expire beginning in 2013. The annual
limitation may result in the expiration of our net operating
loss and tax credit carryforwards before they can be used.
Recent Accounting Pronouncements
In December 2004, the FASB issued SFAS 123(R),
Share-Based Payment
, which is a revision of
SFAS 123,
Accounting for Stock-Based Compensation.
SFAS 123(R) is effective for public companies for the
first interim or annual period beginning after June 15,
2005, supersedes APB Opinion No. 25,
Accounting for
Stock Issued to Employees
, and amends FAS 95,
Statement of Cash Flows.
Generally, the approach in
SFAS 123(R) is similar to the approach described in
FAS 123. However, SFAS 123(R) requires all share-based
payments to employees, including grants of employee stock
options, to be recognized in the income statement based on their
fair values. Pro forma disclosure is no longer an alternative.
The new standard will be effective for us beginning
January 1, 2006. Under SFAS 123(R), we must determine
the appropriate fair value model to be used for valuing
share-based payments, the amortization method for compensation
cost and the transition method to be used at the date of
adoption. The transition methods include prospective and
retroactive adoption options. Under the retroactive adoption
option, prior periods may be restated either as of the beginning
of the year of adoption or for all periods presented. The
prospective method requires that compensation expense be
recorded for all unvested stock options at the beginning of the
first quarter of adoption of SFAS 123(R), while the
retroactive method would record compensation expense for all
unvested stock options beginning with the first period restated.
Management is evaluating the requirements of SFAS 123(R)
and expects that its adoption may have a material impact on our
consolidated results of operations and earnings per share.
Management has not yet determined the method of adoption or the
effect of adopting SFAS 123(R), and has not determined
whether the adoption will result in amounts that are similar to
the current pro forma disclosures under SFAS 123.
Qualitative and Quantitative Disclosures About Market Risk
The primary objective of our investment activities is to
preserve our capital for the purpose of funding operations while
at the same time maximizing the income we receive from our
investments without significantly increasing risk. To achieve
these objectives, our investment policy allows us to maintain a
portfolio of cash equivalents and short-term investments through
a variety of securities, including commercial paper, money
market funds and corporate debt securities. Our cash and cash
equivalents through December 31, 2004, included liquid
money market accounts.
39
BUSINESS
Company Overview
We are a life science company focused on the development and
commercialization of genomic-based clinical diagnostic tests for
cancer that allow physicians and patients to make individualized
treatment decisions. In January 2004, we launched our first test
under the brand name Onco
type
DX for early stage breast
cancer patients. We believe that Onco
type
DX is the first
genomic test with clinical evidence supporting its ability to
predict the likelihood of cancer recurrence, the likelihood of
patient survival within 10 years of diagnosis and the
likelihood of chemotherapy benefit. Our initial test is focused
on patients with early stage, node negative, or N-, estrogen
receptor positive, or ER+, breast cancer who will be treated
with tamoxifen, a frequently used hormonal therapy.
Approximately half of the 230,000 patients expected to be
diagnosed with breast cancer in the United States in 2005 are
predicted to be early stage cancer patients that are N- and ER+.
Many of the diagnostic factors currently used in connection with
early stage breast cancer are subjective, have limited
capability to predict future cancer recurrence and are not
useful in predicting response to chemotherapy. We believe that
the use of Onco
type
DX can provide a deeper understanding
of each patients breast cancer and therefore should result
in better informed and more appropriate treatment decisions.
We developed Onco
type
DX using a multi-step approach,
conducting clinical studies on tumor specimens from more than
2,600 breast cancer patients. Our technology provides
quantitative gene expression information for each patients
tumor, which we refer to as an oncotype. When an oncotype is
correlated with known clinical outcomes, it can be useful in
predicting the likelihood of an individual patients tumor
behavior. Onco
type
DX for breast cancer utilizes a
21-gene panel whose composite gene expression profile can be
represented by a single quantitative score, which we call a
Recurrence Score. The higher the Recurrence Score, the more
aggressive the tumor and the more likely it is to recur. The
lower the Recurrence Score, the less aggressive the tumor and
the less likely it is to recur. Onco
type
DX has been
clinically validated for N-, ER+, tamoxifen-treated breast
cancer patients by two, large independent studies. Moreover, we
have demonstrated that the Recurrence Score correlates with
chemotherapy benefit, and we are undertaking further studies to
support this finding. Onco
type
DX is commercially
available at a list price of $3,460 through our laboratory
located in Redwood City, California, which is accredited under
the Clinical Laboratory Improvement Amendments of 1988, or CLIA,
and by the College of American Pathologists, or CAP. In 2004,
over 500 tests were ordered by treating physicians. In December
2004, our validation study was published in
The New England
Journal of Medicine
and the results of additional clinical
trials were presented at the San Antonio Breast Cancer
Conference. In the six months ended June 30, 2005, over
3,000 tests were ordered by treating physicians. As of
June 30, 2005, Onco
type
DX has been ordered by over
1,400 physicians throughout the United States.
Scientific Background
Limits
of Existing Approaches for Determining Cancer Treatments
Cancer is a group of complex molecular diseases characterized by
the uncontrolled growth and spread of abnormal cells resulting
from genetic mutations or damage that can severely disrupt
normal body functions. In 2005, approximately 1.4 million
people in the United States are expected to be diagnosed with
cancer. Common types of cancer include breast, prostate, lung
and colon. Cancers are difficult to treat because each type
responds differently to treatments depending upon the individual
and the type and location of the cancer.
To treat cancer effectively, physicians diagnose and gauge the
stage of a patients disease to determine the best course
of therapy. The most common practice used to diagnose cancer is
through pathologic evaluation of tumors under a microscope. For
solid tumors, tumor tissue is typically removed through surgery
or needle biopsy, fixed in a chemical preservative and embedded
in paraffin wax. A pathologist places thin sections of this
fixed paraffin embedded, or FPE, tissue onto glass slides so it
can be studied under a microscope. In many cases, pathologists
also use molecular staining techniques, including
protein-specific staining, to improve the quality of their
diagnosis. After visually examining the sample, the pathologist
judges
40
whether the biopsy contains normal or cancerous cells. The
pathologist may also grade the tumor based on how aggressive the
cancer cells appear under the microscope.
Once a pathologist diagnoses cancer, the patients
physician determines the stage of the cancer based on further
analysis of the patients condition using a variety of
clinical measures, including the pathology grade, size of the
tumor, how deeply the tumor has invaded tissues at the site of
origin and the extent of any invasion into surrounding organs,
lymph nodes or distant sites. Patient history, physical signs,
symptoms and information obtained from existing tests are also
evaluated and considered.
Physicians currently rely primarily on tumor pathology grade and
stage when predicting whether a cancer will recur, which is the
key determinant in treatment decisions. Because tumor pathology
and staging are heavily dependent on visual assessment and human
interpretation, physicians and patients make treatment decisions
often using subjective and qualitative information that may not
reflect the molecular nature of the patients cancer. As a
result, many patients are misclassified as high risk when they
are truly low risk for recurrence or low risk when they are high
risk for recurrence, resulting in over-treatment for some and
under-treatment for others.
For many cancer patients, chemotherapy is commonly used as a
treatment. Chemotherapy involves the use of highly toxic drugs
to kill cancer cells. It is often given after surgery to kill
remaining cancer cells that could not be physically removed to
reduce the risk of disease recurrence. Chemotherapy can take
months to complete and can dramatically impact a patients
quality of life. Patients usually experience a wide range of
acute toxicities, including infection, pain in the mouth and
throat, weight loss, fatigue, hair loss, rashes and injection
site reactions. In addition, long-term effects of chemotherapy
can include cognitive impairment, cardiac tissue damage,
infertility, disease of the central nervous system, chronic
fatigue, secondary malignancies and personality changes. Overall
benefits of chemotherapy vary significantly across cancer
populations, and the benefit of treatment may not always justify
the cost of the therapy or the physical and mental burden
patients endure.
Use
of Genomics to Understand Cancer
Genomics is the study of complex sets of genes, their expression
and their function in a particular organism. A gene is a set of
instructions or information that is embedded in the DNA of a
cell. For a gene to be turned on or expressed by a
cell, the cell must first transcribe a copy of its DNA sequence
into messenger RNA, which is then translated by the cell into
protein. Proteins are large molecules that control most
biological processes and make up molecular pathways, which cells
use to carry out their specific functions.
Genomics can also be used to understand diseases at the
molecular level. Diseases can occur when mutated or defective
genes inappropriately activate or block molecular pathways that
are important for normal biological function. Disease can result
from inheriting mutated genes or from developing mutations in
otherwise normal cells. Such mutations can be the cause of
cancer. The ability to detect a mutation or its functional
results and to understand the process by which the mutation
contributes to disease is crucial to understanding the molecular
mechanisms of a disease.
A common form of genomic analysis is the measurement of gene
expression, or the presence and amount of one or more RNA
sequences in a particular cell or tissue. Mutations may change
the gene expression pattern of a cell as the cell responds to an
altered genetic code. Quantifying the differences in gene
expression has become a common way to study the behavior of an
altered cell. This method allows for the measurement of the
expression of single or multiple genes. These expression levels
can be correlated with disease and clinical outcomes.
Advances in genomic technology have accelerated the rate and
lowered the cost of gene expression analysis, thus providing
unprecedented opportunity for clinical utility. We believe gene
expression technology has the potential to improve the quality
of diagnosis and treatment of disease by arming patients and
physicians with an understanding of disease at a molecular level
that is specific to each patient.
41
Cancer results from alterations in cells caused by the molecular
changes of mutated genes. The behavior of cancer is dependent on
many different genes and how they interact. Cancer is
complicated and it may not be possible to identify a single gene
that adequately signals a more aggressive or less aggressive
type of cancer. The ability to analyze multiple genes expressed
by the tumor provides more valuable information, which enables
individualized cancer assessment and treatment.
The key to utilizing genomics in cancer is identifying specific
sets of genes and gene interactions that are important for
diagnosing different subsets of cancers. Studies can be
performed which link response to therapy or the likelihood of
recurrence to the pattern of gene expression in tumors. These
results can then be used to develop tests that quantify gene
expression of an individuals tumor, allowing physicians to
better understand what treatments are most likely to work for an
individual patient or how likely a cancer is to recur.
Our Solution
Our genomic-based diagnostic approach correlates gene expression
information to clinical outcomes and provides information
designed to improve treatment decisions for cancer patients. We
have optimized technology for quantitative gene expression on
FPE tissue by developing methods and processes for screening
hundreds of genes at a time using minimal amounts of tissue.
This technology allows us to analyze archived samples of tissue,
retained by hospitals for most cancer patients, to correlate
gene expression with known clinical outcomes. Once we have
established and validated a test, we can then analyze a
patients tumor and correlate the result to known clinical
outcomes. As a result, each tumors gene expression can be
quantified and correlated with responsiveness to therapy or the
likelihood of cancer recurrence or progression. Onco
type
DX, our first clinically validated product, uses this
quantitative molecular pathology approach to provide an
individualized analysis of each patients tumor.
We believe that our multi-gene analysis, as opposed to
single-gene analysis, provides a more powerful approach to
distinguish tumors as being more or less likely to recur or
progress. Furthermore, as shown in breast cancer, our approach
can be used to determine whether a cancer is more or less likely
to respond to therapy. This information ultimately allows the
physician and patient to choose a course of treatment that is
individualized for each patient.
Our solution fits within current clinical practice and
therapeutic protocols, facilitating product adoption. We analyze
tissues as they are currently handled, processed and stored by
clinical pathology laboratories. Once a patient is diagnosed
with breast cancer and a physician orders Onco
type
DX,
the pathology lab provides us with the tumor block or thin
sections from the biopsy specimen utilized for the diagnosis.
Because the specimens are chemically preserved and embedded in
paraffin wax, they require no special handling and can be sent
by overnight mail to our laboratory in California. We believe
this provides an advantage over tests using fresh or frozen
tissue that require special handling, such as shipping frozen
tissue on dry ice. We typically analyze the tissue and deliver
our results to the treating physician within 10 to 14 days
of receipt of the tissue sample. This is within the crucial
decision window after the tumor has been surgically removed and
before the patient and the treating physician discuss additional
treatment options.
We believe our solution provides information that has the
following benefits:
|
|
|
Improved Quality of Treatment Decisions.
We believe our
approach to genomic-based cancer analysis improves the quality
of cancer treatment decisions by providing an individualized
analysis of each patients tumor that is correlated to
clinical outcome. Our approach represents a substantial
departure from existing approaches to treatment, which often use
subjective, anatomic and qualitative factors to determine
treatments. Onco
type
DX has been shown in clinical
studies to classify many patients into recurrence risk
categories different from classifications based on current
guidelines. Thus, our solution enables patients and physicians
to make more informed decisions about treatment risk-benefit
and, consequently, design an individualized treatment plan.
|
|
|
Improved Economics of Cancer Care.
We believe that
improving the quality of treatment decisions can result in
significant economic benefits. In early stage breast cancer, our
data shows that many patients
|
42
|
|
|
are misclassified as high or low risk under existing treatment
guidelines. Many low risk patients misclassified as high risk
receive toxic and expensive chemotherapy treatment regimens.
Chemotherapy may cost in excess of $20,000, as compared to
Onco
type
DXs list price of $3,460. On the other
hand, some high risk patients misclassified as low risk are not
provided chemotherapy treatment, possibly necessitating future
treatment costing up to $50,000 or more if the cancer recurs.
|
Business Strategy
Our goal is to improve the quality of treatment decisions for
cancer patients by providing individualized information to
patients and their physicians through the genomic analysis of
tumor biopsies. Key elements of our strategy include:
|
|
|
Deliver High-value Genomic-based Diagnostics.
We believe
that treatment decisions are currently being made with little
understanding of the molecular profile of each tumor and that
economic inefficiencies result in the healthcare system when
crucial and expensive treatment decisions are made based on
inadequate and often subjective information. Our strategy is to
identify treatment decisions that can benefit from, and be
guided by, the patients individual genomic information. We
are focused on developing high-value tests that address these
treatment decisions, with the goal of making our genomic-based
tests a standard of care. Our value lies in our ability to
deliver individualized information during the crucial period of
time after diagnosis but prior to the decision to undergo a
specific cancer treatment.
|
|
|
Achieve Broad-based Adoption and Reimbursement.
We intend
to continue to build a strong sales, marketing and reimbursement
effort by interacting directly with medical and surgical
oncologists, pathologists and payors. Because oncology is a
concentrated specialty, we believe that a focused marketing
organization and specialized sales force can effectively serve
the oncology community and provide us with a competitive
advantage. We believe our direct sales approach, coupled with
our plans to conduct multiple clinical studies with results
published in peer-reviewed journals, will increase patient and
physician demand and increase the number of favorable
reimbursement coverage decisions by payors.
|
|
|
Enhance Existing Products and Technologies.
Our goal is
to enhance our marketed products by validating additional
individualized patient information to improve treatment
planning. We also intend to deliver added value by expanding the
clinical categories of patients we can address within a cancer
population. For example, we plan to expand our breast cancer
product to address late-stage breast cancer patients as well as
questions about the responsiveness of an individual tumor to
therapeutic agents such as aromatase inhibitors and taxanes. We
believe that continuous innovation can sustain a competitive
advantage by delivering more information to physicians in
comparison with new competitive products entering the market.
|
|
|
Apply Our Clinical Development Platform to Other Cancers.
We intend to use our clinical development platform to address
multiple cancers for which quantitative molecular pathology
could improve the assessment of the risk of disease progression
and the prediction of response to therapy. In the next several
years, we plan to expand our focus beyond breast cancer,
potentially including colon, prostate, renal cell and lung
cancers and melanoma. We designed our clinical development
platform to enable us to conduct clinical studies with clinical
study groups and opinion leaders using archived biopsy specimens
with years of associated patient data to correlate genomic
information to clinical outcomes. This approach allowed us to
research, develop, validate and commercialize Onco
type
DX
in three years.
|
Our Product: Onco
type
DX
Onco
type
DX uses quantitative molecular pathology to
improve cancer treatment decisions. We offer Onco
type
DX
as a clinical laboratory service, where we analyze tumor tissue
samples in our laboratory and provide physicians with genomic
information specific to the patients tumor. Early stage
breast cancer is the first patient population where we have
commercialized a genomic test that has been shown clinically to
43
predict the likelihood of cancer recurrence, the likelihood of
patient survival within 10 years of diagnosis and the
likelihood of chemotherapy benefit.
Our technology provides quantitative gene expression information
for each patients tumor, which we refer to as an oncotype.
When an oncotype is correlated with known clinical outcomes, it
can be useful in predicting the likelihood of an individual
patients tumor behavior. This allows the physician and
patient to address key issues such as risk of disease recurrence
or progression, likelihood of long-term survival and potential
response to chemotherapy or other treatments. In breast cancer,
we developed our gene panel by narrowing the field of the
approximately 25,000 human genes down to 250 cancer-related
genes through review of existing research literature and
computer analysis of genomic databases. We evaluated the 250
genes in three independent clinical studies to identify a
21-gene panel whose composite gene expression profile can be
represented by a single quantitative score, which we call a
Recurrence Score. The higher the Recurrence Score, the more
aggressive the tumor and the more likely it is to recur. The
lower the Recurrence Score, the less aggressive the tumor and
the less likely it is to recur. Moreover, we have demonstrated
that the Recurrence Score also correlates with chemotherapy
benefit, and we are undertaking further studies to support this
finding.
|
|
|
Oncotype DX for Breast Cancer
|
Approximately 230,000 new cases of breast cancer are expected to
be diagnosed in the United States in 2005. Following diagnosis,
a physician determines the stage of the breast cancer by
examining the following:
|
|
|
|
|
the size of the tumor,
|
|
|
|
node status, referred to as node positive, or N+, where the
tumor has spread to the lymph nodes, and node negative, or N-,
where the tumor has not spread to the lymph nodes, and
|
|
|
|
the extent to which the cancer has spread to other parts of the
body.
|
Breast cancer tumors are classified as
stage I, II, III or IV. Stage I and II are
generally referred to as early stage breast cancer, and
stage III and IV are generally referred to as
late-stage breast cancer. Standard treatment guidelines weigh
the stage of the cancer and additional factors to predict cancer
recurrence and determine treatment protocol such as:
|
|
|
|
|
the presence or absence of estrogen receptors, referred to as
estrogen receptor positive, or ER+, where estrogen receptors are
present, and estrogen receptor negative, or ER-, where estrogen
receptors are not present,
|
|
|
|
the abundance of human epidermal growth factor
receptor-type 2, or HER2, genes or protein in the tumor,
|
|
|
|
the age of the patient, and
|
|
|
|
the histological type and grading of the tumor as reported by
the pathologist.
|
Because these diagnostic factors have limited capability to
predict future recurrence and response to chemotherapy and some
are subjective, a large percentage of early stage breast cancer
patients are classified as high risk. As a consequence, the use
of chemotherapy has become standard practice in these patients
even though the benefit to this patient group as a whole is
small. Most early stage breast cancer patients have N-, ER+
tumors. These patients have been demonstrated to respond well to
hormonal therapy such as tamoxifen. Identifying which of these
patients will further benefit from chemotherapy is a difficult
decision under current guidelines. A National Surgical Adjuvant
Breast and Bowel Project, or NSABP, study published in 2004
showed that after 12 years of follow-up, overall survival
in N-, ER+ breast cancer patients using tamoxifen hormonal
therapy alone was approximately 83% and the overall survival
using tamoxifen hormonal therapy and chemotherapy was 87%.
Therefore, the incremental survival benefit of chemotherapy in
this study was only 4%. Our test is designed to help identify
those patients with aggressive tumors who are most likely to
benefit from chemotherapy and identify those patients with less
aggressive tumors who may receive minimal clinical benefit from
chemotherapy.
44
We believe that Onco
type
DX is the first genomic test
that has clinical evidence supporting its ability to predict the
likelihood of cancer recurrence, the likelihood of patient
survival within 10 years of diagnosis and the likelihood of
chemotherapy benefit in early stage, N-, ER+ breast cancer
patients treated with tamoxifen. Onco
type
DX is currently
available at a list price of $3,460. We accept orders from all
50 states through our commercial laboratory located in
Redwood City, California. Our laboratory is accredited under
CLIA and by CAP.
When the treating physician places an order for Onco
type
DX, the local pathology laboratory sends the tumor sample to
our laboratory. Once we receive the tumor sample, it is logged
in and processed by our pathology department. Suitable samples
then undergo a process by which RNA is extracted and purified.
We then analyze the resulting material and produce a report,
typically within 10 to 14 days of the receipt of the
sample, that shows a Recurrence Score on a continuum between
0-100. The Recurrence Score, along with other data and tests
that physicians obtain, forms the basis for the treatment
decision.
The Recurrence Score has been clinically validated to correlate
with an individuals likelihood of breast cancer recurrence
within 10 years of diagnosis. The lower the Recurrence
Score the less likely the tumor is to recur and the higher the
Recurrence Score the more likely the tumor is to recur. A
Recurrence Score range from 0-100 correlates to an actual
recurrence range from about 3% recurrence to over 30% recurrence
for patients in our validation study using the NSABP Study B-14
population. This continuous range of scores differentiates
Onco
type
DX from other tests that predict only high or
low risk by providing an individualized level of risk. To
evaluate our clinical validation studies and compare Onco
type
DX to other methods of classifying risk, we defined
Recurrence Score ranges for low, intermediate and high risk
groups. A Recurrence Score below 18 correlates with a low
likelihood of recurrence; a Recurrence Score equal to or greater
than 18 but less than 31 correlates with an intermediate
likelihood of recurrence; and a Recurrence Score equal to or
greater than 31 correlates with a high likelihood of recurrence.
Within each risk category, Onco
type
DX further quantifies
the risk for any given patient. For example, a low risk patient
may have as low as a 3% likelihood of recurrence of breast
cancer within 10 years or as high as a 11% likelihood of
recurrence, depending on the individual Recurrence Score. We
believe this represents a substantial improvement upon existing
methods for classifying patient risk.
|
|
|
Clinical Development and Validation of Oncotype DX
|
|
|
|
Clinical Development of the Oncotype DX Recurrence Score
|
We developed Onco
type
DX using a multi-step approach,
conducting clinical studies on tumor specimens from more than
2,600 breast cancer patients. First, we developed methods, using
RT-PCR, to quantify the expression of hundreds of genes in RNA
isolated from fixed paraffin embedded tumor tissue. We then
selected 250 cancer-related genes using computer analysis of
genomic databases and our knowledge of cancer pathways. Third,
we performed three independent breast cancer clinical studies in
a total of 447 patients with known clinical outcomes to
test the relationship between the expression of the 250
cancer-related genes and recurrence. Two of these studies were
conducted at Providence Saint Joseph Medical Center and Rush
University Medical Center, using samples from patients with N-
and N+ tumors who received tamoxifen, chemotherapy or both. A
third study was conducted in our specific target population of
N-, ER+ patients treated with tamoxifen.
From these studies we selected a panel of 21 genes, comprised of
16 cancer-related genes and five reference genes, with which we
developed the Recurrence Score utilizing a number of statistical
approaches. The Recurrence Score is obtained by first
normalizing the expression of the cancer-related genes against
the reference genes and then applying the Recurrence Score
formula to calculate a single score scaled between 0-100.
Clinical
Validation of Prediction of Recurrence and Survival in N-, ER+
Patients Treated with Tamoxifen
Our clinical validation studies were designed to answer two
questions about the utility of the Recurrence Score when N-, ER+
breast cancer patients treated with tamoxifen make additional
treatment decisions. First, we wanted to test whether
Onco
type
DX could differentiate patients with a high
likelihood of recurrence from
45
patients with a low likelihood of recurrence. Second, we wanted
to expand these results with a second study to demonstrate
success in predicting breast cancer survival in a community
hospital setting.
Oncotype DX Predicts the Likelihood of
Recurrence.
Our initial validation study was performed
in 2003 in collaboration with the NSABP to determine whether
Onco
type
DX predicts the likelihood of breast cancer
recurrence. This study, which was reported at the
San Antonio Breast Cancer Conference in December 2003 and
published in
The New England Journal of Medicine
in
December 2004, evaluated the ability of Onco
type
DX to
quantify the likelihood of breast cancer recurrence over
10 years. The study involved 668 patients who were
enrolled in the NSABP Study B-14 between 1982 and 1988. Each
patient sample was analyzed in a blinded fashion and the results
provided back to the NSABP through a neutral party at the
University of Pittsburgh for analysis. The Recurrence Score was
used to prospectively define the following three risk groups
based on our clinical development studies described above:
|
|
|
|
|
a low risk group, with a Recurrence Score of less than 18,
classified 51% of patients with an average recurrence rate of
6.8%;
|
|
|
|
an intermediate risk group, with a Recurrence Score equal to or
greater than 18 but less than 31, classified 22% of the
patients with an average recurrence rate of 14.3%; and
|
|
|
|
a high risk group, with a Recurrence Score greater than 31,
which included 27% of the patients with an average recurrence
rate of 30.5%.
|
The Recurrence Score was able to assign patients into high and
low risk groups (p<0.001) and, when the Recurrence Score was
examined together with age and tumor size in a multivariate
analysis, only the Recurrence Score remained a significant
predictor of patient outcome (p<0.001). A p-value indicates
the probability that the result obtained in a statistical test
is due to chance rather than a true relationship between
measures. A small p-value, generally less than 0.05, or
p<0.05, indicates that it is very unlikely that the results
were due to chance. In this study we also demonstrated that the
likelihood of distant recurrence at 10 years increased
continuously as the Recurrence Score increased, with a range
from about 3% recurrence for a Recurrence Score of zero to
greater than 30% recurrence for patients in the high Recurrence
Score category.
In addition, in subgroup analysis of various ages, tumor sizes
and pathology grade, the Recurrence Score remained a consistent
predictor of distant recurrence.
Oncotype DX Predicts the Likelihood of Breast Cancer Survival
in a Community Hospital Setting.
In collaboration with
Northern California Kaiser Permanente, we conducted a large,
case-control, epidemiological study of breast cancer patients
diagnosed from 1985 to 1994 at 14 Northern California Kaiser
hospitals. This study was initially reported at the
San Antonio Breast Cancer Conference in December
46
2004 and further detailed results were presented at the annual
meeting of the American Society of Clinical Oncology, or ASCO,
in May 2005. Patients who died of breast cancer, or the cases,
were matched with up to three controls based on each cases
age, race and ethnicity, tamoxifen treatment, facility and
diagnosis year. Controls had to be alive at the time of the
corresponding cases death in order to compare outcomes and
availability of follow-up for those patients alive at time of
each case death. To be eligible, patients had to be N-, less
than 75 years old and not have received adjuvant
chemotherapy. Among a potentially eligible population of
4,964 patients, we identified 220 eligible cases and 570
matched controls. Approximately one-third of the study patients
were treated with tamoxifen. This study was performed to confirm
that the Recurrence Score predicts breast cancer survival at
10 years in ER+ patients treated with tamoxifen. The
likelihood of breast cancer survival at 10 years was more
than five fold higher for patients in the pre-defined low
Recurrence Score group when compared to patients in the
pre-defined high Recurrence Score group (p<0.003). With
respect to the group of ER+ patients treated with tamoxifen, the
absolute risk of breast cancer death at 10 years in the
pre-specified risk groups was 2.8% for the low risk group, 10.7%
for the intermediate risk group and 15.5% for the high risk
group.
Additionally, in the larger population of ER+ patients untreated
with tamoxifen, the Recurrence Score was also statistically
significantly associated with breast cancer death at
10 years (p<0.025). This study, conducted in a
community hospital setting, demonstrates that the Recurrence
Score is independently associated with risk of breast cancer
death and is able to identify subgroups of patients according to
low, intermediate and high risk of death at 10 years.
|
|
|
Additional Questions Addressed by Further Studies
|
Additional studies were conducted to investigate three clinical
and scientific questions:
|
|
|
|
|
How do patients in the different Recurrence Score risk groups
respond to tamoxifen plus chemotherapy versus tamoxifen alone?
|
|
|
|
Does the Recurrence Score predict the likelihood of recurrence,
the benefit from tamoxifen or both?
|
|
|
|
Does the Recurrence Score apply to untreated ER- patients and
untreated ER+ patients?
|
Oncotype DX Predicts the Likelihood of Chemotherapy
Benefit.
We conducted a study in 2004 with the NSABP to
determine whether Onco
type
DX is predictive of the
likelihood of chemotherapy benefit. This study, which was
reported initially at the San Antonio Breast Cancer
Conference in December 2004 and further detailed results were
presented at ASCOs annual meeting in May 2005, included
651 patients from the NSABP Study B-20 with N-, ER+ breast
cancer enrolled from 1988 to 1993. Of these patients, 227 were
treated with tamoxifen alone and 424 were treated with tamoxifen
plus chemotherapy. The results of this
47
study demonstrated that low risk patients, as defined by the
Recurrence Score, had a 96% recurrence-free survival rate at
10 years without chemotherapy compared with a 95% survival
rate with chemotherapy, and intermediate risk patients as
defined by the Recurrence Score had a 90% survival rate without
chemotherapy compared with an 89% rate with chemotherapy. High
risk patients as defined by the Recurrence Score had a 60%
survival rate without chemotherapy compared with an 88% rate
with chemotherapy (p<0.001).
These results demonstrate that Onco
type
DX not only
quantifies recurrence and survival risk but also correlates with
the likelihood of chemotherapy benefit in early stage N-, ER+
breast cancer patients.
Oncotype DX Predicts Likelihood of Recurrence Because it
Predicts both Prognosis and Tamoxifen Benefit.
In 2004,
we conducted an expanded study with the NSABP Study B-14
population to determine whether Onco
type
DX captures
information regarding likelihood of distant recurrence, response
to tamoxifen, or both. This studys conclusions were
reported at the San Antonio Breast Cancer Conference in
December 2004 and further detailed results were presented at
ASCOs annual meeting in May 2005. The study included
645 patients with N-, ER+ breast cancer enrolled from 1982
to 1988, 355 of whom were given placebos and 290 of whom where
treated with tamoxifen. The results of this study demonstrated
that Onco
type
DX predicts the likelihood of distant
disease recurrence in tamoxifen-treated patients with N-, ER+
breast cancer because it captures both prognosis and response to
tamoxifen. Furthermore, this study of Onco
type
DX
demonstrates that low and intermediate risk patients as defined
by the Recurrence Score had the largest benefit of tamoxifen and
high risk patients as defined by the Recurrence Score had
minimal benefit of tamoxifen. The quantitative levels of ER, as
defined by Onco
type
DX, varied by over two-hundred fold
within the ER+ population and increasing levels of quantitative
ER gene expression correlated with increasing response to
tamoxifen. Finally, Onco
type
DX was able to discriminate
between high and low risk patients in a subset of patients not
treated with tamoxifen.
Results Were Inconclusive as to Whether Oncotype DX Predicts
Likelihood of Recurrence in a Mixed Population of N-, Untreated
Patients.
In 2003, we conducted a trial with The M.D.
Anderson Cancer Center to test the predictive power of
Onco
type
DX in untreated breast cancer patients who were
either ER- or ER+. This study was first reported at the
San Antonio Breast Cancer Conference in December 2003 and
published in
Clinical Cancer Research
in May 2005. Out of
a pool of over 4,000 N- patient tissue samples, only
149 patients were untreated and had a sufficient tissue
sample and RNA available to make them eligible for the study.
The study population differed significantly from the NSABP
Study B-14 treatment arm used for our initial validation
study in that none of the patients were treated with tamoxifen,
and the population included ER- and ER+ patients. This study did
not demonstrate a significant predictive power for Onco
type
DX in untreated N- patients. Importantly, it also did not
demonstrate the expected predictive power for other known
predictive factors. For example, tumor grade inversely
correlated with expected outcomes. Subsequent evaluations of
Onco
type
DX in the NSABP Study B-14 placebo arm
using samples from untreated ER+ patients and in the Kaiser
Permanente population-based study using samples from untreated
ER+ and ER- patients demonstrated a correlation between
48
the Recurrence Score and recurrence and survival. These results
were reported at the San Antonio Breast Cancer Conference in
December 2004 and ASCOs annual meeting in May 2005.
|
|
|
Health Economic Benefits of Oncotype DX
|
We are sponsoring third-party studies conducted by researchers
affiliated with academic institutions to examine the health
economic implications of Onco
type
DX. One such study,
which was published in
The American Journal of Managed
Care
, analyzed data from patients in the NSABP
Study B-14 multi-center clinical trial to compare risk
classification based on guideline criteria from the National
Comprehensive Cancer Network, or NCCN, to risk classification by
Onco
type
DX. Of the 668 patients in the NSABP study
population, NCCN guidelines classified 615, or 92%, as high risk
and 53, or 8%, as low risk. Of the 615 patients classified
as high risk by NCCN, Onco
type
DX classified 49% as low
risk, 22% as intermediate risk and 29% as high risk. Of the
53 patients that NCCN classified as low risk, Onco
type
DX classified 6% as high risk, 22% as intermediate risk and
72% as low risk. In each case, Onco
type
DX provided a
more accurate classification of risk than the NCCN guidelines as
measured by 10 year distant recurrence free survival.
Based on these results, a model was designed to forecast
quality-adjusted survival and expected costs, or the net present
value of all costs of treatment until death, if Onco
type
DX was used in patients classified as low risk or high risk
by NCCN guidelines. The model, when applied to a hypothetical
population of 100 patients with the demographic and disease
characteristics of the patients entered in the NSABP
Study B-14, demonstrated an increase to quality-adjusted
survival in this population of 8.6 years and a reduction in
projected aggregate costs of approximately $200,000.
Furthermore, the model showed that as the expected costs and
anticipated toxicity of chemotherapy regimens increase, the use
of the Recurrence Score to identify which patients would benefit
from chemotherapy should lead to larger reductions in projected
overall costs. According to this study, if all early stage
breast cancer patients and their physicians used Onco
type
DX and acted on the information provided by the Recurrence
Score, there would be significant economic benefit to the
healthcare system.
New Product Development
We developed Onco
type
DX using the following multi-phased
clinical development platform that we intend to use in
developing future products for breast and other cancers:
|
|
|
|
|
Clinical Research Phase.
In this phase, we establish
a product definition and research plan. Our research team
initiates the clinical research program with computer-based
screening of the approximately 25,000 genes in the human genome
to select candidate genes. The gene selection process uses
genomic databases and knowledge of key cancer and drug related
pathways. We use internally developed software for optimization
and rapid selection of target DNA sequences in order to develop
quantitative molecular pathology assays for each gene. To date,
we have compiled a library of over 1,000 individual gene tests
for use in multiple product opportunities. We secure access to
archival tumor biopsy samples for feasibility studies as well as
archival tumor biopsy samples correlated with clinical data for
gene identification studies. The goal of these studies is to
identify genes that correlate with a specific clinical outcome
prior to moving the program into development.
|
|
|
|
Development Phase.
We conduct additional clinical
studies to refine the gene set in the specific patient
population of interest. We select the final gene panel through
statistical modeling of the gene correlation data to develop the
best quantitative correlation to the target clinical outcome.
With a gene panel and quantitative methodology established, we
then finalize all of the remaining assay parameters. For
example, for Onco
type
DX we tested and verified protocols
for RNA extraction and amplification, automated chemistry and
reagent quality control and handling to establish a
reproducible, scaleable process. Once the genes, assay
chemistry, automation and analysis specifications are finalized,
tested and verified, we begin clinical validation.
|
|
|
|
Validation Phase.
In this phase, we conduct one or
more validation studies with prospectively designed endpoints to
test our candidate gene panel and the corresponding quantitative
expression score. These studies are conducted with a different
set of archival patient specimens to verify that the test
correlates with the predicted clinical outcome in an independent
patient population. Since we control the quality
|
49
|
|
|
|
|
and reproducibility of our assays using FPE tissues, we are able
to conduct large validation studies with archived samples with
years of clinical outcomes. This allows validation studies to be
performed more rapidly than would be the case with techniques
that require fresh tissue, which must be newly collected and
need many years of follow up before study results can be
obtained.
|
|
|
|
Commercialization and Product Expansion Phase.
Once
a test is commercialized, we may perform additional studies
designed to support the tests clinical utility and
potentially to broaden its use in additional patient populations
or for additional indications. Such studies may include
prospective studies to verify that our test is changing
physician behavior as well as testing a commercial product in
new populations. Multiple clinical studies are also useful for
driving adoption and reimbursement by physicians and payors.
|
Over 550,000 treatment decisions are expected to be made in the
United States in 2005 for patients diagnosed with early stages
of breast, colon, prostate, renal cell and lung cancers and
melanoma. Early stage cancers are often treated with adjuvant
treatments that are administered in conjunction with primary
therapy, such as surgery and radiation, intended to prevent the
recurrence of a particular cancer. The early stage patient
population is generally the larger treatment population for most
cancers. While our products under development focus on early
stage disease, we consider product opportunities in late-stage
disease when appropriate.
50
|
|
|
Product Development Opportunities in Breast Cancer
|
The following table describes our current breast cancer product
and our product opportunities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2005 Estimated
|
|
|
|
|
|
|
|
|
Treatment
|
|
|
|
|
|
|
|
|
Decisions
|
|
|
|
|
|
|
Breast Cancer
|
|
in the
|
|
Anticipated
|
|
Product
|
Breast Cancer Products
|
|
Population
|
|
United States
|
|
Product Attributes
|
|
Stage
|
|
|
|
|
|
|
|
|
|
Onco
type
DX
|
|
N-, ER+
|
|
|
125,000
|
|
|
Recurrence
|
|
Commercial
|
|
|
|
|
|
|
|
|
Response to chemotherapy
|
|
|
|
|
|
|
|
|
|
|
|
Response to chemotherapy or other
therapeutic regimens
|
|
Product
Expansion
|
|
|
|
N+
|
|
|
65,000
|
|
|
Recurrence
|
|
Product
|
|
|
|
|
|
|
|
|
Response to chemotherapy or other
therapeutic regimens
|
|
Expansion
|
|
|
Onco
type
DX
|
|
N-, ER+ and
|
|
|
190,000
|
(1)
|
|
Enhanced recurrence
|
|
Clinical
|
Second Generation
|
|
N+
|
|
|
|
|
|
Enhanced response to chemotherapy
|
|
Research
|
|
|
New Products
|
|
N-, ER-
|
|
|
30,000
|
|
|
Response to taxanes
(2)
|
|
Clinical
|
|
|
|
|
|
|
|
|
Response to chemotherapy
|
|
Research
|
|
|
|
|
|
|
|
|
Recurrence
|
|
|
|
|
|
N+
|
|
|
65,000
|
(3)
|
|
Response to taxanes
|
|
Clinical
|
|
|
|
|
|
|
|
|
Response to chemotherapy
|
|
Research
|
|
|
|
N-, ER+
|
|
|
125,000
|
(4)
|
|
Response to taxanes
|
|
Clinical
Research
|
|
|
(1)
|
Represents the sum of the 125,000 estimated treatment decisions
in 2005 for N-, ER+ patients and the 65,000 estimated treatment
decisions in 2005 for N+ breast cancer patients listed above.
|
|
(2)
|
Taxanes are a class of chemotherapy drugs that are commonly used
for breast cancer.
|
|
(3)
|
This figure is the same as the 65,000 treatment decisions listed
above.
|
|
(4)
|
This figure is the same as the 125,000 treatment decisions
listed above.
|
Oncotype
DX
We are conducting clinical studies with Onco
type
DX to
expand the market and improve certain product features.
Approximately 65,000 patients are expected to be diagnosed in
the United States in 2005 with N+ breast cancer and many may not
benefit from chemotherapy or may have other health issues that
increase the risk of chemotherapy treatment. Our early clinical
research studies with Rush University Medical Center and
Providence Saint Joseph Medical Center support further
investigation of Onco
type
DX for this patient population.
Additional studies are in the planning stage to investigate
whether Onco
type
DX predicts the likelihood of recurrence
in patients who use other hormonal therapies instead of
tamoxifen. Additionally, we believe that individual gene scores
which contribute to the Recurrence Score may have additional
utility in predicting outcomes for specific therapies or disease
subtypes. For example, a quantitative ER score may be a
clinically useful predictor of response to tamoxifen based on
our studies of the NSABP Study B-14 population.
Second
Generation Oncotype DX
We are in the clinical research phase to investigate additional
genes and gene combinations that may add to the predictive power
of Onco
type
DX. A second generation product, if
successful, could further refine and
51
improve the classification of patients and result in better
information for treatment decisions. We have identified multiple
genes through research and development studies that, in varying
combinations, may provide improved prediction of recurrence risk
and likelihood of response to chemotherapy.
Recurrence
and Response Test for N-, ER- Breast Cancer
We are in the clinical research phase to develop a product to
predict the likelihood of recurrence and response to
chemotherapy in N-, ER- breast cancer patients. This population
is expected to represent approximately 30,000 patients in
the United States in 2005. To date, we have conducted several
clinical research studies that included N-, ER- breast cancer
patients, and we plan to continue to explore opportunities in
this population, including tests to better define ER- patients
based on quantitative molecular pathology.
Taxane
Response Test
We are also in the clinical research phase to develop a product
to predict the response of patients to taxanes. Taxanes are a
class of chemotherapy drugs that are used in addition to
traditional chemotherapy regimens in some patients but have side
effects and are most often used in patients with aggressive or
later stage tumors. The potential population for this product
includes the estimated 65,000 N+ breast cancer patients as well
as N-, ER-patients at high risk and N- patients at high risk in
the United States in 2005. We have developed a number of
hypotheses and selected a gene panel to investigate this product
opportunity further.
52
Product
Development Opportunities in Other Cancers
The following table describes our new products in development
for cancers other than breast cancer:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2005 Estimated
|
|
|
|
|
|
|
|
|
Total Incidence
|
|
2005 Estimated
|
|
|
|
|
|
|
in the
|
|
Addressable
|
|
|
|
|
Product Opportunity
|
|
United States
|
|
Population
|
|
Anticipated Product Attributes
|
|
Product Stage
|
|
|
|
|
|
|
|
|
|
Colon Cancer
|
|
|
120,000
|
|
|
|
65,000
|
|
|
Recurrence
|
|
Clinical
|
|
|
|
|
|
|
|
|
|
|
Prediction of drug response
|
|
Research
|
Prostate Cancer
|
|
|
250,000
|
|
|
|
195,000
|
|
|
Progression
|
|
Clinical
|
|
|
|
|
|
|
|
|
|
|
Recurrence
|
|
Research
|
Renal Cell Cancer
|
|
|
40,000
|
|
|
|
25,000
|
|
|
Recurrence
|
|
Clinical
|
|
|
|
|
|
|
|
|
|
|
Prediction of drug response
|
|
Research
|
Non-small Cell Lung Cancer
|
|
|
155,000
|
|
|
|
25,000
|
|
|
Recurrence
Prediction of drug response
|
|
Clinical
Research
|
Melanoma
|
|
|
70,000
|
|
|
|
25,000
|
|
|
Recurrence
|
|
Clinical
|
|
|
|
|
|
|
|
|
|
|
Prediction of drug response
|
|
Research
|
Colon
Cancer Recurrence and Response Test
We are in the clinical research phase of developing a test to
predict the likelihood of recurrence and response to
chemotherapy in patients with early stage colon cancer. Colon
cancer is expected to affect approximately 120,000 individuals
in the United States in 2005, of which approximately 65,000
early stage patients will need to decide whether or not to use
chemotherapy for their cancer as well as which chemotherapy to
use. Only a small percentage of colon cancer patients are
expected to have a survival benefit from additional treatment
after surgery. We have developed an investigational 758-gene
panel for colon cancer and have established a collaborative
agreement with the NSABP, as well as other academic groups, to
access colon tissue samples that have associated clinical
outcome data.
Prostate
Cancer Progression and Recurrence Test
We are in the clinical research phase of developing a test to
predict the likelihood of progression and recurrence of prostate
cancer in early stage patients. Approximately 250,000 men are
expected to be diagnosed with prostate cancer in the United
States in 2005, approximately 195,000 of whom will need to make
critical decisions on whether or not to undergo local therapy,
such as surgery or radiation, and on whether or not to have
additional treatment after local therapy. Because the side
effects of surgery and local radiation therapy can be serious, a
need exists for a reliable test to determine the likelihood of
progression. There is also a need for a reliable test to
determine the likelihood of recurrence after local treatment,
because hormonal therapy and chemotherapy have significant side
effects as well. We are in the process of defining our prostate
cancer gene panel and have established a collaborative agreement
with an academic group to conduct initial feasibility studies
and to access clinical samples correlated with outcome data in
prostate cancer.
Renal
Cell Cancer Recurrence and Response Test
We are in the clinical research phase of developing a test to
predict the likelihood of recurrence and response to therapy in
renal cell cancer. Approximately 40,000 individuals are expected
to be diagnosed with renal cell cancer in the United States in
2005. Recently reported studies suggest that some of these
patients may respond to new treatments. We have conducted
initial feasibility studies to extract RNA from renal cell
cancer specimens and are currently working to define potential
products for patients with renal cell cancer under a
collaborative agreement with an academic group that has access
to clinical samples correlated to outcome data.
Non-small
Cell Lung Cancer Recurrence and Response Test
We are in the clinical research phase of developing a test to
predict the likelihood of response to chemotherapy in early
stage, non-small cell lung cancer. Approximately 155,000
individuals are expected to be diagnosed with non-small cell
lung cancer in the United States in 2005, of which approximately
25,000 of
53
those patients are expected to be diagnosed before the cancer
spreads and will need to make chemotherapy treatment decisions.
Recent clinical studies suggest that at least some of those
early stage patients will benefit from chemotherapy. The use of
chemotherapy in early stage non-small cell lung cancer is
relatively recent and is likely to accelerate. We have completed
initial feasibility studies in lung tissues as a part of our
EGFR inhibitor program described below and are in the process of
defining our lung cancer gene panel. We have a collaborative
agreement with an academic group that has access to clinical
samples correlated to outcome data.
Melanoma
Recurrence and Response Test
We are in the research phase of developing a test to predict the
likelihood of recurrence and response to therapy for patients
with melanoma. Approximately 70,000 individuals are expected to
be diagnosed with melanoma in the United States in 2005.
Recently reported studies suggest that some of these patients
may respond to new treatments. We have conducted initial
feasibility studies to extract RNA from melanoma cancer
specimens and are currently working to define potential products
for melanoma under a collaborative agreement with an academic
group that has access to tissue samples that have been
correlated to outcome data.
Product
Development Opportunities for Targeted Therapeutics
New anti-cancer drugs in clinical development are designed to
provide more targeted treatment which should improve efficacy
and reduce side effects. A need exists to identify those
patients who, based on the genomic profile of their tumors, are
most likely to benefit from these therapies. We believe our
individualized genomic analysis has the potential to improve
patient selection for these therapies. We have had a number of
discussions with pharmaceutical companies regarding the use of
Onco
type
DX or our clinical development platform to
identify subsets of patients more likely to respond to a
particular therapy. We have completed several studies with
different companies to evaluate our technology, and we are
marketing our clinical development platform to pharmaceutical
companies for exploratory clinical studies.
Epidermal
Growth Factor Receptor, or EGFR, Inhibitor Response Test
We are in the clinical research phase to develop tests to
predict the likelihood of response to the EGFR inhibitor class
of drugs. The market opportunity for these tests will initially
be limited to metastatic disease in lung and colon cancer, with
an estimated 60,000 patients in the United States in 2005,
where such drugs are currently approved. We have conducted three
small clinical research studies in lung cancer, colon cancer and
head and neck cancer which allowed us to identify and file
patent applications on a number of genes which may predict the
response to EGFR inhibitors. Further clinical development may
require partnerships with pharmaceutical companies that have
access to appropriate clinical trial specimens.
In July 2005, we signed a collaborative agreement with
Bristol-Myers Squibb Company and ImClone Systems Incorporated to
develop a genomic test to predict the likelihood of response to
Erbitux in colorectal carcinoma. Erbitux is a targeted therapy
currently approved for the treatment of metastatic colorectal
carcinoma. Consistent with terms we generally require in our
collaborative agreements, the agreement provides for research
funding support and milestone payments and provides us
commercial rights to diagnostic tests that result from the
collaboration.
We cannot assure you that any of the above product opportunities
or products in development will ever be commercialized or, if
commercialized, will ever be successful.
Research
and Development Expenses
Our research and development expenses were $7.1 million,
$9.1 million and $10.0 million for the years ended
December 31, 2002, 2003 and 2004, respectively, and
$4.6 million for the six months ended June 30, 2005.
54
Technology
We utilize existing technologies such as RT-PCR and information
technologies and optimize and integrate them into new processes.
We expect to continue to extend the capabilities of the various
components of our process to develop effective products. Our
technology allows us to:
Extract
RNA from FPE-tumor Biopsies
Our product development requires that we be able to quantify the
relative amounts of RNA in patients FPE tissue specimens.
We have developed proprietary technology, intellectual property
and know-how for optimized and automated methods for extraction
and analysis of RNA from FPE tissue. Although others can extract
RNA from FPE tissue, to our knowledge the process has not been
optimized and scaled up for high-throughput clinical testing and
large-scale clinical development studies involving large numbers
of genes. Our process uses commercially available reagents and
instruments with our own proprietary process and automation
protocols, which results in RNA extraction from the range of
tissues used in our clinical development studies and our
commercial laboratory test.
Amplify
and Detect Diminished Amounts of RNA Consistently
We use a well-established technology that we license from Roche
called RT-PCR as the basis for our quantitative molecular
pathology assays. This technology uses PCR along with
fluorescent detection methods to quantify the relative amount of
RNA in a biological specimen. Our technology platform has the
following advantages:
|
|
|
|
|
Sensitivity.
We have developed protocols for
extracting and quantifying RNA utilizing RT-PCR. Our method for
amplifying small fragmented RNA is designed to allow us in the
future to conduct studies with hundreds to thousands of genes
from 10 micron sections of FPE tissue. Together with the
inherent amplification of PCR, our platform provides us with
sophisticated capabilities to quantify RNA levels from minimal
amounts of tissue. The ability to amplify RNA allows us to
maintain a repository of RNA from limited tissue samples that
can be used for later studies.
|
|
|
|
Specificity.
Human tissues contain thousands of
different genes that are often highly related in sequence
content, making it challenging for genomic tests to specifically
identify molecules of interest. Our RT-PCR platform is highly
specific because it works only when three different test
reagents, called DNA probes and primers, independently match
each gene to be measured. In addition, we have designed and
implemented proprietary software for selecting optimal probe and
primer sequences in an automated, high-throughput process. Our
technology is also capable of quantifying non-coding RNA
sequences that are present in miniscule quantities within
tissues. The ability to utilize these sequences allows us to
design highly specific assays for closely related genes.
|
|
|
|
Precision and Reproducibility.
The reagents,
materials, instruments and controls in our processes are used by
trained personnel following validated standard operating
procedures. Validation studies have shown that these standard
operating procedures precisely quantify tested RNA with minimal
variability in the assay system across days, instruments and
operators. This enables our laboratory to produce consistently
precise and accurate gene expression results. Our quality
control methods for our reagents and processes, along with our
software for automation, sample tracking, data quality control
and statistical analysis, add to the reproducibility and
precision of our test.
|
|
|
|
Dynamic Range.
Because our RT-PCR platform can
amplify small amounts of RNA in proportion to the amount present
in the sample, we are able to measure RNA levels across as much
as a hundred thousand fold range of differing RNA expression.
Having a broad range of high resolution testing capability
increases the quality of our correlations with clinical outcomes
and therefore the predictive power of our tests.
|
55
Analyze
Hundreds of Genes
Historically, RT-PCR has been used to screen one or, at most, a
few genes at a time. The methods and know-how we have developed
allow us to expand RT-PCR technology to a scale that enables
screening of hundreds of genes at a time while using minimal
amounts of tissue. During our initial years of operation, we
typically screened 48 to 96 genes from a standard FPE
tissue sample using RNA from three 10 micron sections of
tissue. By 2003, we routinely screened 192 genes from each
sample and, by 2004, we screened 384 genes per sample. Today, we
have the capability to screen up to 768 different genes per
sample without sacrificing the sensitivity, specificity and
reproducibility of RT-PCR. With continued investment in
miniaturization and automation, we believe that our technology
will be capable of continued increases in throughput.
Employ
Advanced Information Technology
We have developed computer programs to automate our RT-PCR assay
process. We have also developed a laboratory information
management system to track our gene-specific reagents,
instruments, assay processes and the data generated. Similarly,
we have automated data analysis, storage and process quality
control. We use statistical methods to optimize and monitor
assay performance and to analyze data from our clinical research
and development studies.
Reimbursement
Revenues for clinical laboratory testing services may come from
several sources, including commercial third-party payors, such
as insurance companies and health maintenance organizations,
government payors, such as Medicare and Medicaid, and patients.
To gain broad reimbursement coverage, we are focusing on
educating payors on the following Onco
type
DX attributes:
|
|
|
|
|
Test Performance.
Onco
type
DX provides
results that are reproducible, sensitive, accurate and specific
to the patients tumor. Patients may benefit from treatment
decisions based on prediction of recurrence, survival and
chemotherapy benefit.
|
|
|
|
Clinical Utility.
Patients are provided a Recurrence
Score on a risk continuum that may change decision making
regarding the use of adjuvant chemotherapy, which may increase
the benefits of treatment while reducing its risks and costs. We
believe the large difference in risk of distant recurrence
between tumors with low Recurrence Scores and high Recurrence
Scores is indicative of the clinical utility of our test.
|
|
|
|
Peer-reviewed Publication and Consistent Study
Outcomes.
The 2003 NSABP validation study was
peer-reviewed and published in
The New England Journal of
Medicine
in December 2004. Physicians and payors often
require one, and many require two or more, peer-reviewed
publications to provide a basis for use and reimbursement
decisions. The results of the independent Kaiser Permanente
study reinforce the findings in the NSABP study. We believe that
additional publications, including our findings on chemotherapy
response, will increase usage and create a more favorable
reimbursement environment.
|
|
|
|
Patient and Physician Demand.
Increasing awareness
and demand in the cancer community for Onco
type
DX will
be necessary for widespread payor adoption. Increased usage of
the test by physicians can influence payors and facilitate the
reimbursement decision process.
|
|
|
|
Improved Economics.
We are sponsoring third-party
studies and providing information to payors to demonstrate the
economic benefits that can result from the use of Onco
type
DX. A health economic analysis of Onco
type
DX was
published in
The American Journal of Managed Care
in May
2005.
|
As a relatively new test, Onco
type
DX may be considered
investigational by payors and not covered under their
reimbursement policies. Consequently, we have pursued
case-by-case reimbursement and expect the test will continue to
be reviewed on this basis until policy decisions have been made
by individual payors.
56
We are also working with public and private payors and health
plans to secure coverage for Onco
type
DX based upon
clinical evidence showing the utility of the test. As of August
2005, several regional payors, including Harvard Pilgrim Health
Care, Inc. and Highmark Blue Cross Blue Shield, had issued
policies supporting reimbursement for our test. In addition,
Kaiser Foundation Health Plan, Inc. has entered into a national
clinical laboratory services agreement to reimburse us for
Onco
type
DX tests performed for their patients. Where
policies are not in place, we pursue case-by-case reimbursement.
Through this process, as of June 30, 2005, over 180 payors
had reimbursed one or more Onco
type
DX tests. We believe
that it may take one or more years to achieve successful
reimbursement with a majority of payors. However, we cannot
predict whether, or under what circumstances, payors will
reimburse our products. Payment amounts can also vary across
individual policies. Denial of coverage by payors, or
reimbursement at inadequate levels, would have a material
adverse impact on market acceptance of our products. The current
situation with our primary payors is as follows:
Commercial Third-party Payors and Patient Pay.
Where
there is a payor policy in place, we bill the payor and the
patient in accordance with the established policy. Where there
is no payor policy in place, we pursue reimbursement on behalf
of each patient on a case-by-case basis. We request that
physicians have a billing conversation with patients prior to a
test being submitted to discuss the patients
responsibility should their policy not cover the test. We also
request that the physician inform the patient that we will take
on the primary responsibility for obtaining third-party
reimbursement on behalf of patients, including appeals for
initial denials, prior to billing a patient. With this practice
established, we believe that most patients receiving the
Onco
type
DX test have agreed to the test knowing that
they may be responsible for all or some portion of the cost of
the test should their medical insurer deny or limit coverage.
Our efforts on behalf of patients will take a substantial amount
of time, and bills may not be paid for many months, if at all.
Furthermore, if a third-party payor denies coverage after final
appeal, it may take a substantial amount of time to collect from
the patient, and we may not be successful.
In early 2005, the Medical Advisory Panel of the Blue Cross and
Blue Shield Associations Technology Evaluation Center, or
BCBSA, a technology assessment group, concluded that the
existing clinical data in support of Onco
type
DX does not
meet the panels technology criteria for clinical
effectiveness and appropriateness. This assessment is provided
for informational purposes to members of BCBSA and can be used
by third-party payors and health care providers such as Blue
Cross and Blue Shield, which provide healthcare coverage for
nearly one-third of all Americans, as grounds to deny coverage
for Onco
type
DX.
Medicare and Medicaid.
In December 2004, the
Northern California Medicare contractor with responsibility for
processing and paying claims submitted by us announced that it
would not provide coverage for Onco
type
DX for Medicare
beneficiaries. It also indicated that there could be some
questions concerning whether the hospital must bill Medicare or
we can bill Medicare directly. Finally, it questioned which
Medicare contractor has jurisdiction to determine coverage for
Medicare claims for our test. To date, there is no national
coverage determination on Onco
type
DX by Medicare, which
means coverage is left to the discretion of the local Medicare
contractor. Since the local Medicare contractor responsible for
processing claims submitted by us has announced that it would
not provide coverage for Onco
type
DX, this has resulted
in the denial of Medicare claims. We are appealing these denials
through established processes and working with Medicare to
establish coverage for our test. During this time, we are not
billing Medicare patients directly. However, if we are not
successful in establishing coverage through Medicare, we may
change this policy and bill future Medicare patients directly,
subject to obtaining from patients their advance written
consent. We believe that as much as 20% of our future market for
Onco
type
DX may be derived from patients covered by
Medicare.
Selling and Marketing
Our selling and marketing strategy targets the oncology
community, primarily medical and surgical oncologists. Our
direct sales approach focuses on the clinical and economic
benefits of Onco
type
DX and the scientific validation
supporting our product. As of August 31, 2005, our selling
and marketing team consisted of 40 employees. Our field
staff has significant clinical oncology selling and marketing
experience from leading biopharmaceutical, pharmaceutical and
specialty reference laboratory companies.
57
Our marketing strategy focuses on educating physicians,
laboratory personnel and other healthcare professionals
regarding the development of new genomic technologies and the
value of the quantitative information Onco
type
DX
provides. We also work closely with national and regional
patient advocacy organizations that are focused on breast cancer
care. Our customer service representatives are trained to handle
inquiries from physicians, patients and other
healthcare-providers. We also utilize the Internet for
communicating with external constituencies, and our web site
contains clinical information for healthcare professionals and
educational information for breast cancer patients.
We promote our product through marketing channels commonly used
by the biopharmaceutical and pharmaceutical industries, such as
sponsored continuing medical education, medical meeting
participation and broad-based publication of our scientific and
economic data.
Competition
We believe that we compete primarily on the basis of:
|
|
|
|
|
the value of the quantitative information Onco
type
DX
provides;
|
|
|
|
the clinical validation of Onco
type
DXs ability to
predict recurrence and survival, and the demonstration of
Onco
type
DXs ability to predict the likelihood of
chemotherapy benefit;
|
|
|
|
our ability to perform clinical studies using archival tissue as
it is currently processed, handled and stored;
|
|
|
|
our ability to screen hundreds of genes at a time;
|
|
|
|
the speed with which our clinical development platform can
commercialize products;
|
|
|
|
our clinical collaborations with clinical study groups; and
|
|
|
|
the level of customer service we provide, both to patients and
health care professionals.
|
We believe that we compete favorably with respect to these
factors, although we cannot assure you that we will be able to
continue to do so in the future or that new products that
perform better than Onco
type
DX will not be introduced.
We believe that our continued success depends on our ability to:
|
|
|
|
|
continue to innovate and maintain scientifically advanced
technology;
|
|
|
|
enhance Onco
type
DX for breast cancer to provide
information in response to additional indications;
|
|
|
|
continue to validate our products, especially with respect to
chemotherapy benefit;
|
|
|
|
obtain positive reimbursement decisions from payors;
|
|
|
|
expand Onco
type
DX for use in other forms of cancer;
|
|
|
|
attract and retain skilled scientific and sales personnel;
|
|
|
|
obtain patents or other protection for our products;
|
|
|
|
obtain and maintain our clinical laboratory accreditations and
licenses; and
|
|
|
|
successfully market and sell Onco
type
DX.
|
Currently, our principal competition comes from existing
diagnostic methods utilized by pathologists and oncologists,
which generally involve assessing and evaluating the grade and
stage of cancerous tumors when determining risk of recurrence.
These methods, which have been used for many years and are
therefore difficult to change or supplement, are typically
accomplished in a short period of time without much expense. In
addition, companies offering capital equipment and inexpensive
kits or reagents to local pathology laboratories represent
another source of potential competition. These kits are used
directly by the pathologist, which facilitates adoption more
readily than tests like Onco
type
DX that are performed
outside the pathology laboratory. In addition, few diagnostic
methods are as expensive as Onco
type
DX and others may
develop lower-priced, less complex tests that could be viewed as
the equivalent of ours.
58
We also face competition from companies such as Agendia B.V.
which offer products or have conducted research to profile gene
expression in breast cancer using fresh or frozen tissue.
Commercial laboratories with strong distribution networks for
diagnostic tests, such as Genzyme Corporation, Laboratory
Corporation of America Holdings and Quest Diagnostics
Incorporated, may become competitors. Other potential
competitors include companies that develop diagnostic tests such
as Bayer Healthcare LLC, Celera Genomics, a division of Applera
Corporation, Roche Diagnostics, a division of F.
Hoffmann-La Roche Ltd, and Veridex LLC, a
Johnson & Johnson company, as well as academic and
research institutions.
Many of our present and potential competitors have widespread
brand recognition and substantially greater financial and
technical resources and development, production and marketing
capabilities than we do. Competition among these entities to
recruit and retain highly qualified scientific, technical and
professional personnel and consultants is also intense. If we
are unable to compete successfully against current or future
competitors, we may be unable to increase market acceptance for
and sales of our test, which could prevent us from increasing or
sustaining our revenues, or achieving or sustaining
profitability.
Regulation
Medicare
and Medicaid Coverage
In determining whether or not Medicare will pay for a service,
the Centers for Medicare and Medicaid Services, or CMS, which
oversees Medicare, can permit the contractors, who process and
pay Medicare claims, to make that determination or it can make a
national coverage determination, which will bind all Medicare
contractors. To date, CMS has not issued a national coverage
determination on Onco
type
DX. As a result, whether or not
Medicare will cover the test is the decision of NHIC California,
the current local Medicare carrier for California and the
contractor with jurisdiction to process claims submitted by us.
In December 2004, NHIC published an article on its website
stating that it would not provide coverage for Onco
type
DX for Medicare beneficiaries and that there could be some
questions concerning which provider must bill Medicare for the
test and which contractor had jurisdiction to determine coverage
for Medicare claims for our test.
In addition, in February 2005, CMS issued a notice that would
affect how the date of service for a laboratory service is
determined. Based on this notice, CMS could determine that the
date of service for the test is the date on which the
patients initial surgery was performed. As a result,
Onco
type
DX could be considered a hospital service, which
would mean that we would be required to bill and be paid by the
hospital and that the hospital would be required to bill
Medicare for the test as part of its prospective payment for the
admission or encounter during which the surgery was performed.
This could also result in lower reimbursement rates in the event
coverage is provided.
We intend to work with Medicare to establish coverage for
Medicare beneficiaries, and we are also working with NHIC
California and CMS to resolve the issue concerning which entity
is required to bill Medicare for our tests. In the meantime, we
intend to appeal denials received on a case-by-case basis. We
cannot provide any assurance, however, that coverage will be
provided in the future by Medicare, that our appeals will
ultimately be successful or that other issues will be favorably
resolved. In addition, each state Medicaid program, which pays
for services furnished to the eligible medically indigent, will
usually make its own decision whether or not to cover
Onco
type
DX. To date, no state Medicaid program has
decided to pay for the test.
Payment
Clinical laboratory testing services, when covered by
third-party payors, are paid under various methodologies,
including prospective payment systems and fee schedules. Under
Medicare, payment is generally made under the Clinical
Laboratory Fee Schedule with amounts assigned to specific
procedure billing codes. Each Medicare carrier jurisdiction has
a fee schedule that establishes the price for each specific
laboratory billing code. The Social Security Act establishes
that these fee schedule amounts are to be increased annually by
the percentage increase in the consumer price index, or CPI, for
the prior year. Congress has frequently legislated that the CPI
increase not be implemented. In the Medicare Prescription
59
Drug, Improvement and Modernization Act, or MMA, Congress
eliminated the CPI update through 2008. In addition, the
National Limitation Amount, or NLA, which acts as a ceiling on
Medicare reimbursement, is set at a percentage of the median of
all the carrier fee schedule amounts for each test code. In the
past, Congress has frequently lowered the percentage of the
median used to calculate the NLA in order to achieve budget
savings. Currently, the NLA ceiling is set at 74% of the medians
for established tests and 100% of the median for diagnostic
tests for which no limitation amount was established prior to
2001. Thus, no carrier can pay more than the NLA amount for any
specific code.
At the present time, there is no specific code to report
Onco
type
DX. Therefore, the test must be reported under a
non-specific unlisted procedure code, which is subject to manual
review of each claim. Furthermore, because there is no specific
code for this test, there is also no set Medicare payment
amount. We are moving forward with plans to obtain procedure
coding, but there is no assurance that a specific procedure code
will be adopted or that adequate payment will be assigned if and
when a code is adopted.
Several provisions of the Medicare Prescription Drug,
Improvement and Modernization Act of 2003 may affect future
payments for clinical laboratory testing services, including
Onco
type
DX. First, the Clinical Laboratory Fee Schedule
payments under Medicare are frozen through 2008 with
zero-percent annual adjustment. This would affect Medicare and
Medicaid payments for Onco
type
DX if a specific procedure
code and Clinical Laboratory Fee Schedule payment are assigned
to the test. Second, Congress authorized the Medicare program to
conduct a demonstration project on applying competitive bidding
to certain clinical laboratory tests. It is not clear whether
competitive bidding will be applied more broadly to clinical
laboratory services under Medicare at some point in the future
and, if so, whether this would impact payment for Onco
type
DX, which is provided solely by us. Third, Medicare is
reforming the local contractor process to replace current
contracts with fiscal intermediaries, which are billed by
hospitals and other institutional providers, and carriers, which
are billed by physicians, independent laboratories and other
suppliers, with new contracts. These reforms may result in a
change in the contractors to whom we send Medicare claims, which
may affect coverage for Onco
type
DX. Finally, on several
occasions, including in 2003 during the negotiations over the
MMA, Congress has considered imposing a 20% co-insurance amount
on clinical laboratory services, which would require
beneficiaries to pay a portion of the cost of their clinical
laboratory testing. Although that requirement has not been
enacted at this time, Congress could decide to impose such an
obligation at some point in the future. If so, it could make it
more difficult for us to collect payment for Onco
type
DX.
Clinical
Laboratory Improvement Amendments of 1988
As a clinical laboratory, we are required to hold certain
federal, state and local licenses, certifications and permits to
conduct our business. Under CLIA, we are required to hold a
certificate applicable to the type of work we perform and to
comply with standards covering personnel, facilities
administration, quality systems and proficiency testing.
We have a certificate of accreditation under CLIA to perform
testing and are accredited by CAP. To renew our CLIA
certificate, we are subject to survey and inspection every two
years to assess compliance with program standards. The standards
applicable to the testing which we perform may change over time.
We cannot assure you that we will be able to operate profitably
should regulatory compliance requirements become substantially
more costly in the future.
If our laboratory is out of compliance with CLIA requirements,
we may be subject to sanctions such as suspension, limitation or
revocation of our CLIA certificate, as well as directed plan of
correction, state on-site monitoring, civil money penalties,
civil injunctive suit or criminal penalties. We must maintain
CLIA compliance and certification to be eligible to bill for
services provided to Medicare beneficiaries. If we were to be
found out of compliance with CLIA program requirements and
subjected to sanction, our business could be harmed.
60
Food
and Drug Administration
The U.S. Food and Drug Administration, or the FDA,
regulates the sale or distribution, in interstate commerce, of
medical devices, including in vitro diagnostic test kits.
Devices subject to FDA regulation must undergo premarket review
prior to commercialization unless the device is of a type
exempted from such review. In addition, manufacturers of medical
devices must comply with various regulatory requirements under
the Federal Food, Drug and Cosmetic Act and regulations
promulgated under that Act, including quality system review
regulations, unless exempted from those requirements for
particular types of devices. Entities that fail to comply with
FDA requirements can be liable for criminal or civil penalties,
such as recalls, detentions, orders to cease manufacturing and
restrictions on labeling and promotion.
Clinical laboratory services are not subject to FDA regulation,
but in vitro diagnostic test kits and reagents and
equipment used by these laboratories may be subject to FDA
regulation. Clinical laboratory tests that are developed and
validated by a laboratory for use in examinations the laboratory
performs itself are called home brew tests. Most
home brew tests currently are not subject to premarket review by
FDA although analyte-specific reagents or software provided to
us by third parties and used by us to perform home brew tests
may be subject to review by the FDA prior to marketing. We
believe that Onco
type
DX is a type of home brew test. We
believe that Onco
type
DX is not subject to regulation
under current FDA policies and have communicated this conclusion
to FDA staff. We believe that the container we provide for
collection and transport of tumor samples from a pathology
laboratory to our laboratory is a medical device subject to FDA
regulation but exempt from premarket review. At this time, we
believe the FDA is reviewing the regulatory status of
Onco
type
DX. We cannot provide any assurance that FDA
regulation, including premarket review, will not be required in
the future for Onco
type
DX. If premarket review is
required, this would adversely affect our business until such
review is completed and approval or clearance to market is
obtained. If premarket review is required by the FDA, there can
be no assurance that our test will be cleared or approved on a
timely basis, if at all. Ongoing compliance with FDA regulations
would increase the cost of conducting our business, subject us
to inspection by the FDA and to the requirements of the FDA and
penalties for failure to comply with the requirements of the
FDA. Should any of the clinical laboratory device reagents
obtained by us from vendors and used in conducting our home brew
test be affected by future regulatory actions, we could be
adversely affected by those actions, including increased cost of
testing or delay, limitation or prohibition on the purchase of
reagents necessary to perform testing.
Health
Insurance Portability and Accountability Act
Under the federal Health Insurance Portability and
Accountability Act of 1996, or HIPAA, the U.S. Department
of Health and Human Services, or HHS, has issued regulations to
protect the privacy and security of protected health information
used or disclosed by health care providers, such as us. HIPAA
also regulates standardization of data content, codes and
formats used in health care transactions and standardization of
identifiers for health plans and providers. Penalties for
violations of HIPAA regulations include civil and criminal
penalties.
We have developed policies and procedures to comply with these
regulations by the respective compliance enforcement dates. The
requirements under these regulations may change periodically and
could have an effect on our business operations if compliance
becomes substantially more costly than under current
requirements.
In addition to federal privacy regulations, there are a number
of state laws governing confidentiality of health information
that are applicable to our operations. New laws governing
privacy may be adopted in the future as well. We have taken
steps to comply with health information privacy requirements to
which we are aware that we are subject. However, we can provide
no assurance that we are or will remain in compliance with
diverse privacy requirements in all of the jurisdictions in
which we do business. Failure to comply with privacy
requirements could result in civil or criminal penalties, which
could have a materially adverse impact on our business.
61
Federal
and State Self-referral Prohibitions
We are subject to the federal self-referral prohibitions
commonly known as the Stark Law, and to similar restrictions
under Californias Physician Ownership and Referral Act,
commonly known as PORA. Together these restrictions generally
prohibit us from billing a patient or any governmental or
private payor for any test when the physician ordering the test,
or any member of such physicians immediate family, has an
investment interest in, or compensation arrangement with, us,
unless the arrangement meets an exception to the prohibition.
Both the Stark Law and PORA contain an exception for referrals
made by physicians who hold investment interests in a publicly
traded company that has stockholders equity of
$75 million at the end of its most recent fiscal year or on
average during the previous three fiscal years, and which
satisfies certain other requirements. In addition, both the
Stark Law and PORA contain an exception for compensation paid to
a physician for personal services rendered by the physician. We
have compensation arrangements with a number of physicians for
personal services, such as speaking engagements and specimen
tissue preparation. We have structured these arrangements with
terms intended to comply with the requirements of the personal
services exception to Stark and PORA. However, we can not be
certain that regulators would find these arrangements to be in
compliance with Stark, PORA or similar state laws. We would be
required to refund any payments we receive pursuant to a
referral prohibited by these laws to the patient, the payor or
the Medicare program, as applicable.
Sanctions for a violation of the Stark Law include the following:
|
|
|
|
|
denial of payment for the services provided in violation of the
prohibition;
|
|
|
|
refunds of amounts collected by an entity in violation of the
Stark Law;
|
|
|
|
a civil penalty of up to $15,000 for each service arising out of
the prohibited referral;
|
|
|
|
exclusion from federal healthcare programs, including the
Medicare and Medicaid programs; and
|
|
|
|
a civil penalty of up to $100,000 against parties that enter
into a scheme to circumvent the Stark Laws prohibition.
|
These prohibitions apply regardless of the reasons for the
financial relationship and the referral. No finding of intent to
violate the Stark Law is required for a violation. In addition,
under an emerging legal theory, knowing violations of the Stark
Law may also serve as the basis for liability under the Federal
False Claims Act.
Further, a violation of PORA is a misdemeanor and could result
in civil penalties and criminal fines. Finally, other states
have self-referral restrictions with which we have to comply
that differ from those imposed by federal and California law.
While we have attempted to comply with the Stark Law, PORA and
similar laws of other states, it is possible that some of our
financial arrangements with physicians could be subject to
regulatory scrutiny at some point in the future, and we cannot
provide an assurance that we will be found to be in compliance
with these laws following any such regulatory review.
Federal
and State Anti-kickback Laws
Federal Anti-kickback Law makes it a felony for a provider or
supplier, including a laboratory, to knowingly and willfully
offer, pay, solicit or receive remuneration, directly or
indirectly, in order to induce business that is reimbursable
under any federal health care program. A violation of the
Anti-kickback Law may result in imprisonment for up to five
years and fines of up to $250,000 in the case of individuals and
$500,000 in the case of organizations. Convictions under the
Anti-kickback Law result in mandatory exclusion from federal
health care programs for a minimum of five years. In addition,
HHS has the authority to impose civil assessments and fines and
to exclude health care providers and others engaged in
prohibited activities from the Medicare, Medicaid and other
federal health care programs.
Actions which violate the Anti-kickback Law or similar laws may
also involve liability under the Federal False Claims Act, which
prohibits the knowing presentation of a false, fictitious or
fraudulent claim for
62
payment to the U.S. Government. Actions under the False
Claims Act may be brought by the Department of Justice or by a
private individual in the name of the government.
Although the Anti-kickback Law applies only to federal health
care programs, a number of states, including California, have
passed statutes substantially similar to the Anti-kickback Law
pursuant to which similar types of prohibitions are made
applicable to all other health plans and third-party payors.
Californias anti-kickback statute, commonly referred to as
Section 650, has been interpreted by the California
Attorney General and California courts in substantially the same
way as the HHS and the courts have interpreted the Anti-kickback
Law. A violation of Section 650 is punishable by
imprisonment and fines of up to $50,000.
Federal and state law enforcement authorities scrutinize
arrangements between health care providers and potential
referral sources to ensure that the arrangements are not
designed as a mechanism to induce patient care referrals and
opportunities. The law enforcement authorities, the courts and
Congress have also demonstrated a willingness to look behind the
formalities of a transaction to determine the underlying purpose
of payments between health care providers and actual or
potential referral sources. Generally, courts have taken a broad
interpretation of the scope of the Anti-kickback Law, holding
that the statute may be violated if merely one purpose of a
payment arrangement is to induce future referrals.
In addition to statutory exceptions to the Anti-kickback Law,
regulations provide for a number of safe harbors. If an
arrangement meets the provisions of a safe harbor, it is deemed
not to violate the Anti-kickback Law. An arrangement must fully
comply with each element of an applicable safe harbor in order
to qualify for protection. There are no safe harbors to
Californias Section 650.
Among the safe harbors that may be relevant to us is the
discount safe harbor. The discount safe harbor applies to
discounts provided by providers and suppliers, including
laboratories, to clients with respect to Medicare, Medicaid,
private pay or HMO patients, where the referring physician bills
the payor for the test, not when the service provider bills the
payor directly. If the terms of the discount safe harbor are
met, the discounts will not be considered prohibited
remuneration under the Anti-kickback Law.
California does not have a discount safe harbor. However,
certain licensees, such as hospitals or physicians, may only
mark-up laboratory tests purchased by those licensees from a
laboratory if certain disclosures are made to patients and third
party payors regarding the mark-up. Therefore, if and when we
elect to offer discounts to California customers, including any
hospital or physician, such discounts would not likely be viewed
by regulators as prohibited under Section 650 because the
mark-up would be disclosed by the customer to its buyer under
Californias mark-up laws. In contrast, any such discounts
provided by us to our non-California customers would have to be
analyzed under Californias Section 650.
The personal services safe harbor to the Anti-kickback Law
provides that remuneration paid to a referral source for
personal services will not violate the Anti-kickback Law
provided all of the elements of that safe harbor are met. One
element is that, if the agreement is intended to provide for the
services of the physician on a periodic, sporadic or part-time
basis, rather than on a full-time basis for the term of the
agreement, the agreement specifies exactly the schedule of such
intervals, their precise length, and the exact charge for such
intervals. Our personal services arrangements with some
physicians did not meet the specific requirement of this safe
harbor that the agreement specify exactly the schedule of the
intervals of time to be spent on the services because the nature
of the services, for example, speaking engagements, does not
lend itself to exact scheduling and therefore meeting this
element of the personal services safe harbor is impractical.
Failure to meet the terms of the safe harbor does not render an
arrangement illegal. Rather, an arrangement would not have the
protections of the safe harbor if challenged by a regulator and,
if necessary, the parties might be required to demonstrate why
the arrangement does not violate the Anti-kickback Law.
While we believe that we are in compliance with the
Anti-kickback Law and Section 650, there can be no
assurance that our relationships with physicians, hospitals and
other customers will not be subject to investigation or a
successful challenge under such laws. If imposed for any reason,
sanctions under the Anti-kickback Law and Section 650 could
have a negative effect on our business.
63
Other
Federal Fraud and Abuse Laws
In addition to the requirements that are discussed above, there
are several other health care fraud and abuse laws that could
have an impact on our business. For example, provisions of the
Social Security Act permit Medicare and Medicaid to exclude an
entity that charges the federal health care programs
substantially in excess of its usual charges for its services.
The terms usual charge and substantially in
excess are ambiguous and subject to varying
interpretations.
Further, the Federal False Claims Act prohibits a person from
knowingly submitting a claims or making a false record or
statement in order to secure payment by the federal government.
In addition to actions initiated by the government itself, the
statute authorizes actions to be brought on behalf of the
federal government by a private party having knowledge of the
alleged fraud. Because the complaint is initially filed under
seal, the action may be pending for some time before the
defendant is even aware of the action. If the government is
ultimately successful in obtaining redress in the matter or if
the plaintiff succeeds in obtaining redress without the
governments involvement, then the plaintiff will receive a
percentage of the recovery. Finally, the Social Security Act
includes its own provisions that prohibit the filing of false
claims or submitting false statements in order to obtain
payment. Violation of these provisions may result in fines,
imprisonment or both, and possible exclusion from Medicare or
Medicaid.
California
Laboratory Licensing
In addition to federal certification requirements of
laboratories under CLIA, licensure is required and maintained
for our laboratory under California law. Such laws establish
standards for the day-to-day operation of a clinical laboratory,
including the training and skills required of personnel and
quality control. In addition, California laws mandate
proficiency testing, which involves testing of specimens that
have been specifically prepared for the laboratory.
If our laboratory is out of compliance with California
standards, the California Department of Health Services, or DHS,
may suspend, restrict or revoke our license to operate our
laboratory; assess substantial civil money penalties; or impose
specific corrective action plans. Any such actions could
materially affect our business. We maintain a current license in
good standing with DHS. However, we cannot provide assurance
that DHS will at all times in the future find us to be in
compliance with all such laws.
New
York Laboratory Licensing
Because we receive specimens from New York state, our clinical
laboratory is required to be licensed by New York. We maintain
such licensure for our laboratory under New York state laws and
regulations, which establish standards for:
|
|
|
|
|
day-to-day operation of a clinical laboratory, including
training and skill levels required of laboratory personnel;
|
|
|
|
physical requirements of a facility;
|
|
|
|
equipment; and
|
|
|
|
quality control.
|
New York law also mandates proficiency testing for laboratories
licensed under New York state law, regardless of whether or not
such laboratories are located in New York. If a laboratory is
out of compliance with New York statutory or regulatory
standards, the New York State Department of Health, or the DOH,
may suspend, restrict or revoke the laboratorys New York
license or assess civil money penalties. Statutory or regulatory
noncompliance may result in a laboratorys being found
guilty of a misdemeanor under New York law. Should we be found
out of compliance with New York laboratory requirements, we
could be subject to such sanctions, which could harm our
business. We maintain a current license in good standing with
the DOH. However, we cannot provide assurance that the DOH will
at all times find us to be in compliance with all such laws.
64
Other
States Laboratory Testing
New Jersey may require out-of-state laboratories which accept
specimens from New Jersey to be licensed in New Jersey. We have
spoken with regulators at the New Jersey Department of Health
and Senior Services, Clinical Laboratory Improvement Services,
and are following their instructions with respect to compliance
with New Jersey law. In addition, Florida, Maryland,
Pennsylvania and Rhode Island require out-of-state laboratories
which accept specimens from those states to be licensed. We have
obtained licenses in those four states and believe we are in
compliance with applicable licensing laws.
From time to time, we may become aware of other states that
require out of state laboratories to obtain licensure in order
to accept specimens from the state, and it is possible that
other states do have such requirements or will have such
requirements in the future. If we identify any other state with
such requirements or if we are contacted by any other state
advising us of such requirements, we intend to follow
instructions from the state regulators as to how we should
comply with such requirements.
Patents and Proprietary Technology
In order to remain competitive, we must develop and maintain
protection on the proprietary aspects of our technologies. We
rely on a combination of patents, copyrights, trademarks, trade
secret laws and confidentiality, material data transfer
agreements, licenses and invention assignment agreements to
protect our intellectual property rights. We also rely upon
unpatented trade secrets and improvements, unpatented know-how
and continuing technological innovation to develop and maintain
our competitive position. We generally protect this information
with reasonable security measures.
As of August 31, 2005, we had 16 pending U.S. patent
applications, including provisional and non-provisional filings.
Ten of these U.S. patent applications also have
corresponding pending applications under the Patent Cooperation
Treaty. We have filed one of our patent applications nationally
in Canada, Europe and Japan, three of our patent applications in
Canada, Australia, Europe and Japan, and an additional patent
application in Canada, Australia and Japan.
In these patent applications, we have either sole or joint
ownership positions. In those cases where joint ownership
positions were created, we have negotiated contractual
provisions providing us with the opportunity to acquire
exclusive rights under the patent applications. Under three
patent applications, we have elected to allow exclusive options
to lapse without exercising the option. The joint ownership
agreements generally are in the form of material data transfer
agreements that were executed at the onset of our collaborations
with third parties.
Our patent applications relate to two main areas: gene
expression technology methods, and gene markers for cancer
recurrence and drug response in certain forms of cancer. We
intend to file additional patent applications in the United
States and abroad to strengthen our intellectual property
rights. Our patent applications may not result in issued
patents, and we cannot assure you that any patents that might
issue will protect our technology. Any patents issued to us in
the future may be challenged by third parties as being invalid
or unenforceable, or third parties may independently develop
similar or competing technology that are not covered by our
patents. We cannot be certain that the steps we have taken will
prevent the misappropriation of our intellectual property,
particularly in foreign countries where the laws may not protect
our proprietary rights as fully as in the United States.
From time to time, we may receive, notices of claims of
infringement, misappropriation or misuse of other parties
proprietary rights. Some of these claims may lead to litigation.
We cannot assure you that we will prevail in these actions, or
that other actions alleging misappropriation or misuse by us of
third-party trade secrets, infringement by us of third-party
patents and trademarks or the validity of patents issued to us
in the future, will not be asserted or prosecuted against us, or
that any assertions of misappropriation, infringement or misuse
or prosecutions seeking to establish the validity of our patents
will not materially or adversely affect our business, financial
condition and results of operations.
An adverse determination in litigation or interference
proceedings to which we may become a party relating to any
patents issued to us in the future or any patents owned by third
parties could subject us to significant liabilities to third
parties or require us to seek licenses from third parties.
Furthermore, if we are
65
found to willfully infringe these patents, we could, in addition
to other penalties, be required to pay treble damages. Although
patent and intellectual property disputes in this area have
often been settled through licensing or similar arrangements,
costs associated with such arrangements may be substantial and
could include ongoing royalties. We may be unable to obtain
necessary licenses on satisfactory or commercially feasible
terms, if at all. If we do not obtain necessary licenses, we may
not be able to redesign Onco
type
DX or other of our tests
to avoid infringement, or such redesign may take considerable
time, and force us to reassess our business plans. Adverse
determinations in a judicial or administrative proceeding or
failure to obtain necessary licenses could prevent us from
manufacturing and selling Onco
type
DX or other of our
tests, which would have a significant adverse impact on our
business.
All employees and technical consultants working for us are
required to execute confidentiality agreements in connection
with their employment and consulting relationships with us.
Confidentiality agreements provide that all confidential
information developed or made known to others during the course
of the employment, consulting or business relationship shall be
kept confidential except in specified circumstances. Agreements
with employees provide that all inventions conceived by the
individual while employed by us are our exclusive property. We
cannot provide any assurance that employees and consultants will
abide by the confidentiality or assignment terms of these
agreements. Despite measures taken to protect our intellectual
property, unauthorized parties might copy aspects of our
technology or obtain and use information that we regard as
proprietary.
Roche License
We have obtained from Roche Molecular Systems, Inc. a
non-exclusive license under a number of U.S. patents claiming
nucleic acid amplification processes known as polymerase chain
reaction, or PCR, homogeneous polymerase chain reaction, and
reverse transcription polymerase chain reaction, or RT-PCR. We
use these processes in our research and development and in the
processing of our tests. The Roche license is limited to the
performance of clinical laboratory services within the United
States and Puerto Rico, and does not include the right to make
or sell products using the patented processes. The license
continues as long as the underlying patent rights are in effect,
but is subject to early termination by Roche under the following
circumstances:
|
|
|
|
|
a change in our ownership;
|
|
|
|
a declaration of bankruptcy or insolvency, the making of an
assignment for the benefit of our creditors, having a receiver
appointed, or losing the federal or state licenses necessary for
our operation;
|
|
|
|
a change in our status to a non-profit entity or government
institution; or
|
|
|
|
our breach of or default under a material term of the license.
|
If the Roche license is terminated, we will be unable to use the
licensed processes to conduct research and development or to
perform our tests. As payment for the licenses granted to us, we
make royalty payments to Roche consisting of a specified
percentage of our net revenues.
Incyte Agreements
In connection with the sale of series C convertible
preferred stock to Incyte Corporation in March 2001, we entered
into three agreements with Incyte: a LifeSeq collaborative
agreement, a patent license agreement and a collaboration and
technology transfer agreement. We also entered into a Proteome
BioKnowledge Library license agreement with Proteome, Inc., a
then wholly owned subsidiary of Incyte.
Under the LifeSeq collaborative agreement, we obtained access to
Incytes genomic database products and received the right
to non-exclusively license certain of Incytes patent
rights and know-how relating to the database information. Under
the agreement, we paid database access fees to Incyte of
$2.0 million in 2002 and $1.0 million in each of 2003
and 2004, or an aggregate of $4.0 million from 2002 to
2004. Upon commercialization of Onco
type
DX, we were
required to make a one-time milestone payment of $100,000 and
are obligated to pay royalties to Incyte each quarter based on
net sales of Onco
type
DX. There are no
66
remaining access fees or milestone payments owing under this
agreement. The LifeSeq collaborative agreement continues in
perpetuity until terminated. The agreement may be terminated by
us or Incyte if the other party materially fails to comply with
its obligations under the agreement. If the agreement is
terminated, we must pay Incyte an annual fee in order to retain
any license we obtained under the agreement. We must continue to
pay this fee until the license is terminated or until we make a
milestone payment for the license, after which the license will
continue in perpetuity.
Under the patent license agreement, we license various classes
of patents from Incyte pertaining to the manipulation of genes,
the detection of pathological conditions, comparative gene
analysis, methods for fabricating tests of biological samples
and the use of proteins as markers for cancers. In 2001, we paid
Incyte an aggregate of $5.0 million in non-refundable
license fees for all classes of patents that we license under
this agreement. The non-refundable license fees were one-time
payments and no future licensing fees are owing under this
agreement. We are also obligated to pay Incyte continuing
royalties based on a percentage of our net sales of products
which incorporate each class of licensed patents. The patent
license agreement continues until the underlying patent rights
expire, unless it is terminated earlier. Incyte may terminate
the patent license agreement if we fail to satisfy our
obligations under the agreement or otherwise materially breach
the agreement. We have the right to terminate the agreement on a
patent by patent basis for any reason. If we terminate the
agreement early, all of our patent rights under the agreement
will expire, but we must continue to pay royalty obligations
that we accrued prior to termination. In March 2004, we
terminated our rights to some of these patents.
Under the collaboration and technology transfer agreement, we
agreed to collaborate on a project with Incyte relating to
developing technology for the recovery and extraction of RNA
from tissues embedded in paraffin. Under this agreement, Incyte
agreed to provide us access to Incytes technology
regarding paraffin extraction for a period of 15 months
ending in June 2002. We also agreed to pay Incyte continuing
royalties based on the sales of products commercialized using
the technology provided by Incyte under this agreement. The
collaboration and technology transfer agreement expires on
March 30, 2006, but may be terminated earlier if we and
Incyte mutually agree in writing. The agreement may also be
terminated by us or Incyte if the other party:
|
|
|
|
|
materially breaches or defaults under the agreement;
|
|
|
|
is subject to bankruptcy, insolvency, or dissolution proceedings
or makes an assignment for the benefit of creditors; or
|
|
|
|
if substantially all of the assets of the other party are seized
or attached.
|
All of our rights and obligations under the agreement will
terminate when the agreement is terminated, except that
termination of the agreement will not release us from any
liabilities that accrued prior to termination.
Under the Proteome BioKnowledge Library license agreement, we
licensed certain software and were provided access to certain
biological databases from Proteome, Inc. This agreement expired
in March 2002.
Oxford Finance Agreements
We have entered into a master security agreement and a number of
promissory notes with Oxford Finance Corporation to finance
equipment leases and computer and software leases. Under the
master security agreement, we granted a security interest to
Oxford in all of our goods, equipment, instruments and
investment property. The following events would constitute a
default by us under the master security agreement:
|
|
|
|
|
our failure to pay an obligation when due;
|
|
|
|
an attempt by us to sell, lease, transfer or encumber the
collateral;
|
|
|
|
our failure to maintain liability insurance as required by the
agreement;
|
|
|
|
any of the collateral being subject to attachment or levy;
|
|
|
|
our dissolving, becoming insolvent, filing for bankruptcy or
having a receiver appointed;
|
67
|
|
|
|
|
a change in our ownership;
|
|
|
|
a material impairment of Oxfords security interest in the
collateral; or
|
|
|
|
a material adverse change in our financial condition, business
or operations.
|
If we default under the master security agreement, Oxford may
declare all of our indebtedness under the promissory notes to be
immediately due and payable.
The promissory notes provide that amounts borrowed will be
repaid in periodic installments. Principal underlying promissory
notes to finance equipment leases must be paid in
45 monthly installments, and principal underlying
promissory notes to finance computer and software leases must be
paid in 36 monthly installments. Prepayment of indebtedness
under a promissory note is subject to a prepayment penalty and
is allowed only after the first anniversary of the note. As of
August 31, 2005, the outstanding principal amount under
these promissory notes was $3.7 million.
Employees
As of August 31, 2005, we had 117 full-time employees
and two part-time employees, including 19 in research and
development, 18 in commercial operations, 14 in medical, three
in regulatory, 40 in selling and marketing, 13 in information
technology and 12 in administrative functions. None of our
employees are covered by collective bargaining arrangements, and
our management considers its relationships with our employees to
be good.
Properties
We currently sublease approximately 25,000 square feet of
laboratory and office space in Redwood City, California under a
sublease that expires in February 2006. From June 30, 2005
to the end of its term, the monthly rent under this sublease is
$54,000. In September 2005, we entered into a lease directly
with the facility owner that has a term of six years. When our
existing sublease expires in February 2006, the new lease will
apply to the existing 25,000 square feet of laboratory and
office space we currently occupy. Under the new lease, we also
lease approximately 23,000 square feet of additional space which
we expect to first occupy in March 2006. If we first occupy
space under this new lease in March 2006, we will be required to
make aggregate rent payments of $460,000 in 2006, $730,000 in
2007, $753,000 in 2008, $779,000 in 2009, $799,000 in 2010,
$827,000 in 2011 and $139,000 in 2012.
Legal Proceedings
From time to time, we may be party to lawsuits in the ordinary
course of business. We are currently not a party to any legal
matters.
68
MANAGEMENT
Executive Officers and Directors
The following table shows information about our executive
officers and directors:
|
|
|
|
|
Name
|
|
Age
|
|
Position(s)
|
|
|
|
|
|
Randal W. Scott, Ph.D.
|
|
47
|
|
Chairman of the Board and Chief Executive Officer
|
Kimberly J. Popovits
|
|
46
|
|
President, Chief Operating Officer and Director
|
Joffre B. Baker, Ph.D.
|
|
57
|
|
Chief Scientific Officer
|
Steven Shak, M.D.
|
|
55
|
|
Chief Medical Officer
|
G. Bradley Cole
|
|
49
|
|
Executive Vice President, Chief Financial Officer and Secretary
|
Julian C. Baker
|
|
39
|
|
Director
|
Brook H. Byers(1)
|
|
60
|
|
Director
|
Fred E. Cohen, M.D., Ph.D.(1)(2)
|
|
49
|
|
Director
|
Samuel D. Colella(1)(2)(3)
|
|
65
|
|
Director
|
Michael D. Goldberg(2)(3)
|
|
47
|
|
Director
|
Randall S. Livingston(3)
|
|
52
|
|
Director
|
|
|
(1)
|
Will be a member of the Compensation Committee upon the date of
this prospectus.
|
|
(2)
|
Will be a member of the Nominating and Corporate Governance
Committee upon the date of this prospectus.
|
|
(3)
|
Will be a member of the Audit Committee upon the date of this
prospectus.
|
Randal W. Scott, Ph.D.
, has served as our Chairman
of the Board and Chief Executive Officer since our inception in
August 2000 and served as President from August 2000 until
February 2002, Chief Financial Officer from December 2000 until
April 2004, and Secretary from August 2000 until December 2000
and from May 2003 until February 2005. Dr. Scott was a
founder of Incyte Corporation, a genomic information company,
and served Incyte in various roles, including Chairman of the
Board from August 2000 to December 2001, President from January
1997 to August 2000, and Chief Scientific Officer from March
1995 to August 2000. Dr. Scott holds a B.S. in Chemistry
from Emporia State University and a Ph.D. in Biochemistry from
the University of Kansas.
Kimberly J. Popovits
has served as our President and
Chief Operating Officer since February 2002 and as a director
since March 2002. From November 1987 to February 2002,
Ms. Popovits served in various roles at Genentech, Inc., a
biotechnology company, most recently serving as Senior Vice
President, Marketing and Sales from February 2001 to February
2002, and as Vice President, Sales from October 1994 to February
2001. Prior to joining Genentech, she served as Division
Manager, Southeast Region, for American Critical Care, a
Division of American Hospital Supply, a supplier of health care
products to hospitals. Ms. Popovits is a director of
Nuvelo, Inc., a biotechnology company. Ms. Popovits holds a
B.A. in Business from Michigan State University.
Joffre B. Baker, Ph.D.
, has served as our Chief
Scientific Officer since December 2000. From March 1997 to
October 2000, Dr. Baker served as the Vice President for
Research Discovery at Genentech. From March 1993 to October
2000, Dr. Baker oversaw Research Discovery at Genentech,
which includes the Departments of Cardiovascular Research,
Oncology, Immunology, Endocrinology, and Pathology. From July
1991 to October 1993, he served as Genentechs Director of
Cardiovascular Research. Prior to joining Genentech,
Dr. Baker was a member of the faculty of the Department of
Biochemistry at the University of Kansas. He holds a B.S. in
Biology and Chemistry from the University of California,
San Diego and a Ph.D. in Biochemistry from the University
of Hawaii.
Steven Shak, M.D.
, has served as our Chief Medical
Officer since December 2000. From July 1996 to October 2000,
Dr. Shak served in various roles in Medical Affairs at
Genentech, most recently as Senior
69
Director and Staff Clinical Scientist. From November 1989 to
July 1996, Dr. Shak served as a Director of Discovery
Research at Genentech, where he was responsible for Pulmonary
Research, Immunology, and Pathology. Prior to joining Genentech,
Dr. Shak was an Assistant Professor of Medicine and
Pharmacology at the New York University School of Medicine.
Dr. Shak holds a B.A. in Chemistry from Amherst College and
an M.D. from the New York University School of Medicine, and
completed his post-doctoral training at the University of
California, San Francisco.
G. Bradley Cole
has served as our Executive Vice
President and Chief Financial Officer since July 2004 and our
Secretary from February 2005. From December 1997 to May 2004, he
served in various positions at Guidant Corporation, a medical
device company, most recently serving as Vice President, Finance
and Business Development for the Endovascular Solutions Group
from January 2001 until May 2004, and serving as Vice President
and General Manager of the Vascular Surgery Business Unit from
December 1998 until December 2000 and as Vice President, Finance
and IT Systems of the Cardiac and Vascular Surgery Group from
December 1997 until November 1998. From July 1994 to December
1997, Mr. Cole was Vice President, Finance and Chief
Financial Officer of Endovascular Technologies, Inc., a medical
device company that was acquired by Guidant Corporation. From
December 1988 to February 1994, he served as Vice President,
Finance and Chief Financial Officer of Applied Biosystems
Incorporated, a life sciences systems company. Mr. Cole
holds a B.S. in Business from Biola University and an M.B.A.
from San Jose State University.
Julian C. Baker
has served as a director of Genomic
Health since January 2001. Mr. Baker is a Managing Member
of Baker Bros. Advisors, LLC, which he and his brother, Felix
Baker, Ph.D., founded in 2000. Mr. Bakers firm
manages Baker Brothers Investments, a family of long-term
investment funds for major university endowments and
foundations, which are focused on publicly traded life sciences
companies. Mr. Bakers career as a fund-manager began
in 1994 when he co-founded a biotechnology investing partnership
with the Tisch Family, which led to the establishment in 2000 of
Baker/ Tisch Advisors, LLC. Mr. Baker is currently a
Managing Member of Baker/ Tisch Advisors. Previously,
Mr. Baker was employed from 1988 to 1993 by the private
equity investment arm of Credit Suisse First Boston Corporation.
He is also a director of Incyte Corporation, Neurogen
Corporation, Theravance, Inc. and Trimeris, Inc. Mr. Baker
holds an A.B. in Social Studies from Harvard University.
Brook H. Byers
has served as a director of Genomic Health
since January 2001. Mr. Byers is a general partner of
Kleiner Perkins Caufield & Byers, a venture capital
firm which he joined in 1977. He was the founding president and
chairman of four life science companies: Hybritech Inc., IDEC
Pharmaceuticals Corporation, InSite Vision Inc. and Ligand
Pharmaceuticals Inc. Mr. Byers currently serves as a
director of a number of privately held technology, healthcare
and biotechnology companies. Mr. Byers holds a B.S. in
Electrical Engineering from the Georgia Institute of Technology
and an M.B.A. from the Stanford Graduate School of Business.
Fred E. Cohen, M.D., Ph.D.
, has served as a
director of Genomic Health since April 2002. In 2001,
Dr. Cohen joined TPG Ventures, a venture capital firm, as a
Managing Director. Dr. Cohen is also a Professor of
Medicine and Pharmacology at the University of California,
San Francisco, where he has taught since July 1988.
Dr. Cohen is a director of Matrix Laboratories Limited and
a number of privately held companies. Dr. Cohen holds a
B.S. in Molecular Biophysics and Biochemistry from Yale
University, a Ph.D. in Molecular Biophysics from Oxford
University, and an M.D. from Stanford University.
Samuel D. Colella
has served as a director of Genomic
Health since January 2001. In 1999, Mr. Colella co-founded
Versant Ventures, a healthcare and biotechnology venture capital
firm. From 1984 to 1999, Mr. Colella was a general partner
of Institutional Venture Partners, a venture capital firm.
Mr. Colella currently serves as a director of Symyx
Technologies, Inc. and a number of privately held technology and
biotechnology companies. Mr. Colella has a B.S. in Business
and Engineering from the University of Pittsburgh and an M.B.A.
from the Stanford Graduate School of Business.
Michael D. Goldberg
has served as a director of Genomic
Health since October 2001. In January 2005, Mr. Goldberg
joined Mohr Davidow Ventures, a venture capital firm, as a
general partner. From October 2000 to December 2004,
Mr. Goldberg served as the Managing Director of Jasper
Capital, a management and financial consultancy business. In
1995, Mr. Goldberg founded OnCare, Inc., an oncology
practice
70
management company, and served as Chairman until August 2001 and
as Chief Executive Officer until March 1999. Previously,
Mr. Goldberg was the founder, President and Chief Executive
Officer of Axion Inc., a cancer-focused health care service
company. Prior to Axion, Mr. Goldberg was a partner at the
venture capital firm Sevin Rosen Funds, and was director of
Corporate Development and a member of the Operating Committee at
Cetus Corporation. He is also a director of several privately
held companies. Mr. Goldberg holds a B.A. in Philosophy
from Brandeis University and an M.B.A. from the Stanford
Graduate School of Business.
Randall S. Livingston
has served as a director of Genomic
Health since October 2004. In 2001, Mr. Livingston was
appointed Vice President for Business Affairs and Chief
Financial Officer of Stanford University. From 1999 to 2001,
Mr. Livingston served as Executive Vice President and Chief
Financial Officer of OpenTV Corp., a provider of interactive
television services. From 1996 until 1999, Mr. Livingston
served as a consultant and part-time executive for several
Silicon Valley technology companies. Prior to 1996,
Mr. Livingston worked for Heartport, Inc., Taligent, Apple
Computer, Ingres Corporation and McKinsey & Company.
Mr. Livingston holds a B.S. in Mechanical Engineering from
Stanford University and an M.B.A. from the Stanford Graduate
School of Business.
Board of Directors
Our board of directors currently consists of eight members. Each
of Messrs. Baker, Byers, Cohen, Colella, Goldberg and
Livingston is an independent director as defined by The Nasdaq
Stock Market, Inc. listing standards set forth in
Rule 4200(a)(15) adopted by the National Association of
Securities Dealers.
Our directors are elected annually to serve until the next
annual meeting of stockholders, until their successors are duly
elected and qualified or until their earlier death, resignation,
disqualification or removal. With limited exceptions, our board
of directors is required to have a majority of independent
directors at all times. The authorized number of directors may
be changed by resolution of the board. Vacancies on the board
can be filled by resolution of the board of directors.
Board Committees
As of the date of this prospectus, our board of directors will
have an audit committee, a compensation committee and a
nominating and corporate governance committee, each of which
will have the composition and responsibilities described below:
Audit Committee.
As of the date of this prospectus, the
audit committee will consist of Messrs. Colella, Goldberg
and Livingston, with Mr. Livingston serving as the chairman
of the committee. The audit committee provides assistance to the
board of directors in fulfilling its legal and fiduciary
obligations in matters involving our accounting, auditing,
financial reporting, internal control and legal compliance
functions by approving the services performed by our independent
accountants and reviewing their reports regarding our accounting
practices and systems of internal accounting controls. The audit
committee will be responsible for the appointment, compensation,
retention and oversight of the independent accountants and takes
those actions as it deems necessary to satisfy itself that the
accountants are independent of management. Mr. Livingston
is our audit committee financial expert as currently defined
under the rules of the Securities and Exchange Commission. We
believe that our audit committee will comply with the
requirements of the Sarbanes Oxley Act of 2002, the current
rules of The Nasdaq Stock Market and Securities and Exchange
Commission rules and regulations.
Compensation Committee
. The compensation committee
determines our general compensation policies and the
compensation provided to our directors and officers. The
compensation committee also reviews and determines bonuses for
our officers and other employees. In addition, the compensation
committee reviews and determines equity-based compensation for
our directors, officers, employees and consultants and
administers our stock option plans. The current members of the
compensation committee are Messrs. Byers, Cohen and
Colella, each of whom is a non-management member of our board of
directors, with Mr. Colella serving as the chairman of the
committee. We believe that our compensation committee complies
with the
71
applicable requirements of the Sarbanes-Oxley Act of 2002, the
current rules of The Nasdaq Stock Market and Securities and
Exchange Commission rules and regulations.
Nominating and Corporate Governance Committee
. The
nominating and corporate governance committee is responsible for
making recommendations to the board of directors regarding
candidates for directorships and the size and composition of the
board. In addition, the nominating and corporate governance
committee is responsible for overseeing our corporate governance
guidelines and reporting and making recommendations to the board
concerning corporate governance matters. The current members of
the nominating and governance committee are Messrs. Cohen,
Colella and Goldberg, with Mr. Cohen serving as the
chairman of the committee. We believe that our nominating and
governance committee complies with the applicable requirements
of the Sarbanes-Oxley Act of 2002, the current rules of The
Nasdaq Stock Market and Securities and Exchange Commission rules
and regulations.
Director Compensation
Directors who are employees do not receive any additional
compensation for their service on the board. Our non-employee
directors are reimbursed for reasonable out-of-pocket expenses
incurred in connection with attending board and committee
meetings. We currently pay Mr. Goldberg and
Mr. Livingston an annual cash retainer of $20,000 each for
their services as members of our board of directors. After the
closing of this offering, we will pay each non-employee director
an annual cash retainer of $20,000 and the chairman of our audit
committee of the board of directors an annual cash retainer of
$30,000.
During the year ended December 31, 2004 and the three
months ended March 31, 2005, we paid Mr. Goldberg
$20,000 and $5,000, respectively, for consulting services
separate from his services as a member of our board of
directors. This consulting agreement was terminated effective as
of March 31, 2005.
In October 2001, we granted Mr. Goldberg an option to
purchase 25,000 shares of our common stock when he joined
our board of directors. The option had an exercise price per
share of $0.66 and became fully vested in October 2004. In
October 2004, we granted Mr. Livingston an option to
purchase 17,340 shares of our common stock when he joined
our board of directors. The option has an exercise price per
share of $1.33 and vests ratably over a four-year period ending
in October 2008. After the closing of this offering, each new
non-employee director will receive an initial stock option grant
to purchase 16,500 shares of our common stock and each
non-employee director will receive an option to purchase
8,250 shares of common stock following each annual meeting
of stockholders. See Employee Benefit Plans
2005 Stock Incentive Plan.
Compensation Committee Interlocks and Insider
Participation
None of the members of our compensation committee at any time
has been one of our officers or employees. There are no familial
relationships among any of our directors or officers. No
interlocking relationship exists between our board of directors
or compensation committee and the board of directors or
compensation committee of any other entity, nor has any
interlocking relationship existed in the past.
72
Executive Compensation
The following table summarizes all compensation paid to our
Chief Executive Officer and to our four other most highly
compensated executive officers whose total annual salary and
bonus exceeded $100,000, for services rendered in all capacities
to us during the year ended December 31, 2004.
Summary Compensation Table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual
|
|
|
Long-Term Compensation
|
|
|
|
|
|
Compensation
|
|
|
|
|
|
|
|
|
|
|
|
Restricted
|
|
|
Shares
|
|
|
All Other
|
|
|
|
|
|
Salary
|
|
|
Bonus
|
|
|
Stock Awards
|
|
|
Underlying
|
|
|
Compensation
|
|
Name and Position(s)
|
|
Year
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
Options
|
|
|
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Randal W. Scott, Ph.D.
|
|
|
2004
|
|
|
$
|
200,000
|
|
|
|
|
|
|
|
|
|
|
|
69,362
|
|
|
|
|
|
|
Chief Executive Officer and Chairman
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kimberly J. Popovits
|
|
|
2004
|
|
|
|
275,000
|
|
|
|
|
|
|
|
|
|
|
|
69,361
|
|
|
|
|
|
|
President and Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Joffre B. Baker, Ph.D.
|
|
|
2004
|
|
|
|
275,000
|
|
|
|
|
|
|
|
|
|
|
|
69,362
|
|
|
|
|
|
|
Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Steven Shak, M.D.
|
|
|
2004
|
|
|
|
275,000
|
|
|
|
|
|
|
|
|
|
|
|
69,362
|
|
|
|
|
|
|
Chief Medical Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
G. Bradley Cole(1)
|
|
|
2004
|
|
|
|
120,311
|
|
|
|
|
|
|
|
|
|
|
|
173,407
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Mr. Cole became our Executive Vice President and Chief
Financial Officer in July 2004 and his annual salary is $250,000.
|
Stock option grants to our executive officers have been made in
the discretion of our board of directors. Beginning in 2005,
stock options grants to our executive officers will be made by
the independent members of our board of directors, after
considering the recommendations of the compensation committee of
the board. The board considered a variety of factors in
determining stock option awards, including our business and
financial results, the executives performance, competitive
market data for similar positions at comparable companies, and
the executives overall total compensation.
73
Stock Options
The following tables set forth certain information for the year
ended December 31, 2004 with respect to stock options
granted to and exercised by the individuals named in the Summary
Compensation Table above. The percentage of total options
granted is based on an aggregate of 942,751 shares
underlying options granted in 2004.
Option Grants in Last Fiscal Year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Individual Grants
|
|
|
|
|
|
|
|
|
|
|
Potential Realizable Value at
|
|
|
Number of
|
|
% of Total
|
|
|
|
|
|
Assumed Annual Rates of Stock
|
|
|
Securities
|
|
Options
|
|
|
|
|
|
Price Appreciation for Option
|
|
|
Underlying
|
|
Granted to
|
|
|
|
|
|
Term(3)
|
|
|
Options
|
|
Employees in
|
|
Exercise Price
|
|
Expiration
|
|
|
Name
|
|
Granted
|
|
Fiscal Year
|
|
Per Share(1)
|
|
Date(2)
|
|
5%($)
|
|
10%($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Randal W. Scott, Ph.D.
|
|
|
69,362
|
|
|
|
7.4
|
%
|
|
|
$3.17
|
|
|
|
12/2/2009
|
|
|
|
930,833
|
|
|
|
1,232,209
|
|
Kimberly J. Popovits
|
|
|
69,361
|
|
|
|
7.4
|
|
|
|
2.88
|
|
|
|
12/2/2014
|
|
|
|
1,268,765
|
|
|
|
2,138,761
|
|
Joffre B. Baker, Ph.D.
|
|
|
69,362
|
|
|
|
7.4
|
|
|
|
2.88
|
|
|
|
12/2/2014
|
|
|
|
1,268,786
|
|
|
|
2,138,795
|
|
Steven Shak, M.D.
|
|
|
69,362
|
|
|
|
7.4
|
|
|
|
2.88
|
|
|
|
12/2/2014
|
|
|
|
1,268,786
|
|
|
|
2,138,795
|
|
G. Bradley Cole
|
|
|
17,340
|
|
|
|
1.8
|
|
|
|
2.88
|
|
|
|
12/2/2014
|
|
|
|
317,187
|
|
|
|
534,683
|
|
G. Bradley Cole
|
|
|
156,067
|
|
|
|
16.6
|
|
|
|
1.33
|
|
|
|
6/10/2014
|
|
|
|
3,097,817
|
|
|
|
5,055,369
|
|
|
|
(1)
|
Except for the grant to Dr. Scott, the exercise price for
each grant is equal to 100% of the fair market value of our
common stock on the date of grant. The exercise price of
Dr. Scotts grant is equal to 110% of the fair market
value of our common stock on the date of grant.
|
|
(2)
|
The options have a term of 10 years, unless issued to a 10%
or greater stockholder, in which case they have a term of five
years. All options are subject to termination in certain events
related to termination of employment. The options vest as to 25%
of the shares one year after the date of grant and as to
1
/
48
th
of the shares each month thereafter.
|
|
(3)
|
Potential realizable values are calculated by:
|
|
|
|
|
|
multiplying the number of shares of our common stock subject to
a given option by the mid-point of the initial public offering
price range of $13.00 per share;
|
|
|
|
assuming that the aggregate stock value derived from that
calculation compounds at the annual 5% or 10% rates shown in the
table for the entire five-year or ten-year term of the option,
as applicable; and
|
|
|
|
subtracting from that result the total option exercise price.
|
The 5% and 10% assumed rates of appreciation are suggested by
the rules of the Securities and Exchange Commission and do not
represent our estimate or projection of the future common stock
price. There can be no assurance that any of the values
reflected in the table will be achieved.
Aggregated Option Exercises and Fiscal Year-End Option
Value
The following table assumes a fair market value of
$13.00 per share, the mid-point of the initial public
offering price range.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of Unexercised
|
|
|
Shares
|
|
|
|
Number of Unexercised
|
|
In-the-Money Options at
|
|
|
Acquired on
|
|
Value
|
|
Options at Fiscal Year-End(#)
|
|
Fiscal Year-End($)
|
Name
|
|
Exercise(#)
|
|
Realized($)
|
|
Exercisable/Unexercisable
|
|
Exercisable/Unexercisable
|
|
|
|
|
|
|
|
|
|
Randal W. Scott, Ph.D.
|
|
|
|
|
|
/ 69,362
|
|
/ 681,708
|
Kimberly J. Popovits
|
|
100,000
|
|
1,234,000
|
|
8,670 / 190,747
|
|
107,210 / 2,202,949
|
Joffre B. Baker, Ph.D.
|
|
|
|
|
|
/ 69,362
|
|
/ 701,708
|
Steven Shak, M.D.
|
|
|
|
|
|
/ 69,362
|
|
/ 701,708
|
G. Bradley Cole
|
|
|
|
|
|
/ 173,407
|
|
/ 1,997,293
|
74
Employee Benefit Plans
2001 Stock Incentive Plan
General.
Our 2001 stock incentive plan was adopted
by our board of directors in January 2001 and was subsequently
approved by our stockholders.
Administration.
The 2001 stock incentive plan
provided for the granting of incentive stock options within the
meaning of Section 422 of the Internal Revenue Code of
1986, as amended, to employees, officers and employee directors
and the granting of nonstatutory stock options and stock
purchase rights to employees, officers, directors (including
non-employee directors) and consultants. The administrator
determined the term of options, which was prohibited from
exceeding 10 years (five years in the case of an incentive
stock option granted to a stockholder holding more than 10% of
the voting shares of our company). To the extent an optionee
would have the right in any calendar year to exercise for the
first time one or more incentive stock options for shares having
an aggregate fair market value in excess of $100,000, any such
excess options would be treated as nonstatutory stock options.
Authorized Shares.
As of August 31, 2005,
459,011 shares of common stock remained available for
future issuance under our 2001 stock incentive plan. As of
August 31, 2005, options to purchase a total of
1,416,206 shares of common stock were outstanding under the
2001 stock incentive plan at a weighted average exercise price
of $1.91 per share. Following the completion of this
offering, no shares of our common stock will remain available
for future issuance under the 2001 stock incentive plan. Shares
that are subject to options that expire, terminate, or are
cancelled or as to which options have not been granted under the
2001 stock incentive plan will not be available for option
grants or share issuances under our 2005 stock incentive plan
after this offering is completed.
Plan Features.
Options granted under the 2001 stock
incentive plan generally vest at the rate of
1
/
4
of the total number of shares subject to the options
12 months after the vesting commencement date, and
1
/
48
of the total number of shares subject to the options each month
thereafter. No option may be transferred by the optionee other
than by will or the laws of descent or distribution. Each option
may be exercised during the lifetime of the optionee only by
such optionee. The 2001 stock incentive plan provides that in
the event of a recapitalization, stock split or similar capital
transaction, we will make appropriate adjustments in order to
preserve the benefits of options outstanding under the plan. If
we are involved in a merger or consolidation, options granted
under the 2001 stock incentive plan may be terminated
immediately prior to the effective date of such transaction,
unless the surviving or acquiring company assumes them.
|
|
|
2005 Stock Incentive Plan
|
General.
The 2005 stock incentive plan was adopted
by our board of directors on September 8, 2005,
subject to stockholder approval, and will become effective upon
the completion of this offering.
Administration.
The 2005 stock incentive plan will
be administered by our compensation committee. The 2005 stock
incentive plan provides for the grant of options to purchase
shares of common stock, restricted stock, stock appreciation
rights and stock units. Incentive stock options may be granted
only to employees. Nonstatutory stock options and other
stock-based awards may be granted to employees, non-employee
directors, advisors and consultants. The board of directors will
be able to amend or modify the 2005 stock incentive plan at any
time, with stockholder approval, if required.
Authorized Shares.
5,000,000 shares of common
stock have been authorized for issuance under the 2005 stock
incentive plan. Shares subject to awards that expire unexercised
or are forfeited or terminated will again become available for
issuance under the 2005 stock incentive plan. No participant in
the 2005 stock incentive plan can receive option grants,
restricted shares, stock appreciation rights or stock units for
more than 1,650,000 shares total in any calendar year.
75
Plan Features.
Under the 2005 stock incentive plan:
|
|
|
|
|
Nondiscretionary, automatic grants of nonstatutory stock options
will be made to outside directors. An outside director joining
our board of directors after this offering will be granted
automatically an initial option to purchase 16,500 shares
upon first becoming a member of our board. The initial option
will vest and become exercisable over four years, with the first
25% of the shares subject to the initial option vesting on the
first anniversary of the date of grant date and the remainder
vesting monthly thereafter. Immediately after each of our
regularly scheduled annual meetings of stockholders, each
outside director will be automatically granted a nonstatutory
option to purchase 8,250 shares of our common stock,
provided the director has served on our board for at least six
months. Each annual option will be fully vested and exercisable
on the first anniversary of the date of grant or, if earlier,
the date of our next annual meeting of stockholders. The options
granted to outside directors will have a per share exercise
price equal to 100% of the fair market value of the underlying
shares on the date of grant, and will become fully vested if we
are subject to a change of control.
|
|
|
|
Generally, if we merge with or into another corporation, we may
accelerate the vesting or exercisability of outstanding options
and terminate any unexercised options unless they are assumed or
substituted for by any surviving entity or a parent or
subsidiary of the surviving entity.
|
|
|
|
The plan terminates ten years after its initial adoption, unless
terminated earlier by the board. The board of directors may
amend or terminate the plan at any time, subject to stockholder
approval where required by applicable law. Any amendment or
termination may not impair the rights of holders of outstanding
awards without their consent.
|
We have established a tax-qualified employee savings and
retirement plan for which our employees are generally eligible.
Under our 401(k) plan, employees may elect to reduce their
compensation and have the amount of this reduction contributed
to the 401(k) plan. We do not make matching contributions.
The 401(k) plan is intended to qualify under
Section 401 of the Internal Revenue Code, so that
contributions to the 401(k) plan, and income earned on plan
contributions, are not taxable to employees until withdrawn from
the plan, and so that contributions by us, if any, will be
deductible by us when made.
Indemnification Agreements
We enter into agreements to indemnify our directors and
executive officers. We believe that these provisions and
agreements are necessary to attract and retain qualified persons
as directors and executive officers. Our certificate of
incorporation and our bylaws contain provisions that limit the
liability of our directors. A description of these provisions is
contained under the heading Description of Capital
Stock Limitation of Liability and Indemnification
Matters.
Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and
persons controlling us pursuant to the foregoing provisions, we
have been informed that in the opinion of the Securities and
Exchange Commission, this indemnification is against public
policy as expressed in the Securities Act and is therefore
unenforceable.
76
RELATED PARTY TRANSACTIONS
Transactions with Officers, Directors and 5% Stockholders
|
|
|
Founders Stock Purchase Agreements
|
In October 2000, in connection with our formation, we issued an
aggregate of 1,200,000 shares of restricted common stock at
a price per share of $0.003 to the following executive officers
pursuant to separate founders stock purchase agreements:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares of
|
|
|
Aggregate Purchase
|
|
Name
|
|
Date of Sale
|
|
Common Stock
|
|
|
Price
|
|
|
|
|
|
|
|
|
|
|
Randal W. Scott, Ph.D.
|
|
October 16, 2000
|
|
|
600,000
|
|
|
$
|
1,800
|
|
Joffre B. Baker, Ph.D.
|
|
October 16, 2000
|
|
|
300,000
|
|
|
|
900
|
|
Steven Shak, M.D.
|
|
October 16, 2000
|
|
|
300,000
|
|
|
|
900
|
|
Under each founders stock purchase agreement, we were
granted a right to repurchase the shares of common stock sold.
Our repurchase right lapsed as to 25% of the shares on
October 16, 2001, and lapsed with respect to the balance of
the shares in 36 equal monthly installments thereafter ending
October 16, 2004.
Since January 1, 2002, we sold shares of preferred stock in
private financings as follows:
|
|
|
|
|
In March 2002, May 2002 and November 2002, we sold
4,073,913 shares of series D preferred stock at a
price of $2.30 per share for aggregate consideration of
approximately $9.4 million to 11 investors.
|
|
|
|
In February 2004, March 2004, April 2004 and December 2004, we
sold 18,543,980 shares of series E preferred stock at a
price of $2.82 per share for aggregate consideration of
approximately $52.3 million to 75 investors.
|
The series D preferred stock will convert into one share of
common stock for every three shares held upon the closing of
this offering. If the initial public offering price of our
common stock is greater than or equal to $11.40 per share,
then every three shares of series E preferred stock will
convert into one share of common stock upon the closing of this
offering. If the initial public offering price of our common
stock is less than $11.40 per share, then we will not pay
the conditional dividend to our stockholders prior to this
offering. Instead, every three shares of series E preferred
stock will convert into 1.128 shares of common stock upon
the closing of this offering, resulting in the issuance of
791,210 shares of common stock to the Series E holders
in lieu of the conditional dividend to all stockholders. The
purchasers of the series D preferred stock and
series E preferred stock include the following directors,
officers, holders of 5% or more of our securities, and their
affiliated entities:
|
|
|
|
|
|
|
|
|
|
|
Number of Shares of
|
|
|
Number of Shares of
|
|
|
|
Series D Preferred
|
|
|
Series E Preferred
|
|
Investor
|
|
Stock
|
|
|
Stock
|
|
|
|
|
|
|
|
|
5% Stockholders:
|
|
|
|
|
|
|
|
|
Kleiner Perkins Caufield & Byers Affiliated Entities
|
|
|
|
|
|
|
1,418,440
|
|
Versant Ventures Affiliated Entities
|
|
|
|
|
|
|
1,418,440
|
|
TPG Ventures Affiliated Entities
|
|
|
3,043,479
|
|
|
|
2,464,539
|
|
Andrew H., Daniel R., James S. and Thomas J. Tisch
|
|
|
|
|
|
|
851,064
|
|
Julian C. Baker and Felix J. Baker
|
|
|
|
|
|
|
1,737,589
|
|
J.P. Morgan Direct Venture Capital Affiliated Entities
|
|
|
|
|
|
|
2,739,362
|
|
Directors and Executive Officers:
|
|
|
|
|
|
|
|
|
Joffre B. Baker, Ph.D.
|
|
|
|
|
|
|
35,460
|
|
G. Bradley Cole
|
|
|
|
|
|
|
35,460
|
|
Michael D. Goldberg
|
|
|
|
|
|
|
35,460
|
|
Randall S. Livingston
|
|
|
|
|
|
|
17,730
|
|
Kimberly J. Popovits
|
|
|
|
|
|
|
35,460
|
|
Randal W. Scott, Ph.D.
|
|
|
|
|
|
|
35,460
|
|
Steven Shak, M.D.
|
|
|
|
|
|
|
35,460
|
|
|
|
|
Agreements with Incyte Corporation
|
In March 2001, we sold 2,252,252 shares of series C
preferred stock to Incyte Corporation for aggregate
consideration of $5.0 million. Every three shares of
series C preferred stock will convert into one share
of common stock upon closing of this offering.
77
The conversion price of the series C preferred stock is
subject to adjustment to prevent dilution in the event that we
issue additional shares of preferred stock, common stock or
common stock equivalents at a purchase price less than the
then-effective conversion price. If our board of directors
declares any dividends on our capital stock, holders of
series C preferred stock and our other outstanding
preferred stock will be entitled to receive dividends before
holders of our common stock receive any dividends.
In the event of our liquidation, dissolution or winding up,
holders of series C preferred stock are entitled, on a
basis equal to that of our other outstanding preferred stock, to
a liquidation preference prior to payment to holders of common
stock of $2.22 per share plus any declared but unpaid dividends.
Series C preferred stockholders are entitled to the number
of votes they would have upon conversion of their preferred
stock into common stock on the record date.
At the time of the series C sale to Incyte, we entered into
the following agreements with Incyte and one of its
subsidiaries: a LifeSeq collaborative agreement, a patent
license agreement, a collaboration and technology transfer
agreement and a Proteome BioKnowledge Library license agreement.
At that time, Incyte provided genomic information products and
services. From January 1, 2002 to December 31, 2004,
we paid Incyte an aggregate of $5.4 million under these
agreements.
Under the LifeSeq Collaborative Agreement, we license certain of
Incytes patent rights and know-how regarding cloning, DNA
sequencing, and data analysis technologies. We use this license
to conduct research and develop our clinical diagnostic
products. Under the Patent License Agreement, we license various
classes of patents from Incyte pertaining to the manipulation of
genes, the detection of pathological conditions, comparative
gene analysis, methods for fabricating tests of biological
samples and the use proteins as markers for cancers. Under the
Collaboration and Technology Transfer Agreement, we received
access to certain of Incytes technology regarding paraffin
extraction until June 2002. Under the Proteome BioKnowledge
Library license agreement, which expired in March 2002, we
licensed certain software and were provided access to certain
biological databases.
Under the series C preferred stock purchase agreement,
Incyte granted us a right, which may be exercised only once, to
cause Incyte to purchase an aggregate of $5.0 million of
shares of our common stock upon closing this offering at the
initial public offering price. We expect to exercise this right
in connection with this offering and sell to Incyte
384,615 shares of common stock at an assumed public
offering price per share of $13.00.
As of August 31, 2005, Incyte owned approximately 6.0% of
our outstanding capital stock, and will own approximately
6.2% of our outstanding common stock after this
offering assuming we exercise our put right. Randal W. Scott,
our Chairman and Chief Executive Officer, was a founder of
Incyte and served as a member of its board of directors until
December 2001. In addition, Julian C. Baker, one of our
directors, is also a member of Incytes board of directors,
and holds shares, directly or beneficially, of both companies.
Registration Rights
We have entered into an investors rights agreement with
each of the purchasers of preferred stock listed above. Under
this agreement, these and other stockholders will be entitled to
registration rights with respect to their shares of common stock
issuable upon the automatic conversion of their convertible
preferred stock upon the closing this offering. For additional
information, see Description of Capital Stock
Registration Rights.
Insider Participation in the Offering
Several of our significant existing stockholders, including
funds affiliated with Julian C. Baker, Felix J. Baker and
Integral Capital Partners VI, L.P. or their affiliates, have
indicated an interest in purchasing up to an aggregate of
500,000 shares of our common stock in this offering, less any
shares sold to our employees pursuant to our directed share
program. However, because indications of interest are not
binding upon us or the prospective purchasers, these
stockholders may not acquire any shares in this offering.
Indemnification Agreements
We have entered into indemnification agreements with each of our
current directors and executive officers. These agreements will
require us to indemnify these individuals to the fullest extent
permitted under Delaware law against liabilities that may arise
by reason of their service to us, and to advance expenses
incurred as a result of any proceeding against them as to which
they could be indemnified. We also intend to enter into
indemnification agreements with our future directors and
executive officers.
78
PRINCIPAL STOCKHOLDERS
The following table sets forth information regarding beneficial
ownership of our common stock as of August 31, 2005, and as
adjusted to reflect the shares of common stock to be issued and
sold in the offering assuming no exercise of the
underwriters over-allotment option, by:
|
|
|
|
|
each person or group of affiliated persons known by us to be the
beneficial owner of more than 5% of our common stock;
|
|
|
|
each of our directors;
|
|
|
|
each of our named executive officers; and
|
|
|
|
all of our executive officers and directors as a group.
|
Unless otherwise noted below, the address of each person listed
on the table is c/o Genomic Health, Inc., 301 Penobscot
Drive, Redwood City, California 94063.
We have determined beneficial ownership in accordance with the
rules of the Securities Exchange Commission. Except as indicated
by the footnotes below, we believe, based on the information
furnished to us, that the persons and entities named in the
table below have sole voting and investment power with respect
to the shares of common stock that they beneficially own,
subject to applicable community property laws.
Applicable percentage ownership is based on
18,934,044 shares of common stock outstanding on
August 31, 2005, which gives effect to the conversion of
our preferred stock into an equal number of shares of common
stock before the closing of this offering and the dividend we
expect to distribute to our stockholders of record prior to this
offering. For the purposes of the table below, we have assumed
that 24,335,381 shares of common stock will be outstanding
upon completion of this offering, which includes
384,615 shares that we expect to sell to Incyte Corporation
in a concurrent private sale at an assumed initial public
offering price of $13.00 per share. The percentage
ownership information assumes no exercise of the
underwriters over-allotment option and does not reflect
the purchase of up to an aggregate of 500,000 shares of our
common stock that several of our significant existing
stockholders have indicated an interest in purchasing in this
offering. In computing the number of shares of common stock
beneficially owned by a person and the percentage ownership of
that person, we deemed outstanding shares of common stock
subject to options held by that person that are currently
exercisable or exercisable within 60 days of
August 31, 2005. We did not deem these shares outstanding,
however, for the purpose of computing the percentage ownership
of any other person.
79
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of Common Stock
|
|
|
Number of Shares of
|
|
Beneficially Owned
|
|
|
Common Stock
|
|
|
Name of Beneficial Owner
|
|
Beneficially Owned
|
|
Before Offering
|
|
After Offering
|
|
|
|
|
|
|
|
5% Stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities Affiliated with Kleiner Perkins Caufield &
Byers(1)
|
|
|
2,366,627
|
|
|
|
12.5
|
%
|
|
|
9.7
|
%
|
Entities Affiliated with Versant Ventures(2)
|
|
|
2,366,623
|
|
|
|
12.5
|
|
|
|
9.7
|
|
Entities Affiliated with TPG Ventures(3)
|
|
|
1,910,273
|
|
|
|
10.1
|
|
|
|
7.9
|
|
Incyte Corporation(4)
|
|
|
1,512,552
|
|
|
|
6.0
|
|
|
|
6.2
|
|
Andrew H., Daniel R., James S. and Thomas J. Tisch(5)
|
|
|
1,213,760
|
|
|
|
6.4
|
|
|
|
5.0
|
|
Julian C. Baker and Felix J. Baker(6)
|
|
|
996,299
|
|
|
|
5.3
|
|
|
|
4.1
|
|
Entities Affiliated with J.P. Morgan Direct Venture
Capital(7)
|
|
|
950,056
|
|
|
|
5.0
|
|
|
|
3.9
|
|
Directors and Named Executive Officers:
|
|
|
|
|
|
|
|
|
|
|
|
|
Julian C. Baker(8)
|
|
|
996,299
|
|
|
|
5.3
|
%
|
|
|
4.1
|
%
|
Brook H. Byers(9)
|
|
|
2,366,627
|
|
|
|
12.5
|
|
|
|
9.7
|
|
Fred E. Cohen, M.D., Ph.D.(10)
|
|
|
1,964,895
|
|
|
|
10.4
|
|
|
|
8.1
|
|
Samuel D. Colella(11)
|
|
|
2,366,623
|
|
|
|
12.5
|
|
|
|
9.7
|
|
Michael D. Goldberg
|
|
|
48,713
|
|
|
|
*
|
|
|
|
*
|
|
Randall S. Livingston(12)
|
|
|
10,484
|
|
|
|
*
|
|
|
|
*
|
|
Joffre B. Baker, Ph.D.(13)
|
|
|
428,478
|
|
|
|
2.3
|
|
|
|
1.8
|
|
G. Bradley Cole(14)
|
|
|
64,322
|
|
|
|
*
|
|
|
|
*
|
|
Kimberly J. Popovits(15)
|
|
|
376,456
|
|
|
|
1.9
|
|
|
|
1.5
|
|
Randal W. Scott, Ph.D.(16)
|
|
|
2,248,796
|
|
|
|
11.9
|
|
|
|
9.2
|
|
Steven Shak, M.D.(17)
|
|
|
428,478
|
|
|
|
2.3
|
|
|
|
1.8
|
|
All directors and executive officers as a group (18)
(11 persons)
|
|
|
11,300,171
|
|
|
|
59.3
|
%
|
|
|
46.1
|
%
|
|
|
|
|
*
|
Represents beneficial ownership of less than 1%.
|
|
|
(1)
|
Principal address for Kleiner Perkins Caufield & Byers
affiliated entities is 2750 Sand Hill Road, Menlo Park,
California 94025. Includes 1,556,459 shares held by Kleiner
Perkins Caufield & Byers X-A, L.P., 43,899 shares
held by Kleiner Perkins Caufield & Byers X-B, L.P., and
766,269 shares held by individual entities affiliated with
Kleiner Perkins Caufield & Byers. Mr. Byers, who
is also one of our directors, is a managing member of
KPCB X Associates, LLC, the general partner of these funds
and, as such, has shared voting and investment authority over
these shares. However, Mr. Byers disclaims beneficial
ownership of these shares except to the extent of his pecuniary
interest therein.
|
|
(2)
|
Principal address for Versant Ventures affiliated entities is
3000 Sand Hill Road, Bldg 4, Suite 210, Menlo Park,
California 94025. Includes 2,192,151 shares held by Versant
Venture Capital I, L.P., 42,412 shares held by
Versant Affiliates Fund I-A, L.P., 89,066 shares held
by Versant Affiliates Fund I-B, L.P. and 42,994 shares
held by Versant Side Fund I, L.P. Mr. Colella, who is
also one of our directors, is a managing director of Versant
Ventures I, LLC, the general partner of Versant Venture
Capital I, Versant Affiliates Fund I-A, Versant
Affiliates Fund I-B and Versant Side Fund. In such
capacity, Mr. Colella may be deemed to share voting and
investment power with respect to the shares held by Versant
Venture Capital I, Versant Affiliates Fund I-A,
Versant Affiliates Fund I-B and Versant Side Fund I.
Mr. Colella disclaims beneficial ownership of the shares
owned by these funds, except to the extent of his pecuniary
interest therein.
|
|
(3)
|
Principal address for TPG Ventures affiliated entities is 345
California Street, Suite 2600, San Francisco,
California 94104. Includes 573,081 shares owned by TPG
Ventures, L.P. and 1,337,192 shares owned by TPG
Biotechnology Partners, L.P. After offering amounts exclude an
additional 30,885 shares issuable as of the closing of this
offering pursuant to antidilution provisions applicable to
series E preferred stock if the initial public offering
price per share is less than $11.40. Dr. Cohen, who is also
one of our directors, is a managing director of Texas Pacific
Group Ventures. In such capacity, Dr. Cohen may be deemed
to share voting and investment power with respect to the
|
80
|
|
|
shares held by TPG Ventures, L.P.
and TPG Biotechnology Partners, L.P. Dr. Cohen disclaims
beneficial ownership of the shares owned by these funds, except
to the extent of his pecuniary interest therein.
|
|
(4)
|
Principal address is Experimental
Station, Route 141 & Henry Clay Road, Building E336,
Wilmington, Delaware 19880. Number of shares of common stock
beneficially owned by Incyte is comprised of
1,127,937 shares prior to offering and 384,615 shares
purchased by Incyte in a concurrent private sale at an assumed
initial public offering price of $13.00 per share.
|
|
(5)
|
Principal address is 655 Madison
Avenue, 19th Floor, New York, New York 10021. Includes
1,213,760 shares held by Four Partners. By virtue of their
status as managing trustees of the trusts which are the general
partners of Four Partners, each of Andrew H. Tisch, James S.
Tisch, Daniel R. Tisch and Thomas J. Tisch may be deemed to have
shared beneficial ownership of shares owned by Four Partners and
shared power to vote or direct the vote and dispose or direct
the disposition of these shares.
|
|
(6)
|
Principal address is
667 Madison Avenue, New York, New York 10021. Includes
173,897 shares owned by Baker Bros. Investments, L.P.,
173,897 shares owned by Baker/ Tisch Investments, L.P.,
15,314 shares owned by Baker Bros. Investments II, L.P.,
158,486 shares owned by Baker Biotech Fund I, L.P.,
142,794 shares owned by Baker Biotech Fund II, L.P.,
19,583 shares owned by Baker Biotech Fund II (Z),
L.P., 116,213 shares owned by Baker Biotech Fund III,
L.P., 22,218 shares owned by Baker Biotech Fund III
(Z), L.P. and 173,897 shares owned by FBB Associates, a
general partnership. After offering amounts exclude an
additional 35,408 shares issuable as of the closing of this
offering pursuant to antidilution provisions applicable to
series E preferred stock if the initial public offering
price per share is less than $11.40. Julian C. Baker, who is
also one of our directors, and Felix J. Baker, by virtue of
their control of entities that have the power to control the
investment decisions of Baker Bros. Investments, L.P., Baker/
Tisch Investments, L.P., Baker Bros. Investments II, L.P., Baker
Biotech Fund I, L.P., Baker Biotech Fund II, L.P.,
Baker Biotech Fund II (Z), L.P., Baker Biotech
Fund III, L.P., Baker Biotech Fund III (Z), L.P.
and FBB Associates, may each be deemed to be the beneficial
owner of shares held by such entities and may be deemed to have
shared power to vote or direct the vote of and to dispose or
direct the disposition of the shares.
|
|
(7)
|
Principal address for
J.P. Morgan Direct Venture Capital affiliated entities is
522 Fifth Avenue, New York, New York 10036. Includes
735,486 shares held by J.P. Morgan Direct Venture
Capital Institutional Investors II LLC, 209,821 shares
held by J.P. Morgan Direct Venture Capital Private
Investors II LLC and 4,749 shares held by
522 Fifth Avenue Fund, L.P. (collectively, the Global
Fund Entities). After offering amounts exclude an
additional 79,943 shares issuable as of the closing of this
offering pursuant to antidilution provisions applicable to
series E preferred stock if the initial public offering
price per share is less than $11.40. The investment advisor of
the Global Fund Entities is J.P. Morgan Investment
Management Inc. (JPMIM). JPMIM has sole voting power
with respect to the shares held by the Global
Fund Entities. In addition, interests in 522 Fifth
Avenue Fund, L.P. are owned both by a wholly owned subsidiary of
JPMorgan Chase & Co. (JPM Chase), a
publicly traded company, and employees of JPM Chase. As a
result, each of JPMIM, JPM Chase and employees of JPM Chase may
be deemed beneficial owners of the shares held by the Global
Fund Entities, however, each disclaim such beneficial
ownership except to the extent of such persons pecuniary
interest therein.
|
|
(8)
|
Includes 173,897 shares owned
by Baker Bros. Investments, L.P., 173,897 shares owned
by Baker/ Tisch Investments, L.P., 15,314 shares owned by
Baker Bros. Investments II, L.P., 158,486 shares owned by
Baker Biotech Fund I, L.P., 142,794 shares owned by
Baker Biotech Fund II, L.P., 19,583 shares owned by
Baker Biotech Fund II (Z), L.P., 116,213 shares owned
by Baker Biotech Fund III, L.P., 22,218 shares owned
by Baker Biotech Fund III (Z), L.P. and 173,897 shares
owned by FBB Associates, a general partnership. After offering
amounts exclude an additional 35,408 shares issuable as of
the closing of this offering pursuant to antidilution provisions
applicable to series E preferred stock if the initial
public offering price per share is less than $11.40.
Mr. Baker disclaims beneficial ownership of the shares held
by these entities except to the extent of his pecuniary interest
therein.
|
|
(9)
|
Includes 2,366,627 shares held
by Kleiner Perkins Caufield & Byers affiliated
entities. Mr. Byers disclaims beneficial ownership of these
shares except to the extent of his pecuniary interest therein.
|
|
|
(10)
|
Includes 1,910,273 shares held by TPG Ventures affiliated
entities, 5,203 shares issuable upon exercise of options
that are exercisable within 60 days of July 31, 2005
and 6,068 shares held by family trusts of which
Dr. Cohen is a trustee. After offering amounts exclude an
additional 28,965 shares issuable as of the closing of this
offering pursuant to antidilution provisions applicable to
series E preferred stock if the initial public offering
price per share is less than $11.40. Dr. Cohen disclaims
beneficial ownership of the shares held by the TPG Ventures
affiliated entities except to the extent of his pecuniary
interest therein.
|
|
(11)
|
Includes 2,366,623 shares held by Versant Ventures
affiliated entities. Mr. Colella disclaims beneficial
ownership of these shares except to the extent of his pecuniary
interest therein.
|
81
|
|
(12)
|
Includes 4,335 shares issuable upon exercise of options
that are exercisable within 60 days of August 31,
2005. After offering amounts exclude an additional
517 shares issuable as of the closing of this offering
pursuant to antidilution provisions applicable to series E
preferred stock if the initial public offering price per share
is less than $11.40.
|
|
(13)
|
Includes 116,343 shares held by a family trust of which
Dr. Baker is a trustee.
|
|
(14)
|
Includes 52,024 shares issuable upon exercise of options
that are exercisable within 60 days of August 31,
2005. After offering amounts exclude an additional
1,034 shares issuable as of the closing of this offering
pursuant to antidilution provisions applicable to series E
preferred stock if the initial public offering price per share
is less than $11.40.
|
|
(15)
|
Includes 17,342 shares issuable upon exercise of options
that are exercisable within 60 days of August 31, 2005.
|
|
(16)
|
Includes 5,199 shares held in trust for the benefit of
Dr. Scotts minor children, of which
Dr. Scotts sister is the trustee.
|
|
(17)
|
After offering amounts exclude an additional 17 shares
issuable as of the closing of this offering pursuant to
antidilution provisions applicable to series E preferred
stock if the initial public offering price per share is
less than $11.40.
|
|
(18)
|
Includes 78,904 shares issuable upon exercise of options
that are exercisable within 60 days of August 31, 2005.
|
82
DESCRIPTION OF CAPITAL STOCK
General
The following description of our capital stock and provisions of
our restated certificate of incorporation and bylaws is only a
summary. You should also refer to the copies of our restated
certificate of incorporation and bylaws that have been filed
with the Securities and Exchange Commission as exhibits to our
registration statement, of which this prospectus forms a part,
and to the provisions of Delaware law.
Upon completion of this offering, after giving effect to the
conversion of all outstanding preferred stock into common stock
and the amendment of our certificate of incorporation, our
authorized capital stock will consist of 100,000,000 shares
of common stock, par value $0.0001 per share, and
5,000,000 shares of undesignated preferred stock, par value
$0.0001 per share.
Common Stock
As of August 31, 2005, there were 18,197,987 shares of
common stock outstanding held by approximately
177 stockholders of record, assuming the automatic
conversion of each outstanding share of preferred stock upon the
closing of this offering.
Each holder of common stock is entitled to one vote for each
share of common stock held on all matters submitted to a vote of
stockholders. We have not provided for cumulative voting for the
election of directors in our certificate of incorporation. This
means that the holders of a majority of the shares voted can
elect all of the directors then standing for election. Subject
to preferences that may apply to shares of preferred stock
outstanding at the time, the holders of outstanding shares of
our common stock are entitled to receive dividends out of assets
legally available at the times and in the amounts that our board
of directors may determine from time to time. Upon our
liquidation, dissolution or winding-up, the holders of common
stock are entitled to share ratably in all assets remaining
after payment of all liabilities and the liquidation preferences
of any outstanding preferred stock. Holders of common stock have
no preemptive or conversion rights or other subscription rights.
There are no redemption or sinking fund provisions applicable to
the common stock. All outstanding shares of common stock are
fully paid and nonassessable, and the shares of common stock to
be issued in this offering, when they are paid for, will be
fully paid and nonassessable.
Preferred Stock
Upon the closing of this offering, every three outstanding
shares of our series A, B, C and D preferred stock will be
converted into one share of common stock. If the initial public
offering price of our common stock is greater than or equal to
$11.40 per share, then upon the closing of this offering every
three outstanding shares of series E preferred stock will
convert into one share of common stock, or an aggregate of
approximately 6,181,326 shares of common stock. If the initial
public offering price of our common stock is less than $11.40
per share, then upon the closing of this offering every three
outstanding shares of series E preferred stock will convert
into 1.128 shares of common stock, or an aggregate of
approximately 6,972,536 shares of common stock. As a result, if
the initial public offering price of our common stock is less
than $11.40 per share, an aggregate of 791,210 additional shares
of our common stock will be issued to holders of outstanding
shares of series E preferred stock.
On September 8, 2005, our board of directors declared a
conditional dividend of 791,210 shares of our common stock,
which will be distributed upon the closing of this offering on a
pro rata basis to all of our stockholders of record as of the
date of this prospectus only if the initial public offering
price of our common stock is $11.40 or greater. This conditional
dividend will not be distributed if the initial public offering
price of our common stock is lower than $11.40. Our outstanding
stock options will be proportionately adjusted in the event this
conditional stock dividend is distributed. Based on our
outstanding stock options as of August 31, 2005, we would
issue approximately 736,142 shares pursuant to this
dividend, less an aggregate of 85 shares for which cash
will be paid in lieu of fractional interests, and the number of
shares underlying outstanding stock options would be increased
by approximately 55,068 shares. The sum of the total number
of shares issuable pursuant to the conditional dividend and the
additional shares issuable upon exercise of our
83
outstanding stock options as a result of the proportionate
adjustments will equal 791,210 shares. The result of the
declaration of this conditional dividend is that the sum of the
number of outstanding shares of common stock and shares
underlying outstanding options will be substantially the same
regardless of the price per share of our initial public
offering. The proportionate ownership of our existing investors
will differ depending on whether the holders of our
series E preferred stock receive more shares pursuant to
the terms of our restated certificate of incorporation or the
conditional dividend is paid to all of our stockholders of
record.
Following the conversion, our certificate of incorporation will
be amended to delete all references to the prior series of
preferred stock, and 5,000,000 shares of undesignated
preferred stock will be authorized. Our board of directors will
have the authority, without further action by our stockholders,
to issue from time to time the preferred stock in one or more
series, to establish the number of shares to be included in each
series, and to fix the powers, preferences and rights of the
shares of each wholly unissued series and any of its
qualifications, limitations or restrictions. Our board of
directors will also be able to increase or decrease the number
of shares of any series, but not below the number of shares of
that series then outstanding, without any further vote or action
by the stockholders.
The board of directors may authorize the issuance of preferred
stock with voting or conversion rights that could harm the
voting power or other rights of the holders of the common stock,
or that could decrease the amount of earnings and assets
available for distribution to the holders of common stock. The
issuance of preferred stock, while providing flexibility in
connection with possible acquisitions and other corporate
purposes, could, among other things, have the effect of
delaying, deferring or preventing a change in control of us and
might harm the market price of our common stock and the voting
and other rights of the holders of common stock. We have no
current plans to issue any shares of preferred stock.
Registration Rights
After this offering, the holders of 17,579,758 shares of
common stock issued upon conversion of the preferred stock will
be entitled to contractual rights to require us to register
those shares under the Securities Act. If we propose to register
any of our securities under the Securities Act for our own
account, holders of those shares are entitled to include their
shares in our registration, provided, among other conditions,
that the underwriters of any such offering have the right to
limit the number of shares included in the registration. These
holders have waived their rights to include their shares in this
offering. Six months after the effective date of the
registration statement of which this prospectus is a part, and
subject to limitations and conditions specified in the investor
rights agreement with the holders, holders of a majority of the
shares of common stock issued upon conversion of the preferred
stock may require us to prepare and file a registration
statement under the Securities Act at our expense covering those
shares, provided that the shares to be included in the
registration have an anticipated aggregate public offering price
of at least $10 million. We are not obligated to effect
more than two of these stockholder-initiated registrations.
Holders of those shares may also require us to file additional
registration statements, subject to limitations specified in the
investor rights agreement.
Anti-Takeover Effects of Delaware Law and Our Certificate of
Incorporation and Bylaws
The provisions of Delaware law, our certificate of incorporation
and our bylaws described below may have the effect of delaying,
deferring or discouraging another party from acquiring control
of us.
We will be subject to the provisions of Section 203 of the
Delaware General Corporation Law regulating corporate takeovers.
In general, those provisions prohibit a Delaware corporation
from engaging in any
84
business combination with any interested stockholder for a
period of three years following the date that the stockholder
became an interested stockholder, unless:
|
|
|
|
|
the transaction is approved by the board before the date the
interested stockholder attained that status;
|
|
|
|
upon consummation of the transaction that resulted in the
stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the
corporation outstanding at the time the transaction
commenced; or
|
|
|
|
on or after the date the business combination is approved by the
board and authorized at a meeting of stockholders by at least
two-thirds of the outstanding voting stock that is not owned by
the interested stockholder.
|
Section 203 defines business combination to
include the following:
|
|
|
|
|
any merger or consolidation involving the corporation and the
interested stockholder;
|
|
|
|
any sale, transfer, pledge or other disposition of 10% or more
of the assets of the corporation involving the interested
stockholder;
|
|
|
|
subject to certain exceptions, any transaction that results in
the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder;
|
|
|
|
any transaction involving the corporation that has the effect of
increasing the proportionate share of the stock of any class or
series of the corporation beneficially owned by the interested
stockholder; or
|
|
|
|
the receipt by the interested stockholder of the benefit of any
loans, advances, guarantees, pledges or other financial benefits
provided by or through the corporation.
|
In general, Section 203 defines an interested stockholder
as any entity or person beneficially owning 15% or more of the
outstanding voting stock of the corporation and any entity or
person affiliated with or controlling or controlled by any of
these entities or persons.
A Delaware corporation may opt out of this provision either with
an express provision in its original certificate of
incorporation or in an amendment to its certificate of
incorporation or bylaws approved by its stockholders. However,
we have not opted out, and do not currently intend to opt out
of, this provision. The statute could prohibit or delay mergers
or other takeover or change in control attempts and,
accordingly, may discourage attempts to acquire us.
Following the completion of this offering, our certificate of
incorporation and bylaws will provide that:
|
|
|
|
|
our bylaws may be amended or repealed only by a two-thirds vote
of our board of directors or a two-thirds stockholder vote;
|
|
|
|
no action can be taken by stockholders except at an annual or
special meeting of the stockholders called in accordance with
our bylaws, and stockholders may not act by written consent;
|
|
|
|
stockholders may not call special meetings of the stockholders
or fill vacancies on the board;
|
|
|
|
the approval of holders of two-thirds of the shares entitled to
vote at an election of directors will be required to amend or
repeal the provisions of our certificate of incorporation
regarding the inability of stockholders to take action by
written consent;
|
|
|
|
our board of directors will be authorized to issue preferred
stock without stockholder approval, as described above; and
|
85
|
|
|
|
|
we will indemnify officers and directors against losses that
they may incur in investigations and legal proceedings resulting
from their services to us, which may include services in
connection with takeover defense measures.
|
Limitation of Liability and Indemnification Matters
We have adopted provisions in our certificate of incorporation
that limit the liability of our directors for monetary damages
for breach of their fiduciary duty as directors, except for
liability that cannot be eliminated under the Delaware General
Corporation Law. Delaware law provides that directors of a
company will not be personally liable for monetary damages for
breach of their fiduciary duty as directors, except for
liabilities:
|
|
|
|
|
for any breach of their duty of loyalty to us or our
stockholders;
|
|
|
|
for acts or omissions not in good faith or which involve
intentional misconduct or a knowing violation of law;
|
|
|
|
for unlawful payment of dividend or unlawful stock repurchase or
redemption, as provided under Section 174 of the Delaware
General Corporation Law; or
|
|
|
|
for any transaction from which the director derived an improper
personal benefit.
|
Any amendment or repeal of these provisions requires the
approval of the holders of shares representing at least
two-thirds of the shares entitled to vote in the election of
directors, voting as one class.
Our certificate of incorporation and bylaws also provide that we
will indemnify our directors and officers to the fullest extent
permitted by Delaware law. Our certificate of incorporation and
bylaws also permit us to purchase insurance on behalf of any
officer, director, employee or other agent for any liability
arising out of that persons actions as our officer,
director, employee or agent, regardless of whether Delaware law
would permit indemnification. We have entered into separate
indemnification agreements with our directors and executive
officers that could require us, among other things, to indemnify
them against certain liabilities that may arise by reason of
their status or service as directors and to advance their
expenses incurred as a result of any proceeding against them as
to which they could be indemnified. We believe that the
limitation of liability provision in our certificate of
incorporation and the indemnification agreements will facilitate
our ability to continue to attract and retain qualified
individuals to serve as directors and officers.
Nasdaq Symbol
We have applied to list our common stock for quotation on the
Nasdaq National Market under the symbol GHDX.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is
Computershare Investor Services.
86
SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering, there has been no public market for our
common stock. We cannot predict the effect, if any, that market
sales of shares or the availability of shares for sale will have
on the market price prevailing from time to time. As described
below, no shares will be available for sale shortly after this
offering due to contractual and legal restrictions on resale.
Nevertheless, sales of our common stock in the public market
after the restrictions lapse, or the perception that those sales
may occur, could cause the prevailing market price to decrease
or to be lower than it might be in the absence of those sales or
perceptions.
Sale of Restricted Shares
Upon completion of this offering, we will have outstanding
24,335,381 shares of common stock. The shares of common
stock being sold in this offering will be freely tradable, other
than by any of our affiliates as defined in
Rule 144(a) under the Securities Act or anyone who purchase
in our directed share program who are subject to a 180-day
lockup agreement, without restriction or registration under the
Securities Act. All remaining shares were issued and sold by us
in private transactions and are eligible for public sale if
registered under the Securities Act or sold in accordance with
Rule 144 or Rule 701 under the Securities Act. These
remaining shares are restricted securities within
the meaning of Rule 144 under the Securities Act.
As a result of the lockup agreements, other contractual
restrictions on resale and the provisions of Rules 144,
144(k) and 701 described below, the restricted securities will
be available for sale in the public market as follows:
|
|
|
|
|
no shares will be eligible for sale prior to 180 days after
the date of this prospectus;
|
|
|
|
19,318,659 shares will be eligible for sale upon the
expiration of the lock-up agreements, described below, beginning
180 days after the date of this prospectus (subject to
extension) and when permitted under Rule 144, 144(k) or
701; and
|
|
|
|
641,691 shares will be eligible for sale upon the exercise
of vested options 180 days after the date of this
prospectus.
|
Lock-up Agreements
Our directors, executive officers and substantially all of our
stockholders and optionholders, who collectively hold an
aggregate of approximately 17,873,737 shares of common
stock (representing approximately 94.4% of our shares of common
stock outstanding prior to this offering), have agreed that they
will not sell any common stock owned by them without the prior
written consent of J.P. Morgan Securities Inc. and Lehman
Brothers Inc. on behalf of the underwriters for a period of
180 days from the date of this prospectus, subject to
extension as described below. At any time and without public
notice, J.P. Morgan Securities Inc. and Lehman Brothers Inc. may
in their sole discretion release some or all of the securities
from these lock-up agreements. To the extent shares are released
before the expiration of the lockup period and these shares are
sold into the market, the market price of our common stock could
decline. Immediately following the 180-day lockup period, shares
of our common stock outstanding after this offering will become
available for sale, subject to legal restrictions on resale. The
180-day lock-up period may be extended under certain
circumstances where we release, or pre-announce a release of,
our earnings or announce material news or a material event
shortly before or after the termination of the 180-day period.
See Underwriting Lock-Up Agreements.
Rule 144
In general, under Rule 144 as currently in effect,
beginning 90 days after the date of this prospectus, a
person deemed to be our affiliate, or a person holding
restricted shares who beneficially owns shares that were
87
not acquired from us or our affiliate within the previous one
year, would be entitled to sell within any three-month period a
number of shares that does not exceed the greater of:
|
|
|
|
|
1% of the then outstanding shares of common stock, or
approximately 243,353 shares immediately after this offering,
assuming no exercise of the underwriters over-allotment
option; or
|
|
|
|
the average weekly trading volume of the common stock during the
four calendar weeks preceding the date on which notice of the
sale is filed with the Securities and Exchange Commission.
|
Sales under Rule 144 are subject to requirements relating
to manner of sale, notice and availability of current public
information about us.
Rule 144(k)
A person, or persons whose shares are aggregated, who is not
deemed to have been our affiliate at any time during the
90 days immediately preceding the sale, and who
beneficially owned the shares proposed to be sold for at least
two years, including the holding period of any prior owner who
was not an affiliate of ours, may sell restricted securities
after this offering under Rule 144(k) without complying
with the volume limitations, manner of sale provisions, public
information or notice requirements of Rule 144. We
currently expect that approximately 1,977,962 shares will
qualify as Rule 144(k) shares within
180 days after the date of this prospectus; however, this
number may increase or decrease depending on a particular
stockholders status as an affiliate during the
90 days immediately preceding the sale.
Rule 701
Subject to various limitations on the aggregate offering price
of a transaction and other conditions, Rule 701 may be
relied upon with respect to the resale of securities originally
purchased from us by our employees, directors, officers,
consultants or advisers prior to the closing of this offering,
pursuant to written compensatory benefit plans or written
contracts relating to the compensation of such persons. In
addition, the Securities and Exchange Commission has indicated
that Rule 701 will apply to stock options granted by us
before this offering, along with the shares acquired upon
exercise of those options. Securities issued in reliance on
Rule 701 are deemed to be restricted securities and,
beginning 90 days after the date of this prospectus, unless
subject to the contractual restrictions described above, may be
sold by persons other than affiliates subject only to the manner
of sale provisions of Rule 144 and by affiliates under
Rule 144 without compliance with the minimum holding period
requirements.
Stock Options
We intend to file a registration statement under the Securities
Act covering 5,000,000 shares of common stock reserved for
issuance under our stock plans. This registration statement is
expected to be filed soon after the date of this prospectus and
will automatically become effective upon filing. Accordingly,
shares registered under this registration statement will be
available for sale in the open market, unless those shares are
subject to vesting restrictions with us or the contractual
restrictions described above.
Registration Rights
In addition, after this offering, the holders of approximately
17,579,758 shares of common stock will be entitled to
rights to cause us to register the sale of those shares under
the Securities Act. Registration of these shares under the
Securities Act would result in these shares, other than shares
purchased by our affiliates, becoming freely tradable without
restriction under the Securities Act immediately upon the
effectiveness of the registration. See Description of
Capital Stock Registration Rights.
88
UNDERWRITING
J.P. Morgan Securities Inc. and Lehman Brothers Inc. are
the joint book-running managers and, together with Piper
Jaffray & Co., Thomas Weisel Partners LLC and JMP
Securities LLC, are acting as representatives of the
underwriters. Under the terms of an Underwriting Agreement,
which is filed as an exhibit to the registration statement, each
of the underwriters named below has severally agreed to purchase
from us the respective number of common stock shown opposite its
name below:
|
|
|
|
|
|
|
|
Number of
|
|
Underwriter
|
|
Shares
|
|
|
|
|
|
J.P. Morgan Securities Inc.
|
|
|
|
|
Lehman Brothers Inc.
|
|
|
|
|
Piper Jaffray & Co.
|
|
|
|
|
Thomas Weisel Partners LLC
|
|
|
|
|
JMP Securities LLC
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
5,016,722
|
|
The underwriting agreement provides that the underwriters
obligation to purchase shares of common stock depends on the
satisfaction of the conditions contained in the underwriting
agreement including:
|
|
|
|
|
the obligation to purchase all of the shares of common stock
offered hereby, if any of the shares are purchased;
|
|
|
|
the representations and warranties made by us to the
underwriters are true in all material respects;
|
|
|
|
there is no material change in the financial markets; and
|
|
|
|
we deliver customary closing documents to the underwriters.
|
Commissions and Expenses
The following table summarizes the underwriting discounts and
commissions we will pay to the underwriters. These amounts are
shown assuming both no exercise and full exercise of the
underwriters option to purchase additional shares. The
underwriting fee is the difference between the initial price to
the public and the amount the underwriters pay to us for the
shares.
|
|
|
|
|
|
|
|
|
|
|
No Exercise
|
|
|
Full Exercise
|
|
|
|
|
|
|
|
|
Per share
|
|
$
|
|
|
|
$
|
|
|
Total
|
|
$
|
|
|
|
$
|
|
|
The representatives of the underwriters have advised us that the
underwriters propose to offer the shares of common stock
directly to the public at the public offering price on the cover
of this prospectus and to selected dealers, which may include
the underwriters, at such offering price less a selling
concession not in excess of
$ per
share. The underwriters may allow, and the selected dealers may
re-allow, a discount from the concession not in excess of
$ per
share to other dealers. After the offering, the representatives
may change the offering price and other selling terms.
The expenses of the offering that are payable by us are
estimated to be $1.8 million (exclusive of underwriting
discounts and commissions).
Option to Purchase Additional Shares
We have granted the underwriters an option exercisable for
30 days after the date of the underwriting agreement, to
purchase, from time to time, in whole or in part, up to an
aggregate of 752,508 shares at the public offering price
less underwriting discounts and commissions. This option may be
exercised if the
89
underwriters sell more than 5,016,722 shares in connection
with this offering. To the extent that this option is exercised,
each underwriter will be obligated, subject to certain
conditions, to purchase its pro rata portion of these additional
shares based on the underwriters percentage underwriting
commitment in the offering as indicated in the table at the
beginning of this Underwriting section.
Lock-up Agreements
We, all of our directors and executive officers and
substantially all of our stockholders and optionholders have
agreed that, without the prior written consent of each of
J.P. Morgan Securities Inc. and Lehman Brothers Inc. on
behalf of the underwriters, we and they will not, subject to
some exceptions, and limited extensions in certain
circumstances, directly or indirectly, offer, pledge, announce
the intention to sell, sell, contract to sell, sell an option or
contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, or otherwise
transfer or dispose of (or enter into any transaction or device,
that is designed to, or could be expected to, result in the
disposition by any person at any time in the future of) any
common stock or any securities which may be converted into or
exchanged for any common stock or enter into any swap or other
agreement that transfers, in whole or in part, any of the
economic consequences of ownership of the common stock for a
period of 180 days from the date of this prospectus.
The 180-day restricted period described in the preceding
paragraph will be extended if:
|
|
|
|
|
during the last 17 days of the 180-day restricted period we
issue an earnings release or announce material news or a
material event relating to us; or
|
|
|
|
prior to the expiration of the 180-day restricted period, we
announce that we will release earnings results during the 16-day
period beginning on the last day of the 180-day period,
|
in which case the restrictions described in the preceding
paragraph will continue to apply until the expiration of the
18-day period beginning on the issuance of the earnings release
or the announcement of the material news or material event.
Offering Price Determination
Prior to this offering, there has been no public market for our
common stock. The initial public offering price will be
negotiated between the representatives and us. In determining
the initial public offering price of our common stock, the
representatives will consider:
|
|
|
|
|
the history and prospectus for the industry in which we compete,
|
|
|
|
our financial information,
|
|
|
|
the ability of our management and our business potential and
earning prospects,
|
|
|
|
the prevailing securities markets at the time of this
offering, and
|
|
|
|
the recent market prices of, and the demand for, publicly traded
shares of generally comparable companies.
|
Indemnification
We have agreed to indemnify the underwriters against certain
liabilities, including liabilities under the Securities Act of
1933, as amended, and to contribute to payments that the
underwriters may be required to make for these liabilities.
90
Stabilization, Short Positions and Penalty Bids
The representatives may engage in stabilizing transactions,
short sales and purchases to cover positions created by short
sales, and penalty bids or purchases for the purpose of pegging,
fixing or maintaining the price of the common stock, in
accordance with Regulation M under the Securities Exchange
Act of 1934:
|
|
|
|
|
Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a
specified maximum.
|
|
|
|
A short position involves a sale by the underwriters of shares
in excess of the number of shares the underwriters are obligated
to purchase in the offering, which creates the syndicate short
position. This short position may be either a covered short
position or a naked short position. In a covered short position,
the number of shares involved in the sales made by the
underwriters in excess of the number of shares they are
obligated to purchase is not greater than the number of shares
that they may purchase by exercising their option to purchase
additional shares. In a naked short position, the number of
shares involved is greater than the number of shares in their
option to purchase additional shares. The underwriters may close
out any short position by either exercising their option to
purchase additional shares and/or purchasing shares in the open
market. In determining the source of shares to close out the
short position, the underwriters will consider, among other
things, the price of shares available for purchase in the open
market as compared to the price at which they may purchase
shares through their option to purchase additional shares. A
naked short position is more likely to be created if the
underwriters are concerned that there could be downward pressure
on the price of the shares in the open market after pricing that
could adversely affect investors who purchase in the offering.
|
|
|
|
Syndicate covering transactions involve purchases of the common
stock in the open market after the distribution has been
completed in order to cover syndicate short positions.
|
|
|
|
Penalty bids permit the representatives to reclaim a selling
concession from a syndicate member when the common stock
originally sold by the syndicate member is purchased in a
stabilizing or syndicate covering transaction to cover syndicate
short positions.
|
These stabilizing transactions, syndicate covering transactions
and penalty bids may have the effect of raising or maintaining
the market price of our common stock or preventing or retarding
a decline in the market price of the common stock. As a result,
the price of the common stock may be higher than the price that
might otherwise exist in the open market. These transactions may
be effected on the Nasdaq National Market or otherwise and, if
commenced, may be discontinued at any time.
Neither we nor any of the underwriters make any representation
or prediction as to the direction or magnitude of any effect
that the transactions described above may have on the price of
the common stock. In addition, neither we nor any of the
underwriters make representation that the representatives will
engage in these stabilizing transactions or that any
transaction, once commenced, will not be discontinued without
notice.
Electronic Distribution
A prospectus in electronic format may be made available on the
Internet sites or through other online services maintained by
one or more of the underwriters and/or selling group members
participating in this offering, or by their affiliates. In those
cases, prospective investors may view offering terms online and,
depending upon the particular underwriter or selling group
member, prospective investors may be allowed to place orders
online. The underwriters may agree with us to allocate a
specific number of shares for sale to online brokerage account
holders. Any such allocation for online distributions will be
made by the representatives on the same basis as other
allocations.
Other than the prospectus in electronic format, the information
on any underwriters or selling group members web
site and any information contained in any other web site
maintained by an underwriter or selling group member is not part
of the prospectus or the registration statement of which this
prospectus forms a part, has not been approved and/or endorsed
by us or any underwriter or selling group member in its capacity
as underwriter or selling group member and should not be relied
upon by investors.
91
The Nasdaq National Market
We have applied to list our shares of common stock for quotation
on the Nasdaq National Market under the symbol GHDX.
Discretionary Sales
The underwriters have informed us that they do not intend to
confirm sales to discretionary accounts that exceed 5% of the
total number of shares offered by them.
Stamp Taxes
If you purchase shares of common stock offered in this
prospectus, you may be required to pay stamp taxes and other
charges under the laws and practices of the country of purchase,
in addition to the offering price listed on the cover page of
this prospectus.
Relationships
The underwriters and their affiliates may in the future perform
investment banking and advisory services for us from time to
time for which they may in the future receive customary fees and
expenses. The underwriters and their affiliates may, from time
to time, engage in transactions with or perform services for our
affiliates and us in the ordinary course of their business.
Certain affiliates of J.P. Morgan Securities Inc., one of
the representatives of the underwriters, purchased an aggregate
of 869,565 shares of our series D preferred stock for
approximately $2.0 million in May 2002.
Directed Share Program
At our request, the underwriters have reserved at the initial
public offering price up to 10% of the shares offered hereby for
our employees, less any shares sold to several of our
significant existing stockholders as described below. The number
of shares available for sale to the general public will be
reduced to the extent our employees purchase reserved shares.
Any reserved shares not purchased will be offered by the
underwriters to the general public on the same basis as the
other shares offered hereby. The directed share program will be
arranged through one of our underwriters, Lehman Brothers.
Insider Participation in the Offering
Several of our significant existing stockholders, including
funds affiliated with Julian C. Baker, Felix J. Baker
and Integral Capital Partners VI, L.P. or their affiliates, have
indicated an interest in purchasing up to an aggregate of
500,000 shares of our common stock in this offering, less any
shares sold to our employees pursuant to our directed share
program. However, because indications of interest are not
binding upon us or the prospective purchasers, these
stockholders may not acquire any shares in this offering.
European Economic Area
In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a
Relevant Member State), each underwriter has
represented and agreed that with effect from and including the
date on which the Prospectus Directive is implemented in that
Relevant Member State (the Relevant Implementation
Date) it has not made and will not make an offer of shares
of common stock being offered hereby to the public in that
Relevant Member State prior to the publication of a prospectus
in relation to such shares which has been approved by the
competent authority in that Relevant Member State or, where
appropriate, approved in another Relevant Member State and
notified to the competent authority in that Relevant Member
State, all in accordance with the Prospectus Directive. However,
with effect from and including the Relevant Implementation Date,
it may make an offer of shares of our common stock to the public
in that Relevant Member State at any time:
|
|
|
|
|
to legal entities which are authorized or regulated to operate
in the financial markets or, if not so authorized or regulated,
whose corporate purpose is solely to invest in securities;
|
92
|
|
|
|
|
to any legal entity which has two or more of (1) an average
of at least 250 employees during the last financial year;
(2) a total balance sheet of more than
43,000,000 and
(3) an annual net turnover of more than
50,000,000, as
shown in its last annual or consolidated accounts; or
|
|
|
|
in any other circumstances which do not require the publication
by the issuer of a prospectus pursuant to Article 3 of the
Prospectus Directive.
|
For the purposes of this provision, the expression an
offer of shares of our common stock to the public in
any Relevant Member State means the communication in any form
and by any means of sufficient information on the terms of the
offer and the shares to be offered so as to enable an investor
to decide to purchase or subscribe such shares, as may be varied
in that Member State by any measure implementing the Prospectus
Directive in that Member State and the expression
Prospectus Directive means Directive 2003/71/ EC and
includes any relevant implementing measure in each Relevant
Member State.
Germany
The shares have not been and will not be offered to the public
within the meaning of the German Sales Prospectus Act
(
Verkaufsprospektgesetz
) or the German Investment Act
(
Investmentgesetz
). The shares have not been and will not
be listed on a German exchange. No sales prospectus pursuant to
the German Sales Prospectus Act has been or will be published or
circulated in Germany or filed with the German Federal Financial
Supervisory Authority (
Bundesanstalt für
Finanzdienstleistungsaufsicht
) or any other governmental or
regulatory authority in Germany. This prospectus does not
constitute an offer to the public in Germany and it does not
serve for public distribution of the shares in Germany. Neither
this prospectus, nor any other document issued in connection
with this offering, may be issued or distributed to any person
in Germany except under circumstances which do not constitute an
offer to the public within the meaning of the German Sales
Prospectus Act or the German Investment Act.
Italy
The offering has not been registered with the Commissione
Nazionale per le Società e la Borsa (CONSOB) pursuant
to Italian securities legislation. The shares may not be offered
or sold nor may the prospectus or any other offering materials
be distributed in the Republic of Italy unless such offer, sale
or distribution is:
|
|
|
(1) made by an investment firm, bank or financial
intermediary permitted to conduct such activities in the
Republic of Italy in accordance with Legislative Decree
No. 385 of September 1, 1993 (Decree No. 385),
Legislative Decree No. 58 of February 24, 1998, CONSOB
Regulation No. 11971 or May 14, 1999 and any other
applicable laws and regulations;
|
|
|
(2) made (i) to professional investors (operatori
qualificati) as defined in Article 31, second paragraph of
CONSOB Regulation No. 11422 of July 1, 1998, as
amended, or Regulation No. 11522, (ii) in
circumstances where an exemption from the rules governing
solicitations to the public at large applies pursuant to
Article 100 of Legislative Decree No. 58 of February
24, 1998 and Article 33, first paragraph, of CONSOB
Regulation No. 11971 of May 14, 1999, as amended
or (iii) to persons located in the Republic of Italy who
submit an unsolicited request to purchase shares; and
|
|
|
(3) in compliance with all relevant Italian securities and
tax laws and regulations.
|
Switzerland
The shares may not be offered or sold to any investors in
Switzerland other than on a non-public basis. This prospectus
does not constitute a prospectus within the meaning of
Article 652a and Art. 1156 of the Swiss Code of Obligations
(
Schweizerisches Obligationenrecht
). Neither this
offering nor the shares have been or will be approved by any
Swiss regulatory authority.
93
United Kingdom
Each underwriter has represented, warranted and agreed that:
|
|
|
(1) it has not offered or sold and, prior to the expiry of
a period of six months from the closing date, will not offer or
sell any shares to persons in the United Kingdom except to
persons whose ordinary activities involve them in acquiring,
holding, managing or disposing of investments (as principal or
agent) for the purposes of their businesses or otherwise in
circumstances which have not resulted and will not result in an
offer to the public in the United Kingdom within the meaning of
the Public Offers of Securities Regulations 1995;
|
|
|
(2) it has only communicated or caused to be communicated
and will only communicate or cause to be communicated any
invitation or inducement to engage in investment activity
(within the meaning of section 21 of the Financial Services and
Markets Act 2000, or FSMA) received by it in connection with the
issue or sale of any shares in circumstances in which section
21(1) of the FSMA does not apply to the Issuer; and
|
|
|
(3) it has complied and will comply with all applicable
provisions of the FSMA with respect to anything done by it in
relation to the shares in, from or otherwise involving the
United Kingdom.
|
94
LEGAL MATTERS
The validity of the common stock offered by this prospectus will
be passed upon for us by Pillsbury Winthrop Shaw Pittman LLP,
San Francisco and Palo Alto, California. An entity in which
attorneys and former attorneys of Pillsbury Winthrop Shaw
Pittman LLP are members, and certain attorneys of Pillsbury
Winthrop Shaw Pittman LLP, own beneficially an aggregate of
19,035 shares of our common stock. Selected legal matters
relating to the offering will be passed upon for the
underwriters by Simpson Thacher & Bartlett LLP, Palo
Alto, California.
EXPERTS
The consolidated financial statements of Genomic Health, Inc. at
December 31, 2003 and 2004, and for each of the three years
in the period ended December 31, 2004, appearing in this
prospectus and registration statement have been audited by
Ernst & Young LLP, independent registered public
accounting firm, as set forth in their report thereon appearing
elsewhere herein, and are included in reliance upon such report
given on the authority of such firm as experts in accounting and
auditing.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the Securities and Exchange Commission a
registration statement under the Securities Act of 1933 with
respect to the common stock offered by this prospectus. This
prospectus does not contain all of the information set forth in
the registration statement and the exhibits and schedules to the
registration statement. Please refer to the registration
statement, exhibits and schedules for further information with
respect to the common stock offered by this prospectus.
Statements contained in this prospectus regarding the contents
of any contract or other document are only summaries. With
respect to any contract or document filed as an exhibit to the
registration statement, you should refer to the exhibit for a
copy of the contract or document, and each statement in this
prospectus regarding that contract or document is qualified by
reference to the exhibit. A copy of the registration statement
and its exhibits and schedules may be inspected without charge
at the Securities and Exchange Commissions public
reference room, located at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the Securities and
Exchange Commission at 1-800-SEC-0330 for further information on
the public reference room. Our Securities and Exchange
Commission filings are also available to the public from the
Securities and Exchange Commissions website at www.sec.gov.
Upon completion of this offering, we will be subject to the
information reporting requirements of the Securities Exchange
Act of 1934 and we intend to file reports, proxy statements and
other information with the Securities and Exchange Commission.
95
GENOMIC HEALTH, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders
Genomic Health, Inc.
We have audited the accompanying consolidated balance sheets of
Genomic Health, Inc. as of December 31, 2003 and 2004 and
the related consolidated statements of operations, convertible
preferred stock and stockholders equity (deficit) and cash
flows for each of the three years in the period ended
December 31, 2004. These financial statements are the
responsibility of the Companys management. Our
responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. We were not engaged to perform an
audit of the Companys internal control over financial
reporting. Our audits included consideration of internal control
over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not
for the purpose of expressing an opinion on the effectiveness of
the Companys internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by
management, and evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable
basis for our opinion.
In our opinion, the financial statements referred to above
present fairly, in all material respects, the consolidated
financial position of Genomic Health, Inc. at December 31,
2003 and 2004 and the consolidated results of its operations and
its cash flows for each of the three years in the period ended
December 31, 2004, in conformity with U.S. generally
accepted accounting principles.
Palo Alto, California
May 13, 2005,
except for the ninth paragraph of Note 1,
as to which the date is September 8, 2005.
F-2
Genomic Health, Inc.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro Forma
|
|
|
|
December 31,
|
|
|
|
|
Stockholders
|
|
|
|
|
|
|
June 30,
|
|
|
Equity at
|
|
|
|
2003
|
|
|
2004
|
|
|
2005
|
|
|
June 30, 2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
11,062
|
|
|
$
|
38,275
|
|
|
$
|
25,231
|
|
|
|
|
|
|
Accounts receivable
|
|
|
|
|
|
|
|
|
|
|
100
|
|
|
|
|
|
|
Prepaid expenses and other current assets
|
|
|
563
|
|
|
|
901
|
|
|
|
2,265
|
|
|
|
|
|
|
Employee note receivable - current portion
|
|
|
|
|
|
|
75
|
|
|
|
75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
11,625
|
|
|
|
39,251
|
|
|
|
27,671
|
|
|
|
|
|
Employee note receivable - long-term portion
|
|
|
|
|
|
|
38
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
1,288
|
|
|
|
2,116
|
|
|
|
3,010
|
|
|
|
|
|
Restricted cash
|
|
|
50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets
|
|
|
133
|
|
|
|
133
|
|
|
|
151
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
13,096
|
|
|
$
|
41,538
|
|
|
$
|
30,832
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity (deficit)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
827
|
|
|
$
|
1,101
|
|
|
$
|
2,009
|
|
|
|
|
|
|
Accrued compensation
|
|
|
342
|
|
|
|
603
|
|
|
|
747
|
|
|
|
|
|
|
Accrued expenses and other current liabilities
|
|
|
249
|
|
|
|
776
|
|
|
|
832
|
|
|
|
|
|
|
Notes payable - current portion
|
|
|
|
|
|
|
|
|
|
|
777
|
|
|
|
|
|
|
Note payable due to related party
|
|
|
161
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
1,579
|
|
|
|
2,480
|
|
|
|
4,365
|
|
|
|
|
|
Notes payable - long-term portion
|
|
|
|
|
|
|
|
|
|
|
2,483
|
|
|
|
|
|
Convertible preferred stock, $0.0001 par value;
101,216,958 shares authorized, 29,936,839, 48,480,819 and
48,480,819 shares issued and outstanding at
December 31, 2003 and 2004 and June 30, 2005
(unaudited), respectively; aggregate liquidation preference of
$103,599 at December 31, 2004 and June 30, 2005
(unaudited); no shares issued and outstanding pro forma
|
|
|
51,064
|
|
|
|
103,212
|
|
|
|
103,212
|
|
|
$
|
|
|
Stockholders equity (deficit):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, $0.0001 par value; 105,000,000 shares
authorized, 1,674,113, 1,875,530 and 1,932,921 shares
issued and outstanding at December 31, 2003 and 2004 and
June 30, 2005 (unaudited), respectively;
18,884,404 shares issued and outstanding pro forma
(unaudited)
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
2
|
|
|
Additional paid-in capital
|
|
|
279
|
|
|
|
4,123
|
|
|
|
5,085
|
|
|
|
108,296
|
|
|
Deferred stock-based compensation
|
|
|
|
|
|
|
(3,456
|
)
|
|
|
(3,793
|
)
|
|
|
(3,793
|
)
|
|
Accumulated deficit
|
|
|
(39,827
|
)
|
|
|
(64,822
|
)
|
|
|
(80,521
|
)
|
|
|
(80,521
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity (deficit)
|
|
|
(39,547
|
)
|
|
|
(64,154
|
)
|
|
|
(79,228
|
)
|
|
$
|
23,984
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity (deficit)
|
|
$
|
13,096
|
|
|
$
|
41,538
|
|
|
$
|
30,832
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
F-3
Genomic Health, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
|
Year Ended December 31,
|
|
|
June 30,
|
|
|
|
|
|
|
|
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenues
|
|
$
|
|
|
|
$
|
|
|
|
$
|
227
|
|
|
$
|
33
|
|
|
$
|
1,585
|
|
|
Contract revenues
|
|
|
|
|
|
|
125
|
|
|
|
100
|
|
|
|
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
|
|
|
|
125
|
|
|
|
327
|
|
|
|
33
|
|
|
|
1,685
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenues
|
|
|
|
|
|
|
|
|
|
|
1,828
|
|
|
|
931
|
|
|
|
2,874
|
|
|
Research and development
|
|
|
7,053
|
|
|
|
9,069
|
|
|
|
10,040
|
|
|
|
5,182
|
|
|
|
4,630
|
|
|
Selling and marketing
|
|
|
754
|
|
|
|
2,805
|
|
|
|
9,856
|
|
|
|
4,449
|
|
|
|
7,415
|
|
|
General and administrative
|
|
|
3,753
|
|
|
|
3,686
|
|
|
|
3,869
|
|
|
|
1,832
|
|
|
|
2,787
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
11,560
|
|
|
|
15,560
|
|
|
|
25,593
|
|
|
|
12,394
|
|
|
|
17,706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(11,560
|
)
|
|
|
(15,435
|
)
|
|
|
(25,266
|
)
|
|
|
(12,361
|
)
|
|
|
(16,021
|
)
|
Interest income
|
|
|
502
|
|
|
|
199
|
|
|
|
295
|
|
|
|
121
|
|
|
|
393
|
|
Interest expense
|
|
|
(13
|
)
|
|
|
(14
|
)
|
|
|
(4
|
)
|
|
|
(3
|
)
|
|
|
(72
|
)
|
Other (expense) income, net
|
|
|
3
|
|
|
|
|
|
|
|
(20
|
)
|
|
|
(20
|
)
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(11,068
|
)
|
|
$
|
(15,250
|
)
|
|
$
|
(24,995
|
)
|
|
$
|
(12,263
|
)
|
|
$
|
(15,699
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(11.95
|
)
|
|
$
|
(12.43
|
)
|
|
$
|
(14.38
|
)
|
|
$
|
(7.26
|
)
|
|
$
|
(8.28
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing basic and diluted net loss per share
|
|
|
925,814
|
|
|
|
1,226,444
|
|
|
|
1,737,652
|
|
|
|
1,687,964
|
|
|
|
1,895,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma net loss per share (unaudited)
|
|
|
|
|
|
|
|
|
|
$
|
(1.60
|
)
|
|
|
|
|
|
$
|
(0.83
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing pro forma net loss per share (unaudited)
|
|
|
|
|
|
|
|
|
|
|
15,632,759
|
|
|
|
|
|
|
|
18,847,108
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
F-4
Genomic Health, Inc.
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND
STOCKHOLDERS EQUITY (DEFICIT)
(In thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock
|
|
|
|
Common Stock
|
|
|
Additional
|
|
|
Deferred
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
Paid-In
|
|
|
Stock-based
|
|
|
|
|
Stockholders
|
|
|
|
Shares
|
|
|
Amount
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Compensation
|
|
|
Accumulated Deficit
|
|
|
Equity (Deficit)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2001
|
|
|
25,862,926
|
|
|
$
|
41,783
|
|
|
|
|
1,373,750
|
|
|
$
|
|
|
|
$
|
27
|
|
|
|
|
|
|
$
|
(13,509
|
)
|
|
$
|
(13,482
|
)
|
Issuance of Series D convertible preferred stock in March,
May and November 2002 to investors at $2.30 per share for cash
(net of issuance costs of $79)
|
|
|
4,073,913
|
|
|
|
9,290
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock to consultants upon exercise of stock
options at $0.66 to $0.69 per share for cash
|
|
|
|
|
|
|
|
|
|
|
|
13,133
|
|
|
|
1
|
|
|
|
9
|
|
|
|
|
|
|
|
|
|
|
|
10
|
|
Issuance of common stock to an employee upon exercise of stock
options at $0.66 per share for cash
|
|
|
|
|
|
|
|
|
|
|
|
3,333
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
Stock-based compensation related to consultant options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36
|
|
|
|
|
|
|
|
|
|
|
|
36
|
|
Net loss and comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,068
|
)
|
|
|
(11,068
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2002
|
|
|
29,936,839
|
|
|
|
51,073
|
|
|
|
|
1,390,216
|
|
|
|
1
|
|
|
|
74
|
|
|
|
|
|
|
|
(24,577
|
)
|
|
|
(24,502
|
)
|
Issuance of common stock to consultants upon exercise of stock
options at $0.60 to $0.69 per share for cash
|
|
|
|
|
|
|
|
|
|
|
|
36,500
|
|
|
|
|
|
|
|
25
|
|
|
|
|
|
|
|
|
|
|
|
25
|
|
Issuance of common stock to employees upon exercise of stock
options at $0.60 to $0.69 per share for cash
|
|
|
|
|
|
|
|
|
|
|
|
247,396
|
|
|
|
|
|
|
|
163
|
|
|
|
|
|
|
|
|
|
|
|
163
|
|
Series E issuance costs
|
|
|
|
|
|
|
(9
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation related to consultant options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
17
|
|
Net loss and comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(15,250
|
)
|
|
|
(15,250
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2003
|
|
|
29,936,839
|
|
|
|
51,064
|
|
|
|
|
1,674,113
|
|
|
|
1
|
|
|
|
279
|
|
|
|
|
|
|
|
(39,827
|
)
|
|
|
(39,547
|
)
|
Issuance of common stock to consultants upon exercise of stock
options at $0.66 to $1.38 per share for cash
|
|
|
|
|
|
|
|
|
|
|
|
1,125
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
Repurchase of common stock issued to founders
|
|
|
|
|
|
|
|
|
|
|
|
(13,672
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock to employees upon exercise of stock
options at $0.66 to $1.38 per share for cash
|
|
|
|
|
|
|
|
|
|
|
|
213,964
|
|
|
|
|
|
|
|
143
|
|
|
|
|
|
|
|
|
|
|
|
143
|
|
Issuance of Series E convertible preferred stock at
$2.82 per share for cash (net of issuance costs of $146)
|
|
|
18,543,980
|
|
|
|
52,148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,647
|
|
|
|
(3,647
|
)
|
|
|
|
|
|
|
|
|
Amortization of deferred stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
191
|
|
|
|
|
|
|
|
191
|
|
Stock-based compensation related to consultant options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
53
|
|
|
|
|
|
|
|
|
|
|
|
53
|
|
Net loss and comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(24,995
|
)
|
|
|
(24,995
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2004
|
|
|
48,480,819
|
|
|
|
103,212
|
|
|
|
|
1,875,530
|
|
|
|
1
|
|
|
|
4,123
|
|
|
|
(3,456
|
)
|
|
|
(64,822
|
)
|
|
|
(64,154
|
)
|
Issuance of common stock to employees upon exercise of stock
options at $0.66 to $1.38 per share for cash (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
56,058
|
|
|
|
|
|
|
|
56
|
|
|
|
|
|
|
|
|
|
|
|
56
|
|
Issuance of common stock to consultants upon exercise of stock
options at $0.69 to $3.00 per share for cash (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
1,333
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
Stock-based compensation related to consultant options
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58
|
|
|
|
|
|
|
|
|
|
|
|
58
|
|
Deferred stock-based compensation (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
846
|
|
|
|
(846
|
)
|
|
|
|
|
|
|
|
|
Amortization of deferred stock-based compensation (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
509
|
|
|
|
|
|
|
|
509
|
|
Net loss and comprehensive loss (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(15,699
|
)
|
|
|
(15,699
|
)
|
Balance at June 30, 2005 (unaudited)
|
|
|
48,480,819
|
|
|
$
|
103,212
|
|
|
|
|
1,932,921
|
|
|
$
|
1
|
|
|
$
|
5,085
|
|
|
$
|
(3,793
|
)
|
|
$
|
(80,521
|
)
|
|
$
|
(79,228
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
F-5
Genomic Health, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
|
Year Ended December 31,
|
|
|
June 30,
|
|
|
|
|
|
|
|
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
Operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(11,068
|
)
|
|
$
|
(15,250
|
)
|
|
$
|
(24,995
|
)
|
|
$
|
(12,263
|
)
|
|
$
|
(15,699
|
)
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
642
|
|
|
|
824
|
|
|
|
1,008
|
|
|
|
486
|
|
|
|
690
|
|
|
Amortization of deferred stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
191
|
|
|
|
9
|
|
|
|
509
|
|
|
Non-employee stock-based compensation expense
|
|
|
36
|
|
|
|
17
|
|
|
|
53
|
|
|
|
10
|
|
|
|
58
|
|
|
Loss on disposal of property and equipment
|
|
|
6
|
|
|
|
|
|
|
|
20
|
|
|
|
20
|
|
|
|
(31
|
)
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(100
|
)
|
|
|
Employee note receivable
|
|
|
18
|
|
|
|
|
|
|
|
(113
|
)
|
|
|
|
|
|
|
38
|
|
|
|
Prepaid expenses and other current assets
|
|
|
(366
|
)
|
|
|
(61
|
)
|
|
|
(338
|
)
|
|
|
(243
|
)
|
|
|
(1,364
|
)
|
|
|
Other assets
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(18
|
)
|
|
|
Accounts payable
|
|
|
(105
|
)
|
|
|
655
|
|
|
|
274
|
|
|
|
332
|
|
|
|
908
|
|
|
|
Note payable to related party
|
|
|
(1,527
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses and other liabilities
|
|
|
17
|
|
|
|
116
|
|
|
|
527
|
|
|
|
148
|
|
|
|
144
|
|
|
|
Accrued compensation
|
|
|
|
|
|
|
155
|
|
|
|
261
|
|
|
|
85
|
|
|
|
56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(12,344
|
)
|
|
|
(13,544
|
)
|
|
|
(23,112
|
)
|
|
|
(11,416
|
)
|
|
|
(14,809
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of property and equipment
|
|
|
(737
|
)
|
|
|
(739
|
)
|
|
|
(1,856
|
)
|
|
|
(797
|
)
|
|
|
(1,553
|
)
|
Restricted cash
|
|
|
106
|
|
|
|
|
|
|
|
50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(631
|
)
|
|
|
(739
|
)
|
|
|
(1,806
|
)
|
|
|
(797
|
)
|
|
|
(1,553
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from (repayment of) long-term debt due to related party
|
|
|
313
|
|
|
|
(152
|
)
|
|
|
(161
|
)
|
|
|
(79
|
)
|
|
|
|
|
Proceeds from notes payable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,260
|
|
Proceeds from issuance of common stock
|
|
|
11
|
|
|
|
188
|
|
|
|
144
|
|
|
|
32
|
|
|
|
58
|
|
Sale of property and equipment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds from issuance of convertible preferred stock
|
|
|
9,291
|
|
|
|
(9
|
)
|
|
|
52,148
|
|
|
|
29,919
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
9,615
|
|
|
|
27
|
|
|
|
52,131
|
|
|
|
29,872
|
|
|
|
3,318
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
(3,360
|
)
|
|
|
(14,256
|
)
|
|
|
27,213
|
|
|
|
17,659
|
|
|
|
(13,044
|
)
|
Cash and cash equivalents at the beginning of period
|
|
|
28,678
|
|
|
|
25,318
|
|
|
|
11,062
|
|
|
|
11,062
|
|
|
|
38,275
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the end of period
|
|
$
|
25,318
|
|
|
$
|
11,062
|
|
|
$
|
38,275
|
|
|
$
|
28,721
|
|
|
$
|
25,231
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
1
|
|
|
$
|
26
|
|
|
$
|
4
|
|
|
$
|
3
|
|
|
$
|
72
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
F-6
Genomic Health, Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Information subsequent to December 31, 2004 and
pertaining to June 30, 2005 and
the six months ended June 30, 2004 and 2005 is
unaudited)
|
|
Note 1.
|
The Company and Summary of Significant Accounting Policies
|
|
|
|
Description of Business and Principles of
Consolidation
|
Genomic Health, Inc. (the Company) was incorporated
in Delaware in August 2000. The Company was organized to deliver
individualized genomic information to patients and their
physicians to improve the quality of treatment decisions for
patients with cancer.
Since the Companys inception in 2000, the focus of its
operations has consisted principally of the development of
initial products, raising capital, establishing facilities and
recruiting personnel. In January 2004, the Company
commercialized its first product, Onco
type
DX, a genomic
test used to quantify the likelihood of recurrence in early
stage breast cancer.
The Company has incurred significant losses and expects to incur
additional losses in the foreseeable future as commercial and
development efforts continue. If financing arrangements
contemplated by management are not realized, the Company may
have to seek other sources of capital or re-evaluate its
operating plan.
In October 2003, the Company established a wholly owned
subsidiary, Oncotype Laboratories, Inc. The entity is currently
inactive. All intercompany transactions are eliminated in
consolidation.
The preparation of the consolidated financial statements in
conformity with U.S. generally accepted accounting
principles requires management to make estimates and assumptions
that affect the amounts reported in the consolidated financial
statements and accompanying notes. Actual results may differ,
and those differences may be material.
|
|
|
Unaudited Interim Consolidated Results
|
The accompanying consolidated balance sheet as of June 30,
2005, the consolidated statements of operations and cash flows
for the six months ended June 30, 2004 and 2005 and the
consolidated statements of convertible preferred stock and
stockholders equity (deficit) for the six months ended
June 30, 2005 are unaudited. The unaudited interim
financial statements have been prepared on the same basis as the
annual financial statements and, in the opinion of management,
reflect all the adjustments, which include only normal recurring
adjustments, necessary to present fairly the Companys
financial position as of June 30, 2005. Results for the six
months ended June 30, 2004 and 2005 are not necessarily
indicative of the results to be expected for the year ended
December 31, 2005 or for any future interim period or for
any future year.
|
|
|
Unaudited Pro Forma Information
|
The pro forma information assumes all of the convertible
preferred stock outstanding will automatically convert into
16,160,273 shares of common stock, based on the shares of
convertible preferred stock outstanding at June 30, 2005.
The Company has filed a registration statement with the
Securities and Exchange Commission to sell shares of its common
stock to the public. If the initial public offering price of the
Companys common stock is less than $11.40 per share,
every three shares of Series A, B, C, and D preferred stock
will convert into one share of common stock and every three
shares of Series E preferred stock will convert into 1.128
shares of common stock, or an aggregate of
16,951,483 shares of common stock. Unaudited pro forma
stockholders equity, as adjusted for the assumed
conversion of the convertible preferred stock, is set forth on
the consolidated balance sheet.
F-7
On September 8, 2005, the board of directors of the Company
declared a conditional stock dividend of 791,210 shares to
stockholders of record prior to the date of the Companys
initial public offering. The conditional stock dividend will be
distributable if the initial public offering price of the
Companys common stock is greater than or equal to $11.40 a
share. The conditional stock dividend, if paid, will be a
ratable distribution to all holders of the Companys common
stock outstanding prior to closing of the initial public
offering and after giving effect to the conversion of all of the
Companys outstanding preferred stock. The Companys
outstanding stock options will be proportionately adjusted in
the event the conditional stock dividend is distributed. If the
conditional stock dividend is distributed, it will be recorded
in the quarter ended September 30, 2005. This dividend has
no material impact on the pro forma balance sheet because of the
Companys accumulated deficit. The 791,210 shares have been
included in the pro forma net loss per share calculation.
On September 8, 2005, the board of directors of the Company
approved a 1-for-3 reverse stock split of the Companys
outstanding shares of common stock. The reverse stock split will
be effected by filing an amended and restated certificate of
incorporation of the Company immediately prior to the
Companys initial public offering. All common share and per
share amounts contained in the consolidated financial statements
have been retroactively adjusted to reflect this stock split.
|
|
|
Cash and Cash Equivalents
|
The Company considers all highly liquid investments with
maturities of three months or less when purchased to be cash
equivalents. The Company invests in money market securities
through a major U.S. bank and is exposed to credit risk in
the event of default by the financial institution to the extent
of amounts recorded on the balance sheets.
The amortized cost of debt securities is adjusted for
amortization of premiums and accretion of discounts to maturity.
Such amortization is included in interest income. Realized gains
and losses and declines in the fair value of available-for-sale
securities below their cost that are deemed to be
other-than-temporary are reflected in other income. The cost of
securities sold is based on the specific identification method.
Interest on investments is included in interest income.
In connection with a bank agreement pertaining to a corporate
credit card account, the Company was required to hold a
certificate of deposit at 100% of the credit limit per account,
which totaled $50,000 as of December 31, 2003, and was
classified as restricted cash. During July 2004, this
restriction was removed by the bank and the amount was removed
from restricted cash on the balance sheet.
|
|
|
Fair Value of Financial Instruments
|
The carrying amounts of certain of the Companys financial
instruments, including cash and cash equivalents, approximate
fair value due to their short maturities. Based on borrowing
rates currently available to the Company for loans and capital
lease obligations with similar terms, the carrying value of the
Companys debt obligations approximates fair value.
Property and equipment are stated at cost. Depreciation is
calculated using the straight-line method over the estimated
useful lives of the assets, which range from three to five
years. Leasehold improvements are amortized using the
straight-line method over the estimated useful lives of the
assets or the term of the lease, whichever is shorter.
The Company reviews long-lived assets, including property and
equipment, for impairment whenever events or changes in business
circumstances indicate that the carrying amounts of the assets
may not be fully
F-8
recoverable. An impairment loss would be recognized when
estimated discounted future cash flows expected to result from
the use of the asset and its eventual disposition is less then
its carrying amount. Impairment, if any, is assessed using
discounted cash flows. Through June 30, 2005, there have
been no such losses.
Research and development expenses comprise the following types
of costs incurred in performing research and development
activities: salaries and benefits, allocated overhead and
facility occupancy costs, contract services and other outside
costs, and costs to acquire in-process research and development
projects and technologies that have no alternative future use.
Research and development expenses also include costs related to
activities performed under contracts with biopharmaceutical and
pharmaceutical companies. Research and development costs are
expensed as incurred.
One customer accounted for approximately 9% of the
Companys total revenue for the six months ended
June 30, 2005, and approximately 11% of the Companys
total revenue for the quarter ended June 30, 2005.
The Company displays comprehensive loss and its components as
part of the statements of convertible preferred stock and
stockholders equity (deficit). Comprehensive loss consists
entirely of net loss.
The Company accounts for software developed or obtained for
internal use in accordance with Statement of Position 98-1,
Accounting for the Costs of Computer Software Developed or
Obtained for Internal Use.
The statement requires
capitalization of certain costs incurred in the development of
internal-use software, including external direct material and
service costs and employee payroll and payroll-related costs.
Capitalized software costs, which are included in property and
equipment, are depreciated over three to five years.
|
|
|
Guarantees and Indemnifications
|
The Company, as permitted under Delaware law and in accordance
with its Bylaws, indemnifies its officers and directors for
certain events or occurrences, subject to certain limits, while
the officer or director is or was serving at the Companys
request in such capacity. The term of the indemnification period
is for the officers or directors lifetime. The
maximum amount of potential future indemnification is unlimited;
however, the Company has a director and officer insurance policy
that limits its exposure and may enable it to recover a portion
of any future amounts paid. The Company believes the fair value
of these indemnification agreements is minimal. Accordingly, the
Company has not recorded any liabilities for these agreements as
of December 31, 2004 or June 30, 2005.
The Company uses the liability method for income taxes, whereby
deferred income taxes are provided on items recognized for
financial reporting purposes over different periods than for
income tax purposes. Valuation allowances are provided when the
expected realization of tax assets does not meet a
more-likely-than-not criterion.
As permitted by Statement of Financial Accounting Standards
(SFAS) No. 123,
Accounting for
Stock-Based Compensation
(SFAS 123), as
amended by SFAS No. 148, the Company has elected to
follow Accounting Principles Board (APB)
Opinion 25,
Accounting for Stock Issued to Employees
(APB 25), and related interpretations in
accounting for stock option grants to employees using the
intrinsic value method and to disclose the pro forma effect of
SFAS 123. The information regarding net loss and net loss
per share
F-9
prepared in accordance with SFAS 123 has been determined as
if the Company had accounted for employee stock options under
the fair value method prescribed by SFAS 123 and the net
loss per share method under SFAS 148. The resulting effect
on net loss and net loss per share pursuant to SFAS 123 is
not likely to be representative of the effects in future years,
due to subsequent years including additional grants and years of
vesting.
The Company estimated the fair value of these options at the
date of grant using the Black-Scholes option valuation model
with the following weighted-average assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
June 30,
|
|
|
|
|
|
|
|
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
Volatility factor
|
|
|
80%
|
|
|
|
80%
|
|
|
|
80%
|
|
|
|
80%
|
|
|
|
80%
|
|
Average risk-free interest rate
|
|
|
4.0%
|
|
|
|
2.0%
|
|
|
|
2.8%
|
|
|
|
2.0%
|
|
|
|
4.0%
|
|
Dividend yield
|
|
|
0%
|
|
|
|
0%
|
|
|
|
0%
|
|
|
|
0%
|
|
|
|
0%
|
|
Expected life of options
|
|
|
4 years
|
|
|
|
4 years
|
|
|
|
4 years
|
|
|
|
4 years
|
|
|
|
4 years
|
|
In connection with the grant of certain stock options to
employees during the year ended December 31, 2004 and six
months ended June 30, 2005, the Company recorded deferred
stock compensation within stockholders equity
(deficit) of $3,647,000 and $846,000, respectively. This
represents the difference between the reassessed fair value of
common stock and the option exercise price at the date of grant.
Such amounts will be amortized over the vesting period of the
applicable options on a straight-line basis. For the year ended
December 31, 2004 and six months ended June 30, 2005,
the Company recorded stock-based compensation expense of
$191,000 and $509,000, respectively. The expected future
amortization expense under APB 25 for deferred stock-based
compensation for stock options granted through June 2005, is as
follows (in thousands):
|
|
|
|
|
Years Ending December 31,
|
|
|
|
|
|
2005 (remainder of the year)
|
|
$
|
559
|
|
2006
|
|
|
1,117
|
|
2007
|
|
|
1,117
|
|
2008 (and thereafter)
|
|
|
1,000
|
|
|
|
|
|
|
|
$
|
3,793
|
|
|
|
|
|
For purposes of disclosures pursuant to SFAS 123, as
amended by SFAS 148, the estimated fair value of options is
amortized to expense straight-line over the options
vesting period. The following table shows the pro forma effect
on net loss and net loss per common share if the fair value
provisions of SFAS 123 had been applied (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
June 30,
|
|
|
|
|
|
|
|
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
Net loss as reported
|
|
$
|
(11,068
|
)
|
|
$
|
(15,250
|
)
|
|
$
|
(24,995
|
)
|
|
$
|
(12,263
|
)
|
|
$
|
(15,699
|
)
|
Add: Total stock-based employee compensation expense included in
net loss
|
|
|
|
|
|
|
|
|
|
|
191
|
|
|
|
9
|
|
|
|
509
|
|
Deduct: Total stock-based employee compensation expense
determined under the fair-value based method for all awards
|
|
|
(27
|
)
|
|
|
(87
|
)
|
|
|
(320
|
)
|
|
|
(63
|
)
|
|
|
(633
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma net loss
|
|
$
|
(11,095
|
)
|
|
$
|
(15,337
|
)
|
|
$
|
(25,124
|
)
|
|
$
|
(12,317
|
)
|
|
$
|
(15,823
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share applicable to common stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted, as reported
|
|
$
|
(11.95
|
)
|
|
$
|
(12.43
|
)
|
|
$
|
(14.38
|
)
|
|
$
|
(7.26
|
)
|
|
$
|
(8.28
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted, pro forma
|
|
$
|
(11.98
|
)
|
|
$
|
(12.51
|
)
|
|
$
|
(14.46
|
)
|
|
$
|
(7.30
|
)
|
|
$
|
(8.35
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-10
Equity instruments granted to nonemployees are valued using the
Black-Scholes method and accounted for as prescribed by
SFAS 123 and Emerging Issues Task Force Consensus
No. 96-18,
Accounting for Equity Instruments that Are
Issued to Other Than Employees for Acquiring, or in Conjunction
with Selling, Goods or Services
, and will be subject to
periodic revaluation over their vesting terms.
Revenue Recognition
The Companys product revenues for tests performed are
recognized when the following criteria of revenue recognition
are met: (1) persuasive evidence that an arrangement
exists; (2) delivery has occurred or services rendered;
(3) the fee is fixed and determinable; and
(4) collectibility is reasonably assured.
Criterion (2) is satisfied when the Company performs the
test and generates and delivers a report to the physician.
Determination of criteria (3) and (4) is based on
managements judgments regarding the nature of the fee
charged for products or services delivered and the
collectibility of those fees. Product revenues where the
criteria set forth in (1) and (2) above are met, and (3)
and (4) above are not met, are recognized on a cash basis when
cash is received.
The Company generally bills third-party payors for
Onco
type
DX upon generation and delivery of a
Recurrence Score report to the physician. As such, the Company
takes assignment of benefits and the risk of collection with the
third-party payor. The Company usually bills the patient
directly for amounts owed after multiple requests for payment
have been denied or only partially paid by the insurance
carrier. As a relatively new test, Onco
type
DX may
be considered investigational by payors and not covered under
their reimbursement policies. Consequently, the Company pursues
case-by-case reimbursement where policies are not in place or
payment history has not been established. As a result, at the
time of delivery of the Recurrence Score to the physician, and
in the absence of a reimbursement contract or sufficient payment
history, collectibility cannot reasonably be assured and
revenues are therefore recognized at the time cash is collected.
Contract revenues are derived from studies conducted with
biopharmaceutical and pharmaceutical companies and are
recognized on a contract specific basis. Under certain
contracts, our input, measured in terms of full-time equivalent
level of effort or running a set of assays through our
laboratory under a contractual protocol, triggers payment
obligations and revenues are recognized as costs are incurred or
assays are processed. Certain contracts have payment obligations
that are triggered as milestones are complete, such as
completion of a successful set of experiments. In these cases,
revenues are recognized when the milestones are achieved.
|
|
|
Recently Issued Accounting Pronouncements
|
In December 2004, the FASB issued SFAS No. 123(R),
Share-Based Payment,
which is a revision of
SFAS 123,
Accounting for Stock-Based Compensation.
SFAS 123(R) is effective for public companies for the first
interim or annual period beginning after June 15, 2005,
supersedes APB 25, and amends SFAS No. 95,
Statement of Cash Flows.
Generally, the approach in
SFAS 123(R) is similar to the approach described in
SFAS 123, however, SFAS 123(R) requires all
share-based payments to employees, including grants of employee
stock options, to be recognized in the income statement based on
their fair values. Pro forma disclosure is no longer an
alternative. The new standard will be effective for the Company
beginning January 1, 2006.
Under SFAS 123(R), the Company must determine the appropriate
fair value model to be used for valuing share-based payments,
the amortization method for compensation cost and the transition
method to be used at date of adoption. The transition methods
include prospective and retroactive adoption options. Under the
retroactive adoption option, prior periods may be restated
either as of the beginning of the year of adoption or for all
periods presented. The prospective method requires that
compensation expense be recorded for all unvested stock options
at the beginning of the first quarter of adoption of
SFAS 123(R), while the retroactive method would record
compensation expense for all unvested stock options beginning
with the first period restated.
F-11
The Company is evaluating the requirements of SFAS 123(R)
and expects that its adoption may have a material impact on the
Companys consolidated results of operations and earnings
per share. The Company has not yet determined the method of
adoption or the effect of adopting SFAS 123(R), and has not
determined whether the adoption will result in amounts that are
similar to the current pro forma disclosures under SFAS 123.
Basic loss per share is calculated by dividing the loss
applicable to common stockholders by the weighted-average number
of common shares outstanding for the period less the weighted
average unvested common shares subject to repurchase and without
consideration for potential common shares. Diluted loss per
share is computed by dividing the loss applicable to common
stockholders by the weighted-average number of common shares
outstanding for the period less the weighted average unvested
common shares subject to repurchase and dilutive potential
common shares for the period determined using the treasury-stock
method. For purposes of this calculation, preferred stock and
options to purchase stock are considered to be potential common
shares and are only included in the calculation of diluted loss
per share when their effect is dilutive.
The unaudited pro forma basic and diluted loss per share
calculations assume the conversion of all outstanding shares of
preferred stock into shares of common stock using the
as-if-converted method as of January 1, 2004 or the date of
issuance, if later.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months
|
|
|
|
Year Ended December 31,
|
|
|
Ended June 30,
|
|
|
|
|
|
|
|
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousand, except share and per share data)
|
|
|
|
|
|
(Unaudited)
|
|
Historical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss applicable to common stockholders
|
|
$
|
(11,068
|
)
|
|
$
|
(15,250
|
)
|
|
$
|
(24,995
|
)
|
|
$
|
(12,263
|
)
|
|
$
|
(15,699
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding
|
|
|
1,381,907
|
|
|
|
1,429,022
|
|
|
|
1,737,652
|
|
|
|
1,687,964
|
|
|
|
1,895,958
|
|
|
Less: Weighted-average unvested common shares subject to
repurchase
|
|
|
(456,093
|
)
|
|
|
(202,578
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic and diluted loss per share applicable to
common stockholders
|
|
|
925,814
|
|
|
|
1,226,444
|
|
|
|
1,737,652
|
|
|
|
1,687,964
|
|
|
|
1,895,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share allocable to common stockholders
|
|
$
|
(11.95
|
)
|
|
$
|
(12.43
|
)
|
|
$
|
(14.38
|
)
|
|
$
|
(7.26
|
)
|
|
$
|
(8.28
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
$
|
(24,995
|
)
|
|
|
|
|
|
$
|
(15,699
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used above
|
|
|
|
|
|
|
|
|
|
|
1,737,652
|
|
|
|
|
|
|
|
1,895,625
|
|
Pro forma adjustments to reflect assumed weighted-average effect
of conversion of preferred stock
|
|
|
|
|
|
|
|
|
|
|
13,103,898
|
|
|
|
|
|
|
|
16,160,273
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma adjustments to reflect effect of stock dividend
|
|
|
|
|
|
|
|
|
|
|
791,210
|
|
|
|
|
|
|
|
791,210
|
|
Shares used to compute pro forma basic and diluted net loss
per share
|
|
|
|
|
|
|
|
|
|
|
15,632,759
|
|
|
|
|
|
|
|
18,847,108
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma basic and diluted net loss per share
|
|
|
|
|
|
|
|
|
|
$
|
(1.60
|
)
|
|
|
|
|
|
$
|
(0.83
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Historical outstanding dilutive securities not included in
diluted loss per share applicable to common stockholders
calculation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock
|
|
|
9,978,946
|
|
|
|
9,978,946
|
|
|
|
16,160,273
|
|
|
|
13,525,045
|
|
|
|
16,160,273
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options to purchase common stock
|
|
|
736,166
|
|
|
|
683,051
|
|
|
|
1,368,566
|
|
|
|
751,906
|
|
|
|
1,424,393
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,715,112
|
|
|
|
10,661,997
|
|
|
|
17,528,839
|
|
|
|
14,276,951
|
|
|
|
17,584,666
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-12
|
|
Note 2.
|
License and Collaborative Agreements
|
In March 2001, the Company entered into various licensing,
collaborative and technology transfer agreements with Incyte
Corporation (Incyte, formerly Incyte Genomics,
Inc.), a related party, to utilize certain intellectual
property, technologies and know-how in exchange for milestone
and royalty payments. The Company is required to make milestone
and royalty payments on net sales of products covered by certain
licenses granted under these agreements. Total expense
associated with these agreements (including royalties due) was
$3.0 million, $1.2 million, $1.3 million,
$684,000 and $6,000 for the years ended December 31, 2002,
2003 and 2004 and the six months ended June 30, 2004 and
2005, respectively. All such amounts have been recorded as
research and development expense or, in the case of royalties,
as cost of product revenues.
Collaborative and Technology Transfer Agreement.
Under
the Collaborative and Technology Transfer Agreement, the Company
agreed to fund a collaborative research and development project
relating to specific technologies. The total consideration paid
under this agreement was recorded as research and development
expense in 2001 on a straight-line basis over the term of the
agreement that was terminated in December 2001. Additionally, as
part of this agreement, Incyte transferred certain technology
and know-how to the Company. The total consideration paid for
this technology and know-how was recorded as research and
development expense on a straight-line basis through
December 31, 2002, which was the end of the estimated
useful life of the technology and know-how received.
Patent License Agreement.
Incyte granted the Company
certain patent rights under a Patent License Agreement. The
amount paid to Incyte under this agreement was recorded as
research and development expense in 2001, as the Company
determined at that time that it did not anticipate receiving
benefit from these patent rights in the future. In March 2004,
the Company terminated its rights to some of these patents.
LifeSeq Collaborative Agreement.
Under the LifeSeq
Collaborative Agreement, Incyte has agreed to grant the Company
access to certain database products and information. One of the
genes in the Onco
type
DX 21-gene panel is licensed under
this agreement. Upon commercialization of Onco
type
DX,
the Company was required to make a milestone payment and pay
royalties each quarter based on net sales of Onco
type
DX.
Incyte agreed to defer a portion of the payments originally due
during 2002. The deferred amounts, plus interest, were repaid in
eight quarterly installments beginning January 1, 2003 and
ending October 1, 2004. The remaining consideration is
being recorded as research and development expense on a
straight-line basis through the end of the access term in April
2005.
|
|
Note 3.
|
Specimen Transfer and Collaboration Agreements
|
The Company has entered into a variety of specimen transfer and
collaboration agreements relating to its development efforts.
The Company recorded research and development expenses of
$240,000, $844,000 and $1.1 million for the years ended
December 31, 2002, 2003 and 2004, respectively, and
$827,000 and $34,000 for the six months ended June 30, 2004
and 2005, respectively, relating to services provided in
connection with these agreements. In addition to these expenses,
certain agreements contain provisions for possible royalties
from inventions from these collaborations.
Future milestone payments, exclusive of royalty payments,
relating to the launch and commercialization of
Onco
type
DX total approximately $2.5 million
and are payable as follows (in thousands):
|
|
|
|
|
|
|
|
Milestone
|
|
|
|
Payments
|
|
|
|
|
|
January 2006
|
|
$
|
300
|
|
January 2007
|
|
|
300
|
|
January 2008
|
|
|
475
|
|
January 2009
|
|
|
475
|
|
January 2010
|
|
|
475
|
|
January 2011
|
|
|
475
|
|
|
|
|
|
|
Total
|
|
$
|
2,500
|
|
|
|
|
|
F-13
If at any time the Company discontinues the sale of commercial
products or services resulting from the collaboration, no future
milestone payments will be payable and the Company will have no
further obligation under the agreement. If the Companys
cash balance is less than $5.0 million on the due date of
any the milestone payments, the Company may be able to defer any
current milestone payment due for a period of up to
12 months.
In addition, the Company has secured certain options and rights
relating to any joint inventions arising out of the
collaborations.
|
|
Note 4.
|
Commercial Technology Licensing Agreements
|
The Company is a party to various agreements under which it
licenses technology on a nonexclusive basis in the field of
human diagnostics. Access to these licenses enables the Company
to process its laboratory tests for Onco
type
DX. Payments
under these agreements for the years ended December 31,
2002, 2003 and 2004 and for the six months ended June 30,
2004 and 2005 were $0, $0, $477,000, $360,000 and $292,000,
respectively, and were included in cost of product revenues.
|
|
Note 5.
|
Property and Equipment
|
Property and equipment consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
June 30,
|
|
|
|
|
|
|
|
|
|
|
2003
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
Computer equipment and software
|
|
$
|
688
|
|
|
$
|
963
|
|
|
$
|
955
|
|
Lab equipment
|
|
|
2,022
|
|
|
|
3,273
|
|
|
|
4,705
|
|
Furniture and fixtures
|
|
|
153
|
|
|
|
183
|
|
|
|
190
|
|
Leasehold improvements
|
|
|
165
|
|
|
|
211
|
|
|
|
332
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,028
|
|
|
|
4,630
|
|
|
|
6,182
|
|
Less accumulated depreciation and amortization
|
|
|
(1,740
|
)
|
|
|
(2,514
|
)
|
|
|
(3,172
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,288
|
|
|
$
|
2,116
|
|
|
$
|
3,010
|
|
|
|
|
|
|
|
|
|
|
|
For the years ended December 31, 2002, 2003, 2004 and the
six months ended June 30, 2004 and 2005, the Company
recorded depreciation and amortization expense of $642,000,
$824,000, $1.0 million, $486,000 and $690,000, respectively.
In March 2005, the Company entered into an arrangement to
finance the acquisition of laboratory equipment, computer
hardware and software, leasehold improvements and office
equipment. In connection with this arrangement, the Company
granted the lender a security interest in the assets purchased
with the borrowed amounts. The Company cannot prepay any amounts
owing under the arrangement until April 2006, at which point it
can prepay all, but not part, of the amounts outstanding under
the arrangement so long as it also pays a 6% premium on the
outstanding principal balance. This premium is reduced to 5% of
the outstanding principal balance in April 2007 and 4% of the
outstanding principal balance in April 2008.
F-14
As of June 30, 2005, the Companys aggregate
commitments under its financing arrangement were as follows (in
thousands):
|
|
|
|
|
|
|
|
Annual
|
|
|
|
Payment
|
|
|
|
Amounts
|
|
|
|
|
|
|
|
(Unaudited)
|
|
Years Ending December 31,
|
|
|
|
|
|
2005 (remainder of the year)
|
|
$
|
533
|
|
|
2006
|
|
|
1,102
|
|
|
2007
|
|
|
1,102
|
|
|
2008
|
|
|
970
|
|
|
2009
|
|
|
229
|
|
|
|
|
|
Total minimum payments
|
|
|
3,936
|
|
Less: interest portion
|
|
|
(676
|
)
|
|
|
|
|
Present value of net minimum payments
|
|
|
3,260
|
|
Less: current portion of obligations
|
|
|
(777
|
)
|
|
|
|
|
Long-term obligations
|
|
$
|
2,483
|
|
|
|
|
|
In June 2001, the Company entered into a four-year sublease
agreement for its current office and research facility. During
2003, the Company entered into an agreement to extend its
sublease through May 31, 2005, wherein monthly rent
beginning October 1, 2003, was modified to be
$75,000 per month. The Company entered into an additional
agreement to extend the term of the sublease agreement through
February 28, 2006, wherein monthly rent beginning
June 1, 2005 was modified to $40,000 per month.
Additionally, as part of this 2005 agreement, the Company agreed
to sublease additional adjacent premises effective
February 8, 2005 through February 28, 2006 at a rate
of $14,000 per month, with first and last monthly payments
of $10,000 and $14,000, respectively. The Company is currently
in negotiations to directly lease its facilities from the
facility owner as of the expiration of the current sublease in
February 2006.
Rent expense under all operating leases amounted to
$1.4 million, $1.3 million, $911,000, $456,000 and
$486,000 for the years ended December 31, 2002, 2003, 2004,
and the six months ended June 30, 2004 and 2005,
respectively.
Future noncancelable commitments under operating leases at
December 31, 2004, were as follows (in thousands):
|
|
|
|
|
|
|
|
Annual
|
|
|
|
Payment
|
|
|
|
Amounts
|
|
|
|
|
|
Years Ending December 31,
|
|
|
|
|
|
2005
|
|
$
|
813
|
|
|
2006
|
|
|
122
|
|
|
2007
|
|
|
9
|
|
|
|
|
|
Total minimum payments
|
|
$
|
944
|
|
|
|
|
|
|
|
Note 7.
|
Convertible Preferred Stock and Stockholders Equity
(Deficit)
|
|
|
|
Convertible Preferred Stock
|
The Company is authorized to issue 101,216,958 shares of
preferred stock in series, which shares have been designated
Series A, A-1, B, B-1, C, C-1, D, D-1, E and E-1 convertible
preferred stock, collectively referred to as preferred
stock.
F-15
As of December 31, 2004 and June 30, 2005, the
convertible preferred stock consisted of the following (in
thousands, except share and per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Share
|
|
|
|
|
Aggregate
|
|
|
|
Designated
|
|
|
Shares Issued and
|
|
|
Liquidation
|
|
|
Carrying
|
|
|
Liquidation
|
|
Series
|
|
Shares
|
|
|
Outstanding
|
|
|
Preference
|
|
|
Amount
|
|
|
Preference
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A
|
|
|
7,935,000
|
|
|
|
7,935,000
|
|
|
$
|
1.00
|
|
|
$
|
7,917
|
|
|
$
|
7,935
|
|
Series A-1
|
|
|
7,935,000
|
|
|
|
|
|
|
$
|
1.00
|
|
|
|
|
|
|
|
|
|
Series B
|
|
|
15,675,674
|
|
|
|
15,675,674
|
|
|
$
|
1.85
|
|
|
|
28,947
|
|
|
|
29,000
|
|
Series B-1
|
|
|
15,675,674
|
|
|
|
|
|
|
$
|
1.85
|
|
|
|
|
|
|
|
|
|
Series C
|
|
|
2,252,252
|
|
|
|
2,252,252
|
|
|
$
|
2.22
|
|
|
|
4,919
|
|
|
|
5,000
|
|
Series C-1
|
|
|
2,252,252
|
|
|
|
|
|
|
$
|
2.22
|
|
|
|
|
|
|
|
|
|
Series D
|
|
|
4,073,913
|
|
|
|
4,073,913
|
|
|
$
|
2.30
|
|
|
|
9,290
|
|
|
|
9,370
|
|
Series D-1
|
|
|
4,073,913
|
|
|
|
|
|
|
$
|
2.30
|
|
|
|
|
|
|
|
|
|
Series E
|
|
|
20,671,640
|
|
|
|
18,543,980
|
|
|
$
|
2.82
|
|
|
|
52,139
|
|
|
|
52,294
|
|
Series E-1
|
|
|
20,671,640
|
|
|
|
|
|
|
$
|
2.82
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101,216,958
|
|
|
|
48,480,819
|
|
|
|
|
|
|
$
|
103,212
|
|
|
$
|
103,599
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In November 2000, January 2001, March 2001, March through
November 2002, and February through December 2004 the Company
completed private placements for the sale of 7,935,000,
15,675,674, 2,252,252, 4,073,913 and 18,543,980 shares of
Series A, B, C, D and E convertible preferred stock,
respectively, resulting in gross proceeds of $7.9 million,
$29.0 million, $5.0 million, $9.4 million and
$52.3 million, respectively.
Every three shares of Series A, B, C, D and E preferred stock is
convertible into one share of common stock upon any of the
following events:
|
|
|
|
|
with respect to shares held by any stockholder, at any time at
the stockholders option;
|
|
|
|
automatically upon the closing of an underwritten public
offering with aggregate offering proceeds not less than
$20.0 million and a per share price not less than
$11.40; and
|
|
|
|
upon agreement of the majority of holders of the outstanding
shares of preferred stock voting as a single class, at the
then-effective conversion price.
|
However, if the conversion occurs by reason of an agreement of
the majority of holders of the outstanding shares of preferred
stock in connection with an underwritten public offering with
aggregate offering proceeds either less than $20.0 million
or with a per share price less than $11.40, then every three
shares of Series E preferred stock will convert into
1.128 shares of common stock. If the Companys initial
public offering price of its common stock is less than $11.40
per share, it will be necessary to record a charge relating to
the beneficial conversion feature, or BCF, of the Companys
series E preferred stock. The Company currently estimates
the BCF charge, if recorded, would be approximately $803,000. If
the charge is recorded, it would increase the net loss
attributable to common stockholders and the net loss per share
attributable to common stockholders, but will have no impact on
cash and cash equivalents, total stockholders equity
(deficit) or net loss in the period in which the initial
public offering is completed.
The conversion price of the Companys preferred stock is
subject to adjustment to prevent dilution in the event that the
Company issues additional shares of preferred stock, common
stock, or common stock equivalents at a purchase price less than
the then-effective conversion price, provided, however, that
without triggering antidilution adjustments, the Company may
issue up to 2,500,000 shares of common stock that are
reserved for issuance under the Companys stock option plan
to directors, officers, employees, or consultants, or may issue
shares in connection with a bona fide acquisition or other
strategic transactions that are approved by the Board of
Directors.
F-16
Holders of preferred stock are entitled to noncumulative
dividends of $0.08, $0.148, $0.177, $0.184 and $0.226 per
share per annum for Series A, B, C, D and E, respectively,
if and when declared by the Board of Directors (adjusted for any
stock splits, stock dividends, recapitalization, or similar
events). These dividends are to be paid in advance of any
distributions to common stockholders. No dividends have been
declared through June 30, 2005.
In the event of a liquidation, dissolution, or winding up of the
Company, holders of Series A, B, C, D and E convertible
preferred stock shall have a liquidation preference prior to
payment to holders of common stock of $1.00, $1.85, $2.22, $2.30
and $2.82 per share, respectively, plus any declared but
unpaid dividends. After the payment to the holders of preferred
stock, the remaining assets of the Company shall be distributed
pro rata to the holders of common stock.
Preferred stockholders are entitled to the number of votes they
would have upon conversion of their preferred stock into common
stock on the record date.
The convertible preferred stock is classified outside of equity
in accordance with Rule 5-02.28 of Regulation S-X because
certain features of the Companys Restated Certificate of
Incorporation would allow holders of preferred stock to redeem
the preferred stock at their option and to trigger liquidation
preferences for the preferred stock. The preferred stock
constitutes a majority of the outstanding stock entitled to
vote, giving the preferred stockholders the ability to amend the
Companys Restated Certificate of Incorporation to allow
redemption of the preferred stock. A majority of the members of
our board of directors is comprised of individuals elected by
holders of our preferred stock. Thus, the preferred stockholders
have the ability to cause the Company to take corporate actions
that would trigger a liquidation preference of the preferred
stock. Because the holders of preferred stock can trigger
liquidation preferences and redeem the preferred stock at their
option, the preferred stock is redeemable upon the occurrence of
an event not solely within the control of the Company and is
therefore not considered a permanent equity security under Rule
5-02.28.
In 2000, the Company issued 1,345,000 shares of common
stock to founders at $0.003 per share, which the Company
determined to be the fair value of the common stock upon
formation of the Company. The shares sold to the founders are
subject to a right of repurchase by the Company subject to
vesting, which is over a four year period. There were 456,093,
202,578, zero and zero shares subject to repurchase at
December 31, 2002, 2003 and 2004 and June 30, 2005,
respectively.
On January 2, 2001, the Company adopted the 2001 Stock
Incentive Plan (the Plan), under which incentive
stock options and nonstatutory stock options may be granted to
employees, officers, and directors of, or consultants to, the
Company and its affiliates. Options granted under the Plan
expire no later than 10 years from the date of grant. The
option price of each incentive stock option shall be at least
100% of the fair value on the date of grant, and the option
price for each nonstatutory stock option shall be not less than
85% of the fair value on the date of grant, as determined by the
Board of Directors. Options for employees may be granted with
different vesting terms from time to time, but not to exceed
five years from the date of grant.
As of December 31, 2002, 2003 and 2004, and June 30,
2005, a total of 1,166,666, 1,166,666, 2,500,000 and
2,500,000 shares of common stock have been reserved for
issuance under the Plan.
F-17
Activity under the Plan is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding Options
|
|
|
|
|
|
|
|
|
|
Shares Available
|
|
|
Number of
|
|
|
Weighted Average
|
|
|
|
for Grant
|
|
|
Shares
|
|
|
Exercise Price
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2002
|
|
|
379,033
|
|
|
|
736,166
|
|
|
$
|
0.66
|
|
Options granted
|
|
|
(245,500
|
)
|
|
|
245,500
|
|
|
$
|
0.99
|
|
Options exercised
|
|
|
|
|
|
|
(283,896
|
)
|
|
$
|
0.66
|
|
Options canceled
|
|
|
14,719
|
|
|
|
(14,719
|
)
|
|
$
|
0.66
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2003
|
|
|
148,252
|
|
|
|
683,051
|
|
|
$
|
0.78
|
|
Options authorized
|
|
|
1,333,333
|
|
|
|
|
|
|
|
|
|
Options granted
|
|
|
(906,099
|
)
|
|
|
906,099
|
|
|
$
|
2.28
|
|
Options exercised
|
|
|
|
|
|
|
(215,089
|
)
|
|
$
|
0.66
|
|
Options canceled
|
|
|
5,495
|
|
|
|
(5,495
|
)
|
|
$
|
0.99
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2004
|
|
|
580,981
|
|
|
|
1,368,566
|
|
|
$
|
1.77
|
|
|
|
|
|
|
|
|
|
|
|
Options granted (unaudited)
|
|
|
(118,999
|
)
|
|
|
118,999
|
|
|
$
|
3.00
|
|
Options exercised (unaudited)
|
|
|
|
|
|
|
(57,391
|
)
|
|
$
|
1.02
|
|
Options canceled (unaudited)
|
|
|
5,781
|
|
|
|
(5,781
|
)
|
|
$
|
1.83
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2005 (unaudited)
|
|
|
467,763
|
|
|
|
1,424,393
|
|
|
$
|
1.86
|
|
|
|
|
|
|
|
|
|
|
|
The following table summarizes information concerning
outstanding and exercisable options as of December 31, 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding
|
|
|
Options Exercisable
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
|
|
|
|
Number
|
|
|
Years Remaining
|
|
|
Weighted Average
|
|
|
Number
|
|
|
Weighted Average
|
|
Exercise Price
|
|
Outstanding
|
|
|
Contractual Life
|
|
|
Exercise Price
|
|
|
Exercisable
|
|
|
Exercise Price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.60
|
|
|
50,000
|
|
|
|
6.07
|
|
|
$
|
0.60
|
|
|
|
48,819
|
|
|
$
|
0.60
|
|
$0.66
|
|
|
169,571
|
|
|
|
6.97
|
|
|
$
|
0.66
|
|
|
|
32,367
|
|
|
$
|
0.66
|
|
$0.69
|
|
|
143,562
|
|
|
|
7.54
|
|
|
$
|
0.69
|
|
|
|
50,255
|
|
|
$
|
0.69
|
|
$1.38
|
|
|
520,433
|
|
|
|
9.39
|
|
|
$
|
1.38
|
|
|
|
35,635
|
|
|
$
|
1.38
|
|
$3.00
|
|
|
418,333
|
|
|
|
9.92
|
|
|
$
|
3.00
|
|
|
|
|
|
|
|
|
|
$3.30
|
|
|
66,667
|
|
|
|
4.92
|
|
|
$
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,368,566
|
|
|
|
|
|
|
|
|
|
|
|
167,076
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted average grant date fair value of options granted as
of December 31, 2002, 2003 and 2004 was $0.66, $0.78 and
$4.98, respectively.
F-18
The following table summarizes information concerning
outstanding and exercisable options as of June 30, 2005:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding
|
|
|
Options Exercisable
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
|
|
|
|
Number
|
|
|
Years Remaining
|
|
|
Weighted Average
|
|
|
Number
|
|
|
Weighted Average
|
|
Exercise Price
|
|
Outstanding
|
|
|
Contractual Life
|
|
|
Exercise Price
|
|
|
Exercisable
|
|
|
Exercise Price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.60
|
|
|
50,000
|
|
|
|
5.58
|
|
|
$
|
0.60
|
|
|
|
50,000
|
|
|
$
|
0.60
|
|
$0.66
|
|
|
152,134
|
|
|
|
6.50
|
|
|
$
|
0.66
|
|
|
|
84,694
|
|
|
$
|
0.66
|
|
$0.69
|
|
|
129,790
|
|
|
|
7.01
|
|
|
$
|
0.69
|
|
|
|
59,123
|
|
|
$
|
0.69
|
|
$1.38
|
|
|
490,469
|
|
|
|
8.91
|
|
|
$
|
1.38
|
|
|
|
67,899
|
|
|
$
|
1.38
|
|
$3.00
|
|
|
535,333
|
|
|
|
9.52
|
|
|
$
|
3.00
|
|
|
|
3,667
|
|
|
$
|
3.00
|
|
$3.30
|
|
|
66,667
|
|
|
|
4.42
|
|
|
$
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,424,393
|
|
|
|
|
|
|
|
|
|
|
|
265,383
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted average grant date fair value of options granted as
of June 30, 2005 was $8.55.
|
|
|
Deferred Stock-based Compensation
|
No employee stock compensation expense was reflected in the
Companys reported net loss in any period prior to 2004, as
all options granted had an exercise price equal to the estimated
fair value of the underlying common stock on the date of grant.
During 2004, stock options were granted with exercise prices
that were equal to the estimated fair value of the common stock
on the date of grant as determined by the Board of Directors.
Subsequent to the commencement of the initial public offering
process, the Company reassessed the fair value of its common
stock and determined that options granted from January 2004
through June 2005 were granted at exercise prices that were
below the reassessed fair value of the common stock on the date
of grant. Accordingly, deferred stock-based compensation of
$3.6 million was recorded during 2004 in accordance with
APB Opinion No. 25. In the six months ended June 30,
2005, an additional $846,000 of deferred stock-based
compensation was recorded. The deferred stock-based compensation
will be amortized on a straight-line basis over the vesting
period of the related awards, which is generally four years. For
the year ended December 31, 2004 and the six months ended
June 2005, the Company recorded employee stock-based
compensation expense of $191,000 and $509,000, respectively.
The Company has established a tax-qualified employee savings and
retirement plan for which its employees are generally eligible.
Under the 401(k) plan, Company employees may elect to
reduce their compensation and have the amount of this reduction
contributed to the 401(k) plan. The Company does not make
matching contributions. The 401(k) plan is intended to
qualify under Section 401 of the Internal Revenue Code, so
that contributions to the 401(k) plan, and income earned on
plan contributions, are not taxable to employees until withdrawn
from the plan, and so that contributions by the Company, if any,
will be deductible by the Company when made.
F-19
|
|
|
Stock Options Granted to Nonemployees
|
The Company grants options to consultants from time to time in
exchange for services performed for the Company. During the
years ended December 31, 2002, 2003 and 2004, and the six
months ended June 30, 2005, the Company granted options to
purchase 27,333, 33,000, 8,333 and 5,333 shares,
respectively, of common stock to consultants. The fair value of
these option grants was determined using the Black-Scholes
option pricing model using the following assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
June 30,
|
|
|
|
|
|
|
|
|
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2004
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
Volatility factor
|
|
|
80%
|
|
|
|
80%
|
|
|
|
80%
|
|
|
|
80%
|
|
|
|
80%
|
|
Average risk-free interest rate
|
|
|
4.0%
|
|
|
|
2.0%
|
|
|
|
2.4%
|
|
|
|
2.0%
|
|
|
|
4.0%
|
|
Dividend yield
|
|
|
0%
|
|
|
|
0%
|
|
|
|
0%
|
|
|
|
0%
|
|
|
|
0%
|
|
Expected life of options
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
In general, the options vest over the contractual period of the
consulting arrangement and, therefore, the Company will revalue
the options periodically and record additional compensation
expense related to these options over the remaining vesting
period. During the years ended December 31, 2002, 2003 and
2004, and the six months ended June 30, 2005, compensation
expense related to these options was $36,000, $18,000, $53,000
and $58,000, respectively.
As of December 31, 2004, the Company had reserved shares of
common stock for future issuance as follows:
|
|
|
|
|
Stock option plan
|
|
|
1,949,547
|
|
Conversion of preferred stock
|
|
|
16,160,273
|
|
|
|
|
|
|
|
|
18,109,820
|
|
|
|
|
|
As of June 30, 2005, the Company had reserved shares of
common stock for future issuance as follows:
|
|
|
|
|
Stock option plan
|
|
|
1,892,155
|
|
Conversion of preferred stock
|
|
|
16,160,273
|
|
|
|
|
|
|
|
|
18,052,428
|
|
|
|
|
|
|
|
Note 8.
|
Related Party Transactions
|
The Company has entered into various agreements with Incyte
Corporation. See Note 2. The Companys Chief Executive
Officer and Chairman of the Board is a stockholder of both
Incyte and the Company, and until December 31, 2001, was
the Chairman of the Board of Incyte. In November 2000, pursuant
to a Series A preferred stock purchase agreement, Incyte
purchased 1,000,000 shares of the Companys Series A
preferred stock at a price of $1.00 per share. In March 2001,
pursuant to a Series C preferred stock purchase agreement,
Incyte purchased 2,252,252 shares of the Companys
Series C preferred stock at a price of $2.22 per
share. Under this agreement, Incyte granted the Company the
right to cause Incyte to purchase an aggregate of
$5.0 million of shares of the Companys common stock
upon closing an initial public offering of the Companys
shares of common stock, at the initial public offering, price so
long as such offering results in gross proceeds to the Company
of at least $10.0 million, excluding any amounts received
by the Company from Incyte.
F-20
As of December 31, 2003 and 2004, the Company had deferred
tax assets of approximately $15.5 million and
$25.6 million, respectively. Realization of the deferred
tax assets is dependent upon future taxable income, if any, the
amount and timing of which are uncertain. Accordingly, the net
deferred tax assets have been fully offset by a valuation
allowance. The net valuation allowance increased by
approximately $4.6 million, $6.6 million, and
$10.1 million during the years ended December 31,
2002, 2003 and 2004, respectively. Deferred tax assets primarily
relate to net operating loss and tax credit carryforwards.
Deferred tax assets and liabilities consist of the following (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
|
|
|
|
2003
|
|
|
2004
|
|
|
|
|
|
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
|
Net operating loss carryforwards
|
|
$
|
14,008
|
|
|
$
|
23,944
|
|
|
Capitalized costs
|
|
|
1,664
|
|
|
|
1,546
|
|
|
Research tax credits
|
|
|
821
|
|
|
|
1,424
|
|
|
Other
|
|
|
74
|
|
|
|
98
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
|
16,567
|
|
|
|
27,012
|
|
Valuation allowance
|
|
|
(16,567
|
)
|
|
|
(27,012
|
)
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
As of December 31, 2004, the Company had federal and state
net operating loss carryforwards of approximately
$60.2 million and $57.8 million, respectively, and
federal and state research and development tax credit
carryforwards of approximately $855,000 and $569,000,
respectively. The net operating loss and tax credit
carryforwards will expire at various dates beginning in 2021 if
not utilized.
Utilization of the net operating loss and tax credit
carryforwards may be subject to a substantial annual limitation
due to ownership change limitations defined by the Internal
Revenue Code of 1986, as amended, and similar state provisions.
The annual limitation may result in the expiration of net
operating losses and credits before utilization.
Note 10. Subsequent Events (Unaudited)
2005 Stock Incentive Plan
On September 8, 2005, the Company adopted the 2005 Stock
Incentive Plan. 5,000,000 shares of the Companys
common stock have been reserved for issuance under the
2005 Plan. Subject to stockholder approval, the
2005 Plan will become effective upon the closing of the
Companys initial public offering. Pursuant to the
2005 Plan, stock options, restricted shares, stock units,
and stock appreciation rights may be granted to employees,
consultants, and outside directors of the Company. Options
granted may be either incentive stock options or nonstatutory
stock options.
Stock options are governed by stock option agreements between
the Company and recipients of stock options. Incentive stock
options may be granted under the 2005 Plan at an exercise
price of not less than 100% of the fair market value of the
common stock on the date of grant, determined by the
Compensation Committee of the board of directors. Nonstatutory
stock options may be granted under the 2005 Plan at an
exercise price of not less than 80% of the fair market value of
the common stock on the date of grant, determined by the
Compensation Committee of the board of directors. Options become
exercisable and expire as determined by the Compensation
Committee, provided that the term of incentive stock options may
not exceed 10 years from the date of grant. Stock option
agreements may provide for accelerated exercisability in the
event of an optionees death, disability, or retirement or
other events.
Under the 2005 Plan, each outside director who joins the
board after the effective date of the 2005 Plan will
receive an automatic nonstatutory stock option grant that vests
at a rate of 25% at the end of the first year, with the
remaining balance vesting over the next three years. On the
first business day following the
F-21
annual meeting of the Companys stockholders, each outside
director who is continuing board service and who was not
initially elected to the board at the annual meeting will
receive an additional nonstatutory stock option grant, which
will vest in full immediately prior to the next annual meeting
of the Companys stockholders. Nonstatutory stock options
granted to outside directors must have an exercise price equal
to 100% of the fair market value of the common stock on the date
of grant. Nonstatutory stock options terminate on the earlier of
the day before the tenth anniversary of the date of grant or the
date twelve months after termination of the outside
directors service as a member of the board of directors.
Restricted shares, stock appreciation rights, and stock units
granted under the 2005 Plan are governed by restricted
stock agreements, SAR agreements, and stock unit agreements
between the Company and recipients of the awards. Terms of the
agreements are determined by the Compensation Committee.
Lease
In September 2005, the Company entered into a lease agreement
that will apply to the 25,000 square feet of laboratory and
office space the Company currently occupies. Under the lease,
the Company also leases approximately 23,000 square feet of
additional space that the Company expects to first occupy in
March 2006. If the Company first occupies space under this new
lease in March 2006, the Company will be required to make
aggregate rent payments of approximately $4.5 million
throughout the entire term of the lease.
F-22
Part II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of
Issuance and Distribution
The following table sets forth the various expenses expected to
be incurred by the Registrant in connection with the sale and
distribution of the securities being registered hereby, other
than underwriting discounts and commissions. All amounts are
estimated except the Securities and Exchange Commission
registration fee, the National Association of Securities
Dealers, Inc. filing fee and the Nasdaq National Market listing
fee.
|
|
|
|
|
Securities and Exchange Commission registration fee
|
|
$
|
9,507
|
|
National Association of Securities Dealers, Inc. filing fee
|
|
|
8,000
|
|
Nasdaq National Market listing fee
|
|
|
100,000
|
|
Blue Sky fees and expenses
|
|
|
5,000
|
|
Accounting fees and expenses
|
|
|
550,000
|
|
Legal fees and expenses
|
|
|
900,000
|
|
Printing and engraving expenses
|
|
|
180,000
|
|
Registrar and Transfer Agents fees
|
|
|
13,000
|
|
Miscellaneous fees and expenses
|
|
|
34,493
|
|
|
|
|
|
Total
|
|
$
|
1,800,000
|
|
|
|
|
|
Item 14. Indemnification of
Directors and Officers
Section 145 of the Delaware General Corporation Law
provides for the indemnification of officers, directors, and
other corporate agents in terms sufficiently broad to indemnify
such persons under certain circumstances for liabilities
(including reimbursement for expenses incurred) arising under
the Securities Act of 1933, as amended (the Act).
Article VIII of the Registrants Restated Certificate
of Incorporation (Exhibit 3.3) and Article 5 of the
Registrants Bylaws (Exhibit 3.5) provide for
indemnification of the Registrants directors, officers,
employees and other agents to the extent and under the
circumstances permitted by the Delaware General Corporation Law.
The Registrant has also entered into agreements with our
directors and officers that will require the Registrant, among
other things, to indemnify them against certain liabilities that
may arise by reason of their status or service as directors or
officers to the fullest extent not prohibited by law.
The Underwriting Agreement (Exhibit 1.1) provides for
indemnification by the Underwriters of the Registrant, our
directors and officers, and by the Registrant of the
Underwriters, for certain liabilities, including liabilities
arising under the Act, and affords certain rights of
contribution with respect thereto.
Item 15. Recent Sales of
Unregistered Securities
The following information does not give effect to the reverse
common stock split to be effected prior to the completion of
this offering.
On various dates between January 1, 2002 and
August 31, 2005, we sold 1,934,223 shares of our
common stock to employees, directors and consultants pursuant to
the exercise of options granted under our 2001 stock incentive
plan. The exercise prices per share ranged from $0.22 to $1.00,
for an aggregate consideration of $443,215.03
In March 2002, May 2002 and November 2002, we
sold 4,073,913 shares of series D preferred stock for
aggregate consideration of $9,370,000 to 11 accredited investors.
In February 2004, March 2004, April 2004 and
December 2004, we sold 18,543,980 shares of
series E preferred stock for aggregate consideration of
$52,294,024 to 75 accredited investors.
II-1
The sales of the above securities were considered to be exempt
from registration under the Securities Act in reliance on
Section 4(2) of the Securities Act, or Regulation D
promulgated thereunder, or Rule 701 promulgated under
Section 3(b) of the Securities Act, as transactions by an
issuer not involving a public offering or transactions under
compensatory benefit plans and contracts relating to
compensation as provided under Rule 701. The recipients of
securities in each of these transactions represented their
intention to acquire the securities for investment only and not
with a view to or for sale with any distribution thereof, and
appropriate legends were affixed to the share certificates and
instruments issued in these transactions. All recipients had
adequate access, through their relationship with the registrant,
to information about the registrant.
Item 16. Exhibits and
Financial Statement Schedules
(a) Exhibits
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
|
1.1**
|
|
|
Form of Underwriting Agreement.
|
|
3.1**
|
|
|
Restated Certificate of Incorporation of the Registrant.
|
|
3.2**
|
|
|
Form of Restated Certificate of Incorporation of the Registrant
to be filed prior to the effective date of this Registration
Statement.
|
|
3.3**
|
|
|
Form of Restated Certificate of Incorporation of the Registrant,
to be filed upon the closing of the offering to which this
Registration Statement relates.
|
|
3.4**
|
|
|
Bylaws of the Registrant.
|
|
3.5**
|
|
|
Form of Amended and Restated Bylaws of the Registrant, to be
effective upon the closing of the offering to which this
Registration Statement relates.
|
|
4.1**
|
|
|
Specimen Common Stock Certificate.
|
|
4.2**
|
|
|
Amended and Restated Investors Rights Agreement, dated
February 9, 2004 between the Registrant and certain of its
stockholders.
|
|
5.1**
|
|
|
Opinion of Pillsbury Winthrop Shaw Pittman LLP.
|
|
10.1**
|
|
|
Form of Indemnification Agreement between the Registrant and its
officers and directors.
|
|
10.2**
|
|
|
2001 Stock Incentive Plan and forms of agreements thereunder.
|
|
10.3**
|
|
|
2005 Stock Incentive Plan and forms of agreements thereunder.
|
|
10.4.1**
|
|
|
Sublease Agreement dated June 1, 2001 between the
Registrant and Corixa Corporation.
|
|
10.4.2**
|
|
|
First Amendment to Sublease Agreement dated October 29,
2003 between the Registrant and Corixa Corporation.
|
|
10.4.3**
|
|
|
Second Amendment to Sublease Agreement dated January 31,
2005 between the Registrant and Corixa Corporation.
|
|
10.5.1*
|
*
|
|
Lifeseq Collaborative Agreement dated March 30, 2001
between the Registrant and Incyte Corporation.
|
|
10.5.2**
|
|
|
Amendment No. 1 to Lifeseq Collaborative Agreement dated
December 21, 2001 between the Registrant and Incyte
Corporation.
|
|
10.5.3*
|
*
|
|
Amendment No. 2 to Lifeseq Collaborative Agreement dated
July 19, 2002 between the Registrant and Incyte Corporation.
|
|
10.5.4*
|
*
|
|
Amendment No. 3 to Lifeseq Collaborative Agreement dated
October 25, 2004 between the Registrant and Incyte
Corporation.
|
|
10.6.1*
|
*
|
|
Patent License Agreement dated March 30, 2001 between the
Registrant and Incyte Corporation.
|
|
10.6.2*
|
*
|
|
Amendment to Patent License Agreement dated December 21,
2001 between the Registrant and Incyte Corporation.
|
|
10.7.1*
|
*
|
|
Collaboration and Technology Transfer Agreement dated
March 30, 2001 between the Registrant and Incyte
Corporation.
|
|
10.7.2*
|
*
|
|
Amendment to Collaboration and Technology Transfer Agreement
dated December 21, 2001 between the Registrant and Incyte
Corporation.
|
II-2
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
|
10.8**
|
|
|
PCR Patent License Agreement dated February 21, 2005
between the Registrant and Roche Molecular Systems, Inc.
|
|
10.9.1**
|
|
|
Master Security Agreement dated March 30, 2005 between the
Registrant and Oxford Finance Corporation.
|
|
10.9.2**
|
|
|
Form of Promissory Note (Equipment) issued by the Registrant in
favor of Oxford Finance Corporation.
|
|
10.9.3**
|
|
|
Form of Promissory Note (Computers and Software) issued by the
Registrant in favor of Oxford Finance Corporation.
|
|
10.9.4**
|
|
|
Schedule of Promissory Notes issued by the Registrant in favor
of Oxford Finance Corporation.
|
|
10.10
|
|
|
Lease dated September 23, 2005 between the Registrant and
Metropolitan Life Insurance Company.
|
|
21.1**
|
|
|
List of Subsidiaries.
|
|
23.1
|
|
|
Consent of Ernst & Young LLP, independent registered
public accounting firm.
|
|
23.2**
|
|
|
Consent of Pillsbury Winthrop Shaw Pittman LLP (included in
Exhibit 5.1).
|
|
24.1**
|
|
|
Power of Attorney.
|
|
|
|
Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the Registration
Statement and submitted separately to the Securities and
Exchange Commission.
|
(b) Financial Statement Schedules
No financial statement schedules are provided because the
information called for is not required or is shown either in the
financial statements or the notes thereto.
Item 17. Undertakings
Insofar as indemnification for liabilities arising under the
Securities Act of 1933, as amended (the Act), may be
permitted to directors, officers and controlling persons of the
Registrant pursuant to the foregoing provisions, or otherwise,
the Registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is
against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the
securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Act and will be
governed by the final adjudication of such issue.
The undersigned Registrant hereby undertakes that:
|
|
|
|
(1)
|
For purposes of determining any liability under the Act, the
information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and
contained in a form of prospectus filed by the Registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Act
shall be deemed to be part of this registration statement as of
the time it was declared effective.
|
|
|
(2)
|
For the purpose of determining any liability under the Act, each
post effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona
fide offering thereof.
|
|
|
(3)
|
It will provide to the underwriters at the closing(s) specified
in the underwriting agreement certificates in such denominations
and registered in such names as required by the underwriters to
permit prompt delivery to each purchaser.
|
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant has duly caused this Amendment No. 5 to this
Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Redwood
City, State of California, on the
26
th
day of September, 2005.
|
|
|
|
|
Randal W. Scott, Ph.D.
|
|
Chief Executive Officer and Chairman
|
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed below by the following
persons in the capacities and on the dates indicated.
|
|
|
|
|
|
|
Name
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ Randal W. Scott
Randal W. Scott, Ph.D.
|
|
Chairman of the Board of Directors and Chief Executive Officer
(Principal Executive Officer)
|
|
September 26, 2005
|
|
/s/ G. Bradley Cole
G. Bradley Cole
|
|
Executive Vice President and Chief Financial Officer (Principal
Financial and Accounting Officer)
|
|
September 26, 2005
|
|
*
Kimberly J. Popovits
|
|
President, Chief Operating Officer and Director
|
|
September 26, 2005
|
|
*
Julian C. Baker
|
|
Director
|
|
September 26, 2005
|
|
*
Brook H. Byers
|
|
Director
|
|
September 26, 2005
|
|
*
Fred E. Cohen, M.D., Ph.D.
|
|
Director
|
|
September 26, 2005
|
|
*
Samuel D. Colella
|
|
Director
|
|
September 26, 2005
|
|
*
Michael D. Goldberg
|
|
Director
|
|
September 26, 2005
|
|
*
Randall S. Livingston
|
|
Director
|
|
September 26, 2005
|
|
*By:
|
|
/s/ Randal W. Scott
Randal W. Scott, Ph.D.
Attorney-in-Fact
|
|
|
|
|
II-4
Exhibit Index
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
1.1**
|
|
Form of Underwriting Agreement.
|
3.1**
|
|
Restated Certificate of Incorporation of the Registrant.
|
3.2**
|
|
Form of Restated Certificate of Incorporation of the Registrant
to be filed prior to the effective date of this Registration
Statement.
|
3.3**
|
|
Form of Restated Certificate of Incorporation of the Registrant,
to be filed upon the closing of the offering to which this
Registration Statement relates.
|
3.4**
|
|
Bylaws of the Registrant.
|
3.5**
|
|
Form of Amended and Restated Bylaws of the Registrant, to be
effective upon the closing of the offering to which this
Registration Statement relates.
|
4.1**
|
|
Specimen Common Stock Certificate.
|
4.2**
|
|
Amended and Restated Investors Rights Agreement, dated
February 9, 2004 between the Registrant and certain of its
stockholders.
|
5.1**
|
|
Opinion of Pillsbury Winthrop Shaw Pittman LLP.
|
10.1**
|
|
Form of Indemnification Agreement between the Registrant and its
officers and directors.
|
10.2**
|
|
2001 Stock Incentive Plan and forms of agreements thereunder.
|
10.3**
|
|
2005 Stock Incentive Plan and forms of agreements thereunder.
|
10.4.1**
|
|
Sublease Agreement dated June 1, 2001 between the
Registrant and Corixa Corporation.
|
10.4.2**
|
|
First Amendment to Sublease Agreement dated October 29,
2003 between the Registrant and Corixa Corporation.
|
10.4.3**
|
|
Second Amendment to Sublease Agreement dated January 31,
2005 between the Registrant and Corixa Corporation.
|
10.5.1**
|
|
Lifeseq Collaborative Agreement dated March 30, 2001
between the Registrant and Incyte Corporation.
|
10.5.2**
|
|
Amendment No. 1 to Lifeseq Collaborative Agreement dated
December 21, 2001 between the Registrant and Incyte
Corporation.
|
10.5.3**
|
|
Amendment No. 2 to Lifeseq Collaborative Agreement dated
July 19, 2002 between the Registrant and Incyte Corporation.
|
10.5.4**
|
|
Amendment No. 3 to Lifeseq Collaborative Agreement dated
October 25, 2004 between the Registrant and Incyte
Corporation.
|
10.6.1**
|
|
Patent License Agreement dated March 30, 2001 between the
Registrant and Incyte Corporation.
|
10.6.2**
|
|
Amendment to Patent License Agreement dated December 21,
2001 between the Registrant and Incyte Corporation.
|
10.7.1**
|
|
Collaboration and Technology Transfer Agreement dated
March 30, 2001 between the Registrant and Incyte
Corporation.
|
10.7.2**
|
|
Amendment to Collaboration and Technology Transfer Agreement
dated December 21, 2001 between the Registrant and Incyte
Corporation.
|
10.8**
|
|
PCR Patent License Agreement dated February 21, 2005
between the Registrant and Roche Molecular Systems, Inc.
|
10.9.1**
|
|
Master Security Agreement dated March 30, 2005 between the
Registrant and Oxford Finance Corporation.
|
10.9.2**
|
|
Form of Promissory Note (Equipment) issued by the Registrant in
favor of Oxford Finance Corporation.
|
10.9.3**
|
|
Form of Promissory Note (Computers and Software) issued by the
Registrant in favor of Oxford Finance Corporation.
|
10.9.4**
|
|
Schedule of Promissory Notes issued by the Registrant in favor
of Oxford Finance Corporation.
|
10.10
|
|
Lease dated September 23, 2005 between the Registrant and
Metropolitan Life Insurance Company.
|
21.1**
|
|
List of Subsidiaries.
|
23.1
|
|
Consent of Ernst & Young LLP, independent registered
public accounting firm.
|
23.2**
|
|
Consent of Pillsbury Winthrop Shaw Pittman LLP (included in
Exhibit 5.1).
|
24.1**
|
|
Power of Attorney.
|
|
|
|
|
|
Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the Registration
Statement and submitted separately to the Securities and
Exchange Commission.
|
Exhibit 10.10
LEASE
BETWEEN
METROPOLITAN LIFE INSURANCE COMPANY (LANDLORD)
AND
GENOMIC HEALTH, INC. (TENANT)
SEAPORT CENTRE
Redwood City, California
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
PAGE
|
|
ARTICLE ONE BASIC LEASE PROVISIONS
|
|
|
1
|
|
1.01
|
|
BASIC LEASE PROVISIONS
|
|
|
1
|
|
1.02
|
|
ENUMERATION OF EXHIBITS & RIDER(S)
|
|
|
3
|
|
1.03
|
|
DEFINITIONS
|
|
|
3
|
|
|
|
|
|
|
|
|
ARTICLE TWO PREMISES, TERM, FAILURE TO GIVE POSSESSION, COMMON AREAS AND PARKING
|
|
|
7
|
|
2.01
|
|
LEASE OF PREMISES
|
|
|
7
|
|
2.02
|
|
TERM
|
|
|
7
|
|
2.03
|
|
FAILURE TO GIVE POSSESSION
|
|
|
7
|
|
2.04
|
|
AREA OF PREMISES
|
|
|
7
|
|
2.05
|
|
CONDITION OF PREMISES
|
|
|
7
|
|
2.06
|
|
COMMON AREAS & PARKING
|
|
|
7
|
|
|
|
|
|
|
|
|
ARTICLE THREE RENT
|
|
|
7
|
|
|
|
|
|
|
|
|
ARTICLE FOUR OPERATING EXPENSES RENT ADJUSTMENTS AND PAYMENTS
|
|
|
8
|
|
4.01
|
|
TENANTS SHARE OF OPERATING EXPENSES
|
|
|
8
|
|
4.02
|
|
RENT ADJUSTMENTS
|
|
|
8
|
|
4.03
|
|
STATEMENT OF LANDLORD
|
|
|
9
|
|
4.04
|
|
BOOKS AND RECORDS
|
|
|
9
|
|
4.05
|
|
TENANT OR LEASE SPECIFIC TAXES
|
|
|
9
|
|
|
|
|
|
|
|
|
ARTICLE FIVE SECURITY
|
|
|
9
|
|
|
|
|
|
|
|
|
ARTICLE SIX UTILITIES & SERVICES
|
|
|
11
|
|
6.01
|
|
LANDLORDS GENERAL SERVICES
|
|
|
11
|
|
6.02
|
|
TENANT TO OBTAIN & PAY DIRECTLY
|
|
|
11
|
|
6.03
|
|
TELEPHONE SERVICES
|
|
|
11
|
|
6.04
|
|
FAILURE OR INTERRUPTION OF UTILITY OR SERVICE
|
|
|
11
|
|
6.05
|
|
INTENTIONALLY OMITTED
|
|
|
11
|
|
6.06
|
|
SIGNAGE
|
|
|
12
|
|
|
|
|
|
|
|
|
ARTICLE SEVEN POSSESSION, USE AND CONDITION OF PREMISES
|
|
|
12
|
|
7.01
|
|
POSSESSION AND USE OF PREMISES
|
|
|
12
|
|
7.02
|
|
HAZARDOUS MATERIAL
|
|
|
12
|
|
7.03
|
|
LANDLORD ACCESS TO PREMISES; APPROVALS
|
|
|
14
|
|
7.04
|
|
QUIET ENJOYMENT
|
|
|
14
|
|
|
|
|
|
|
|
|
ARTICLE EIGHT MAINTENANCE & HVAC
|
|
|
14
|
|
8.01
|
|
LANDLORDS MAINTENANCE
|
|
|
14
|
|
8.02
|
|
TENANTS MAINTENANCE
|
|
|
14
|
|
8.03
|
|
ADDITIONAL PROVISIONS REGARDING HVAC
|
|
|
15
|
|
|
|
|
|
|
|
|
ARTICLE NINE ALTERATIONS AND IMPROVEMENTS
|
|
|
16
|
|
9.01
|
|
TENANT ALTERATIONS
|
|
|
16
|
|
9.02
|
|
LIENS
|
|
|
16
|
|
|
|
|
|
|
|
|
ARTICLE TEN ASSIGNMENT AND SUBLETTING
|
|
|
17
|
|
10.01
|
|
ASSIGNMENT AND SUBLETTING
|
|
|
17
|
|
10.02
|
|
RECAPTURE
|
|
|
18
|
|
10.03
|
|
EXCESS RENT
|
|
|
18
|
|
10.04
|
|
TENANT LIABILITY
|
|
|
19
|
|
10.05
|
|
ASSUMPTION AND ATTORNMENT
|
|
|
19
|
|
|
|
|
|
|
|
|
ARTICLE ELEVEN DEFAULT AND REMEDIES
|
|
|
19
|
|
11.01
|
|
EVENTS OF DEFAULT
|
|
|
19
|
|
11.02
|
|
LANDLORDS REMEDIES
|
|
|
19
|
|
11.03
|
|
ATTORNEYS FEES
|
|
|
21
|
|
11.04
|
|
BANKRUPTCY
|
|
|
21
|
|
11.05
|
|
LANDLORDS DEFAULT
|
|
|
21
|
|
|
|
|
|
|
|
|
ARTICLE TWELVE SURRENDER OF PREMISES
|
|
|
22
|
|
12.01
|
|
IN GENERAL
|
|
|
22
|
|
12.02
|
|
LANDLORDS RIGHTS
|
|
|
22
|
|
|
|
|
|
|
|
|
ARTICLE THIRTEEN HOLDING OVER
|
|
|
22
|
|
|
|
|
|
|
|
|
ARTICLE FOURTEEN DAMAGE BY FIRE OR OTHER CASUALTY
|
|
|
22
|
|
i
|
|
|
|
|
|
|
|
|
|
|
|
PAGE
|
|
14.01
|
|
SUBSTANTIAL UNTENANTABILITY
|
|
|
22
|
|
14.02
|
|
INSUBSTANTIAL UNTENANTABILITY
|
|
|
23
|
|
14.03
|
|
RENT ABATEMENT
|
|
|
23
|
|
14.04
|
|
WAIVER OF STATUTORY REMEDIES
|
|
|
23
|
|
|
|
|
|
|
|
|
ARTICLE FIFTEEN EMINENT DOMAIN
|
|
|
23
|
|
15.01
|
|
TAKING OF WHOLE OR SUBSTANTIAL PART
|
|
|
23
|
|
15.02
|
|
TAKING OF PART
|
|
|
24
|
|
15.03
|
|
COMPENSATION
|
|
|
24
|
|
|
|
|
|
|
|
|
ARTICLE SIXTEEN INSURANCE
|
|
|
24
|
|
16.01
|
|
TENANTS INSURANCE
|
|
|
24
|
|
16.02
|
|
FORM OF POLICIES
|
|
|
24
|
|
16.03
|
|
LANDLORDS INSURANCE
|
|
|
24
|
|
16.04
|
|
WAIVER OF SUBROGATION
|
|
|
25
|
|
16.05
|
|
NOTICE OF CASUALTY
|
|
|
25
|
|
|
|
|
|
|
|
|
ARTICLE SEVENTEEN WAIVER OF CLAIMS AND INDEMNITY
|
|
|
25
|
|
17.01
|
|
WAIVER OF CLAIMS
|
|
|
25
|
|
17.02
|
|
INDEMNITY BY TENANT
|
|
|
25
|
|
17.03
|
|
WAIVER OF CONSEQUENTIAL DAMAGES
|
|
|
26
|
|
|
|
|
|
|
|
|
ARTICLE EIGHTEEN RULES AND REGULATIONS
|
|
|
26
|
|
18.01
|
|
RULES
|
|
|
26
|
|
18.02
|
|
ENFORCEMENT
|
|
|
26
|
|
|
|
|
|
|
|
|
ARTICLE NINETEEN LANDLORDS RESERVED RIGHTS
|
|
|
26
|
|
|
|
|
|
|
|
|
ARTICLE TWENTY ESTOPPEL CERTIFICATE
|
|
|
26
|
|
20.01
|
|
IN GENERAL
|
|
|
26
|
|
20.02
|
|
ENFORCEMENT
|
|
|
27
|
|
|
|
|
|
|
|
|
ARTICLE TWENTY-ONE INTENTIONALLY OMITTED
|
|
|
27
|
|
|
|
|
|
|
|
|
ARTICLE TWENTY-TWO REAL ESTATE BROKERS
|
|
|
27
|
|
|
|
|
|
|
|
|
ARTICLE TWENTY-THREE MORTGAGEE PROTECTION
|
|
|
27
|
|
23.01
|
|
SUBORDINATION AND ATTORNMENT
|
|
|
27
|
|
23.02
|
|
MORTGAGEE PROTECTION
|
|
|
27
|
|
|
|
|
|
|
|
|
ARTICLE TWENTY-FOUR NOTICES
|
|
|
28
|
|
|
|
|
|
|
|
|
ARTICLE TWENTY-FIVE EXERCISE FACILITY
|
|
|
28
|
|
|
|
|
|
|
|
|
ARTICLE TWENTY-SIX MISCELLANEOUS
|
|
|
28
|
|
26.01
|
|
LATE CHARGES
|
|
|
28
|
|
26.02
|
|
NO JURY TRIAL; VENUE; JURISDICTION
|
|
|
29
|
|
26.03
|
|
DEFAULT UNDER OTHER LEASE
|
|
|
29
|
|
26.04
|
|
OPTION
|
|
|
29
|
|
26.05
|
|
TENANT AUTHORITY
|
|
|
29
|
|
26.06
|
|
ENTIRE AGREEMENT
|
|
|
29
|
|
26.07
|
|
MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE
|
|
|
29
|
|
26.08
|
|
EXCULPATION
|
|
|
29
|
|
26.09
|
|
ACCORD AND SATISFACTION
|
|
|
29
|
|
26.10
|
|
LANDLORDS OBLIGATIONS ON SALE OF BUILDING
|
|
|
30
|
|
26.11
|
|
BINDING EFFECT
|
|
|
30
|
|
26.12
|
|
CAPTIONS
|
|
|
30
|
|
26.13
|
|
TIME; APPLICABLE LAW; CONSTRUCTION
|
|
|
30
|
|
26.14
|
|
ABANDONMENT
|
|
|
30
|
|
26.15
|
|
LANDLORDS RIGHT TO PERFORM
TENANTS DUTIES
|
|
|
30
|
|
26.16
|
|
SECURITY SYSTEM
|
|
|
30
|
|
26.17
|
|
NO LIGHT, AIR OR VIEW EASEMENTS
|
|
|
30
|
|
26.18
|
|
RECORDATION
|
|
|
30
|
|
26.19
|
|
SURVIVAL
|
|
|
30
|
|
26.20
|
|
EXHIBITS OR RIDERS
|
|
|
31
|
|
ii
LEASE
ARTICLE ONE
BASIC LEASE PROVISIONS
1.01
|
|
BASIC LEASE PROVISIONS
|
In the event of any conflict between these Basic Lease Provisions and any other Lease provision,
such other Lease provision shall control.
(1)
|
|
BUILDING AND ADDRESS:
|
As of the Date of Lease, the Building has street addresses of 301 & 351 Penobscot Drive
Redwood City, California 94063
Building Number 11, located in Phase II (Tenants Phase) of Seaport Centre
(2)
|
|
LANDLORD AND ADDRESS:
|
Metropolitan Life Insurance Company,
a New York corporation
Notices to Landlord shall be addressed:
Metropolitan Life Insurance Company
c/o Seaport Centre Manager
701 Chesapeake Drive
Redwood City, CA 94063
with copies to the following:
Metropolitan Life Insurance Company
400 South El Camino Real, Suite 800
San Mateo, CA 94402
Attention: Assistant Vice President
(3)
|
|
TENANT; CURRENT ADDRESS & TAX ID:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
Name:
|
|
Genomic Health, Inc. (Genomic Health)
|
|
|
|
|
|
|
(b)
|
|
State of incorporation:
|
|
a Delaware corporation
|
|
|
|
|
|
|
(c)
|
|
Tax Identification Number:
|
|
77-0552594
|
|
|
|
|
|
|
Tenant shall notify Landlord of any change in the foregoing.
|
Notices to Tenant shall be addressed:
Genomic Health, Inc.
301 Penobscot Drive
Redwood City, CA 94063
Attention: Chief Financial Officer
with a copy to:
Pillsbury Winthrop Shaw Pittman LLP
50 Fremont Street
San Francisco, CA 94105
Attention: Hilda A. Senseney
(4)
|
|
DATE OF LEASE: as of September 23, 2005
|
(5)
|
|
LEASE TERM: For each of the Initial Premises and the Expansion Premises, the Term will
commence separately on the Initial Premises Commencement Date and the Expansion Premises
Commencement Date, as defined and described in Rider 2, and the Lease Term shall expire (as to
the entire Premises) on the last day of the six-year period which commences on the Initial
Premises Commencement Date.
|
(6)
|
|
COMMENCEMENT DATES: For each of the Initial Premises and the Expansion Premises, the Term
will commence separately on the Initial Premises Commencement Date and the Expansion Premises
Commencement Date, as defined and described in Rider 2.
|
(7)
|
|
EXPIRATION DATE: The last day of the six-year period which commences on the Initial Premises
Commencement Date.
|
(8)
|
|
MONTHLY BASE RENT: Monthly Base Rent for the Premises is the combined Monthly Base Rent for
each of the Initial Premises and the Expansion Premises, as and when due as set forth in this
Lease. In light of the differences for each such space in the respective rate of Monthly Base
Rent, timing of the Commencement Date and increases in rates, the amount of Monthly Base Rent
for each such space is set forth separately below. The initial monthly installment for both
parts of the Premises is due upon Tenants execution.
|
1
Initial Premises
:
|
|
|
|
|
Period from Initial Premises
|
|
|
|
|
Commencement Date through
|
|
|
|
|
Expiration Date
|
|
Monthly
|
|
Monthly Rate/SF of Rentable Area
|
Months 01 12*
|
|
$24,448.90*
|
|
$1.06*
|
Months 13 24
|
|
$25,140.85
|
|
$1.09
|
Months 25 36
|
|
$25,832.80
|
|
$1.12
|
Months 37 48
|
|
$26,755.40
|
|
$1.16
|
Months 49 60
|
|
$27,447.35
|
|
$1.19
|
Months 61 72 (Expiration Date)
|
|
$28,369.95
|
|
$1.23
|
|
|
*
|
Notwithstanding any provision of this Lease to the contrary, provided that Tenant is not in
Default under this Lease, Landlord agrees to forbear in collection of the Monthly Base Rent
for the Initial Premises for the first four (4) months after the Initial Premises
Commencement Date, and further provided that Tenant is not in Default under this Lease for a
full year after expiration of the fourth month of the Term, the Monthly Base Rent for the
Initial Premises for such first four months of the Term shall be waived.
|
Expansion Premises
:
|
|
|
|
|
Period from Expansion Premises
|
|
|
|
|
Commencement Date through
|
|
|
|
|
Expiration Date
|
|
Monthly
|
|
Monthly Rate/SF of Rentable Area
|
Months 01 12*
|
|
$34,769.00*
|
|
$1.40*
|
Months 13 24
|
|
$36,010.75
|
|
$1.45
|
Months 25 36
|
|
$37,252.50
|
|
$1.50
|
Months 37 48
|
|
$38,494.25
|
|
$1.55
|
Months 49 60
|
|
$39,376.00
|
|
$1.60
|
Months 61 Expiration Date
|
|
$40,977.75
|
|
$1.65
|
|
|
*
|
Notwithstanding any provision of this Lease to the contrary, provided that Tenant is not in
Default under this Lease, Landlord agrees to forbear in collection of the Monthly Base Rent
for the Expansion Premises for the first month after the Expansion Premises Commencement
Date, and further provided that Tenant is not in Default under this Lease for a full year
after expiration of such first month, the Monthly Base Rent for the Expansion Premises for
such first month shall be waived.
|
(9) RENT ADJUSTMENT DEPOSIT (initial monthly rate, until further notice): Until the Commencement
Date has occurred for both the Initial Premises and the Expansion Premises, the Rent Adjustment
Deposit payable by Tenant during the Term shall be only for that part of the Premises for which the
Commencement Date has occurred. It is agreed that the Rent Adjustment Deposit (at the initial
monthly rate, until further notice) for the Initial Premises shall be Fourteen Thousand Nineteen
Dollars ($14,019.00). The initial monthly installment for both parts of the Premises is
Twenty-nine Thousand One Hundred Fourteen Dollars ($29,114.00) and is due upon Tenants execution.
(10) RENTABLE AREA OF THE PREMISES:
Initial Premises: 23,065 square feet
Expansion Premises: 24,835 square feet
Premises (both parts): 47,900
(11)
|
|
RENTABLE AREA OF THE BUILDING 47,900 square feet
|
|
(12)
|
|
RENTABLE AREA OF THE PHASE: 235,620 square feet
|
|
(13)
|
|
RENTABLE AREA OF THE PROJECT: 537,444 square feet
|
(14)
|
|
SECURITY: The cash and/or Letter of Credit in the amount of Five Hundred Thousand Dollars and
no/100 ($500,000.00) (and any proceeds of the Letter of Credit drawn and held by Landlord) as
provided in Article Five.
|
|
(15)
|
|
SUITE NUMBER &/OR ADDRESS OF PREMISES:
|
Initial Premises: 351 Penobscot Drive
Expansion Premises 301 Penobscot Drive
Premises (both parts) 301 Penobscot Drive, until further notice
|
|
|
|
|
For Initial Premises only until Expansion Premises Commencement Date:
|
|
Tenants Building Share:
|
|
|
48.1524
|
%
|
Tenants Phase Share:
|
|
|
09.7891
|
%
|
Tenants Project Share:
|
|
|
04.2916
|
%
|
2
|
|
|
|
|
For Full Premises on & after Expansion Premises Commencement Date:
|
|
Tenants Building Share:
|
|
|
100
|
%
|
Tenants Phase Share:
|
|
|
20.3293
|
%
|
Tenants Project Share:
|
|
|
08.9126
|
%
|
(17)
|
|
TENANTS USE OF PREMISES: General office use; biotechnology/pharmaceutical research and development,
assembly, biotechnical or pharmaceutical manufacturing, and warehousing.
|
|
(18)
|
|
PARKING SPACES:
|
For Initial Premises only until Expansion Premises Commencement Date: 76
For Full Premises on & after Expansion Premises Commencement Date: 158
Landlords Broker: Cornish & Carey Commercial
Tenants Broker: BT Commercial and Technology Commercial
1.02
|
|
ENUMERATION OF EXHIBITS & RIDER(S)
|
The Exhibits and Rider(s) set forth below and attached to this Lease are incorporated in this Lease
by this reference:
EXHIBIT A
Plan of Premises
EXHIBIT B
Workletter Agreement
EXHIBIT C
Site Plan of Project
EXHIBIT D
Permitted Hazardous Material
EXHIBIT E
Form of Letter of Credit Acceptable from Silicon Valley Bank
EXHIBIT F
Fair Market Rental Rate
EXHIBIT G
Tenants Personal Property
EXHIBIT H
Form of Letter of Credit
RIDER 1
Commencement Date Agreement
RIDER 2
Additional Provisions
For purposes hereof, the following terms shall have the following meanings:
ADJUSTMENT YEAR: The applicable calendar year or any portion thereof after the Commencement Date
of this Lease for which a Rent Adjustment computation is being made.
AFFILIATE: Any Person (as defined below) which is controlled by, controls, or is under common
control with Tenant. The word Person means an individual, partnership, trust, corporation, limited
liability company, firm or other entity. For purposes of this definition, the word control,
means, with respect to a Person that is a corporation or a limited liability company, the right to
exercise, directly or indirectly, more than sixty percent (60%) of the voting rights attributable
to the shares or membership interests of the controlled Person and, with respect to a Person that
is not a corporation, the possession, directly or indirectly, of the power at all times to direct
or cause the direction of the management of the controlled Person.
BUILDING: Each building in which the Premises is located, as specified in Section 1.01(1).
BUILDING OPERATING EXPENSES: Those Operating Expenses described in Section 4.01.
COMMENCEMENT DATE: The dates specified in Section 1.01(6) as the Commencement Dates, unless
changed by operation of Article Two or Rider 2.
COMMON AREAS: All areas of the Project made available by Landlord from time to time for the
general common use or benefit of the tenants of the Building or Project, and their employees and
invitees, or the public, as such areas currently exist and as they may be changed from time to
time.
DECORATION: Tenant Alterations which do not require a building permit and which do not affect the
facade or roof of the Building, or involve any of the structural elements of the Building, or
involve any of the Buildings systems, including its electrical, mechanical, plumbing, security,
heating, ventilating, air-conditioning, communication, and fire and life safety systems.
DEFAULT RATE: Two (2) percentage points above the rate then most recently announced by Bank of
America N.T.& S.A. at its San Francisco main office as its corporate base lending rate, from time
to time announced, but in no event higher than the maximum rate permitted by Law.
DELIVERY DATE: The date for Landlords delivery to Tenant of possession of the Premises, if
different from the Commencement Date, as provided in Rider 2.
ENVIRONMENTAL LAWS: All Laws governing the use, storage, disposal or generation of any Hazardous
Material or pertaining to environmental conditions on, under or about the Premises or any part of
the Project, including the Comprehensive Environmental Response Compensation and Liability Act of 1980, as
amended (42
3
U.S.C. Section 9601
et
seq
.), and the Resource Conservation and
Recovery Act of 1976, as amended (42 U.S.C. Section 6901
et
seq
.).
EXPANSION PREMISES: The space under the Prior Sublease (defined in Rider 2) which becomes part of
the Premises on the Expansion Premises Commencement Date, as more particularly provided in this
Lease. The Expansion Premises is deemed to be 24,835 square feet of Rentable Area, is commonly
known as 301 Penobscot Drive (as of the execution date of this Lease), is depicted on
Exhibit
A
hereto, and is further described in Section 1.01, definition of Premises and Rider 2.
EXPIRATION DATE: The date specified in Section 1.01(7) unless changed by operation of Article Two
or Rider 2.
FORCE MAJEURE: Any accident, casualty, act of God, war or civil commotion, strike or labor
troubles, or any cause whatsoever beyond the reasonable control of Landlord, including water
shortages, energy shortages or governmental preemption in connection with an act of God, a national
emergency, or by reason of Law, or by reason of the conditions of supply and demand which have been
or are affected by act of God, war or other emergency.
HAZARDOUS MATERIAL: Such substances, material and wastes which are or become regulated under any
Environmental Law; or which are classified as hazardous or toxic or medical waste or biohazardous
waste under any Environmental Law; and explosives, firearms and ammunition, flammable material,
radioactive material, asbestos, polychlorinated biphenyls and petroleum and its byproducts.
INITIAL PREMISES: The part of the Premises to be delivered initially to Tenant after execution of
this Lease and part as to which the Term first commences, as more particularly provided in this
Lease. The Initial Premises is deemed to be 23,065 square feet of Rentable Area, is commonly known
as 351 Penobscot Drive (as of the execution date of this Lease), is depicted on
Exhibit A
hereto, and is further described in Section 1.01, definition of Premises and Rider 2.
INDEMNITEES: Collectively, Landlord, any Mortgagee or ground lessor of the Property, the property
manager and the leasing manager for the Property and their respective directors, officers, agents
and employees.
LAND: The parcel(s) of real estate on which the Building and Project are located.
LANDLORD WORK: The construction or installation of improvements to be furnished by Landlord, if
any, specifically described in Rider 2 attached hereto.
LAWS OR LAW: All laws, ordinances, rules, regulations, other requirements, orders, rulings or
decisions adopted or made by any governmental body, agency, department or judicial authority having
jurisdiction over the Property, the Premises or Tenants activities at the Premises and any
covenants, conditions or restrictions of record which affect the Property.
LEASE: This instrument and all exhibits and riders attached hereto, as may be amended from time to
time.
LEASE YEAR: The twelve month period beginning on the first day of the first month following the
Initial Premises Commencement Date (unless the Commencement Date is the first day of a calendar
month in which case beginning on the Commencement Date), and each subsequent twelve month, or
shorter, period until the Expiration Date.
MONTHLY BASE RENT: The monthly rent specified in Section 1.01(8).
MORTGAGEE: Any holder of a mortgage, deed of trust or other security instrument encumbering the
Property.
NATIONAL HOLIDAYS: New Years Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and
Christmas Day and other holidays recognized by the Landlord and the janitorial and other unions
servicing the Building in accordance with their contracts.
OPERATING EXPENSES: All Taxes, costs, expenses and disbursements of every kind and nature which
Landlord shall pay or become obligated to pay in connection with the ownership, management,
operation, maintenance, replacement and repair of the Property (including the amortized portion of
any capital expenditure or improvement, together with interest thereon, expenses of changing
utility service providers, and any dues, assessments and other expenses pursuant to any covenants,
conditions and restrictions, or any reciprocal easements, or any owners association now or
hereafter affecting the Project; provided however that with respect to any expenses, dues,
assessments and other expenses pursuant to any covenants, conditions and restrictions, or any
reciprocal easements, or any owners association hereafter affecting the Project, then such costs
and expenses shall only be deemed to be Operating Expenses to the extent that such costs or
expenses could otherwise be deemed to be Operating Expenses pursuant to the provisions set forth in
this section). Operating Expenses shall be allocated among the categories of Project Operating
Expenses, Building Operating Expenses or Phase Operating Expenses as provided in Article Four. If
any Operating Expense relates to more than one calendar year, such expense shall be proportionately
allocated among such related calendar years. Operating Expenses shall include the following, by
way of illustration only and not limitation: (1) all Taxes; (2) all insurance premiums and other
costs (including deductibles), including the cost of rental insurance; (3) all license, permit and
inspection fees; (4) all costs of utilities, fuels and related services, including water, sewer,
light, telephone, power and steam connection, service and related charges; (5) all costs to repair,
maintain and operate heating, ventilating and air conditioning systems, including preventive
maintenance incurred by Landlord, if any; (6) all janitorial, landscaping and security services;
(7) all wages, salaries, payroll taxes, fringe benefits and other labor costs, including the cost
of workers compensation and disability insurance; (8) all costs of operation,
maintenance and repair of all parking facilities and other common areas; (9) all supplies,
materials, equipment
4
and tools; (10) dues, assessments and other expenses pursuant to any
covenants, conditions and restrictions, or any reciprocal easements, or any owners association now
or hereafter affecting the Project; (11) modifications to the Building or the Project occasioned by
Laws now or hereafter in effect, but only as amortized over the useful life of the capital item as
reasonably determined by Landlord; (12) the total charges of any independent contractors employed
in the care, operation, maintenance, repair, leasing and cleaning of the Project, including
landscaping, roof maintenance, and repair, maintenance and monitoring of life-safety systems,
plumbing systems, electrical wiring and Project signage; (13) the cost of accounting services
necessary to compute the rents and charges payable by tenants at the Project; (14) exterior window
and exterior wall cleaning and painting; (15) managerial and administrative expenses; (16) all
costs in connection with the exercise facility at the Project; (17) all costs and expenses related
to Landlords retention of consultants in connection with the routine review, inspection, testing,
monitoring, analysis and control of Hazardous Material, and retention of consultants in connection
with the clean-up of Hazardous Material (to the extent not recoverable from a particular tenant of
the Project), and all costs and expenses related to the implementation of recommendations made by
such consultants concerning the use, generation, storage, manufacture, production, storage,
release, discharge, disposal or clean-up of Hazardous Material on, under or about the Premises or
the Project (to the extent not recoverable from a particular tenant of the Project); (18) all
capital improvements made for the purpose of reducing or controlling other Operating Expenses, and
all other capital expenditures, but only as amortized over the useful life of such capital
improvement as reasonably determined by Landlord, together with interest on the unamortized
portion; (19) all property management costs and fees, including all costs in connection with the
Project property management office; and (20) all fees or other charges incurred in conjunction with
voluntary or involuntary membership in any energy conservation, air quality, environmental, traffic
management or similar organizations. Operating Expenses shall not include: (a) costs of
alterations of space to be occupied by new or existing tenants of the Project; (b) depreciation
charges; (c) interest and principal payments on loans (except for loans for capital expenditures or
improvements which Landlord is allowed to include in Operating Expenses as provided above); (d)
ground rental payments; (e) real estate brokerage and leasing commissions; (f) advertising and
marketing expenses; (g) costs of Landlord reimbursed by insurance proceeds; (h) costs for which the
Landlord is reimbursed by any other tenant or occupant of the Building (other than payments
comparable to Rent Adjustments hereunder) or by any tenants insurance carrier or by anyone else,
and electric power costs for which any tenant directly contracts with the local public service
company; (i) expenses incurred in negotiating leases of other tenants in the Project or enforcing
lease obligations of other tenants in the Project; (j) Landlords property managers corporate
general overhead or corporate general administrative expenses; (k) the wages and benefits of any
employee who does not devote substantially all of his or her employed time to the Building, Project
or Phase, unless such wages and benefits are prorated to reflect time spent on operation and
managing the Building, Project or Phase; (l) Landlords corporate general overhead or corporate
general administrative expenses associated with the operation of the business of the entity which
constitutes the Landlord, as the
same are distinguished from the costs of operation of the
Building, Project or Phase; (m) executives salaries; (n) any bad debt loss, rent loss, or reserves
for bad debts or rent loss; (o) costs of Landlords charitable or political contributions; (p) the
acquisition and installation costs of the replacement of 150 tons of HVAC (which includes
mechanical units, associated controls and ductwork, and related materials and expenses), as
described in Section 8.03 below; (q) the costs of any Tenant Work (as defined in the Workletter),
and (r) costs incurred in connection with Hazardous Materials to the extent such Hazardous
Materials were present on the Project prior to the Delivery Date.
PHASE: Phase means any individual Phase of the Project, as more particularly described in the
definition of Project.
PHASE OPERATING EXPENSES: Those Operating Expenses described in Section 4.01.
PREMISES: The Premises consists of the entire Rentable Area of the Building at the initial Suite
Number(s) listed in Section 1.01 and is depicted on
Exhibit A
attached hereto. The
Premises is classified in two parts, namely the Initial Premises and the Expansion Premises, for
purposes of separately determining and providing as to each part for the Delivery Date,
Commencement Date of the Term and commencement of Rent as to each, and certain other rights and
obligations of the parties, as more particularly provided in Rider 2, the Workletter and other
provisions of this Lease.
PROJECT or PROPERTY: As of the date hereof, the Project is known as Seaport Centre and consists of
those buildings (including the Building) whose general location is shown on the Site Plan of the
Project attached as
Exhibit C
, located in Redwood City, California, associated vehicular
and parking areas, landscaping and improvements, together with the Land, any associated interests
in real property, and the personal property, fixtures, machinery, equipment, systems and apparatus
located in or used in conjunction with any of the foregoing. The Project may also be referred to
as the Property. As of the date hereof, the Project is divided into Phase I and Phase II, which
are generally designated on
Exhibit C
, each of which may individually be referred to as a
Phase. Landlord reserves the right from time to time to add or remove buildings, areas and
improvements to or from a Phase or the Project, or to add or remove a Phase to or from the Project.
In the event of any such addition or removal which affects Rentable Area of the Project or a
Phase, Landlord shall make a corresponding recalculation and adjustment of any affected Rentable
Area and Tenants Share.
PROJECT OPERATING EXPENSES: Those Operating Expenses described in Section 4.01.
REAL PROPERTY: The Property excluding any personal property.
RENT: Collectively, Monthly Base Rent, Rent Adjustments and Rent Adjustment Deposits, and all
other charges, payments, late fees or other amounts required to be paid by Tenant under this Lease.
RENT ADJUSTMENT: Any amounts owed by Tenant for payment of Operating Expenses. The Rent
Adjustments shall be determined and paid as provided in Article Four.
5
RENT ADJUSTMENT DEPOSIT: An amount equal to Landlords estimate of the Rent Adjustment
attributable to each month of the applicable Adjustment Year. On or before the Commencement Date
and the beginning of each subsequent Adjustment Year or with Landlords Statement (defined in
Article Four), Landlord may estimate and notify Tenant in writing of its estimate of Operating
Expenses, including Project Operating Expenses, Building Operating Expenses and Phase Operating
Expenses, and Tenants Share of each, for the applicable Adjustment Year. The Rent Adjustment
Deposit applicable for the calendar year in which the Commencement Date occurs shall be the amount,
if any, specified in Section 1.01(9). Nothing contained herein shall be construed to limit the
right of Landlord from time to time during any calendar year to revise its estimates of Operating
Expenses and to notify Tenant in writing thereof and of revision by prospective adjustments in
Tenants Rent Adjustment Deposit payable over the remainder of such year. The last estimate by
Landlord shall remain in effect as the applicable Rent Adjustment Deposit unless and until Landlord
notifies Tenant in writing of a change.
RENTABLE AREA OF THE BUILDING: The amount of square footage set forth in Section 1.01(11)
RENTABLE AREA OF THE PHASE: The amount of square footage set forth in Section 1.01(12)
RENTABLE AREA OF THE PREMISES: The amount of square footage set forth in Section 1.01(10).
RENTABLE AREA OF THE PROJECT: The amount of square footage set forth in Section 1.01(13), which
represents the sum of the rentable area of all space intended for occupancy in the Project.
SECURITY: The cash and/or Letter of Credit specified in Section 1.01, if any, paid or delivered to
Landlord as security for Tenants performance of its obligations under this Lease, and any proceeds
of the Letter of Credit drawn and held by Landlord, all as more particularly provided in Article
Five.
SUBSTANTIALLY COMPLETE: The completion of the Landlord Work or Tenant Work, as the case may be,
except for minor insubstantial details of construction, decoration or mechanical adjustments which
remain to be done.
TAXES: All federal, state and local governmental taxes, assessments (including assessment bonds)
and charges of every kind or nature, whether general, special, ordinary or extraordinary, which
Landlord shall pay or become obligated to pay because of or in connection with the ownership,
leasing, management, control or operation of the Property or any of its components (including any
personal property used in connection therewith), which may also include any rental or similar taxes
levied in lieu of or in addition to general real and/or personal property taxes. For purposes
hereof, Taxes for any year shall be Taxes which are assessed for any period of such year, whether
or not such Taxes are billed and payable in a subsequent calendar year. There shall be included in
Taxes for any year the amount of all fees, costs and expenses (including reasonable attorneys
fees) paid by Landlord during such year in seeking or obtaining any refund or reduction of Taxes.
Taxes for any year shall be reduced by the net amount of any tax refund received by Landlord
attributable to such year. If a special assessment payable in installments is levied against any
part of the Property, Taxes for any year shall include only the installment of such assessment and
any interest payable or paid during such year. Taxes shall not include any federal or state
inheritance, general income, gift or estate taxes, except that if a change occurs in the method of
taxation resulting in whole or in part in the substitution of any such taxes, or any other
assessment, for any Taxes as above defined, such substituted taxes or assessments shall be included
in the Taxes.
TENANT ADDITIONS: Collectively, Landlord Work, Tenant Work and Tenant Alterations. Tenants
Personal Property (as set forth in
Exhibit G
hereto) shall not be deemed to be included in
the definition of Tenant Additions.
TENANT ALTERATIONS: Any alterations, improvements, additions, installations or construction in or
to the Premises or any Real Property systems serving the Premises done or caused to be done by
Tenant after the date hereof, whether prior to or after the Commencement Date (including Tenant
Work, but excluding Landlord Work).
TENANT DELAY: Any event or occurrence which delays the Substantial Completion of the Landlord Work
which is caused by or is described as follows:
(i) special work, changes, alterations or additions requested or made by Tenant in the
design or finish in any part of the Premises after approval of the plans and specifications
(as described in the Rider 2);
(ii) Tenants delay in submitting plans, supplying information, approving plans,
specifications or estimates, giving authorizations or otherwise;
(iii) failure to approve and pay for such work as Landlord undertakes to complete at
Tenants expense;
(iv) the performance or completion by Tenant or any person engaged by Tenant of any work in
or about the Premises; or
(v) failure to perform or comply with any obligation or condition binding upon Tenant
pursuant to Rider 2, including the failure to approve and pay for such Landlord Work or
other items if and to the extent Rider 2 provides they are to be approved or paid by Tenant.
TENANTS FF&E: The property of Tenant described in Section 5 of the Workletter.
TENANTS PERSONAL PROPERTY: Tenants property described on
Exhibit G
hereto.
6
TENANT WORK: All work installed or furnished to the Premises by Tenant in connection with Tenants
initial occupancy pursuant to Rider 2 and the Workletter.
TENANTS BUILDING SHARE: The share as specified in Section 1.01(16) and Section 4.01.
TENANTS PHASE: The Phase in which the Premises is located, as indicated in Section 1.01(1).
TENANTS PHASE SHARE: The share as specified in Section 1.01(16) and Section 4.01.
TENANTS PROJECT SHARE: The share as specified in Section 1.01(16) and Section 4.01.
TENANTS SHARE: Shall mean collectively, Tenants respective shares of the respective categories
of Operating Expenses, as provided in Section 1.01(16) and Section 4.01.
TERM: The term of this Lease commencing on the Initial Premises Commencement Date and expiring on
the Expiration Date.
TERMINATION DATE: The Expiration Date or such earlier date as this Lease terminates or Tenants
right to possession of the Premises terminates.
WORKLETTER: The Agreement regarding the completion of Tenant Work and Landlord Work, if any, set
forth in Rider 2 and
Exhibit B
hereto.
ARTICLE TWO
PREMISES, TERM, FAILURE TO GIVE POSSESSION, COMMON AREAS AND PARKING
Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises for the Term
and upon the terms, covenants and conditions provided in this Lease.
2.02
|
|
TERM (See Rider 2)
|
|
2.03
|
|
FAILURE TO GIVE POSSESSION (See Rider 2)
|
|
2.04
|
|
AREA OF PREMISES
|
Landlord and Tenant agree that for all purposes of this Lease the Rentable Area of the Premises,
the Rentable Area of the Building, the Rentable Area of the Phase and the Rentable Area of the
Project as set forth in Article One are controlling, and are not subject to revision after the date
of this Lease, except as otherwise provided herein.
2.05
|
|
CONDITION OF PREMISES (See Rider 2)
|
|
2.06
|
|
COMMON AREAS & PARKING
|
(a)
Right to Use Common Areas
. Tenant shall have the non-exclusive right, in common
with others, to the use of any common entrances, ramps, drives and similar access and serviceways
and other Common Areas in the Project. The rights of Tenant hereunder in and to the Common Areas
shall at all times be subject to the rights of Landlord and other tenants and owners in the Project
who use the same in common with Tenant, and it shall be the duty of Tenant to keep all the Common
Areas free and clear of any obstructions created or permitted by Tenant or resulting from Tenants
operations. Tenant shall not use the Common Areas or common facilities of the Building or the
Project, including the Buildings electrical room, parking lot or trash enclosures, for storage
purposes. Nothing herein shall affect the right of Landlord at any time to remove any persons not
authorized to use the Common Areas or common facilities from such areas or facilities or to prevent
their use by unauthorized persons.
(b)
Changes in Common Areas
. Landlord reserves the right, at any time and from time
to time to (i) make alterations in or additions to the Common Areas or common facilities of the
Project, including constructing new buildings or changing the location, size, shape or number of
the driveways, entrances, parking spaces, parking areas, loading and unloading areas, landscape
areas and walkways, (ii) designate property to be included in or eliminate property from the Common
Areas or common facilities of the Project, (iii) close temporarily any of the Common Areas or
common facilities of the Project for maintenance purposes, and (iv) use the Common Areas and common
facilities of the Project while engaged in making alterations in or additions and repairs to the
Project; provided, however, that (x) such changes do not materially adversely affect Tenants use
of the Premises or increase Tenants costs hereunder, and (y) reasonable access to the Premises and
parking at or near the Project remains available.
(c)
Parking
. During the Term, Tenant shall have the right to use the number of
Parking Spaces specified in Section 1.01(18) for parking on an unassigned basis on that portion of
the Project designated by Landlord from time to time for parking. Tenant acknowledges and agrees
that the parking spaces in the Projects parking facility may include a mixture of spaces for
compact vehicles as well as full-size passenger automobiles, and that Tenant shall not use parking
spaces for vehicles larger than the striped size of the parking spaces. Tenant shall comply with
any and all parking rules and regulations if and as from time to time established by Landlord.
Tenant shall not allow any vehicles using Tenants parking privileges to be parked, loaded or
unloaded except in accordance with this Section, including in the areas and in the manner
designated by Landlord for such activities. If any vehicle owned or operated by Tenant or any Tenant Parties
(as defined in Article Seven) is using the parking or loading areas contrary to any provision of
this Section, Landlord shall have
7
the right, in addition to all other rights and remedies of
Landlord under this Lease, to remove or tow away the vehicle without prior notice to Tenant, and
the cost thereof shall be paid to Landlord within ten (10) business days after notice from Landlord
to Tenant.
ARTICLE THREE
RENT
Tenant agrees to pay to Landlord via wire transfer in accordance with instructions set forth below
(as modified by Landlord from time to time), or to such other persons, or at such other places or
in such manner designated by Landlord, without any prior demand therefor in immediately available
funds and without any deduction or offset whatsoever, Rent, including Monthly Base Rent and Rent
Adjustments in accordance with Article Four, during the Term. Monthly Base Rent shall be paid
monthly in advance on the first day of each month of the Term, except that the first installment of
Monthly Base Rent shall be paid by Tenant to Landlord concurrently with execution of this Lease by
means of Tenants check payable to the order of Metropolitan Life Insurance Company. Monthly Base
Rent shall be prorated for partial months within the Term. Unpaid Rent shall bear interest at the
Default Rate from the date due until paid. Tenants covenant to pay Rent shall be independent of
every other covenant in this Lease. Until further notice to Tenant, Rent paid by wire transfer
shall be wired to:
Wells Fargo Bank, San Francisco, CA,
A/C # 482-9605856
Routing # 121000248
A/C Name: CBRE ITF Seaport II
ARTICLE FOUR
OPERATING EXPENSES, RENT ADJUSTMENTS AND PAYMENTS
4.01
|
|
TENANTS SHARE OF OPERATING EXPENSES
|
Tenant shall pay Tenants Share of Operating Expenses in the respective shares of the respective
categories of Operating Expenses as set forth below.
(a) Tenants Project Share of Project Operating Expenses, which is the percentage
obtained by dividing the rentable square footage of the Premises by the rentable square
footage of the Project and as of the date hereof equals the percentage set forth in Section
1.01(16);
(b) Tenants Building Share of Building Operating Expenses, which is the percentage
obtained by dividing the rentable square footage of the Premises respectively for each
building in which the Premises is located by the total rentable square footage of such
building and as of the date hereof equals the percentage set forth in Section 1.01(16);
(c) Tenants Phase Share of Phase Operating Expenses, which is the percentage obtained
by dividing the aggregate rentable square footage of the Premises by the total rentable
square footage of Tenants Phase and as of the date hereof equals the percentage set forth
in Section 1.01(16);
(d) Project Operating Expenses shall mean all Operating Expenses that are not included
as Phase Operating Expenses (defined below) and that are not either Building Operating
Expenses or operating expenses directly and separately identifiable to the operation,
maintenance or repair of any other building located in the Project, but Project Operating
Expenses includes operating expenses allocable to any areas of the Building or any other
building during such time as such areas are made available by Landlord for the general
common use or benefit of all tenants of the Project, and their employees and invitees, or
the public, as such areas currently exist and as they may be changed from time to time;
(e) Building Operating Expenses shall mean Operating Expenses that are directly and
separately identifiable to each building in which the Premises or part thereof is located;
(f) Phase Operating Expenses shall mean Operating Expenses that Landlord may allocate
to a Phase as directly and separately identifiable to all buildings located in the Phase
(including but not limited to the Building) and may include Project Operating Expenses that
are separately identifiable to a Phase;
(g) Landlord shall have the right to allocate a particular item or portion of
Operating Expenses as any one of Project Operating Expenses, Building Operating Expenses or
Phase Operating Expenses; however, in no event shall any portion of Building Operating
Expenses, Project Operating Expenses or Phase Operating Expenses be assessed or counted
against Tenant more than once; and.
(h) Notwithstanding anything to the contrary contained in this Section 4.01, as to
each specific category of Operating Expense which one or more tenants of the Building either
pays directly to third parties or specifically reimburses to Landlord (for example,
separately contracted janitorial services or property taxes directly reimbursed to
Landlord), then, on a category by category basis, the amount of Operating Expenses for the
affected period shall be adjusted as follows: (1) all such tenant payments with respect to
such category of expense and all of Landlords costs reimbursed thereby shall be excluded
from Operating Expenses and Tenants Building Share, Tenants Phase Share or Tenants
Project Share, as the case may be, for such category of Operating Expense shall be adjusted
by excluding the square footage of all such tenants, and (2) if Tenant pays or directly
reimburses Landlord for such category of Operating Expense, such category of Operating
Expense shall be excluded from the determination of Operating Expenses for the purposes of
this Lease.
8
Tenant shall pay to Landlord Rent Adjustments with respect to each Adjustment Year as follows:
(a) The Rent Adjustment Deposit shall be paid monthly during the Term with the payment
of Monthly Base Rent, except the first installment which shall be paid by Tenant to Landlord
concurrently with execution of this Lease. The Rent Adjustment Deposit represents, on a
monthly basis, Tenants Share of Landlords estimate of Operating Expenses, as described in
Section 4.01, for the applicable Adjustment Year (or portion thereof); and
(b) Any Rent Adjustments due in excess of the Rent Adjustment Deposits in accordance
with Section 4.03.
4.03
|
|
STATEMENT OF LANDLORD
|
Within one hundred twenty (120) days after the end of each calendar year or as soon thereafter as
reasonably possible, Landlord will furnish Tenant a statement (Landlords Statement) showing the
following:
(a) Operating Expenses for the last Adjustment Year showing in reasonable detail the
actual Operating Expenses categorized among Project Operating Expenses, Building Operating
Expenses and Phase Operating Expenses for such period and Tenants Share of each as
described in Section 4.01 above;
(b) The amount of Rent Adjustments due Landlord for the last Adjustment Year, less
credit for Rent Adjustment Deposits paid, if any; and
(c) Any change in the Rent Adjustment Deposit due monthly in the current Adjustment
Year, including the amount or revised amount due for months preceding any such change
pursuant to Landlords Statement.
Tenant shall pay to Landlord within ten (10) days after receipt of such statement any amounts for
Rent Adjustments then due in accordance with Landlords Statement. Any amounts due from Landlord
to Tenant pursuant to this Section shall be credited to the Rent Adjustment Deposit next coming
due, or refunded to Tenant if the Term has already expired provided Tenant is not in default
hereunder. No interest or penalties shall accrue on any amounts which Landlord is obligated to
credit or refund to Tenant by reason of this Section 4.03. Landlords failure to deliver
Landlords Statement or to compute the amount of the Rent Adjustments shall not constitute a waiver
by Landlord of its right to deliver such items nor constitute a waiver or release of Tenants
obligations to pay such amounts. The Rent Adjustment Deposit shall be credited against Rent
Adjustments due for the applicable Adjustment Year. During the last complete calendar year or
during any partial calendar year in which the Lease terminates, Landlord may include in the Rent
Adjustment Deposit its estimate of Rent Adjustments which may not be finally determined until after
the termination of this Lease. Tenants obligation to pay Rent Adjustments survives the expiration
or termination of the Lease. Notwithstanding the foregoing, in no event shall the sum of Monthly
Base Rent and the Rent Adjustments be less than the Monthly Base Rent payable.
Landlord shall maintain books and records showing Operating Expenses and Taxes in accordance with
sound accounting and management practices, consistently applied. The Tenant or its representative
(which representative shall be a certified public accountant licensed to do business in the state
in which the Property is located and whose primary business is certified public accounting) shall
have the right, for a period of thirty (30) days following the date upon which Landlords Statement
is delivered to Tenant, to examine the Landlords books and records with respect to the items in
the foregoing statement of Operating Expenses and Taxes during normal business hours, upon written
notice, delivered at least three (3) business days in advance. If Tenant does not object in writing
to Landlords Statement within sixty (60) days of Tenants receipt thereof, specifying the nature
of the item in dispute and the reasons therefor, then Landlords Statement shall be considered
final and accepted by Tenant. Any amount due to the Landlord as shown on Landlords Statement,
whether or not disputed by Tenant as provided herein shall be paid by Tenant when due as provided
above, without prejudice to any such written exception.
4.05
|
|
TENANT OR LEASE SPECIFIC TAXES
|
In addition to Monthly Base Rent, Rent Adjustments, Rent Adjustment Deposits and other charges to
be paid by Tenant, Tenant shall pay to Landlord, upon demand, any and all taxes payable by Landlord
(other than federal or state inheritance, general income, gift or estate taxes) whether or not now
customary or within the contemplation of the parties hereto: (a) upon, allocable to, or measured
by the Rent payable hereunder, including any gross receipts tax or excise tax levied by any
governmental or taxing body with respect to the receipt of such rent; or (b) upon or with respect
to the possession, leasing, operation, management, maintenance, alteration, repair, use or
occupancy by Tenant of the Premises or any portion thereof; or (c) upon the measured value of
Tenants personal property or trade fixtures located in the Premises or in any storeroom or any
other place in the Premises or the Property, or the areas used in connection with the operation of
the Property, it being the intention of Landlord and Tenant that, to the extent possible, Tenant
shall cause such taxes on personal property or trade fixtures to be billed to and paid directly by
Tenant; (d) resulting from Landlord Work, Tenant Work or Tenant Alterations to the Premises,
whether title thereto is in Landlord or Tenant; or (e) upon this transaction. Taxes paid by Tenant pursuant to this Section 4.05 shall not be included in any computation of
Taxes as part of Operating Expenses.
9
ARTICLE FIVE
SECURITY
(a) Tenant, at Tenants sole cost and expense, concurrently with execution of this Lease,
shall either (1) pay Landlord in cash or immediately available funds or (2) provide Landlord the
Letter of Credit (defined below) as more particularly described below, in each case in the amount
of the Security specified in Section 1.01 as security (Security) for the full and faithful
performance by Tenant of each and every term, provision, covenant, and condition of this Lease. If
Tenant fails timely to perform any of the terms, provisions, covenants and conditions of this Lease
or any other document executed by Tenant in connection with this Lease, including, but not limited
to, the payment of the Monthly Base Rent, Rent Adjustment Deposits, Rent Adjustments or the repair
of damage to the Premises caused by Tenant (excluding normal wear and tear) then Landlord may use,
apply, or retain the whole or any part of the Security for the payment of any such Monthly Base
Rent, Rent Adjustment Deposits or Rent Adjustments not paid when due, for the cost of repairing
such damage, for the cost of cleaning the Premises, for the payment of any other sum which Landlord
may expend or may be required to expend by reason of Tenants failure to perform, and otherwise for
compensation of Landlord for any other loss or damage to Landlord occasioned by Tenants failure to
perform, including, but not limited to, any loss of future Rent and any damage or deficiency in the
reletting of the Premises (whether such loss, damages or deficiency accrue before or after summary
proceedings or other reentry by Landlord) and the amount of the unpaid past Rent, future Rent loss,
and all other losses, costs and damages, that Landlord would be entitled to recover if Landlord
were to pursue recovery under California Civil Code Section 1951.2 or 1951.4. If Landlord so uses,
applies or retains all or part of the Security, Tenant shall within five (5) business days after
demand pay or deliver to Landlord in immediately available funds the sum necessary to replace the
amount used, applied or retained, except as specified in (e) below. If Tenant has fully and
faithfully performed and observed all of Tenants obligations under the terms, provisions,
covenants and conditions of this Lease, the Security (except any amount retained for application by
Landlord as provided herein) shall be returned or paid over to Tenant no later than ninety (90)
days after the latest of: (i) the Termination Date; (ii) the removal of Tenant from the Premises;
or (iii) the surrender of the Premises by Tenant to Landlord in accordance with this Lease.
Provided, however, in no event shall any such return be construed as an admission by Landlord that
Tenant has performed all of its obligations hereunder.
(b) The Security, whether in the form of cash, Letter of Credit (defined below) and/or Letter
of Credit Proceeds (defined below), shall not be deemed an advance rent deposit or an advance
payment of any kind, or a measure of Landlords damages with respect to Tenants failure to
perform, nor shall any action or inaction of Landlord with respect to it or its use or application
be a waiver of, or bar or defense to, enforcement of any right or remedy of Landlord. Landlord
shall not be required to keep the Security separate from its general funds and shall not have any
fiduciary duties or other duties (except as set forth in this Section) concerning the Security.
Tenant shall not be entitled to any interest on the Security. In the event of any sale, lease or
transfer of Landlords interest in the Building, Landlord shall have the right to transfer the
Security, or balance thereof, to the vendee, transferee or lessee and any such transfer shall
release Landlord from all liability for the return of the Security. Tenant thereafter shall look
solely to such vendee, transferee or lessee for the return or payment of the Security. Tenant
shall not assign or encumber or attempt to assign or encumber the Security or any interest in it
and Landlord shall not be bound by any such assignment, encumbrance, attempted assignment or
attempted encumbrance, and regardless of one or more assignments of this Lease, Landlord may return
the Security to the original Tenant without liability to any assignee. Tenant hereby waives any
and all rights of Tenant under the provisions of Section 1950.7 of the California Civil Code, and
any and all rights of Tenant under all other provisions of law, now or hereafter enacted, regarding
security deposits.
(c) If Tenant fails timely to perform any obligation under this Article Five, such breach
shall constitute a Default by Tenant under this Lease without any right to or requirement of any
further notice or cure period under any other Article of this Lease, except such notice and cure
period expressly provided under this Article Five.
(d) During the first six months after the date on which this Lease has been executed by both
Tenant and Landlord, Tenant shall have the right, at Tenants sole cost and expense, to provide
Landlord with the Letter of Credit (defined below) as the Security required under this Lease in
substitution for the cash then held by Landlord as Security. In the event that Tenant first
delivered the Security in the form of cash or immediately available funds prior to delivering the
Letter of Credit, then, within thirty (30) days after Tenants delivery to Landlord of the Letter
of Credit, Landlord shall refund to Tenant the amount of cash held by Landlord as Security, less
any amounts thereof used, applied or retained by Landlord pursuant to the provisions of Subsection
(a) and not replenished by Tenant.
(e) As used herein, Letter of Credit shall mean an unconditional, irrevocable sight draft
letter of credit issued, presentable and payable at the San Francisco, California or San Jose,
California office of a major national bank satisfactory to Landlord in its sole discretion (the
Bank), naming Landlord as beneficiary, in an amount equal to Five Hundred Thousand and 00/100
Dollars ($500,000.00). The Letter of Credit shall provide: (i) that Landlord may make partial and
multiple draws thereunder, up to the face amount thereof, and that Landlord may draw upon the
Letter of Credit up to the full amount thereof, as determined by Landlord, and the Bank will pay to
Landlord the amount of such draw upon receipt by the Bank of a sight draft signed by Landlord
without requirement for any additional documents or statements by Landlord; and (ii) that, in the
event of assignment or other transfer of either Landlords interest in this Lease or of any
interest in Landlord (including, without limitation, consolidations, mergers, reorganizations or
other entity changes), the Letter of Credit shall be freely transferable by Landlord, without
charge to Landlord and without recourse, to the assignee or transferee of such interest and the
Bank shall confirm the same to Landlord and such assignee or transferee. The Letter of Credit
shall be in the form attached as
Exhibit H
hereto. Provided however, if Tenant proposes to
use Silicon Valley Bank as the issuer of the Letter of Credit, the form of Letter of Credit set
forth in
Exhibit E
hereto will be acceptable to Landlord. Landlord may (but shall not be required to) draw upon the Letter of Credit
and use the proceeds therefrom (the Letter of Credit Proceeds) or any portion thereof in any
manner Landlord is permitted to use the Security under this Article Five. In the event Landlord
draws upon the Letter of Credit and elects not
10
to terminate the Lease, but to use the Letter of
Credit Proceeds, then within five (5) business days after Landlord gives Tenant written notice
specifying the amount of the Letter of Credit Proceeds so utilized by Landlord, Tenant shall
deliver to Landlord an amendment to the Letter of Credit or a replacement Letter of Credit in an
amount equal to one hundred percent (100%) of the then-required amount of the Letter of Credit.
Tenants failure to deliver such amendment or replacement of the Letter of Credit to Landlord
within five (5) business days after Landlords notice shall constitute a Default by Tenant under
this Lease. The Letter of Credit shall have an initial term of no longer than one (1) year, shall
be evergreen, and shall be extended, reissued or replaced by Tenant, in each case at least thirty
(30) days prior to its expiration in a manner that fully complies with the requirements of this
Article Five, so that in all events the Letter of Credit required hereunder shall be in full force
and effect continuously until the date (the L/C Expiration Date) for return of the Security
described in Subsection (a) above. No more often than once per year, Landlord shall have the right
to require Tenant to deliver to Landlord, on 15 days prior notice, a replacement Letter of Credit
on the same terms and conditions set forth in this Article Five, in the event that Landlord
determines, in its good faith judgment, that the issuing Bank is no longer satisfactory to remain
as the issuer of the Letter of Credit. Any advice from the issuer that it intends to withdraw or
not extend the Letter of Credit prior to any scheduled annual expiration or the L/C Expiration Date
shall entitle the Landlord to immediately draw upon the Letter of Credit.
ARTICLE SIX
UTILITIES & SERVICES
6.01
|
|
LANDLORDS GENERAL SERVICES
|
Landlord shall provide maintenance and services as provided in Article Eight.
6.02
|
|
TENANT TO OBTAIN & PAY DIRECTLY
|
(a) Tenant shall be responsible for and shall pay promptly all charges for gas, electricity,
sewer, heat, light, power, telephone, refuse pickup (to be performed on a regularly scheduled basis
so that accumulated refuse does not exceed the capacity of Tenants refuse bins), janitorial
service and all other utilities, materials and services furnished directly to or used by Tenant in,
on or about the Premises, together with all taxes thereon. Tenant shall contract directly with the
providing companies for such utilities and services.
(b) Notwithstanding any provision of the Lease to the contrary, without, in each instance, the
prior written consent of Landlord, as more particularly provided in Article Nine, Tenant shall not:
(i) make any alterations or additions to the electric or gas equipment or systems or other
Building systems. Tenants use of electric current shall at no time exceed the capacity of the
wiring, feeders and risers providing electric current to the Premises or the Building. The consent
of Landlord to the installation of electric equipment shall not relieve Tenant from the obligation
to limit usage of electricity to no more than such capacity.
All telegraph, telephone, and communication connections which Tenant may desire outside the
Premises shall be subject to Landlords prior written approval, in Landlords sole discretion, and
the location of all wires and the work in connection therewith shall be performed by contractors
approved by Landlord and shall be subject to the direction of Landlord, except that such approval
is not required as to Tenants cabling from the Premises in a route designated by Landlord to any
telephone cabinet or panel provided for Tenants connection to the telephone cable serving the
Building, so long as Tenants equipment does not require connections different than or additional
to those to the telephone cabinet or panel provided. As to any such connections or work outside
the Premises requiring Landlords approval, Landlord reserves the right reasonably to approve the
entity or entities providing telephone or other communication cable installation, removal, repair
and maintenance outside the Premises and reasonably to restrict and control access to telephone
cabinets or panels outside the Premises. Tenant shall be responsible for and shall pay all costs
incurred in connection with the installation of telephone cables and communication wiring in the
Premises, including any hook-up, access and maintenance fees related to the installation of such
wires and cables in the Premises and the commencement of service therein, and the maintenance
thereafter of such wire and cables; and there shall be included in Operating Expenses for the
Building all installation, removal, hook-up or maintenance costs incurred by Landlord in connection
with telephone cables and communication wiring serving the Building which are not allocable to any
individual users of such service but are allocable to the Building generally. If Tenant fails to
maintain all telephone cables and communication wiring in the Premises and such failure affects or
interferes with the operation or maintenance of any other telephone cables or communication wiring
serving the Building, Landlord or any vendor hired by Landlord may enter into and upon the Premises
forthwith and perform such repairs, restorations or alterations as Landlord deems necessary in
order to eliminate any such interference (and Landlord may recover from Tenant all of Landlords
costs in connection therewith). No later than the Termination Date, Tenant agrees to remove all
telephone cables and communication wiring installed by Tenant for and during Tenants occupancy,
which Landlord shall request Tenant to remove. Tenant agrees that neither Landlord nor any of its
agents or employees shall be liable to Tenant, or any of Tenants employees, agents, customers or
invitees or anyone claiming through, by or under Tenant, for any damages, injuries, losses,
expenses, claims or causes of action because of any interruption, diminution, delay or
discontinuance at any time for any reason in the furnishing of any telephone or other communication
service to the Premises and the Building.
6.04
|
|
FAILURE OR INTERRUPTION OF UTILITY OR SERVICE
|
To the extent that any equipment or machinery furnished or maintained by Landlord outside the
Premises is used in the delivery of utilities directly obtained by Tenant pursuant to Section 6.02
and breaks down or ceases to function properly, Landlord shall use reasonable diligence to repair same promptly. In the
event of any failure, stoppage or interruption of, or change in, any utilities or services supplied
by Landlord which are not directly obtained by Tenant, Landlord shall use reasonable diligence to
have service promptly resumed. In either event covered by the preceding two sentences, if the
cause of any such failure, stoppage or interruption of, or change
11
in, utilities or services is
within the control of a public utility, other public or quasi-public entity, or utility provider
outside Landlords control, notification to such utility or entity of such failure, stoppage or
interruption and request to remedy the same shall constitute reasonable diligence by Landlord to
have service promptly resumed. Notwithstanding any other provision of this Section to the
contrary, in the event of any failure, stoppage or interruption of, or change in, any utility or
other service furnished to the Premises or the Project resulting from any cause other than the
gross negligence or willful and wrongful act of Landlord or its agents or contractors, including
changes in service provider or Landlords compliance with any voluntary or similar governmental or
business guidelines now or hereafter published or any requirements now or hereafter established by
any governmental agency, board or bureau having jurisdiction over the operation of the Property:
(a) Landlord shall not be liable for, and Tenant shall not be entitled to, any abatement or
reduction of Rent; (b) no such failure, stoppage, or interruption of any such utility or service
shall constitute an eviction of Tenant or relieve Tenant of the obligation to perform any covenant
or agreement of this Lease to be performed by Tenant; (c) Landlord shall not be in breach of this
Lease nor be liable to Tenant for damages or otherwise.
6.05
|
|
INTENTIONALLY OMITTED
|
|
6.06
|
|
SIGNAGE
|
Except as set forth in
Rider 2
, Tenant shall not install any signage within the Project,
the Building or the Premises without obtaining the prior written approval of Landlord, and Tenant
shall be responsible for procurement, installation, maintenance and removal of any such signage
installed by Tenant, and all costs in connection therewith. Any such signage shall comply with
Landlords current Project signage criteria and all Laws.
ARTICLE SEVEN
POSSESSION, USE AND CONDITION OF PREMISES
7.01
|
|
POSSESSION AND USE OF PREMISES
|
(a) Tenant shall occupy and use the Premises only for the uses specified in Section 1.01(17)
to conduct Tenants business. Tenant shall not occupy or use the Premises (or permit the use or
occupancy of the Premises) for any purpose or in any manner which: (1) is unlawful or in violation
of any Law or Environmental Law; (2) may be dangerous to persons or property or which may increase
the cost of, or invalidate, any policy of insurance carried on the Building or covering its
operations; (3) is contrary to or prohibited by the terms and conditions of this Lease or the rules
and regulations as provided in Article Eighteen; (4) contrary to or prohibited by the articles,
bylaws or rules of any owners association affecting the Project; (5) would obstruct or interfere
with the rights of other tenants or occupants of the Building or the Project, or injure or annoy
them, or would tend to create or continue a nuisance; or (6) would constitute any waste in or upon
the Premises or Project.
(b) Landlord and Tenant acknowledge that the Americans With Disabilities Act of 1990 (42
U.S.C. §12101 et seq.) and regulations and guidelines promulgated thereunder, as all of the same
may be amended and supplemented from time to time (collectively referred to herein as the ADA)
establish requirements for business operations, accessibility and barrier removal, and that such
requirements may or may not apply to the Premises, the Building and the Project depending on, among
other things: (1) whether Tenants business is deemed a public accommodation or commercial
facility, (2) whether such requirements are readily achievable, and (3) whether a given
alteration affects a primary function area or triggers path of travel requirements. The
parties hereby agree that: (a) Landlord shall be responsible for ADA Title III compliance in the
Common Areas, except as provided below, (b) Tenant shall be responsible for ADA Title III
compliance in the Premises, including any leasehold improvements or other work to be performed in
the Premises under or in connection with this Lease, (c) Landlord may perform, or require that
Tenant perform, and Tenant shall be responsible for the cost of, ADA Title III path of travel
requirements triggered by Tenant Additions in the Premises, and (d) Landlord may perform, or
require Tenant to perform, and Tenant shall be responsible for the cost of, ADA Title III
compliance in the Common Areas necessitated by the Building being deemed to be a public
accommodation instead of a commercial facility as a result of Tenants use of the Premises.
Tenant shall be solely responsible for requirements under Title I of the ADA relating to Tenants
employees.
(c) Landlord and Tenant agree to cooperate and use commercially reasonable efforts to
participate in traffic management programs generally applicable to businesses located in or about
the area and Tenant shall encourage and support van and car pooling by, and staggered and flexible
working hours for, its office workers and service employees to the extent reasonably permitted by
the requirements of Tenants business. Neither this Section or any other provision of this Lease
is intended to or shall create any rights or benefits in any other person, firm, company,
governmental entity or the public.
(d) Tenant agrees to cooperate with Landlord and to comply with any and all guidelines or
controls concerning energy management imposed upon Landlord by federal or state governmental
organizations or by any energy conservation association to which Landlord is a party or which is
applicable to the Building.
(a) Tenant shall not use, generate, manufacture, produce, store, handle, release, discharge,
or dispose of, on, under or about the Premises or any part of the Project, or transport to or from
the Premises or any part of the Project, any Hazardous Material, or allow its employees, agents,
contractors, licensees, invitees or any other person or entity under Tenants control (Tenant
Parties) to do so except to the extent expressly provided below. Provided that the Premises are
used only for the uses specified in Section 1.01(17) above, Tenant shall be permitted to use and
store in, and transport to and from, the Premises Hazardous Material
identified on
Exhibit D
hereto and by this reference incorporated herein (Permitted
Hazardous Material) so long as: (i) each item of the Permitted Hazardous Material is used or
stored in, or transported to and from, the Premises only to the extent necessary for Tenants
operation of its business at the Premises; (ii) at no time shall any Permitted Hazardous Material
be in use or storage at the Premises in excess of the quantity specified
12
therefor in
Exhibit D
; (iii) Tenant shall not install any underground tanks of any
type; and (iv) the conditions and provisions set forth in this Section 7.02 are complied with. If
Tenant desires to add additional types or quantities of Hazardous Materials to the list of
Permitted Hazardous Materials specified in
Exhibit D,
Tenant shall give Landlord notice of
the Hazardous Materials and quantities thereof that Tenant desires to use at the Premises and
Landlord shall thereafter have the right to approve or disapprove such additional Hazardous
Materials in Landlords sole discretion within ten (10) days after receipt of such notice. Failure
to notify Tenant in writing of its decision within said ten (10) day period shall be deemed
disapproval by Landlord. Tenant shall comply with and shall cause all Tenant Parties to comply
with all Environmental Laws and other Laws pertaining to Tenants occupancy and use of the Premises
and concerning the proper use, generation, manufacture, production, storage, handling, release,
discharge, removal and disposal of any Hazardous Material introduced to the Premises, the Building
or the Property by Tenant or any of the Tenant Parties. Without limiting the generality of the
foregoing:
(1) Tenant shall provide Landlord promptly with copies of: (x) all permits, licenses and
other governmental and regulatory approvals with respect to the use, generation,
manufacture, production, storage, handling, release, discharge, removal and disposal by
Tenant or any of the Tenant Parties of Hazardous Material at the Project; and (y) each
hazardous material management plan or similar document (Plan(s)) with respect to use,
generation, manufacture, production, storage, handling, release, discharge, removal or
disposal of Hazardous Material by Tenant or any of the Tenant Parties necessary to comply
with Environmental Laws or other Laws prepared by or on behalf of Tenant or any of the
Tenant Parties (whether or not required to be submitted to a governmental agency) and
updates thereof in the event of any change in the Permitted Hazardous Materials used by
Tenant or when otherwise required by Law.
(2) If Tenant is notified of any investigation or violation of any Environmental Laws or
other Laws arising from any activity of Tenant or any of the Tenant Parties at the Property,
or if Tenant knows, or has reasonable cause to believe, that a Hazardous Material has come
to be located in, on, under or about the Premises or the Project, other than as previously
consented to by Landlord, Tenant shall immediately give written notice of such fact to
Landlord, and provide Landlord with a copy of all reports, notices, claims or other
documentation which it has concerning the presence of such Hazardous Material. In such
event Landlord may conduct, at Tenants expense, such tests and studies as Landlord deems
desirable relating to compliance by Tenant or any of the Tenant Parties with this Lease,
Environmental Laws, other Laws, or relating to the alleged presence of Hazardous Material
introduced to the Premises, the Building or the Property by Tenant or any of the Tenant
Parties. Further, Landlord may conduct, at Landlords expense, such tests and studies as
Landlord deems desirable relating to compliance by Tenant or any of the Tenant Parties with
this Lease, Environmental Laws, other Laws, or relating to the alleged presence of Hazardous
Material introduced to the Premises, the Building or the Property by Tenant or any of the
Tenant Parties. In the event such tests and studies done at Landlords expense reasonably
indicate that Tenant or Tenant Parties have violated Environmental Laws or caused a release
of Hazardous Material, then Tenant shall reimburse Landlord the cost of such tests and
studies.
(3) Neither Tenant nor any of the Tenant Parties shall cause or permit any Hazardous
Material to be released, discharged or disposed of in, on, under, or about the Premises or
the Project (including through the plumbing or sanitary sewer system) and shall promptly, at
Tenants expense, take all investigatory and/or remedial action reasonably recommended,
whether or not formally ordered or required, for the cleanup of any contamination of, and
for the maintenance, security and/or monitoring of the Premises, the Project or neighboring
properties, that was caused or materially contributed to by Tenant, or pertaining to or
involving any Hazardous Material brought onto the Premises or the Project by Tenant or any
of the Tenant Parties.
(4) Tenant shall, no later than the Termination Date, surrender the Premises to Landlord
free of Hazardous Material and with all remedial and/or closure plans completed (and deliver
evidence thereof to Landlord).
(b) To the extent permitted by law, Tenant hereby indemnifies and agrees to protect, defend
and hold the Indemnitees harmless against all actions, claims, demands, liability, costs and
expenses, including reasonable attorneys fees and expenses for the defense thereof, arising from
the use, generation, manufacture, production, storage, handling, release, threatened release,
discharge, disposal, transportation to or from, or presence of any Hazardous Material on, under or
about the Premises or any part of the Project caused by Tenant or by any of the Tenant Parties,
whether before, during or after the Term. Tenants obligations under this Section 7.02 shall
survive the expiration or earlier termination of this Lease. In case of any action or proceeding
brought against the Indemnitees by reason of any such claim, upon notice from Landlord, Tenant
covenants to defend such action or proceeding by counsel chosen by Landlord, in Landlords sole
discretion. Landlord reserves the right to settle, compromise or dispose of any and all actions,
claims and demands related to the foregoing indemnity, subject to the prior written approval of
Tenant, which may not unreasonably be withheld.
(c) The right to use and store in, and transport to and from, the Premises the Permitted
Hazardous Material is personal to Genomic Health and may not be assigned or otherwise transferred
by it without the prior written consent of Landlord, which consent may be withheld in Landlords
sole discretion, except (i) to a Permitted Transferee which is an assignee of the Lease and which
has satisfied the requirements of Sections 10.01 and 10.05 of this Lease; and (ii) Genomic Health
may permit a Permitted Transferee which is a sublessee to use and store in, and transport to and
from, the Premises the Permitted Hazardous Material to the same extent as Genomic Health has such
right under this Lease, subject to all the provisions of this Lease. Any consent by Landlord
pursuant to Article Ten to an assignment, transfer, subletting, mortgage, pledge, hypothecation or
encumbrance of this Lease, and any interest therein or right or privilege appurtenant thereto,
shall not constitute consent by Landlord to the use or storage at, or transportation to, the
Premises of any Hazardous Material (including a Permitted Hazardous Material) by any such assignee,
sublessee or transferee unless Landlord expressly agrees otherwise in writing. Provided however,
at the time Tenant requests approval
13
of any proposed assignment or sublease of this Lease by
Tenant, Tenant shall submit to Landlord the proposed Permitted Hazardous Material list of the
proposed assignee or sublessee. Landlord shall have the right, in its sole discretion, to approve
the proposed assignees or sublessees proposed Permitted Hazardous Material list, or to require
modifications to said list. In the event that Landlord does not approve of the proposed assignees
or sublessees Permitted Hazardous Material list, or the proposed assignee or sublessee cannot or
will not modify said list, then it shall be reasonable for purposes of Article Ten hereof for
Landlord to refuse its consent to the proposed assignee or sublessee. In the event that the
proposed Hazardous Material list of the assignee or sublessee includes any Hazardous Material
different from or in greater quantity than those on Tenants Permitted Hazardous Material list,
Tenant shall pay Landlord, whether or not Landlord consents to the proposed list of Permitted
Hazardous Materials and/or to the proposed assignment or sublease, (i) a processing fee of Three
Thousand Dollars ($3,000.00) at the time Tenant submits the request for approval, and (ii) the
reasonable fees and expenses of any consultants retained by Landlord in connection with review of
the proposed Permitted Hazardous Material list and use thereof by the proposed assignee or
sublessee. Any consent by Landlord to the use or storage at, or transportation to or from the
Premises, of any Hazardous Material (including a Permitted Hazardous Material) by an assignee,
sublessee or transferee of Tenant shall not constitute a waiver of Landlords right to refuse such
consent as to any subsequent assignee or transferee.
(d) Tenant acknowledges that the sewer piping at the Project is made of ABS plastic.
Accordingly, without Landlords prior written consent, which may be given or withheld in Landlords
sole discretion, only ordinary domestic sewage is permitted to be put into the drains at the
Premises. UNDER NO CIRCUMSTANCES SHALL Tenant EVER DEPOSIT ANY ESTERS OR KETONES (USUALLY FOUND IN
SOLVENTS TO CLEAN UP PETROLEUM PRODUCTS) IN THE DRAINS AT THE PREMISES. If Tenant desires to put
any substances other than ordinary domestic sewage into the drains, it shall first submit to
Landlord a complete description of each such substance, including its chemical composition, and a
sample of such substance suitable for laboratory testing. Landlord shall promptly determine
whether or not the substance can be deposited into the drains and its determination shall be
absolutely binding on Tenant. Upon demand, Tenant shall reimburse Landlord for expenses incurred
by Landlord in making such determination. If any substances not so approved hereunder are
deposited in the drains in Tenants Premises, Tenant shall be liable to Landlord for all damages
resulting therefrom, including but not limited to all costs and expenses incurred by Landlord in
repairing or replacing the piping so damaged.
7.03 LANDLORD ACCESS TO PREMISES; APPROVALS
(a) Tenant shall permit Landlord to erect, use and maintain pipes, ducts, wiring and conduits
in and through the Premises, so long as Tenants use, layout or design of the Premises is not
materially affected or altered. Landlord or Landlords agents shall have the right to enter upon
the Premises (i) in the event of an emergency, without prior notice, or (ii) with 24-hour prior
notice to inspect the Premises, to perform janitorial and other services (if any), to conduct
safety and other testing in the Premises and to make such repairs, alterations, improvements or
additions to the Premises or the Building or other parts of the Property as Landlord may deem
necessary or desirable (including all alterations, improvements and additions in connection with a
change in service provider or providers). Janitorial and cleaning services (if any) shall be
performed after normal business hours. Any entry or work by Landlord may be during normal business
hours and Landlord may use reasonable efforts to ensure that any entry or work shall not materially
interfere with Tenants occupancy of the Premises.
(b) If Tenant or its agents shall not be personally present to permit an entry into the
Premises when for any reason an entry therein shall be necessary or permissible, Landlord (or
Landlords agents), after having properly notified Tenant (unless Landlord believes an emergency
situation exists), may enter the Premises without rendering Landlord or its agents liable therefor,
and without relieving Tenant of any obligations under this Lease.
(c) Landlord may enter the Premises for the purpose of conducting such inspections, tests and
studies as Landlord may deem desirable or necessary to confirm Tenants compliance with all Laws
and Environmental Laws or for other purposes necessary in Landlords reasonable judgment to ensure
the sound condition of the Property and the systems serving the Property. Landlords rights under
this Section 7.03 (c) are for Landlords own protection only, and Landlord has not, and shall not
be deemed to have assumed, any responsibility to Tenant or any other party as a result of the
exercise or non-exercise of such rights, for compliance with Laws or Environmental Laws or for the
accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.
(d) Landlord may do any of the foregoing, or undertake any of the inspection or work described
in the preceding paragraphs without such action constituting an actual or constructive eviction of
Tenant, in whole or in part, or giving rise to an abatement of Rent by reason of loss or
interruption of business of the Tenant, or otherwise.
(e) The review, approval or consent of Landlord with respect to any item required or permitted
under this Lease is for Landlords own protection only, and Landlord has not, and shall not be
deemed to have assumed, any responsibility to Tenant or any other party, as a result of the
exercise or non-exercise of such rights, for compliance with Laws or Environmental Laws or for the
accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.
7.04 QUIET ENJOYMENT
Landlord covenants, in lieu of any implied covenant of quiet possession or quiet enjoyment, that so
long as Tenant is in compliance with the covenants and conditions set forth in this Lease, Tenant
shall have the right to quiet enjoyment of the Premises without hindrance or interference from
Landlord or those claiming through Landlord, and subject to the covenants and conditions set forth
in the Lease and to the rights of any Mortgagee or ground lessor.
14
ARTICLE EIGHT
MAINTENANCE & HVAC
8.01 LANDLORDS MAINTENANCE
Subject to Article Fourteen and Section 8.02, Landlord shall maintain the structural portions of
the Building, the roof, exterior walls and exterior doors, foundation, and underslab standard sewer
system of the Building in good, clean and safe condition. Notwithstanding the foregoing, Landlord
shall have no responsibility to perform preventive maintenance or service for, or to repair any
heating, ventilation and air conditioning equipment and systems serving the Premises (HVAC), and
all such preventive maintenance, service, and repairs shall be performed by Tenant pursuant to the
terms of Section 8.02. Landlord shall also (a) maintain the landscaping, parking facilities and
other Common Areas of the Project, and (b) wash the outside of exterior windows at intervals
determined by Landlord. Except as provided in Article Fourteen and Article Fifteen, there shall be
no abatement of rent, no allowance to Tenant for diminution of rental value and no liability of
Landlord by reason of inconvenience, annoyance or any injury to or interference with Tenants
business arising from the making of or the failure to make any repairs, alterations or improvements
in or to any portion of the Project or in or to any fixtures, appurtenances or equipment therein.
Tenant waives the right to make repairs at Landlords expense under any law, statute or ordinance
now or hereafter in effect.
8.02 TENANTS MAINTENANCE
(a) Subject to the provisions of Article Fourteen, Tenant shall, at Tenants sole cost and
expense, maintain and make all repairs to the Premises and fixtures therein which Landlord is not
required to make pursuant to Section 8.01, including repairs to the interior walls, ceilings and
windows of the Premises, the interior doors, Tenants signage, and the electrical, life-safety,
plumbing and HVAC, and shall maintain the Premises, the fixtures, HVAC and utilities systems
therein, and the area immediately surrounding the Premises (including all garbage enclosures), in a
good, clean and safe condition. Tenant shall deliver to Landlord a copy of any maintenance
contract entered into by Tenant with respect to the Premises. Tenant shall also, at Tenants
expense, keep any non-standard heating, ventilating and air conditioning equipment and other
non-standard equipment in the Building in good condition and repair, using contractors approved in
advance, in writing, by Landlord, which approval shall not be unreasonably withheld.
Notwithstanding Section 8.01 above, to the extent that Landlord is not reimbursed by insurance and
no waiver set forth in Section 16.04 is applicable, Tenant will pay for any repairs to the Building
or the Project which are caused by any negligence or willful and wrongful act, of Tenant or its
assignees, subtenants or employees, or of the respective agents of any of the foregoing persons, or
of any other persons permitted in the Building or elsewhere in the Project by Tenant or any of
them. Tenant will maintain the Premises, and will leave the Premises upon termination of this
Lease, in a safe, clean, neat and sanitary condition.
(b) With respect to HVAC, Tenant, at Tenants sole cost and expense, shall enter into
contracts (HVAC Service Contracts) for regularly scheduled inspections and preventive maintenance
and service, as to which the contractors, scope of work, frequency of inspection, maintenance or
service, shall be subject to Landlords prior written approval, in its sole discretion. Tenant
shall cause the contractor for such HVAC Service Contracts to deliver written reports to Landlord
within ten (10) days after the date of such inspection, maintenance and/or service. Tenant shall
deliver to Landlord a copy of the initial HVAC Service Contracts within sixty (60) days after the
Initial Premises Commencement Date and of subsequent HVAC Service Contracts entered into by Tenant
within ten (10) days after execution thereof (which subsequent HVAC Service Contracts shall be
subject to the same approval standards and requirements as set forth above with respect to the
initial contract). In the event Tenant fails, in the reasonable judgment of Landlord, to meet the
requirements for such HVAC Service Contracts and cause such inspections, maintenance and service to
be performed, which failure continues at the end of fifteen (15) days following written notice
given by Landlord stating the nature of the failure, Landlord shall have the right (but shall not
be obligated) to obtain such HVAC Service Contracts and to enter the Premises and perform such
inspection, maintenance and service, at Tenants sole cost and expense; provided, however, if the
nature of the maintenance or repair is such that it cannot, with the exercise of reasonable
diligence, be completed within fifteen (15) days of Tenants receipt of Landlords notice, Landlord
shall not undertake such inspection, maintenance and service at Tenants expense provided Tenant
commences such inspection, maintenance and service in the manner required above within said 15-day
period and thereafter diligently and continuously prosecutes the same to completion and provided
further, however, that in the event of an emergency condition, Landlord shall have the right to
make such inspection, maintenance, service and/or repairs on behalf of Tenant at Tenants sole cost
and expense after giving Tenant such notice, if any, as is reasonable under the circumstances.
Landlords right of entry pursuant to Section 7.03 shall include the right to enter and inspect the
Premises for violations of Tenants covenants herein. Tenant shall maintain written records of
HVAC inspection, maintenance, service repairs, and shall use certified technicians approved in
writing by Landlord to perform such maintenance and repairs.
8.03 ADDITIONAL PROVISIONS REGARDING HVAC
Over a period of three years after the Initial Premises Commencement Date, Tenant shall, subject to
reimbursement by Landlord on the schedule provided below, replace 150 tons of non-specialized HVAC
units serving the Building with new equipment of like kind and quality as the existing equipment
(which includes mechanical units, associated controls and ductwork, and related materials and expenses). Tenant
shall pay the cost thereof, subject to reimbursement by Landlord on the schedule provided below,
which reimbursed amounts shall not be recoverable by Landlord from Tenant as items of Building
Operating Expenses. Tenant shall control the work and schedule for the replacement of the 150 tons
of HVAC, subject to the requirements set forth herein and Landlords prior written approval, which
shall not be unreasonably withheld, of the following: (a) the vendors and contractors to supply
and install such HVAC, and Landlord and Tenant agree that Tenant shall obtain bids from a minimum
of three such vendors and contractors; (b) all plans and specifications of and for such HVAC and
installation thereof; (c) the cost of such HVAC and installation thereof, but Landlord and Tenant
agree that the cost reimbursable to Tenant by Landlord hereunder shall in no event exceed the
amount of lowest bid; (d)
15
the contracts for such HVAC and installation thereof, and Landlord and
Tenant agree that, among other things, such contracts shall provide for warranties acceptable to
Landlord and that such warranties shall name Landlord and be issued directly for the benefit of and
enforceable by Landlord. Tenant shall provide a replacement schedule to Landlord. Notwithstanding
the foregoing, in the event Tenant, in its reasonable opinion, determines that it is most efficient
or cost-effective to replace 150 tons of HVAC at the time that Tenant conducts the Tenant Work
pursuant to the Workletter, then Tenant may do so. The replacement costs shall be reimbursed to
Tenant by Landlord over a three year period on each of the subsequent three (3) anniversaries of
the date upon which the replacement work was completed (or first portion thereof was completed, if
Tenant elects not to replace all 150 tons at once). Each annual payment shall be an amount equal
to the lesser of (x) the amount actually expended by Tenant for work done (to the extent not
previously reimbursed) and (y) one-third (1/3) of the total cost of replacement of all 150 tons, as
approved and permitted by this Section; provided however, any amount reimbursable to Tenant
hereunder shall, if not previously reimbursed, be reimbursed to Tenant no later than the third
(3
rd
) anniversary of the Initial Premises Commencement Date. Provided further, at least
thirty (30) days prior to any reimbursement, Tenant shall provide Landlord, with respect to the
work for which reimbursement is sought: (i) a reasonable description of the work, including names
of all contractors, subcontractors and vendors providing labor, services or material; (ii) bills
and invoices, and proof of payment thereof by Tenant; (iii) valid, unconditional mechanics lien
releases; (iv) applicable warranties; and (v) As Built drawings and specifications in the same
form as those required under Section 3.5 of the Workletter. In no event shall any portion of
Tenants Allowance (as defined in the Workletter) be allocated toward the cost of the replacement
of the 150 tons of HVAC, or the ancillary mechanical units, associated controls and ductwork, and
related materials and expenses. Upon installation, such HVAC shall be deemed to be part of the
Building and owned by Landlord.
ARTICLE NINE
ALTERATIONS AND IMPROVEMENTS
9.01 TENANT ALTERATIONS
(a) The following provisions shall apply to the completion of any Tenant Alterations:
(1) Tenant shall not, except as provided herein, without the prior written consent of
Landlord, which consent shall not be unreasonably withheld, make or cause to be made any
Tenant Alterations in or to the Premises or any Property systems serving the Premises.
Prior to making any Tenant Alterations, Tenant shall give Landlord ten (10) days prior
written notice (or such earlier notice as would be necessary pursuant to applicable Law) to
permit Landlord sufficient time to post appropriate notices of non-responsibility. Subject
to all other requirements of this Article Nine, Tenant may, without Landlords prior written
consent, undertake (i) Decoration work and/or (ii) any Alterations that (x) do not adversely
affect the roof, structural portions or the systems or equipment of the Building, (y) are
not visible from the exterior of the Building, and (z) do not cost, in the aggregate, over
the Term of the Lease, in excess of $50,000. Tenant shall furnish Landlord with the names
and addresses of all contractors and subcontractors and copies of all contracts. All Tenant
Alterations shall be completed at such time and in such manner as Landlord may from time to
time designate, and only by contractors or mechanics approved by Landlord, which approval
shall not be unreasonably withheld. The contractors, mechanics and engineers who may be
used are further limited to those whose work will not cause or threaten to cause disharmony
or interference with Landlord or other tenants in the Building and their respective agents
and contractors performing work in or about the Building. Landlord may further condition
its consent upon Tenant furnishing to Landlord and Landlord approving prior to the
commencement of any work or delivery of materials to the Premises related to the Tenant
Alterations such of the following as specified by Landlord: architectural plans and
specifications, opinions from Landlords engineers stating that the Tenant Alterations will
not in any way adversely affect the Buildings systems, necessary permits and licenses,
certificates of insurance, and such other documents in such form reasonably requested by
Landlord. Landlord may, in the exercise of reasonable judgment, request that Tenant provide
Landlord with appropriate evidence of Tenants ability to complete and pay for the
completion of the Tenant Alterations such as a performance bond or letter of credit. Upon
completion of the Tenant Alterations, Tenant shall deliver to Landlord an as-built mylar and
digitized (if available) set of plans and specifications for the Tenant Alterations.
(2) Tenant shall pay the cost of all Tenant Alterations and the cost of decorating the
Premises and any work to the Property occasioned thereby. In connection with completion of
any Tenant Alterations, Tenant shall, upon receipt of Landlords itemized invoice therefor,
pay Landlords actual and reasonable costs to review the plans and specifications for such
Tenant Alterations and to monitor the performance thereof, including a construction
administration fee and all elevator and hoisting charges at Landlords then standard rate.
Upon completion of Tenant Alterations, Tenant shall furnish Landlord with contractors
affidavits and full and final waivers of lien and receipted bills covering all labor and
materials expended and used in connection therewith and such other documentation reasonably
requested by Landlord or Mortgagee.
(3) Tenant agrees to complete all Tenant Alterations (i) in accordance with all Laws,
Environmental Laws, all requirements of applicable insurance companies and in accordance
with Landlords standard construction rules and regulations, and (ii) in a good and
workmanlike manner with the use of good grades of materials. Tenant shall notify Landlord
immediately if Tenant receives any notice of violation of any Law in connection with
completion of any Tenant Alterations and shall immediately take such steps as are necessary
to remedy such violation. In no event shall such supervision or right to supervise by
Landlord nor shall any approvals given by Landlord under this Lease constitute any warranty
by Landlord to Tenant of the adequacy of the design, workmanship or quality of such work or
materials for Tenants intended use or of compliance with the requirements of Section
9.01(a)(3)(i) and (ii) above or impose any liability upon Landlord in connection with the
performance of such work.
16
(b) All Tenant Additions to the Premises whether installed by Landlord or Tenant, shall
without compensation or credit to Tenant, become part of the Premises and the property of Landlord
at the time of their installation and shall remain in the Premises, unless pursuant to Article
Twelve, Tenant may remove them or is required to remove them at Landlords request. Tenants
Personal Property, as set forth in
Exhibit G
, shall at all times remain the property of
Tenant and Tenant shall remove such property at the expiration or earlier termination of this
Lease.
9.02 LIENS
Tenant shall not permit any lien or claim for lien of any mechanic, laborer or supplier or any
other lien to be filed against the Building, the Land, the Premises, or any other part of the
Property arising out of work performed, or alleged to have been performed by, or at the direction
of, or on behalf of Tenant. If any such lien or claim for lien is filed, Tenant shall within ten
(10) days of receiving notice of such lien or claim (a) have such lien or claim for lien released
of record or (b) deliver to Landlord a bond in form, content, amount, and issued by surety,
satisfactory to Landlord, indemnifying, protecting, defending and holding harmless the Indemnitees
against all costs and liabilities resulting from such lien or claim for lien and the foreclosure or
attempted foreclosure thereof. If Tenant fails to take any of the above actions, Landlord, in
addition to its rights and remedies under Article Eleven, without investigating the validity of
such lien or claim for lien, may pay or discharge the same and Tenant shall, as payment of
additional Rent hereunder, reimburse Landlord upon demand for the amount so paid by Landlord,
including Landlords expenses and reasonable attorneys fees.
ARTICLE TEN
ASSIGNMENT AND SUBLETTING
10.01 ASSIGNMENT AND SUBLETTING
(a) Without the prior written consent of Landlord, which may be withheld in Landlords sole
discretion, Tenant may not sublease, assign, mortgage, pledge, hypothecate or otherwise transfer or
permit the transfer of this Lease or the encumbering of Tenants interest therein in whole or in
part, by operation of Law or otherwise or permit the use or occupancy of the Premises, or any part
thereof, by anyone other than Tenant, provided, however, if Landlord chooses not to recapture the
space proposed to be subleased or assigned as provided in Section 10.02, Landlord shall not
unreasonably withhold its consent to a subletting or assignment under this Section 10.01. Tenant
agrees that the provisions governing sublease and assignment set forth in this Article Ten shall be
deemed to be reasonable. If Tenant desires to enter into any sublease of the Premises or
assignment of this Lease, Tenant shall deliver written notice thereof to Landlord (Tenants
Notice), together with the identity of the proposed subtenant or assignee and the proposed
principal terms thereof and financial and other information sufficient for Landlord to make an
informed judgment with respect to such proposed subtenant or assignee at least sixty (60) days
prior to the commencement date of the term of the proposed sublease or assignment. If Tenant
proposes to sublease less than all of the Rentable Area of the Premises, the space proposed to be
sublet and the space retained by Tenant must each be a marketable unit as reasonably determined by
Landlord and otherwise in compliance with all Laws; provided however, so long as the Tenant is
Genomic Health or a Permitted Transferee which is an assignee of the Lease which has satisfied the
requirements of Sections 10.01 and 10.05 below, the foregoing shall not apply to a sublease for a
sublease term of a year or less, for undemised space in the aggregate (for one or more such
subleases in effect at any one time) up to 3,000 square feet of Rentable Area. Landlord shall
notify Tenant in writing of its approval or disapproval of the proposed sublease or assignment or
its decision to exercise its rights under Section 10.02 within thirty (30) days after receipt of
Tenants Notice (and all required information). In no event may Tenant sublease any portion of the
Premises or assign the Lease to any other tenant of the Project. Tenant shall submit for
Landlords approval (which approval shall not be unreasonably withheld) any advertising which
Tenant or its agents intend to use with respect to the space proposed to be sublet.
(b) With respect to Landlords consent to an assignment or sublease, Landlord may take into
consideration any factors which Landlord may deem relevant, and the reasons for which Landlords
denial shall be deemed to be reasonable shall include, without limitation, the following:
(i) the business reputation or creditworthiness of any proposed subtenant or assignee is not
acceptable to Landlord; or
(ii) in Landlords reasonable judgment the proposed assignee or subtenant would diminish the
value or reputation of the Building or Landlord; or
(iii) any proposed assignees or subtenants use of the Premises would violate Section 7.01
of the Lease or would violate the provisions of any other leases of tenants in the Project;
(iv) the proposed assignee or subtenant is either a governmental agency, a school or similar
operation, or a medical related practice; or
(v) the proposed subtenant or assignee is a bona fide prospective tenant of Landlord in the
Project as demonstrated by a written proposal dated within ninety (90) days prior to the
date of Tenants request; or
(vi) the proposed subtenant or assignee would materially increase the estimated pedestrian
and vehicular traffic to and from the Premises and the Building.
In no event shall Landlord be obligated to consider a consent to any proposed assignment of the
Lease which would assign less than the entire Premises. In the event Landlord wrongfully withholds
its consent to any proposed sublease of the Premises or assignment of the Lease, Tenants sole and
exclusive remedy therefor shall be to seek specific performance of Landlords obligations to
consent to such sublease or assignment.
17
(c) Any sublease or assignment shall be expressly subject to the terms and conditions of this
Lease. Any subtenant or assignee shall execute such documents as Landlord may reasonably require
to evidence such subtenant or assignees assumption of the obligations and liabilities of Tenant
under this Lease. Tenant shall deliver to Landlord a copy of all agreements executed by Tenant and
the proposed subtenant and assignee with respect to the Premises. Landlords approval of a
sublease, assignment, hypothecation, transfer or third party use or occupancy shall not constitute
a waiver of Tenants obligation to obtain Landlords consent to further assignments or subleases,
hypothecations, transfers or third party use or occupancy.
(d) For purposes of this Article Ten, an assignment shall be deemed to include a change in the
majority control of Tenant, resulting from any transfer, sale or assignment of shares of stock or
membership interests of Tenant occurring by operation of Law or otherwise, and includes any merger,
acquisition, consolidation or reorganization, except as otherwise provided in this Subsection
below. Notwithstanding any provision of this Section to the contrary, an assignment for purposes
of this Article does not include any transfer of control of the stock or membership interests of
Tenant through (i) any public offering of shares of stock in Tenant in accordance with applicable
State and Federal law, rules, regulations and orders if thereafter the stock shall be listed and
publicly traded through the New York Stock Exchange or the NASDAQ national market; or (ii) public
sale of such stock effected through such Exchange or the NASDAQ national market. If Tenant is a
partnership, any change in the partners of Tenant shall be deemed to be an assignment.
(e) For purposes of this Lease, a Permitted Transferee shall mean any Person which: (i) is
an Affiliate of Tenant; or (ii) is the corporation or other entity (the Successor) resulting from
a merger, conversion, consolidation or non-bankruptcy reorganization with Tenant; or (iii) is not a
Successor but is otherwise a deemed assignee due to a change of control under section 10.01(d)
above; or (iv) purchases, leases or acquires by way of exchange all or substantially all the assets
of Tenant as a going concern (the Purchaser). Notwithstanding anything to the contrary in
Sections 10.01(a) and (b), 10.02 and 10.03, provided there is no uncured Default under this Lease,
Tenant shall have the right, without the prior written consent of Landlord, to assign this Lease to
a Permitted Transferee or to sublease the Premises or any part thereof to a Permitted Transferee
provided that: (1) Landlord receives thirty (30) days prior written notice of an assignment or
sublease (including a pending transaction described in subparts (i), (ii), (iii) or (iv) of this
Section 10.01(e)); provided that Tenant may give notice in less than thirty (30) days in connection
with a pending transaction described in subparts (ii) and (iv) of this Section 10.01(e) to the
extent that Tenant is precluded, by the terms of the transaction or, if Tenants stock is publicly
traded, by applicable securities laws, from making disclosure of the transaction itself; (2) with
respect to an assignment of the Lease or a sublease of more than half the Premises to an entity
described in subparts (ii) or (iv) of this Section 10.01(e), the Permitted Transferees net worth
is not less than Tenants net worth (measured as of the most recent date for which financial
statements prepared in accordance with GAAP are available); (3) with respect to an assignment of
the Lease or a sublease of more than half the Premises to an entity described in subparts (i) or
(iii) of this Section 10.01(e), Tenant (as the assignor or sublandord) continues in existence with
a net worth not less than Tenants net worth immediately prior to such assignment or subletting;
(4) the Permitted Transferee expressly assumes (except a Permitted Transferee which is a deemed
assignee under subpart (iii) of this Section 10.01(e) or which is a sublessee in the event of a
sublease under this Section 10.01(e)) in writing reasonably satisfactory to Landlord all of the
obligations of Tenant under this Lease and delivers such assumption to Landlord no later than
fifteen (15) days (or such lesser time as is appropriate in connection with a pending transaction
described in subparts (ii) and (iv) of this Section 10.01(e) to the extent that Tenant is
precluded, by the terms of the transaction or, if Tenants stock is publicly traded, by applicable
securities laws, from making disclosure of the transaction itself) prior to the effective date of
the assignment; (5) Landlord receives no later than five (5) days before the effective date a fully
executed copy of the applicable assignment or sublease agreement between Tenant and the Permitted
Transferee; and (6) promptly after Landlords written request, Tenant and the Permitted Transferee
provide such reasonable documents and information which Landlord reasonably requests for the
purpose of substantiating whether or not the assignment or sublease is to a Permitted Transferee.
All determinations of net worth for purposes of this Subsection shall exclude any value
attributable to goodwill or going concern value. With respect to any proposed assignment under
subparts (ii) or (iv) of this Section 10.01(e), Tenant shall pay Landlord, no later than fifteen
(15) days prior to the effective date of such proposed assignment or sublease, a processing fee of
Three Thousand Dollars ($3,000.00), which shall be Landlords earned fee whether or not the
proposed assignment or sublease is completed by Tenant.
(f) With respect to any sublease to a Permitted Transferee pursuant to Subsection (e) above,
Tenant hereby irrevocably assigns to Landlord, effective upon any such sublease, all rent and other
payments due from subtenant under the sublease, provided however, that Tenant shall have a license
to collect such rent and other payments until the occurrence of a default by Tenant under any of
the provisions of the Lease, and notice to Tenant of such default shall not be a prerequisite to
Landlords right to collect subrent. At any time at Landlords option, Landlord shall have the
right to give notice to the subtenant of such assignment. Landlord
shall credit Tenant with any rent received by Landlord under such assignment but the acceptance of
any payment on account of rent from the subtenant as the result of any such default shall in no
manner whatsoever serve to release Tenant from any liability under the terms, covenants,
conditions, provisions or agreement under the Lease. No such payment of rent or any other payment
by the subtenant directly to Landlord and/or acceptance of such payment(s) by Landlord, regardless
of the circumstances or reasons therefor, shall in any manner whatsoever be deemed an attornment by
the subtenant to Landlord in the absence of a specific written agreement signed by Landlord to such
an effect. For purposes of this Subsection, any use or occupancy by a Permitted Transferee (unless
it is an assignee) without a formal sublease shall for the purposes of this Subsection be deemed to
be a sublease at the same rental rate as provided in the Lease.
10.02 RECAPTURE
Landlord shall have the option to exclude from the Premises covered by this Lease (recapture),
the space proposed to be sublet or subject to the assignment, so long as (i) the proposed transfer
is not to a Permitted Transferee in accordance with the provisions of Section 10.01(e), and (ii)
the proposed sublease is for the
18
remainder of the term of this Lease and Landlord recaptures the
entire portion of the Premises subject to the proposed sublease. If Landlord elects to recapture,
such recapture shall be effective as of the commencement date of such sublease or assignment,
Tenant shall surrender possession of the space proposed to be subleased or subject to the
assignment to Landlord on the effective date of recapture of such space from the Premises, such
date being the Termination Date for such space. Effective as of the date of recapture of any
portion of the Premises pursuant to this section, the Monthly Base Rent, Rentable Area of the
Premises and Tenants Share shall be adjusted accordingly.
10.03 EXCESS RENT
Except with respect to an assignment or sublease to a Permitted Transferee in accordance with the
provisions of Section 10.01(e), Tenant shall pay Landlord on the first day of each month during the
term of the sublease or assignment, fifty percent (50%) of the amount by which the sum of all rent
and other consideration (direct or indirect) due from the subtenant or assignee for such month
exceeds: (i) that portion of the Monthly Base Rent and Rent Adjustments due under this Lease for
said month which is allocable to the space sublet or assigned; and (ii) the following costs and
expenses for the subletting or assignment of such space: (1) brokerage commissions and reasonable
attorneys fees and expenses, (2) the actual costs paid in making any improvements or substitutions
in the Premises required by any sublease or assignment; and (3) free rent periods, costs of any
inducements or concessions given to subtenant or assignee, moving costs, and other amounts in
respect of such subtenants or assignees other leases or occupancy arrangements. All such costs
and expenses shall be amortized over the term of the sublease or assignment pursuant to sound
accounting principles.
10.04 TENANT LIABILITY
In the event of any sublease or assignment, whether or not with Landlords consent, Tenant shall
not be released or discharged from any liability, whether past, present or future, under this
Lease, including any liability arising from the exercise of any renewal or expansion option, to the
extent such exercise is expressly permitted by Landlord. Tenants liability shall remain primary,
and in the event of default by any subtenant, assignee or successor of Tenant in performance or
observance of any of the covenants or conditions of this Lease, Landlord may proceed directly
against Tenant without the necessity of exhausting remedies against said subtenant, assignee or
successor. After any assignment, Landlord may consent to subsequent assignments or subletting of
this Lease, or amendments or modifications of this Lease with assignees of Tenant, without
notifying Tenant, or any successor of Tenant, and without obtaining its or their consent thereto,
and such action shall not relieve Tenant or any successor of Tenant of liability under this Lease.
If Landlord grants consent to such sublease or assignment, Tenant shall pay all reasonable
attorneys fees and expenses incurred by Landlord with respect to such assignment or sublease. In
addition, if Tenant has any options to extend the term of this Lease or to add other space to the
Premises, such options shall not be available to any subtenant or assignee, directly or indirectly
without Landlords express written consent, which may be withheld in Landlords sole discretion.
10.05 ASSUMPTION AND ATTORNMENT
If Tenant shall assign this Lease as permitted herein, the assignee shall expressly assume all of
the obligations of Tenant hereunder in a written instrument satisfactory to Landlord and furnished
to Landlord not later than fifteen (15) days prior to the effective date of the assignment. If
Tenant shall sublease the Premises as permitted herein, Tenant shall, at Landlords option, within
fifteen (15) days following any request by Landlord, obtain and furnish to Landlord the written
agreement of such subtenant to the effect that the subtenant will attorn to Landlord and will pay
all subrent directly to Landlord.
ARTICLE ELEVEN
DEFAULT AND REMEDIES
11.01 EVENTS OF DEFAULT
The occurrence or existence of any one or more of the following shall constitute a material default
and breach of the Lease (a Default) by Tenant under this Lease:
(i) Tenant fails to pay any installment or other payment of Rent, including Rent
Adjustment Deposits or Rent Adjustments, within three business (3) days after written notice
to Tenant of such failure to pay, provided that after Landlord has twice sent such notice to
Tenant for failure to pay, thereafter such failure shall be a Default if Tenant fails to pay
any such installment or other payment of Rent, including Rent Adjustment Deposits or Rent Adjustments, within three (3) business days
after the date when the same are due;
(ii) Tenant fails to observe or perform any of the other covenants, conditions or
provisions of this Lease or the Workletter and, unless the default involves a hazardous
condition, which shall be cured forthwith or unless the failure to perform is a Default for
which this Lease specifies there is no cure or grace period, fails to cure such default
within thirty (30) days after written notice thereof to Tenant, provided that, if Tenant has
exercised reasonable diligence to cure such failure and such failure cannot reasonably be
cured within such thirty (30) day period despite reasonable diligence, Tenant shall not be
in default under this subsection so long as Tenant diligently and continuously prosecutes
the cure to completion;
(iii) the interest of Tenant in this Lease is levied upon under execution or other
legal process;
(iv) a petition is filed by or against Tenant to declare Tenant bankrupt or seeking a
plan of reorganization or arrangement under any Chapter of the Bankruptcy Act, or any
amendment,
19
replacement or substitution therefor, or to delay payment of, reduce or modify
Tenants debts, which in the case of an involuntary action is not discharged within thirty
(30) days;
(v) Tenant is declared insolvent by Law or any assignment of Tenants property is made
for the benefit of creditors;
(vi) a receiver is appointed for Tenant or Tenants property, which appointment is not
discharged within thirty (30) days;
(vii) any action taken by or against Tenant to reorganize or modify Tenants capital
structure in a materially adverse way which in the case of an involuntary action is not
discharged within thirty (30) days; or
(viii) upon the dissolution of Tenant.
11.02 LANDLORDS REMEDIES
(a) A Default shall constitute a breach of the Lease for which Landlord shall have the rights
and remedies set forth in this Section 11.02 and all other rights and remedies set forth in this
Lease or now or hereafter allowed by Law, whether legal or equitable, and all rights and remedies
of Landlord shall be cumulative and none shall exclude any other right or remedy.
(b) With respect to a Default, at any time Landlord may terminate Tenants right to possession
by written notice to Tenant stating such election. Upon the termination of Tenants right to
possession pursuant to this Section 11.02, Tenants right to possession shall terminate and this
Lease shall terminate, and Tenant shall remain liable as hereinafter provided. Upon such
termination, Landlord shall have the right, subject to applicable Law, to re-enter the Premises and
dispossess Tenant and the legal representatives of Tenant and all other occupants of the Premises
by unlawful detainer or other summary proceedings, or otherwise as permitted by Law, regain
possession of the Premises and remove their property (including their trade fixtures, personal
property and those Tenant Additions which Tenant is required or permitted to remove under Article
Twelve), but Landlord shall not be obligated to effect such removal, and such property may, at
Landlords option, be stored elsewhere, sold or otherwise dealt with as permitted by Law, at the
risk of, expense of and for the account of Tenant, and the proceeds of any sale shall be applied
pursuant to Law. Landlord shall in no event be responsible for the value, preservation or
safekeeping of any such property. Tenant hereby waives all claims for damages that may be caused
by Landlords removing or storing Tenants personal property pursuant to this Section or Section
12.01, and Tenant hereby indemnifies, and agrees to defend, protect and hold harmless, the
Indemnitees from any and all loss, claims, demands, actions, expenses, liability and cost
(including reasonable attorneys fees and expenses) arising out of or in any way related to such
removal or storage. Upon such written termination of Tenants right to possession and this Lease,
Landlord shall have the right to recover damages for Tenants Default as provided herein or by Law,
including the following damages provided by California Civil Code Section 1951.2:
(1) the worth at the time of award of the unpaid Rent which had been earned at the time
of termination;
(2) the worth at the time of award of the amount by which the unpaid Rent which would
have been earned after termination until the time of award exceeds the amount of such Rent
loss that Tenant proves could reasonably have been avoided;
(3) the worth at the time of award of the amount by which the unpaid Rent for the
balance of the term of this Lease after the time of award exceeds the amount of such Rent
loss that Tenant proves could be reasonably avoided; and
(4) any other amount necessary to compensate Landlord for all the detriment proximately
caused by Tenants failure to perform its obligations under this Lease or which in the
ordinary course of things would be likely to result therefrom. The word rent as used in
this Section 11.02 shall have the same meaning as the defined term Rent in this Lease. The
worth at the time of award of the amount referred to in clauses (1) and (2) above is
computed by allowing interest at the Default Rate. The worth at the time of award of the
amount referred to in clause (3) above is computed by discounting such amount at the
discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one
percent (1%). For the purpose of determining unpaid Rent under clause (3) above, the
monthly Rent reserved in this Lease shall be deemed to be the sum of the Monthly Base Rent, and
monthly Storage Space Rent, if any, and the amounts last payable by Tenant as Rent
Adjustments for the calendar year in which Landlord terminated this Lease as provided
hereinabove.
(c) Even if Tenant is in Default and/or has abandoned the Premises, this Lease shall continue
in effect for so long as Landlord does not terminate Tenants right to possession by written notice
as provided in Section 11.02(b) above, and Landlord may enforce all its rights and remedies under
this Lease, including the right to recover Rent as it becomes due under this Lease. In such event,
Landlord shall have all of the rights and remedies of a landlord under California Civil Code
Section 1951.4 (lessor may continue Lease in effect after Tenants Default and abandonment and
recover Rent as it becomes due, if Tenant has the right to sublet or assign, subject only to
reasonable limitations), or any successor statute. During such time as Tenant is in Default, if
Landlord has not terminated this Lease by written notice and if Tenant requests Landlords consent
to an assignment of this Lease or a sublease of the Premises, subject to Landlords option to
recapture pursuant to Section 10.02, Landlord shall not unreasonably withhold its consent to such
assignment or sublease. Tenant acknowledges and agrees that the provisions of Article Ten shall be
deemed to constitute reasonable limitations of Tenants right to assign or sublet. Tenant
acknowledges and agrees that in the absence of written notice pursuant to Section 11.02(b) above
terminating Tenants right to possession, no other act of Landlord shall
20
constitute a termination of Tenants right to possession or an acceptance of Tenants surrender of the Premises, including
acts of maintenance or preservation or efforts to relet the Premises or the appointment of a
receiver upon initiative of Landlord to protect Landlords interest under this Lease or the
withholding of consent to a subletting or assignment, or terminating a subletting or assignment, if
in accordance with other provisions of this Lease.
(d) In the event that Landlord seeks an injunction with respect to a breach or threatened
breach by Tenant of any of the covenants, conditions or provisions of this Lease, Tenant agrees to
pay the premium for any bond required in connection with such injunction.
(e) Tenant hereby waives any and all rights to relief from forfeiture, redemption or
reinstatement granted by Law (including California Civil Code of Procedure Sections 1174 and 1179)
in the event of Tenant being evicted or dispossessed for any cause or in the event of Landlord
obtaining possession of the Premises by reason of Tenants Default or otherwise;
(f) When this Lease requires giving or service of a notice of Default or of a failure of
Tenant to observe or perform any covenant, condition or provision of this Lease which will
constitute a Default unless Tenant so observes or performs within any applicable cure period, and
so long as the notice given or served provides Tenant the longer of any applicable cure period
required by this Lease or by statute, then the giving of any equivalent or similar statutory
notice, including any equivalent or similar notices required by California Code of Civil Procedure
Section 1161 or any similar or successor statute, shall replace and suffice as any notice required
under this Lease. When a statute requires service of a notice in a particular manner, service of
that notice (or a similar notice required by this Lease) in the manner required by Article
Twenty-four shall replace and satisfy the statutory serviceofnotice procedures, except that any
notice of unlawful detainer required by California Code of Civil Procedure Section 1161 or any
similar or successor statute shall be served as required by Code of Civil Procedure Section 1162 or
any similar or successor statute, and for purposes of Code of Civil Procedure Section 1162 or any
similar or successor statute, Tenants place of residence and usual place of business shall
mean the address specified by Tenant for notice pursuant to Section 1.01 of this Lease, as changed
by Tenant pursuant to Article Twenty-four of this Lease.
(g) The voluntary or other surrender or termination of this Lease, or a mutual termination or
cancellation thereof, shall not work a merger and shall terminate all or any existing assignments,
subleases, subtenancies or occupancies permitted by Tenant, except if and as otherwise specified in
writing by Landlord.
(h) No delay or omission in the exercise of any right or remedy of Landlord upon any default
by Tenant, and no exercise by Landlord of its rights pursuant to Section 26.15 to perform any duty
which Tenant fails timely to perform, shall impair any right or remedy or be construed as a waiver.
No provision of this Lease shall be deemed waived by Landlord unless such waiver is in a writing
signed by Landlord. The waiver by Landlord of any breach of any provision of this Lease shall not
be deemed a waiver of any subsequent breach of the same or any other provision of this Lease.
11.03 ATTORNEYS FEES
In the event any party brings any suit or other proceeding with respect to the subject matter or
enforcement of this Lease, the prevailing party (as determined by the court, agency or other
authority before which such suit or proceeding is commenced) shall, in addition to such other
relief as may be awarded, be entitled to recover reasonable attorneys fees, expenses and costs of
investigation as actually incurred, including court costs, expert witness fees, costs and expenses
of investigation, and all reasonable attorneys fees, costs and expenses in any such suit or
proceeding (including in any action or participation in or in connection with any case or
proceeding under the Bankruptcy Code, 11 United States Code Sections 101
et seq
., or any
successor statutes, in establishing or enforcing the right to indemnification, in appellate
proceedings, or in connection with the enforcement or collection of any judgment obtained in any
such suit or proceeding).
11.04 BANKRUPTCY
The following provisions shall apply in the event of the bankruptcy or insolvency of Tenant:
(a) In connection with any proceeding under Chapter 7 of the Bankruptcy Code where the trustee
of Tenant elects to assume this Lease for the purposes of assigning it, such election or
assignment, may only be made upon compliance with the provisions of (b) and (c) below, which
conditions Landlord and Tenant acknowledge to be commercially reasonable. In the event the trustee elects to reject this Lease
then Landlord shall immediately be entitled to possession of the Premises without further
obligation to Tenant or the trustee.
(b) Any election to assume this Lease under Chapter 11 or 13 of the Bankruptcy Code by Tenant
as debtor-in-possession or by Tenants trustee (the Electing Party) must provide for:
The Electing Party to cure or provide to Landlord adequate assurance that it will cure all
monetary defaults under this Lease within fifteen (15) days from the date of assumption and
it will cure all nonmonetary defaults under this Lease within thirty (30) days from the date
of assumption. Landlord and Tenant acknowledge such condition to be commercially
reasonable.
(c) If the Electing Party has assumed this Lease or elects to assign Tenants interest under
this Lease to any other person, such interest may be assigned only if the intended assignee has
provided adequate assurance of future performance (as herein defined), of all of the obligations
imposed on Tenant under this Lease.
For the purposes hereof, adequate assurance of future performance means that Landlord has
ascertained that each of the following conditions has been satisfied:
21
(i) The assignee has submitted a current financial statement, certified by its chief
financial officer, which shows a net worth and working capital in amounts sufficient to
assure the future performance by the assignee of Tenants obligations under this Lease; and
(ii) Landlord has obtained consents or waivers from any third parties which may be
required under a lease, mortgage, financing arrangement, or other agreement by which
Landlord is bound, to enable Landlord to permit such assignment.
(d) Landlords acceptance of rent or any other payment from any trustee, receiver, assignee,
person, or other entity will not be deemed to have waived, or waive, the requirement of Landlords
consent, Landlords right to terminate this Lease for any transfer of Tenants interest under this
Lease without such consent, or Landlords claim for any amount of Rent due from Tenant.
11.05 LANDLORDS DEFAULT
Landlord shall be in default hereunder in the event Landlord has not begun and pursued with
reasonable diligence the cure of any failure of Landlord to meet its obligations hereunder within
thirty (30) days after the receipt by Landlord of written notice from Tenant of the alleged failure
to perform. In no event shall Tenant have the right to terminate or rescind this Lease as a result
of Landlords default as to any covenant or agreement contained in this Lease. Tenant hereby waives
such remedies of termination and rescission and hereby agrees that Tenants remedies for default
hereunder and for breach of any promise or inducement shall be limited to a suit for damages and/or
injunction. In addition, Tenant hereby covenants that, prior to the exercise of any such remedies,
it will give Mortgagee notice and a reasonable time to cure any default by Landlord.
ARTICLE TWELVE
SURRENDER OF PREMISES
12.01 IN GENERAL
Upon the Termination Date, Tenant shall surrender and vacate the Premises immediately and deliver
possession thereof to Landlord in a clean, good and tenantable condition, ordinary wear and tear,
and damage caused by Landlord excepted. Tenant shall deliver to Landlord all keys to the Premises.
Tenant shall remove from the Premises all movable personal property of Tenant and Tenants trade
fixtures, including, subject to Section 6.04, cabling for any of the foregoing. Tenant shall be
entitled to remove such Tenant Additions which at the time of their installation Landlord and
Tenant agreed may be removed by Tenant. Tenant shall also remove such other Tenant Additions as
required by Landlord, including any Tenant Additions containing Hazardous Material. Tenant
immediately shall repair all damage resulting from removal of any of Tenants property,
furnishings, Tenants Personal Property or Tenant Additions, shall close all floor, ceiling and
roof openings and shall restore the Premises to a tenantable condition as reasonably determined by
Landlord. If any of the Tenant Additions which were installed by Tenant involved the lowering of
ceilings, raising of floors or the installation of specialized wall or floor coverings or lights,
then Tenant shall also be obligated to return such surfaces to their condition prior to the
commencement of this Lease. Tenant shall also be required to close any staircases or other
openings between floors. Notwithstanding any of the foregoing to the contrary, if so requested by
Tenant in writing (and prominently in all capital and bold lettering which also states that such
request is pursuant to Section 12.01 of the Lease) at the time Tenant requests approval of any
Tenant Work or subsequent Tenant Alterations, Landlord shall advise Tenant at the time of
Landlords approval of such Tenant Work or Tenant Alterations as to whether Landlord will require
that such Tenant Work or Tenant Alterations be removed by Tenant from the Premises; provided,
however, regardless of the foregoing, in any event, Landlord may require removal of any Tenant
Additions containing Hazardous Material and all Tenants trade fixtures, and, subject to Section
6.03, cabling and wiring installed for Tenants personal property or trade fixtures. In the event
possession of the Premises is not delivered to Landlord when required hereunder, or if Tenant shall
fail to remove those items described above, Landlord may (but shall not be obligated to), at
Tenants expense, remove any of such property and store, sell or otherwise deal with such property
as provided in Section 11.02(b), including the waiver and indemnity obligations provided in that
Section, and undertake, at Tenants expense, such restoration work as Landlord deems necessary or
advisable.
12.02 LANDLORDS RIGHTS
All property which may be removed from the Premises by Landlord shall be conclusively presumed to
have been abandoned by Tenant and Landlord may deal with such property as provided in Section
11.02(b), including the waiver and indemnity obligations provided in that Section. Tenant shall
also reimburse Landlord for all costs and expenses incurred by Landlord in removing any of Tenant
Additions required to be removed pursuant to Section 12.01 above and in restoring the Premises to
the condition required by this Lease at the Termination Date.
ARTICLE THIRTEEN
HOLDING OVER
Tenant shall pay Landlord the greater of (i) 150% of the monthly Rent payable for the month
immediately preceding the holding over (including increases for Rent Adjustments which Landlord may
reasonably estimate) or, (ii) 150% of the fair market rental value of the Premises as reasonably
determined by Landlord for each month or portion thereof that Tenant retains possession of the
Premises, or any portion thereof, after the Termination Date (without reduction for any partial
month that Tenant retains possession). Tenant shall also pay all damages sustained by Landlord by
reason of such retention of possession. The provisions of this Article shall not constitute a
waiver by Landlord of any re-entry rights of Landlord and Tenants continued occupancy of the
Premises shall be as a tenancy in sufferance.
22
ARTICLE FOURTEEN
DAMAGE BY FIRE OR OTHER CASUALTY
14.01 SUBSTANTIAL UNTENANTABILITY
(a) If any fire or other casualty (whether insured or uninsured) renders all or a substantial
portion of the Premises or the Building untenantable, Landlord shall, with reasonable promptness
after the occurrence of such damage, estimate the length of time that will be required to
substantially complete the repair and restoration and shall by notice advise Tenant of such
estimate (Landlords Notice). If Landlord estimates that the amount of time required to
substantially complete such repair and restoration will exceed one hundred eighty (180) days from
the date such damage occurred, then Landlord, or Tenant if all or a substantial portion of the
Premises is rendered untenantable, shall have the right to terminate this Lease as of the date of
such damage upon giving written notice to the other at any time within twenty (20) days after
delivery of Landlords Notice, provided that if Landlord so chooses, Landlords Notice may also
constitute such notice of termination.
(b) In the event that the Building is damaged or destroyed to the extent of more than
twenty-five percent (25%) of its replacement cost or to any extent if no insurance proceeds or
insufficient insurance proceeds are receivable by Landlord, or if the buildings at the Project
shall be damaged to the extent of fifty percent (50%) or more of the replacement value or to any
extent if no insurance proceeds or insufficient insurance proceeds are receivable by Landlord, and
regardless of whether or not the Premises be damaged, Landlord may elect by written notice to
Tenant given within thirty (30) days after the occurrence of the casualty to terminate this Lease
in lieu of so restoring the Premises, in which event this Lease shall terminate as of the date
specified in Landlords notice, which date shall be no later than sixty (60) days following the
date of Landlords notice.
(c) Unless this Lease is terminated as provided in the preceding Subsections 14.01 (a) and
(b), Landlord shall proceed with reasonable promptness to repair and restore the Premises to its
condition as existed prior to such casualty, subject to reasonable delays for insurance adjustments
and Force Majeure delays, and also subject to zoning Laws and building codes then in effect.
Landlord shall have no liability to Tenant, and Tenant shall not be entitled to terminate this
Lease if such repairs and restoration are not in fact completed within the time period estimated by
Landlord so long as Landlord shall proceed with reasonable diligence to complete such repairs and
restoration.
(d) Tenant acknowledges that Landlord shall be entitled to the full proceeds of any insurance
coverage, whether carried by Landlord or Tenant, for damages to the Premises, except for those
proceeds of Tenants insurance of its own personal property and equipment which would be removable
by Tenant at the Termination Date. All such insurance proceeds shall be payable to Landlord
whether or not the Premises are to be repaired and restored, provided, however, if this Lease is
not terminated and the parties proceed to repair and restore Tenant Additions at Tenants cost, to
the extent Landlord received proceeds of Tenants insurance covering Tenant Additions, such
proceeds shall be applied to reimburse Tenant for its cost of repairing and restoring Tenant
Additions.
(e) Notwithstanding anything in this Article Fourteen to the contrary: (i) Landlord shall
have no duty pursuant to this Section to repair or restore any portion of any Tenant Additions or
to expend for any repair or restoration of the Premises or Building amounts in excess of insurance
proceeds paid to Landlord and available for repair or restoration; and (ii) Tenant shall not have
the right to terminate this Lease pursuant to this Section if any damage or destruction was caused
by the gross negligence or willful and wrongful act of Tenant, its agent or employees. Whether or
not the Lease is terminated pursuant to this Article Fourteen, in no event shall Tenant be entitled
to any compensation or damages for loss of the use of the whole or any part of the Premises or for
any inconvenience or annoyance occasioned by any such damage, destruction, rebuilding or
restoration of the Premises or the Building or access thereto.
(f) Any repair or restoration of the Premises performed by Tenant shall be in accordance with
the provisions of Article Nine hereof.
14.02 INSUBSTANTIAL UNTENANTABILITY
Unless this Lease is terminated as provided in the preceding Subsections 14.01 (a) and (b), then
Landlord shall proceed to repair and restore the Building or the Premises other than Tenant
Additions, with reasonable promptness, unless such damage is to the Premises and occurs during the
last six (6) months of the Term, in which event either Tenant or Landlord shall have the right to
terminate this Lease as of the date of such casualty by giving written notice thereof to the other
within twenty (20) days after the date of such casualty. Notwithstanding the foregoing, Landlords
obligation to repair shall be limited in accordance with the provisions of Section 14.01 above.
14.03 RENT ABATEMENT
Except for (i) the willful and wrongful act of Tenant or its agents, employees, contractors or
invitees, or (ii) the gross negligence of Tenant or its agents, employees, contractors or invitees
only if and to the extent Landlord receives rental abatement insurance proceeds covering abatement
of the Rent hereunder, then, if all or any part of the Premises are rendered untenantable by fire
or other casualty and this Lease is not terminated, Monthly Base Rent and Rent Adjustments shall
abate for that part of the Premises which is untenantable on a per diem basis from the date of the
casualty until Landlord has Substantially Completed the repair and restoration work in the Premises
which it is required to perform, provided, that as a result of such casualty, Tenant does not
occupy the portion of the Premises which is untenantable during such period.
23
14.04 WAIVER OF STATUTORY REMEDIES
The provisions of this Lease, including this Article Fourteen, constitute an express agreement
between Landlord and Tenant with respect to any and all damage to, or destruction of, the Premises
or the Property or any part of either, and any Law, including Sections 1932(2), 1933(4), 1941 and
1942 of the California Civil Code, with respect to any rights or obligations concerning damage or
destruction shall have no application to this Lease or to any damage to or destruction of all or
any part of the Premises or the Property or any part of either, and are hereby waived.
ARTICLE FIFTEEN
EMINENT DOMAIN
15.01 TAKING OF WHOLE OR SUBSTANTIAL PART
In the event the whole or any substantial part of the Building or of the Premises is taken or
condemned by any competent authority for any public use or purpose (including a deed given in lieu
of condemnation) and is thereby rendered untenantable, this Lease shall terminate as of the date
title vests in such authority or any earlier date on which possession is required to be surrendered
to such authority, and Monthly Base Rent and Rent Adjustments shall be apportioned as of the
Termination Date. Further, if at least twenty-five percent (25%) of the rentable area of the
Project is taken or condemned by any competent authority for any public use or purpose (including a
deed given in lieu of condemnation), and regardless of whether or not the Premises be so taken or
condemned, Landlord may elect by written notice to Tenant to terminate this Lease as of the date
title vests in such authority or any earlier date on which possession is required to be surrendered
to such authority, and Monthly Base Rent and Rent Adjustments shall be apportioned as of the
Termination Date. Landlord may, without any obligation to Tenant, agree to sell or convey to the
taking authority the Premises, the Building, Tenants Phase, the Project or any portion thereof
sought by the taking authority, free from this Lease and the right of Tenant hereunder, without
first requiring that any action or proceeding be instituted or, if instituted, pursued to a
judgment. Notwithstanding anything to the contrary herein set forth, in the event the taking of
the Building or Premises is temporary (for less than the remaining term of the Lease), Landlord may
elect either (i) to terminate this Lease or (ii) permit Tenant to receive the entire award
attributable to the Premises in which case Tenant shall continue to pay Rent and this Lease shall
not terminate.
15.02 TAKING OF PART
In the event a part of the Building or the Premises is taken or condemned by any competent
authority (or a deed is delivered in lieu of condemnation) and this Lease is not terminated, the
Lease shall be amended to reduce or increase, as the case may be, the Monthly Base Rent and
Tenants Share to reflect the Rentable Area of the Premises or Building, as the case may be,
remaining after any such taking or condemnation. Landlord, upon receipt and to the extent of the
award in condemnation (or proceeds of sale) shall make necessary repairs and restorations to the
Premises (exclusive of Tenant Additions) and to the Building to the extent necessary to constitute
the portion of the Building not so taken or condemned as a complete architectural and economically
efficient unit. Notwithstanding the foregoing, if as a result of any taking, or a governmental
order that the grade of any street or alley adjacent to the Building is to be changed and such
taking or change of grade makes it necessary or desirable to substantially remodel or restore the
Building or prevents the economical operation of the Building, Landlord shall have the right to
terminate this Lease upon ninety (90) days prior written notice to Tenant.
15.03 COMPENSATION
Landlord shall be entitled to receive the entire award (or sale proceeds) from any such taking,
condemnation or sale without any payment to Tenant, and Tenant hereby assigns to Landlord Tenants
interest, if any, in such award; provided, however, Tenant shall have the right separately to
pursue against the condemning authority a separate award in respect of the loss, if any, to Tenant
Additions paid for by Tenant without any credit or allowance from Landlord, for fixtures or
personal property of Tenant, or for relocation or business interruption expenses, so long as there
is no diminution of Landlords award as a result.
ARTICLE SIXTEEN
INSURANCE
16.01 TENANTS INSURANCE
Tenant, at Tenants expense, agrees to maintain in force, with a company or companies acceptable to
Landlord, during the Term: (a) Commercial General Liability Insurance on a primary basis and
without any right of contribution from any insurance carried by Landlord covering the Premises on
an occurrence basis against all claims for personal injury, bodily injury, death and property
damage, including contractual liability covering the indemnification provisions in this Lease.
Such insurance shall be for such limits that are reasonably required by Landlord from time to time
but not less than a combined single limit of Five Million and No/100 Dollars ($5,000,000.00); (b)
Workers Compensation and Employers Liability Insurance to the extent required by and in
accordance with the Laws of the State of California; (c) All Risks property insurance in an
amount adequate to cover the full replacement cost of all Tenant Additions to the Premises,
equipment, installations, fixtures and contents of the Premises in the event of loss; (d) In the
event a motor vehicle is to be used by Tenant in connection with its business operation from the
Premises, Comprehensive Automobile Liability Insurance coverage with limits of not less than Three
Million and No/100 Dollars ($3,000,000.00) combined single limit coverage against bodily injury
liability and property damage liability arising out of the use by or on behalf of Tenant, its
agents and employees in connection with this Lease, of any owned, non-owned or hired motor
vehicles; and (e) such other insurance or coverages as Landlord reasonably requires.
24
16.02 FORM OF POLICIES
Each policy referred to in 16.01 shall satisfy the following requirements. Each policy shall (i)
name Landlord and the Indemnitees as additional insureds (except Workers Compensation and
Employers Liability Insurance), (ii) be issued by one or more responsible insurance companies
licensed to do business in the State of California reasonably satisfactory to Landlord, (iii) where
applicable, provide for deductible amounts satisfactory to Landlord and not permit co-insurance,
(iv) shall provide that such insurance may not be canceled or amended without thirty (30) days
prior written notice to the Landlord, and (v) each policy of All-Risks property insurance shall
provide that the policy shall not be invalidated should the insured waive in writing prior to a
loss, any or all rights of recovery against any other party for losses covered by such policies.
Tenant shall deliver to Landlord, certificates of insurance and at Landlords request, copies of
all policies and renewals thereof to be maintained by Tenant hereunder, not less than ten (10) days
prior to the Commencement Date and not less than ten (10) days prior to the expiration date of each
policy.
16.03 LANDLORDS INSURANCE
Landlord agrees to purchase and keep in full force and effect during the Term hereof, including any
extensions or renewals thereof, insurance under policies issued by insurers of recognized
responsibility, qualified to do business in the State of California on the Building in amounts not
less than the greater of eighty (80%) percent of the then full replacement cost (without
depreciation) of the Building (above foundations and excluding Tenant Additions to the Premises) or
an amount sufficient to prevent Landlord from becoming a co-insurer under the terms of the
applicable policies, against fire and such other risks as may be included in standard forms of all
risk coverage insurance reasonably available from time to time. Landlord agrees to maintain in
force during the Term, Commercial General Liability Insurance covering the Building on an
occurrence basis against all claims for personal injury, bodily injury, death and property damage.
Such insurance shall be for a combined single limit of Five Million and No/100 Dollars
($5,000,000.00). Neither Landlords obligation to carry such insurance nor the carrying of such
insurance shall be deemed to be an indemnity by Landlord with respect to any claim, liability,
loss, cost or expense due, in whole or in part, to Tenants negligent acts or omissions or willful
misconduct. Without obligation to do so, Landlord may, in its sole discretion from time to time,
carry insurance in amounts greater and/or for coverage additional to the coverage and amounts set
forth above.
16.04 WAIVER OF SUBROGATION
(a) Landlord agrees that, if obtainable at no, or minimal, additional cost, and so long as the
same is permitted under the laws of the State of California, it will include in its All Risks
policies appropriate clauses pursuant to which the insurance companies (i) waive all right of
subrogation against Tenant with respect to losses payable under such policies and/or (ii) agree
that such policies shall not be invalidated should the insured waive in writing prior to a loss any
or all right of recovery against any party for losses covered by such policies.
(b) Tenant agrees to include, if obtainable at no, or minimal, additional cost, and so long as
the same is permitted under the laws of the State of California, in its All Risks insurance
policy or policies on Tenant Additions to the Premises, whether or not removable, and on Tenants
furniture, furnishings, fixtures and other property removable by Tenant under the provisions of
this Lease appropriate clauses pursuant to which the insurance company or companies (i) waive the
right of subrogation against Landlord and/or any tenant of space in the Building with respect to
losses payable under such policy or policies and/or (ii) agree that such policy or policies shall
not be invalidated should the insured waive in writing prior to a loss any or all right of recovery
against any party for losses covered by such policy or policies. If Tenant is unable to obtain in
such policy or policies either of the clauses described in the preceding sentence, Tenant shall, if
legally possible and without necessitating a change in insurance carriers, have Landlord named in
such policy or policies as an additional insured. If Landlord shall be named as an additional
insured in accordance with the foregoing, Landlord agrees to endorse promptly to the order of
Tenant, without recourse, any check, draft, or order for the payment of money representing the
proceeds of any such policy or representing any other payment growing out of or connected with said
policies, and Landlord does hereby irrevocably waive any and all rights in and to such proceeds and
payments.
(c) Provided that Landlords right of full recovery under its policy or policies aforesaid is
not adversely affected or prejudiced thereby, Landlord hereby waives any and all right of recovery
which it might otherwise have against Tenant, its servants, agents and employees, for loss or
damage occurring to the Real Property and the fixtures, appurtenances and equipment therein, except
Tenant Additions, to the extent the same is covered by Landlords insurance, notwithstanding that
such loss or damage may result from the negligence or fault of Tenant, its servants, agents or
employees. Provided that Tenants right of full recovery under its aforesaid policy or policies is
not adversely affected or prejudiced thereby, Tenant hereby waives any and all right of recovery
which it might otherwise have against Landlord, its servants, and employees and against every other
tenant in the Real Property who shall have executed a similar waiver as set forth in this Section
16.04 (c) for loss or damage to Tenant Additions, whether or not removable, and to Tenants
furniture, furnishings, fixtures and other property removable by Tenant under the provisions hereof
to the extent the same is covered or coverable by Tenants insurance required under this Lease,
notwithstanding that such loss or damage may result from the negligence or fault of Landlord, its
servants, agents or employees, or such other tenant and the servants, agents or employees thereof.
(d) Landlord and Tenant hereby agree to advise the other promptly if the clauses to be
included in their respective insurance policies pursuant to subparagraphs (a) and (b) above cannot
be obtained on the terms hereinbefore provided and thereafter to furnish the other with a
certificate of insurance or copy of such policies showing the naming of the other as an additional
insured, as aforesaid. Landlord and Tenant hereby also agree to notify the other promptly of any
cancellation or change of the terms of any such policy which would affect such clauses or naming.
All such policies which name both Landlord and Tenant as additional insureds shall, to the extent
obtainable, contain agreements by the insurers to the effect that no act or omission of any
additional insured will invalidate the policy as to the other additional insureds.
25
16.05 NOTICE OF CASUALTY
Tenant shall give Landlord notice in case of a fire or accident in the Premises promptly after
Tenant is aware of such event.
ARTICLE SEVENTEEN
WAIVER OF CLAIMS AND INDEMNITY
17.01 WAIVER OF CLAIMS
To the extent permitted by Law, Tenant releases the Indemnitees from, and waives all claims for,
damage to person or property sustained by the Tenant or any occupant of the Premises or the
Property resulting directly or indirectly from any existing or future condition, defect, matter or
thing in and about the Premises or the Property, or any part of either, or any equipment or
appurtenance therein, or resulting from any accident in or about the Premises or the Property, or
resulting directly or indirectly from any act or neglect of any tenant or occupant of the Property
or of any other person, including Landlords agents and servants, except to the extent caused by
the gross negligence or willful and wrongful act of any of the Indemnitees. If any such damage,
whether to the Premises or the Property or any part of either, or whether to Landlord or to other
tenants in the Property, results from any act or neglect of Tenant, its employees, servants,
agents, contractors, invitees or customers, Tenant shall be liable therefor and Landlord may, at
Landlords option, repair such damage and Tenant shall, upon demand by Landlord, as payment of
additional Rent hereunder, reimburse Landlord within ten (10) days of demand for the total cost of
such repairs, in excess of amounts, if any, paid to Landlord under insurance covering such damages.
Tenant shall not be liable for any such damage caused by its acts or neglect to the extent that
Landlord or a tenant has recovered any amount of the damage from proceeds of insurance policies and
the insurance company has waived its right of subrogation against Tenant.
17.02 INDEMNITY BY TENANT
To the extent permitted by Law, Tenant hereby indemnifies, and agrees to protect, defend and hold
the Indemnitees harmless, against any and all actions, claims, demands, liability, costs and
expenses, including reasonable attorneys fees and expenses for the defense thereof, arising from
Tenants occupancy of the Premises, from the undertaking of any Tenant Additions or repairs to the
Premises, from the conduct of Tenants business on the Premises, or from any breach or default on
the part of Tenant in the performance of any covenant or agreement on the part of Tenant to be
performed pursuant to the terms of this Lease, or from any willful act or negligence of Tenant, its
agents, contractors, servants, employees, customers or invitees, in or about the Premises or the
Property or any part of either. In case of any action or proceeding brought against the
Indemnitees by reason of any such claim, upon notice from Landlord, Tenant covenants to defend such
action or proceeding by counsel chosen by Landlord, in Landlords sole discretion. Landlord
reserves the right to settle, compromise or dispose of any and all actions, claims and demands
related to the foregoing indemnity. The foregoing indemnity shall not operate to relieve an
Indemnitee of liability to the extent such liability is caused by the gross negligence or willful
and wrongful act of such Indemnitee. Further, the foregoing indemnity is subject to and shall not
diminish any waivers in effect in accordance with Section 16.04 by Landlord or its insurers to the
extent of amounts, if any, paid to Landlord under its All-Risks property insurance.
17.03 WAIVER OF CONSEQUENTIAL DAMAGES
To the extent permitted by law, Tenant hereby waives and releases the Indemnitees from any
consequential damages, compensation or claims for inconvenience or loss of business, rents or
profits as a result of any injury or damage, whether or not caused by the willful and wrongful act
of any of the Indemnitees.
ARTICLE EIGHTEEN
RULES AND REGULATIONS
18.01 RULES
Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with all
reasonable rules and regulations for use of the Premises, the Building, the Phase and the Project
imposed by Landlord, as the same may be revised from time to time, including the following: (a)
Tenant shall comply with all of the requirements of Landlords emergency response plan, as the same
may be amended from time to time; and (b) Tenant shall not place any furniture, furnishings,
fixtures or equipment in the Premises in a manner so as to obstruct the windows of the Premises to
cause the Building, in Landlords good faith determination, to appear unsightly from the exterior.
Such rules and regulations are and shall be imposed for the cleanliness, good appearance, proper
maintenance, good order and reasonable use of the Premises, the Building, the Phase and the Project
and as may be necessary for the enjoyment of the Building and the Project by all tenants and their
clients, customers, and employees.
18.02 ENFORCEMENT
Nothing in this Lease shall be construed to impose upon the Landlord any duty or obligation to
enforce the rules and regulations as set forth above or as hereafter adopted, or the terms,
covenants or conditions of any other lease as against any other tenant, and the Landlord shall not
be liable to the Tenant for violation of the same by any other tenant, its servants, employees,
agents, visitors or licensees. Landlord shall use reasonable efforts to enforce the rules and
regulations of the Building in a uniform and non-discriminatory manner.
26
ARTICLE NINETEEN
LANDLORDS RESERVED RIGHTS
Landlord shall have the following rights exercisable without notice to Tenant and without liability
to Tenant for damage or injury to persons, property or business and without being deemed an
eviction or disturbance of Tenants use or possession of the Premises or giving rise to any claim
for offset or abatement of Rent: (1) to change the Buildings name or street address upon thirty
(30) days prior written notice to Tenant; (2) to install, affix and maintain all signs on the
exterior and/or interior of the Building; (3) to designate and/or approve prior to installation,
all types of signs, window shades, blinds, drapes, awnings or other similar items, and all internal
lighting that may be visible from the exterior of the Premises; (4) upon reasonable notice to
Tenant, to display the Premises to prospective purchasers at reasonable hours at any time during
the Term and to prospective tenants at reasonable hours during the last twelve (12) months of the
Term; (5) to grant to any party the exclusive right to conduct any business or render any service
in or to the Building, provided such exclusive right shall not operate to prohibit Tenant from
using the Premises for the purpose permitted hereunder; (6) to change the arrangement and/or
location of entrances or passageways, doors and doorways, corridors, elevators, stairs, washrooms
or public portions of the Building, and to close entrances, doors, corridors, elevators or other
facilities, provided that such action shall not materially and adversely interfere with Tenants
access to the Premises or the Building; (7) to have access for Landlord and other tenants of the
Building to any mail chutes and boxes located in or on the Premises as required by any applicable
rules of the United States Post Office; and (8) to close the Building after Standard Operating
Hours, except that Tenant and its employees and invitees shall be entitled to admission at all
times, under such regulations as Landlord prescribes for security purposes.
ARTICLE TWENTY
ESTOPPEL CERTIFICATE
20.01 IN GENERAL
Within fifteen (15) days after request therefor by Landlord, Mortgagee or any prospective mortgagee
or owner, Tenant agrees as directed in such request to execute an Estoppel Certificate in
recordable form, binding upon Tenant, certifying (i) that this Lease is unmodified and in full
force and effect (or if there have been modifications, a description of such modifications and that
this Lease as modified is in full force and effect); (ii) the dates to which Rent has been paid;
(iii) that Tenant is in the possession of the Premises if that is the case; (iv) that Landlord is
not in default under this Lease, or, if Tenant believes Landlord is in default, the nature thereof
in detail; (v) that Tenant has no offsets or defenses to the performance of its obligations under
this Lease (or if Tenant believes there are any offsets or defenses, a full and complete
explanation thereof); (vi) that the Premises have been completed in accordance with the terms and
provisions hereof, that Tenant has accepted the Premises and the condition thereof and of all
improvements thereto and has no claims against Landlord or any other party with respect thereto;
(vii) that if an assignment of rents or leases has been served upon the Tenant by a Mortgagee,
Tenant will acknowledge receipt thereof and agree to be bound by the provisions thereof; (viii)
that Tenant will give to the Mortgagee copies of all notices required or permitted to be given by
Tenant to Landlord; and (ix) to any other information reasonably requested.
20.02 ENFORCEMENT
In the event that Tenant fails to deliver an Estoppel Certificate within three (3) business days
after Tenant has received notice from Landlord of Tenants failure to deliver an Estoppel
Certificate within the time prescribed in Section 20.01 above, then such failure shall be a Default
for which there shall be no additional cure or grace period. In addition to any other remedy
available to Landlord, Landlord may impose a charge equal to $500.00 for each day that Tenant fails
to deliver an Estoppel Certificate and Tenant shall be deemed to have irrevocably appointed
Landlord as Tenants attorney-in-fact to execute and deliver the subject Estoppel Certificate that
Tenant has failed to deliver.
ARTICLE TWENTY-ONE
INTENTIONALLY OMITTED
ARTICLE TWENTY-TWO
REAL ESTATE BROKERS
Landlord and Tenant represent to each other that in connection with this Lease they are represented
by Tenants Broker identified in Section 1.01(19) and Landlords Broker identified in Section
1.01(19), and that except for Tenants Broker and Landlords Broker, neither has dealt with any
real estate broker, sales person, or finder in connection with this Lease, and no such person
initiated or participated in the negotiation of this Lease. Landlord and Tenant hereby indemnify
and agree to protect, defend and hold the other harmless from and against all claims, losses,
damages, liability, costs and expenses (including, without limitation, reasonable attorneys fees
and expenses) by virtue of any broker, agent or other person claiming a commission or other form of
compensation by virtue of alleged representation of, or dealings or discussions with, Landlord or
Tenant, as applicable, with respect to the subject matter of this Lease, except for Landlords
Broker and except for a commission payable to Tenants Broker to the extent provided for in a
separate written agreement between Tenants Broker and Landlords Broker. Tenant is not obligated
to pay or fund any amount to Landlords Broker, and Landlord hereby agrees to pay such commission,
if any, to which Landlords Broker is entitled in connection with the subject matter of this Lease
pursuant to Landlords separate written agreement with Landlords Broker. Such commission shall
include an amount to be shared by Landlords Broker with Tenants Broker to the extent that
Tenants Broker and Landlords Broker have entered into a separate agreement between themselves to
share the commission paid to Landlords Broker by Landlord. The provisions of this Section shall
survive the expiration or earlier termination of the Lease.
27
ARTICLE TWENTY-THREE
MORTGAGEE PROTECTION
23.01 SUBORDINATION AND ATTORNMENT
This Lease is and shall be expressly subject and subordinate at all times to (i) any ground or
underlying lease of the Real Property, now or hereafter existing, and all amendments, extensions,
renewals and modifications to any such lease, and (ii) the lien of any mortgage or trust deed now
or hereafter encumbering fee title to the Real Property and/or the leasehold estate under any such
lease, and all amendments, extensions, renewals, replacements and modifications of such mortgage or
trust deed and/or the obligation secured thereby, unless such ground lease or ground lessor, or
mortgage, trust deed or Mortgagee, expressly provides or elects that the Lease shall be superior to
such lease or mortgage or trust deed. If any such mortgage or trust deed is foreclosed (including
any sale of the Real Property pursuant to a power of sale), or if any such lease is terminated,
upon request of the Mortgagee or ground lessor, as the case may be, Tenant shall attorn to the
purchaser at the foreclosure sale or to the ground lessor under such lease, as the case may be,
provided, however, that such purchaser or ground lessor shall not be (i) bound by any payment of
Rent for more than one month in advance except payments in the nature of security for the
performance by Tenant of its obligations under this Lease; (ii) subject to any offset, defense or
damages arising out of a default of any obligations of any preceding Landlord; or (iii) bound by
any amendment or modification of this Lease made without the written consent of the Mortgagee or
ground lessor; or (iv) liable for any security deposits not actually received in cash by such
purchaser or ground lessor. This subordination shall be self-operative and no further certificate
or instrument of subordination need be required by any such Mortgagee or ground lessor. In
confirmation of such subordination, however, Tenant shall execute promptly any reasonable
certificate or instrument that Landlord, Mortgagee or ground lessor may request. Tenant hereby
constitutes Landlord as Tenants attorney-in-fact to execute such certificate or instrument for and
on behalf of Tenant upon Tenants failure to do so within fifteen (15) days of a request to do so.
Upon request by such successor in interest, Tenant shall execute and deliver reasonable instruments
confirming the attornment provided for herein.
23.02 MORTGAGEE PROTECTION
Tenant agrees to give any Mortgagee or ground lessor, by registered or certified mail, a copy of
any notice of default served upon the Landlord by Tenant, provided that prior to such notice Tenant
has received notice (by way of service on Tenant of a copy of an assignment of rents and leases, or
otherwise) of the address of such Mortgagee or ground lessor. Tenant further agrees that if
Landlord shall have failed to cure such default within the time provided for in this Lease, then
the Mortgagee or ground lessor shall have an additional thirty (30) days after receipt of notice
thereof within which to cure such default or if such default cannot be cured within that time, then
such additional notice time as may be necessary, if, within such thirty (30) days, any Mortgagee or
ground lessor has commenced and is diligently pursuing the remedies necessary to cure such default
(including commencement of foreclosure proceedings or other proceedings to acquire possession of
the Real Property, if necessary to effect such cure). Such period of time shall be extended by any
period within which such Mortgagee or ground lessor is prevented from commencing or pursuing such
foreclosure proceedings or other proceedings to acquire possession of the Real Property by reason
of Landlords bankruptcy. Until the time allowed as aforesaid for Mortgagee or ground lessor to
cure such defaults has expired without cure, Tenant shall have no right to, and shall not,
terminate this Lease on account of default. This Lease may not be modified or amended so as to
reduce the Rent or shorten the Term, or so as to adversely affect in any other respect to any
material extent the rights of the Landlord, nor shall this Lease be canceled or surrendered,
without the prior written consent, in each instance, of the ground lessor or the Mortgagee.
ARTICLE TWENTY-FOUR
NOTICES
(a) All notices, demands or requests provided for or permitted to be given pursuant to this
Lease must be in writing and shall be personally delivered, sent by Federal Express or other
reputable overnight courier service, or mailed by first class, registered or certified United States mail, return
receipt requested, postage prepaid.
(b) All notices, demands or requests to be sent pursuant to this Lease shall be deemed to have
been properly given or served by delivering or sending the same in accordance with this Section,
addressed to the parties hereto at their respective addresses listed in Sections 1.01(2) and (3).
(c) Notices, demands or requests sent by mail or overnight courier service as described above
shall be effective upon deposit in the mail or with such courier service. However, the time period
in which a response to any such notice, demand or request must be given shall commence to run from
(i) in the case of delivery by mail, the date of receipt on the return receipt of the notice,
demand or request by the addressee thereof, or (ii) in the case of delivery by Federal Express or
other overnight courier service, the date of acceptance of delivery by an employee, officer,
director or partner of Landlord or Tenant. Rejection or other refusal to accept or the inability
to deliver because of changed address of which no notice was given, as indicated by advice from
Federal Express or other overnight courier service or by mail return receipt, shall be deemed to be
receipt of notice, demand or request sent. Notices may also be served by personal service upon any
officer, director or partner of Landlord or Tenant, and shall be effective upon such service.
(d) By giving to the other party at least thirty (30) days written notice thereof, either
party shall have the right from time to time during the term of this Lease to change their
respective addresses for notices, statements, demands and requests, provided such new address shall
be within the United States of America.
28
ARTICLE TWENTY-FIVE
EXERCISE FACILITY
Tenant agrees to inform all employees of Tenant of the following: (i) the exercise facility is
available for the use of the employees of tenants of the Project only and for no other person; (ii)
use of the facility is at the risk of Tenant or Tenants employees, and all users must sign a
release; (iii) the facility is unsupervised; and (iv) users of the facility must report any needed
equipment maintenance or any unsafe conditions to the Landlord immediately. Landlord may
discontinue providing such facility at Landlords sole option at any time without incurring any
liability. As a condition to the use of the exercise facility, Tenant and each of Tenants
employees that uses the exercise facility shall first sign a written release in form and substance
acceptable to Landlord. Landlord may change the rules and/or hours of the exercise facility at any
time, and Landlord reserves the right to deny access to the exercise facility to anyone due to
misuse of the facility or noncompliance with rules and regulations of the facility. To the extent
permitted by Law, Tenant hereby indemnifies, and agrees to protect, defend and hold the Indemnitees
harmless, against any and all actions, claims, demands, liability, costs and expenses, including
reasonable attorneys fees and expenses for the defense thereof, arising from use of the exercise
facility in the Project by Tenant, Tenants employees or invitees, except to the extent due to the
gross negligence or willful and wrongful act of Landlord or Indemnitees. In case of any action or
proceeding brought against the Indemnitees by reason of any such claim, upon notice from Landlord,
Tenant covenants to defend such action or proceeding by counsel chosen by Landlord, in Landlords
sole discretion. Landlord reserves the right to settle, compromise or dispose of any and all
actions, claims and demands related to the foregoing indemnity.
ARTICLE TWENTY-SIX
MISCELLANEOUS
26.01 LATE CHARGES
(a) The Monthly Base Rent, Rent Adjustments and Rent Adjustment Deposits shall be due when and
as specifically provided above. Except for such payments and late charges described below, which
late charge shall be due when provided below (without notice or demand), all other payments
required hereunder to Landlord shall be paid within ten (10) days after Landlords demand therefor.
All Rent and charges, except late charges, not paid when due shall bear interest from the date due
until the date paid at the Default Rate in effect on the date such payment was due.
(b) In the event Tenant is more than five (5) days late in paying any installment of Rent due
under this Lease, Tenant shall pay Landlord a late charge equal to five percent (5%) of the
delinquent installment of Rent. The parties agree that (i) such delinquency will cause Landlord to
incur costs and expenses not contemplated herein, the exact amount of which will be difficult to
calculate, including the cost and expense that will be incurred by Landlord in processing each
delinquent payment of rent by Tenant, and (ii) the amount of such late charge represents a
reasonable estimate of such costs and expenses and that such late charge shall be paid to Landlord
for each delinquent payment in addition to all Rent otherwise due hereunder. The parties further
agree that the payment of late charges and the payment of interest provided for in subparagraph (a)
above are distinct and separate from one another in that the payment of interest is to compensate
Landlord for its inability to use the money improperly withheld by Tenant, while the payment of
late charges is to compensate Landlord for its additional administrative expenses in handling and
processing delinquent payments.
(c) Payment of interest at the Default Rate and/or of late charges shall not excuse or cure
any default by Tenant under this Lease, nor shall the foregoing provisions of this Article or any
such payments prevent Landlord from exercising any right or remedy available to Landlord upon
Tenants failure to pay Rent when due, including the right to terminate this Lease.
26.02 NO JURY TRIAL; VENUE; JURISDICTION
Each party hereto (which includes any assignee, successor, heir or personal representative of a
party) shall not seek a jury trial, hereby waives trial by jury, and hereby further waives any
objection to venue in the County in which the Project is located, and agrees and consents to
personal jurisdiction of the courts of the State of California, in any action or proceeding or
counterclaim brought by any party hereto against the other on any matter whatsoever arising out of
or in any way connected with this Lease, the relationship of Landlord and Tenant, Tenants use or
occupancy of the Premises, or any claim of injury or damage, or the enforcement of any remedy under
any statute, emergency or otherwise, whether any of the foregoing is based on this Lease or on tort
law. No party will seek to consolidate any such action in which a jury has been waived with any
other action in which a jury trial cannot or has not been waived. It is the intention of the
parties that these provisions shall be subject to no exceptions. By execution of this Lease the
parties agree that this provision may be filed by any party hereto with the clerk or judge before
whom any action is instituted, which filing shall constitute the written consent to a waiver of
jury trial pursuant to and in accordance with Section 631 of the California Code of Civil
Procedure. No party has in any way agreed with or represented to any other party that the
provisions of this Section will not be fully enforced in all instances. The provisions of this
Section shall survive the expiration or earlier termination of this Lease.
26.03 DEFAULT UNDER OTHER LEASE
It shall be a Default under this Lease if Tenant or any Affiliate holding any other lease with
Landlord for premises in the Project defaults under such lease and as a result thereof such lease
is terminated or terminable.
26.04 OPTION
This Lease shall not become effective as a lease or otherwise until executed and delivered by both
Landlord and Tenant. The submission of the Lease to Tenant does not constitute a reservation of or
option for the Premises,
29
but when executed by Tenant and delivered to Landlord, the Lease shall
constitute an irrevocable offer by Tenant in effect for fifteen (15) days to lease the Premises on
the terms and conditions herein contained.
26.05 TENANT AUTHORITY
Tenant represents and warrants to Landlord that it has full authority and power to enter into and
perform its obligations under this Lease, that the person executing this Lease is fully empowered
to do so, and that no consent or authorization is necessary from any third party. Landlord may
request that Tenant provide Landlord evidence of Tenants authority.
26.06 ENTIRE AGREEMENT
This Lease, the Exhibits and Riders attached hereto contain the entire agreement between Landlord
and Tenant concerning the Premises and there are no other agreements, either oral or written, and
no other representations or statements, either oral or written, on which Tenant has relied. This
Lease shall not be modified except by a writing executed by Landlord and Tenant.
26.07 MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE
If Mortgagee of Landlord requires a modification of this Lease which shall not result in any
increased cost or expense to Tenant or in any other material and adverse change in the rights and
obligations of Tenant hereunder, then Tenant agrees that the Lease may be so modified.
26.08 EXCULPATION
Tenant agrees, on its behalf and on behalf of its successors and assigns, that any liability or
obligation of Landlord in connection with this Lease shall only be enforced against Landlords
equity interest in the Property up to a maximum of Five Million Dollars ($5,000,000.00) and in no
event against any other assets of the Landlord, or Landlords officers or directors or partners,
and that any liability of Landlord with respect to this Lease shall be so limited and Tenant shall
not be entitled to any judgment in excess of such amount.
26.09 ACCORD AND SATISFACTION
No payment by Tenant or receipt by Landlord of a lesser amount than any installment or payment of
Rent due shall be deemed to be other than on account of the amount due, and no endorsement or
statement on any check or any letter accompanying any check or payment of Rent shall be deemed an
accord and satisfaction, and Landlord may accept such check or payment without prejudice to
Landlords right to recover the balance of such installment or payment of Rent or pursue any other
remedies available to Landlord. No receipt of money by Landlord from Tenant after the termination
of this Lease or Tenants right of possession of the Premises shall reinstate, continue or extend
the Term. Receipt or acceptance of payment from anyone other than Tenant, including an assignee of
Tenant, is not a waiver of any breach of Article Ten, and Landlord may accept such payment on
account of the amount due without prejudice to Landlords right to pursue any remedies available to
Landlord.
26.10 LANDLORDS OBLIGATIONS ON SALE OF BUILDING
In the event of any sale or other transfer of the Building, Landlord shall be entirely freed and
relieved of all agreements and obligations of Landlord hereunder accruing or to be performed after
the date of such sale or transfer (provided, however, that Landlord shall not be freed and relieved of its obligation for
reimbursement of the Security to Tenant unless Landlord has transferred to such transferee the
unapplied balance of Tenants Security held by Landlord at such time), and any remaining liability
of Landlord with respect to this Lease shall be limited to Five Million Dollars ($5,000,000.00) and
Tenant shall not be entitled to any judgment in excess of such amount.
26.11 BINDING EFFECT
Subject to the provisions of Article Ten, this Lease shall be binding upon and inure to the benefit
of Landlord and Tenant and their respective heirs, legal representatives, successors and permitted
assigns.
26.12 CAPTIONS
The Article and Section captions in this Lease are inserted only as a matter of convenience and in
no way define, limit, construe, or describe the scope or intent of such Articles and Sections.
26.13 TIME; APPLICABLE LAW; CONSTRUCTION
Time is of the essence of this Lease and each and all of its provisions. This Lease shall be
construed in accordance with the Laws of the State of California. If more than one person signs
this Lease as Tenant, the obligations hereunder imposed shall be joint and several. If any term,
covenant or condition of this Lease or the application thereof to any person or circumstance shall,
to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such
term, covenant or condition to persons or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each item, covenant or condition of
this Lease shall be valid and be enforced to the fullest extent permitted by Law. Wherever the
term including or includes is used in this Lease, it shall have the same meaning as if followed
by the phrase but not limited to. The language in all parts of this Lease shall be construed
according to its normal and usual meaning and not strictly for or against either Landlord or
Tenant.
30
26.14 ABANDONMENT
In the event Tenant vacates or abandons the Premises but is otherwise in compliance with all the
terms, covenants and conditions of this Lease, Landlord shall (i) have the right to enter into the
Premises in order to show the space to prospective tenants, (ii) have the right to reduce the
services provided to Tenant pursuant to the terms of this Lease to such levels as Landlord
reasonably determines to be adequate services for an unoccupied premises and (iii) during the last
six (6) months of the Term, have the right to prepare the Premises for occupancy by another tenant
upon the end of the Term. Tenant expressly acknowledges that in the absence of written notice
pursuant to Section 11.02(b) or pursuant to California Civil Code Section 1951.3 terminating
Tenants right to possession, none of the foregoing acts of Landlord or any other act of Landlord
shall constitute a termination of Tenants right to possession or an acceptance of Tenants
surrender of the Premises, and the Lease shall continue in effect.
26.15 LANDLORDS RIGHT TO PERFORM TENANTS DUTIES
If Tenant fails timely to perform any of its duties under this Lease, Landlord shall have the right
(but not the obligation), to perform such duty on behalf and at the expense of Tenant without prior
notice to Tenant, and all sums expended or expenses incurred by Landlord in performing such duty
shall be deemed to be additional Rent under this Lease and shall be due and payable upon demand by
Landlord.
26.16 SECURITY SYSTEM
Landlord shall not be obligated to provide or maintain any security patrol or security system.
Landlord shall not be responsible for the quality of any such patrol or system which may be
provided hereunder or for damage or injury to Tenant, its employees, invitees or others due to the
failure, action or inaction of such patrol or system.
26.17 NO LIGHT, AIR OR VIEW EASEMENTS
Any diminution or shutting off of light, air or view by any structure which may be erected on lands
of or adjacent to the Project shall in no way affect this Lease or impose any liability on
Landlord.
26.18 RECORDATION
Neither this Lease, nor any notice nor memorandum regarding the terms hereof, shall be recorded by
Tenant. Any such unauthorized recording shall be a Default for which there shall be no cure or
grace period. Tenant agrees to execute and acknowledge, at the request of Landlord, a memorandum
of this Lease, in recordable form.
26.19 SURVIVAL
The waivers of the right of jury trial, the other waivers of claims or rights, the releases and the
obligations of Tenant under this Lease to indemnify, protect, defend and hold harmless Landlord
and/or Indemnitees shall survive the expiration or termination of this Lease, and so shall all
other obligations or agreements which by their terms survive expiration or termination of the
Lease.
26.20 EXHIBITS OR RIDERS
All exhibits, riders and/or addenda referred to in this Lease as an exhibit, addenda or rider
hereto or attached hereto, are hereby incorporated into and made a part of this Lease.
IN WITNESS WHEREOF, this Lease has been executed as of the date set forth in Section 1.01(4)
hereof.
|
|
|
|
|
|
|
|
|
TENANT:
|
|
|
|
LANDLORD:
|
|
|
|
|
|
|
|
|
|
Genomic Health, Inc.,
|
|
|
|
Metropolitan Life Insurance Company,
|
a Delaware corporation
|
|
|
|
a New York corporation
|
|
|
|
|
|
|
|
|
|
By
|
|
/s/ Randal W. Scott
|
|
|
|
By
|
|
/s/ Greg Hill
|
|
|
|
|
|
|
|
|
|
|
|
Randal Scott, Ph.D.
|
|
|
|
|
|
Greg Hill
|
|
|
|
|
|
|
|
Print name
|
|
|
|
|
|
Print name
|
Its
|
|
Chairman and CEO
|
|
|
|
Its
|
|
Director
|
|
|
|
|
|
|
|
|
|
(Chairman of Board, President or Vice President)
|
|
|
|
|
|
|
|
|
|
|
|
By
|
|
/s/ G. Bradley Cole
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
G. Bradley Cole
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Print name
|
|
|
|
|
|
|
Its
|
|
Executive Vice President and CFO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Secretary, Assistant Secretary, CFO or Assistant Treasurer)
|
31
EXHIBIT A
PLAN OF PREMISES
Exhibit A Page 1
EXHIBIT B
WORKLETTER AGREEMENT
This Workletter Agreement (Workletter) is attached to and a part of a certain Lease by and
between Metropolitan Life Insurance Company, a New York corporation, as Landlord, and Genomic
Health, Inc., a Delaware corporation, as Tenant, for the Premises (the Lease). Terms used herein
and not defined herein shall have the meaning of such terms as defined elsewhere in the Lease. For
purposes of this Workletter, references to State and City shall mean the State and City in
which the Building is located.
1.
Base Building
.
All work performed during the Buildings initial course of construction and modifications
thereto, excluding all original and modified build-outs of any tenant spaces, shall be referred to
as the Base Building Work or Base Building, as applicable. Neither Landlord nor Landlords
representatives have made any representations or promises with respect to the Premises or the Base
Building except as herein expressly set forth. Provided however, Landlord agrees that the Building
Systems (defined in Section 3.2 below) which are part of the Base Building, except to the extent of
any to be removed, demolished or altered by Tenant, will be delivered by Landlord in good working
order and condition.
2.
Landlord Work
.
There shall be no Landlord Work.
3.
Tenants Plans
.
3.1.
Description
. At its expense, Tenant shall employ:
(i) one or more architects reasonably satisfactory to Landlord and licensed by the
State (Tenants Architect) to prepare architectural drawings and specifications for all
layout and Premises improvements not included in, or requiring any change or addition to,
the AS IS condition and Landlord Work, if any.
(ii) one or more engineers reasonably satisfactory to Landlord and licensed by the
State (Tenants Engineers) to prepare structural, mechanical and electrical working
drawings and specifications for all Premises improvements not included in, or requiring any
change or addition to, the AS IS condition and Landlord Work, if any.
All such drawings and specifications are referred to herein as Tenants Plans. Tenants Plans
shall be in form and detail sufficient to secure all applicable governmental approvals. Tenants
Architect shall be responsible for coordination of all engineering work for Tenants Plans and
shall coordinate with any consultants retained by Tenant in connection with the design and
installation of improvements to the Premises (the use of such consultants is subject to Landlords
consent), and Landlords architect or other representative to assure the consistency of Tenants
Plans with the Base Building Work and Landlord Work (if any).
Tenant shall pay Landlord, within ten (10) days of receipt of each invoice from Landlord, the cost
incurred by Landlord for Landlords architects and engineers to review Tenants Plans for
consistency of same with the Base Building Work and Landlord Work, if any. Tenants Plans shall
also include the following:
(a) Final Space Plan: The Final Space Plan for the Premises shall include a full and
accurate description of room titles, floor loads, alterations to the Base Building or
Landlord Work (if any) or requiring any change or addition to the AS IS condition, and the
dimensions and location of all partitions, doors, aisles, plumbing (and furniture and
equipment to the extent same affect floor loading). The Final Space Plan shall (i) be
compatible with the design, construction, systems and equipment of the Base Building and
Landlord Work, if any; (ii) specify only materials, equipment and installations which are
new and of a grade and quality no less than existing components of the Building when they
were originally installed (collectively, (i) and (ii) may be referred to as Building
Standard or Building Standards); (iii) comply with Laws, (iv) be capable of logical
measurement and construction, and (v) contain all such information as may be required for
the preparation of the Mechanical and Electrical Working Drawings and Specifications
(including, without limitation, a capacity and usage report, from engineers designated by
Landlord pursuant to Section 3.1(b). below, for all mechanical and electrical systems in the
Premises).
(b) Mechanical and Electrical Working Drawings and Specifications: Tenant shall employ
engineers approved by Landlord to prepare Mechanical and Electrical Working Drawings and
Specifications showing complete plans for electrical, life safety, automation, plumbing,
water, and air cooling, ventilating, heating and temperature control and shall employ
engineers designated by Landlord to prepare for Landlord a capacity and usage report
(Capacity Report) for all mechanical and electrical systems in the Premises.
(c) Issued for Construction Documents: The Issued for Construction Documents shall
consist of all drawings (1/8 scale) and specifications necessary to construct all Premises
improvements including, without limitation, architectural and structural working drawings
and specifications and Mechanical and Electrical Working Drawings and Specifications and all
applicable governmental authorities plan check corrections.
Exhibit B Page 1
3.2.
Approval by Landlord
. Tenants Plans and any revisions thereof shall be subject
to Landlords approval, which approval or disapproval:
(i) shall not be unreasonably withheld, provided however, that Landlord may disapprove
Tenants Plans in its sole and absolute discretion if they (a) adversely affect the
structural integrity of the Building, including applicable floor loading capacity; (b)
adversely affect any of the Building Systems (as defined below), the Common Areas or any
other tenant space (whether or not currently occupied); (c) fail to fully comply with Laws,
(d) affect the exterior appearance of the Building; (e) provide for improvements which do
not meet or exceed the Building Standards; or (f) involve any installation on the roof, or
otherwise affect the roof, roof membrane or any warranties regarding either (provided
however, that Landlord acknowledges that it has agreed that Tenant shall replace up to 150
tons of HVAC on the roof, including mechanical units and associated controls, ductwork and
materials, which will include certain installations on the roof, all pursuant to Landlords
approval and the requirements set forth in Section 8.03 of the Lease). Building Systems
collectively shall mean the structural, electrical, mechanical (including, without
limitation, heating, ventilating and air conditioning), plumbing, fire and life-safety
(including, without limitation, fire protection system and any fire alarm), communication,
utility, gas (if any), and security (if any) systems in the Building.
(ii) shall not be delayed beyond ten (10) business days with respect to initial
submissions and major change orders (those which impact Building Systems or any other item
listed in subpart (i) of Section 3.2 above) and beyond five (5) business days with respect
to required revisions and any other change orders.
If Landlord disapproves of any of Tenants Plans, Landlord shall advise Tenant of what Landlord
disapproves in reasonable detail. After being so advised by Landlord, Tenant shall submit a
redesign, incorporating the revisions required by Landlord, for Landlords approval. The approval
procedure shall be repeated as necessary until Tenants Plans are ultimately approved. Approval by
Landlord shall not be deemed to be a representation or warranty by Landlord with respect to the
safety, adequacy, correctness, efficiency or compliance with Laws of Tenants Plans. Tenant shall
be fully and solely responsible for the safety, adequacy, correctness and efficiency of Tenants
Plans and for the compliance of Tenants Plans with any and all Laws.
3.3.
Landlord Cooperation
. Landlord shall cooperate with Tenant and make good faith
efforts to coordinate Landlords construction review procedures to expedite the planning,
commencement, progress and completion of Tenant Work. Landlord shall complete its review of each
stage of Tenants Plans and any revisions thereof and communicate the results of such review within
the time periods set forth in Section 3.2 above.
3.4.
City Requirements
. Any changes in Tenants Plans which are made in response to
requirements of the applicable governmental authorities and/or changes which affect the Base
Building Work shall be immediately submitted to Landlord for Landlords review and approval.
3.5.
As-Built Drawings and Specifications
. A CADD-DXF diskette file and a set of
mylar reproducibles of all as-built drawings and specifications of Tenants Work in the Premises
(reflecting all field changes and including, without limitation, architectural, structural,
mechanical and electrical drawings and specifications) prepared by Tenants Architect and Engineers
or by Contractors (defined below) shall be delivered by Tenant at Tenants expense to the Landlord
within thirty (30) days after completion of the Tenant Work. If Landlord has not received such
drawings and diskette(s) within thirty (30) days, Landlord may give Tenant written notice of such
failure. If Tenant does not produce the drawings and diskette(s) within ten (10) days after
Landlords written notice, Landlord may, at Tenants sole cost which may be deducted from the
Allowance, produce the drawings and diskette(s) using Landlords personnel, managers, and outside
consultants and contractors. Landlord shall receive an hourly rate reasonable for such production.
4.
Tenant Work
.
4.1.
Tenant Work Defined
. All tenant improvement work required by the Issued for
Construction Documents (including, without limitation, any approved changes, additions or
alterations pursuant to Section 7 below) is referred to in this Workletter as Tenant Work.
4.2.
Tenant to Construct
. Tenant shall construct all Tenant Work pursuant to this
Workletter, and except to the extent modified by or inconsistent with express provisions of this
Workletter, pursuant with the provisions of the terms and conditions of Article Nine of the Lease,
governing Tenant Alterations (except to the extent modified by this Workletter) and all such Tenant
Work shall be considered Tenant Alterations for purposes of the Lease.
4.3.
Construction Contract
. All contracts and subcontracts for Tenant Work shall
include any terms and conditions reasonably required by Landlord.
4.4.
Contractor
. Tenant shall select one or more contractors to perform the Tenant
Work (Contractor) subject to Landlords prior written approval, which shall not unreasonably be
withheld.
4.5.
Division of Landlord Work and Tenant Work
. Tenant Work is defined in Section
4.1. above and Landlord Work, if any, is defined in Section 2.
5.
Tenants Expense
.
Tenant agrees to pay for all Tenant Work, including, without limitation, the costs of design
thereof, whether or not all such costs are included in the Permanent Improvement Costs (defined
below). Subject to the terms and conditions of this Workletter, Tenant shall apply the Allowance
(defined below) to payment of the Permanent Improvement Costs. Landlord shall provide Tenant a
tenant improvement allowance (Allowance) in
Exhibit B Page 2
the amount equal to Eight Hundred Thirty-three Thousand Eight Hundred Twenty-five and no/100
Dollars ($833,825.00). The Allowance shall be used solely to reimburse Tenant for the Permanent
Improvement Costs. The term Permanent Improvement Costs shall mean the actual and reasonable
costs of construction of that Tenant Work which constitutes permanent improvements to the Premises,
actual and reasonable costs of design thereof and governmental permits therefor, costs incurred by
Landlord for Landlords architects and engineers pursuant to Section 3.1, and Landlords
construction administration fee (defined in Section 8.10 below). Provided, however, Permanent
Improvement Costs shall exclude costs of Tenants FF&E (defined below). For purposes of this
Workletter, Tenants FF&E shall mean Tenants furniture, furnishings, telephone systems, computer
systems, equipment, any other personal property or fixtures, and installation thereof, including,
without limitation, Tenants Personal Property described on
Exhibit G
hereto. If Tenant
does not utilize one hundred percent (100%) of the Allowance for Permanent Improvement Costs no
later than December 31, 2006, Tenant shall have no right to the unused portion of the Allowance.
6.
Application and Disbursement of the Allowance
.
6.1. Tenant shall prepare a budget for all Tenant Work, including the Permanent Improvement
Costs and all other costs of the Tenant Work (Budget), which Budget shall be subject to the
reasonable approval of Landlord. Such Budget shall be supported by a guaranteed maximum price
construction contract and such other documentation as Landlord may require to evidence the total
costs. To the extent the Budget exceeds the available Allowance (Excess Cost), Tenant shall be
solely responsible for payment of such Excess Cost. Further, prior to any disbursement of the
Allowance by Landlord, Tenant shall pay and disburse its own funds for all that portion of the
Permanent Improvement Costs equal to the sum of (a) the Permanent Improvement Costs in excess of
the Allowance; plus (b) the amount of Landlords Retention (defined below). Landlords
Retention shall mean an amount equal to fifteen percent (15%) of the Allowance, which Landlord
shall retain out of the Allowance and shall not be obligated to disburse unless and until after
Tenant has completed the Tenant Work and complied with Section 6.4 below. Further, Landlord shall
not be obligated to make any disbursement of the Allowance unless and until Tenant has provided
Landlord with (i) bills and invoices covering all labor and material expended and used in
connection with the particular portion of the Tenant Work for which Tenant has requested
reimbursement, (ii) an affidavit from Tenant stating that all of such bills and invoices have
either been paid in full by Tenant or are due and owing, and all such costs qualify as Permanent
Improvement Costs, (iii) contractors affidavit covering all labor and materials expended and used,
(iv) Tenant, contractors and architectural completion affidavits (as applicable), and (v) valid
mechanics lien releases and waivers pertaining to any completed portion of the Tenant Work which
shall be conditional or unconditional, as applicable, all as provided pursuant to Section 6.2 and
6.4 below.
6.2. Upon Tenants full compliance with the provisions of Section 6, and if Landlord
determines that there are no applicable or claimed stop notices (or any other statutory or
equitable liens of anyone performing any of Tenant Work or providing materials for Tenant Work) or
actions thereon, Landlord shall disburse the applicable portion of the Allowance as follows:
(a) In the event of conditional releases, to the respective contractor, subcontractor,
vendor, or other person who has provided labor and/or services in connection with the Tenant
Work, upon the following terms and conditions: (i) such costs are included in the Budget,
are Permanent Improvement Costs, are covered by the Allowance, and Tenant has completed and
delivered to Landlord a written request for payment, in form reasonably approved by
Landlord, setting forth the exact name of the contractor, subcontractor or vendor to whom
payment is to be made and the date and amount of the bill or invoice, (ii) the request for
payment is accompanied by the documentation set forth in Section 6.1; and (iii) Landlord, or
Landlords appointed representative, has inspected and approved the work for which Tenant
seeks payment; or
(b) In the event of unconditional releases, directly to Tenant upon the following terms
and conditions: (i) Tenant seeks reimbursement for costs of Tenant Work which have been paid
by Tenant, are included in the Budget, are Permanent Improvement Costs, and are covered by
the Allowance; (ii) Tenant has completed and delivered to Landlord a request for payment, in
form reasonably approved by Landlord, setting forth the name of the contractor,
subcontractor or vendor paid and the date of payment, (iii) the request for payment is
accompanied by the documentation set forth in Section 6.1; and (iv) Landlord, or Landlords
appointed representative, has inspected and approved the work for which Tenant seeks
reimbursement.
6.3. Tenant shall provide Landlord with the aforementioned documents by the 15th of the month
and payment shall be made by the 30th day of the month following the month in which such
documentation is provided.
6.4. Prior to Landlord disbursing the Landlords Retention to Tenant, Tenant shall submit to
Landlord the following items within thirty (30) days after completion of the Tenant Work: (i) As
Built drawings and specifications pursuant to Section 3.5 above, (ii) all unconditional lien
releases from all general contractor(s) and subcontractor(s) performing work, (iii) a Certificate
of Completion prepared by Tenants Architect, and (iv) a final budget with supporting
documentation detailing all costs associated with the Permanent Improvement Costs.
7.
Changes, Additions or Alterations
.
If Tenant desires to make any non-de minimis change, addition or alteration or desires to make
any change, addition or alteration to any of the Building Systems after approval of the Issued for
Construction Documents, Tenant shall prepare and submit to Landlord plans and specifications with
respect to such change, addition or alteration. Any such change, addition or alteration shall be
subject to Landlords approval in accordance with the provisions of Section 3.2 of this Workletter.
Tenant shall be responsible for any submission to and plan check and permit requirements of the
applicable governmental authorities. Tenant shall be
Exhibit B Page 3
responsible for payment of the cost of any such change, addition or alteration if it would increase
the Budget and Excess Cost previously submitted and approved pursuant to Section 6 above.
8.
Miscellaneous
.
8.1.
Scope
. Except as otherwise set forth in the Lease, this Workletter shall not
apply to any space added to the Premises by Lease option or otherwise, but shall apply to the
Initial Premises and the Expansion Premises.
8.2. Tenant Work shall include (at Tenants expense subject to application of the Allowance
towards the costs of such items) for all of the Premises:
(a) Landlord approved lighting sensor controls as necessary to meet applicable Laws;
(b) Building Standard fluorescent fixtures in all Building office areas;
(c) Building Standard meters for each of electricity and chilled water used by Tenant
shall be connected to the Buildings system and shall be tested and certified prior
to Tenants occupancy of the Premises by a State certified testing company;
(d) Building Standard ceiling systems (including tile and grid) and;
(e) Building Standard air conditioning distribution and Building Standard air
terminal units.
8.3.
Sprinklers
. Subject to any terms, conditions and limitations set forth herein,
Landlord shall provide an operative sprinkler system consisting of mains, laterals, and heads AS
IS on the date of delivery of the Premises to Tenant. Tenant shall pay for piping distribution,
drops and relocation of, or additional, sprinkler system heads and Building firehose or firehose
valve cabinets, if Tenants Plans and/or any applicable Laws necessitate such.
8.4.
Floor Loading
. Floor loading capacity shall be within building design capacity.
Tenant may exceed floor loading capacity with Landlords consent, at Landlords sole discretion and
must, at Tenants sole cost and expense, reinforce the floor as required for such excess loading.
8.5.
Work Stoppages
. If any work on the Real Property other than Tenant Work is
delayed, stopped or otherwise affected by construction of Tenant Work, Tenant shall immediately
take those actions necessary or desirable to eliminate such delay, stoppage or effect on work on
the Real Property other than Tenant Work.
8.6.
Life Safety
. Tenant (or Contractor) shall employ the services of a fire and
life-safety subcontractor reasonably satisfactory to Landlord for all fire and life-safety work at
the Building.
8.7.
Locks
. Tenant may purchase locks, cylinders and keys for the Premises from its
own vendor, provided that (a) such vendor and the locks, cylinders and keys to be used are subject
to Landlords prior written approval; (b) of a make and model which are functional, operable and
compatible with Landlords master key system; (c) a master key or keys are provided to Landlord, of
which Landlord may place one such master key in the knox box for use by the fire department and
emergency personnel in the event of an emergency and may retain another key for Landlords use for
entry permitted under the Lease; and (d) the contact information for Tenants vendor for locks,
cylinders and keys used in the Premises shall be provided to Landlord with Tenants request for
approval.
8.8.
Authorized Representatives
. Tenant has designated David Quinn to act as Tenants
representative with respect to the matters set forth in this Workletter. Such representative(s)
shall have full authority and responsibility to act on behalf of Tenant as required in this
Workletter. Tenant may add or delete authorized representatives upon five (5) business days notice
to Landlord.
8.9.
Access to Premises
. After Landlord has recovered possession of the Premises from
any prior Tenant, prior to delivery of possession to Tenant, Tenant and its architects, engineers,
consultants, and contractors shall have access at reasonable times and upon advance notice and
coordination with the Building management, to the Premises for the purpose of planning Tenant Work.
Such access shall not in any manner interfere with Landlord Work, if any. Such access, and all
acts and omissions in connection with it, shall be subject to and governed by all other provisions
of the Lease, including, without limitation, Tenants indemnification obligations, insurance
obligations, etc, except for the payment of Base Rent and Additional Rent. To the extent that such
access by Tenant delays the Substantial Completion of the Landlord Work (if any), such delay shall
be a Tenant Delay and the Landlord Work shall be deemed Substantially Complete on the date such
Landlord Work would have been completed but for such access.
8.10.
Fee
. Landlord shall receive a fee equal to two percent (2.0%) of the Allowance
for Landlords review and supervision of construction of the Tenant Work, which fee shall be paid
by Landlord applying two percent (2.0%) of the Allowance in payment thereof. Such fee is in
addition to Tenants reimbursement of costs incurred by Landlord pursuant to other provisions
hereof, including, without limitation, for Landlords architects and engineers to review Tenants
Plans.
9.
Force and Effect
.
The terms and conditions of this Workletter shall be construed to be a part of the Lease and
shall be deemed incorporated in the Lease by this reference. Should any inconsistency arise
between this Workletter and the Lease as to the specific matters which are the subject of this
Workletter, the terms and conditions of this Workletter shall control.
Exhibit B Page 4
EXHIBIT C
SITE PLAN OF PROJECT
Exhibit C Page 1
EXHIBIT D
PERMITTED HAZARDOUS MATERIAL
Permitted Hazardous Material includes insignificant amounts of substances listed below so long as
(i) such substances are maintained only in such quantities as are reasonably necessary for Tenants
operations in the Premises, or such other specific quantity limit as specified below, (ii) such
substances are used, stored and handled strictly in accordance with the manufacturers
instructions, industry standards and all applicable laws, (iii) such substances are not disposed of
in or about the Building or the Project in a manner which would constitute a release or discharge
thereof, and (iv) all such substances are removed from the Building and the Project by Tenant no
later than the Termination Date.
|
|
|
Type:
|
|
Quantity:
|
Substances typically found or used in general office applications, to
the extent the Premises is used for general offices
|
|
as noted above
|
|
|
|
|
|
|
|
|
|
|
|
HazMat Classification
|
|
Common Chemical or Trade Name
|
|
Tot.
|
|
Unit
|
CL-II
|
|
Combustible Liquid
|
|
Acetic Acid
|
|
|
4
|
|
|
L
|
CL-II
|
|
Combustible Liquid
|
|
Isoamyl Alcohol
|
|
|
1
|
|
|
L
|
CL-II;
CORR-L
|
|
Combustible Liquid;
Corrosive Liquid
|
|
1,3-Diaminopropane
|
|
|
2
|
|
|
L
|
CL-II;
CORR-L
|
|
Combustible Liquid;
Corrosive Liquid
|
|
Ethylenediamine
|
|
|
1
|
|
|
L
|
CL-IIIA
|
|
Combustible Liquid
|
|
Diethylpyrocarbonate
|
|
|
0.5
|
|
|
L
|
CL-IIIA
|
|
Combustible Liquid
|
|
Dimethylsulfoxide
|
|
|
2
|
|
|
L
|
CL-IIIA
|
|
Combustible Liquid
|
|
RNaseZap
|
|
|
3.5
|
|
|
L
|
CL-IIIA
|
|
Combustible Liquid
|
|
Triethylamine/Acetate buffer
|
|
|
0.5
|
|
|
L
|
CORR-L
|
|
Corrosive Liquid
|
|
Ammonium Hydroxide solution
|
|
|
0.5
|
|
|
L
|
CORR-L
|
|
Corrosive Liquid
|
|
Bradford Reagent (protein dye reagent)
|
|
|
0.5
|
|
|
L
|
CORR-L
|
|
Corrosive Liquid
|
|
Formic Acid
|
|
|
1
|
|
|
L
|
CORR-L
|
|
Corrosive Liquid
|
|
Hydrochloric Acid
|
|
|
6
|
|
|
L
|
CORR-L
|
|
Corrosive Liquid
|
|
N,N-Dimethylethylenediamine
|
|
|
0.025
|
|
|
kg
|
CORR-L
|
|
Corrosive Liquid
|
|
Phosphoric Acid
|
|
|
4
|
|
|
L
|
CORR-L
|
|
Corrosive Liquid
|
|
RNaseZap wipes
|
|
|
1
|
|
|
kg
|
CORR-L
|
|
Corrosive Liquid
|
|
Sodium Hydroxide solution
|
|
|
2
|
|
|
L
|
CORR-L
|
|
Corrosive Liquid
|
|
Spermidine
|
|
|
0.5
|
|
|
kg
|
CORR-L
|
|
Corrosive Liquid
|
|
Trifluoroacetic Acid
|
|
|
1
|
|
|
L
|
CORR-L;
CL-IIIA
|
|
Corrosive Liquid;
Combustible Liquid
|
|
Monoethanolamine
|
|
|
4
|
|
|
L
|
CORR-L;
HI
TOX-L
|
|
Corrosive Liquid;
Highly Toxic Liquid
|
|
Phenol/chloroform solution (TRIzol)
|
|
|
6
|
|
|
L
|
CORR-L; HI
TOX-L;
CL-III
|
|
Corrosive Liquid; Highly Toxic Liquid; Combustible Liquid
|
|
Phenol
|
|
|
4
|
|
|
L
|
CORR-S
|
|
Corrosive Solid
|
|
Sodium Hydroxide, Pellets
|
|
|
2
|
|
|
kg
|
CORR-S
|
|
Corrosive Solid
|
|
Tris(2-carboxyethyl)-phosphine hydrochloride
|
|
|
0.01
|
|
|
kg
|
CRYO
|
|
Cryogenic Solid
|
|
Carbon Dioxide, solid
|
|
|
250
|
|
|
lbs
|
CRYO
|
|
Cryogenic Liquid
|
|
Nitrogen, Lquid
|
|
|
400
|
|
|
L
|
FL-1B
|
|
Flammable Liquid
|
|
Acetone
|
|
|
4
|
|
|
L
|
FL-1B
|
|
Flammable Liquid
|
|
Acetonitrile
|
|
|
16
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
(±)-2-Butanol
|
|
|
2
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Ethyl Alcohol, 70-100%, blends
|
|
|
150
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Buffer RW1, Wash Buffer (guanidinium
thiocyanate (2.5-10%); ethanol (2.5-10%)),
Buffer Kit
|
|
|
1
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Cytoseal XYL, Mounting Medium, Xylene-based
|
|
|
1
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Eosin Y
|
|
|
0.05
|
|
|
kg
|
FL-IB
|
|
Flammable Liquid
|
|
Eosin Y, 1% Alcoholic Solution
|
|
|
6
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
EZ-DeWax, Tissue Deparaffinization Solution, Ready-to-Use
|
|
|
1
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Harris Hematoxylin
|
|
|
15
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Isopropyl Alcohol
|
|
|
20
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Methyl Alcohol
|
|
|
8
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Triethylamine
|
|
|
2.5
|
|
|
L
|
FL-IB
|
|
Flammable Liquid
|
|
Xylenes
|
|
|
50
|
|
|
L
|
FL-IC
|
|
Flammable Liquid
|
|
Isoamyl Acetate
|
|
|
1
|
|
|
L
|
FL-IC
|
|
Flammable Liquid
|
|
n-Butanol
|
|
|
2
|
|
|
L
|
Exhibit D Page 1
|
|
|
|
|
|
|
|
|
|
|
HazMat Classification
|
|
Common Chemical or Trade Name
|
|
Tot.
|
|
Unit
|
HI TOX-L
|
|
Highly Toxic Liquid
|
|
Chloroform
|
|
|
6
|
|
|
L
|
HI TOX-L
|
|
Highly Toxic Liquid
|
|
Chloroform/Isoamyl Alcohol (24:1)
|
|
|
1
|
|
|
L
|
HI TOX-L
|
|
Highly Toxic Liquid
|
|
Ethidium Bromide solution
|
|
|
0.1
|
|
|
L
|
HI TOX-L
|
|
Highly Toxic Liquid
|
|
Tetramethylammonium Chloride solution
|
|
|
2.5
|
|
|
L
|
HI TOX-S
|
|
Highly Toxic Solid
|
|
Sodium Azide
|
|
|
0.1
|
|
|
kg
|
NFG
|
|
Non-Flammable Compressed Gas
|
|
Air, Compressed Gas
|
|
|
2000
|
|
|
cu ft
|
NFG
|
|
Non-Flammable Compressed Gas
|
|
Carbon Dioxide, Compressed Gas
|
|
|
300
|
|
|
lbs
|
NFG
|
|
Non-Flammable Compressed Gas
|
|
Helium, Compressed Gas
|
|
|
450
|
|
|
cu ft
|
OXY-L
|
|
Oxidizing Liquid
|
|
Hydrogen Peroxide, <30%
|
|
|
0.1
|
|
|
L
|
OXY-L; CORR-L
|
|
Oxidizing Liquid;
Corrosive Liquid
|
|
Bleach, Household (5-10% sodium hypochlorite)
|
|
|
20
|
|
|
L
|
OXY-L; CORR-L
|
|
Oxidizing Liquid;
Corrosive Liquid
|
|
Nitric Acid
|
|
|
4
|
|
|
L
|
OXY-S
|
|
Oxidizing Solid
|
|
Sodium Perchlorate
|
|
|
1
|
|
|
kg
|
TOX-L
|
|
Toxic Liquid
|
|
1,4-Dithiothreitol
|
|
|
0.1
|
|
|
L
|
TOX-L
|
|
Toxic Liquid
|
|
Formalin, Neutral Buffered
|
|
|
10
|
|
|
L
|
TOX-L
|
|
Toxic Liquid
|
|
2-Mercaptoethanol
|
|
|
1
|
|
|
L
|
TOX-L
|
|
Toxic Liquid
|
|
Formamide
|
|
|
2
|
|
|
L
|
TOX-L
|
|
Toxic Liquid
|
|
N,N-Dimethylformamide
|
|
|
0.2
|
|
|
kg
|
TOX-S
|
|
Toxic Solid
|
|
Diethylenetriaminepentaacetic Acid
|
|
|
0.01
|
|
|
kg
|
TOX-S
|
|
Toxic Solid
|
|
Hexadecyltrimethylammonium Bromide
|
|
|
1
|
|
|
kg
|
TOX-S
|
|
Toxic Solid
|
|
Lithium Chloride
|
|
|
0.5
|
|
|
kg
|
TOX-S
|
|
Toxic Solid
|
|
o-Phenylenediamine
|
|
|
0.25
|
|
|
L
|
Exhibit D Page 2
EXHIBIT E
FORM OF LETTER OF CREDIT ACCEPTABLE FROM SILICON VALLEY BANK
IRREVOCABLE STANDBY LETTER OF CREDIT NO.
SVBSF______
DATED:
__________ ___, 20___
BENEFICIARY:
METROPOLITAN LIFE INSURANCE COMPANY
REAL ESTATE INVESTMENTS
400 SOUTH EL CAMINO REAL, 8
TH
FLOOR
SAN MATEO, CA 94402
APPLICANT:
GENOMIC HEALTH, INC.
301 PENOBSCOT DRIVE
REDWOOD CITY, CA 94063
AMOUNT:
US$500,000.00
(FIVE HUNDRED THOUSAND AND NO/100 U.S. DOLLARS)
EXPIRATION DATE: ___, 2006
LOCATION: AT OUR COUNTERS IN SANTA CLARA, CALIFORNIA
DEAR SIR/MADAM:
WE HEREBY ESTABLISH THIS IRREVOCABLE STANDBY LETTER OF CREDIT IN FAVOR OF THE AFORESAID ADDRESSEE
(BENEFICIARY) FOR DRAWINGS UP TO US$500,000.00 (FIVE HUNDRED THOUSAND NO/100 U.S. DOLLARS)
EFFECTIVE IMMEDIATELY. THIS LETTER OF CREDIT IS ISSUED, PRESENTABLE AND PAYABLE AT OUR OFFICE AT:
3003 TASMAN DRIVE, MAIL SORT HF210, SANTA CLARA, CA 95054 ATTENTION:
GLOBAL FINANCIAL SERVICES
STANDBY LETTER OF CREDIT DEPARTMENT (THE BANKS OFFICE), AND EXPIRES WITH OUR CLOSE OF BUSINESS ON
___, 2006.
THE TERM BENEFICIARY INCLUDES ANY SUCCESSOR BY OPERATION OF LAW OF THE NAMED BENEFICIARY
INCLUDING, WITHOUT LIMITATION, ANY LIQUIDATOR, REHABILITATOR, RECEIVER OR CONSERVATOR.
WE HEREBY UNDERTAKE TO PROMPTLY HONOR YOUR SIGHT DRAFT(S) DRAWN ON US, INDICATING OUR CREDIT NO.
SVBSF___, FOR ALL OR ANY PART OF THIS CREDIT IF PRESENTED AT OUR OFFICE SPECIFIED IN PARAGRAPH
ONE ON OR BEFORE THE EXPIRY DATE OR ANY AUTOMATICALLY EXTENDED EXPIRY DATE TOGETHER WITH THE
ORIGINAL LETTER OF CREDIT AND ALL AMENDMENTS, IF ANY.
EXCEPT AS EXPRESSLY STATED HEREIN, THIS UNDERTAKING IS NOT SUBJECT TO ANY AGREEMENT, CONDITION OR
QUALIFICATION. THE OBLIGATION OF SILICON VALLEY BANK UNDER THIS LETTER OF CREDIT IS THE INDIVIDUAL
OBLIGATION OF SILICON VALLEY BANK, AND IS IN NO WAY CONTINGENT UPON REIMBURSEMENT WITH RESPECT
THERETO.
IT IS A CONDITION OF THIS LETTER OF CREDIT THAT IT IS DEEMED TO BE AUTOMATICALLY EXTENDED WITHOUT
AMENDMENT FOR ONE YEAR FROM THE EXPIRY DATE HEREOF, OR ANY FUTURE EXPIRATION DATE, UNLESS AT LEAST
THIRTY (30) DAYS PRIOR TO AN EXPIRATION DATE WE NOTIFY YOU BY REGISTERED MAIL/COURIER THAT WE ELECT
NOT TO CONSIDER THIS LETTER OF CREDIT EXTENDED FOR ANY SUCH ADDITIONAL PERIOD.
PARTIAL DRAWS ARE ALLOWED.
THIS ORIGINAL LETTER OF CREDIT MUST ACCOMPANY ANY DRAWINGS HEREUNDER FOR ENDORSEMENT OF THE DRAWING
AMOUNT AND WILL BE RETURNED TO THE BENEFICIARY UNLESS IT IS FULLY UTILIZED.
THIS LETTER OF CREDIT MAY BE TRANSFERRED ONE OR MORE TIMES BUT IN EACH INSTANCE TO A SINGLE
BENEFICIARY AND ONLY IN THE FULL AMOUNT AVAILABLE TO BE DRAWN UNDER THIS LETTER OF CREDIT. ANY
SUCH TRANSFER MAY BE EFFECTED ONLY UPON PRESENTATION TO US, THE ISSUING BANK, AT THE BANKS OFFICE
SPECIFIED IN THE FIRST PARAGRAPH ABOVE, OF THE ATTACHED EXHIBIT A DULY COMPLETED AND EXECUTED BY
THE BENEFICIARY AND ACCOMPANIED BY THE ORIGINAL LETTER OF CREDIT AND ALL AMENDMENT(S), IF ANY. ANY
TRANSFER OF THIS LETTER OF CREDIT MAY NOT CHANGE THE PLACE OF EXPIRATION OF THE LETTER OF CREDIT
FROM OUR SPECIFIED OFFICE. EACH TRANSFER SHALL BE EVIDENCED BY OUR ENDORSEMENT ON THE REVERSE OF
THE ORIGINAL LETTER OF CREDIT AND WE SHALL FORWARD THE ORIGINAL LETTER OF CREDIT SO ENDORSED TO THE
TRANSFEREE. EACH SUCH TRANSFER WILL BE EFFECTED AT NO COST TO THE BENEFICIARY OR TRANSFEREE. OUR
TRANSFER FEE
1
/
4
OF 1% OF THE TRANSFER AMOUNT (MINIMUM US$250.00) WILL BE FOR THE ACCOUNT OF THE
APPLICANT. HOWEVER, ANY TRANSFER IS NOT CONTINGENT UPON APPLICANTS ABILITY TO PAY OUR TRANSFER
FEE.
Exhibit E Page 1
DRAFT(S) AND DOCUMENTS MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT.
THIS LETTER OF CREDIT IS SUBJECT TO AND GOVERNED BY THE UNIFORM CUSTOMS AND PRACTICE FOR
DOCUMENTARY CREDITS (1993 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 500 AND THE
LAWS OF THE STATE OF NEW YORK AND, IN THE EVENT OF ANY CONFLICT, THE LAWS OF THE STATE OF NEW YORK
WILL CONTROL. IF THIS CREDIT EXPIRES DURING AN INTERRUPTION OF BUSINESS AS DESCRIBED IN ARTICLE 17
OF SAID PUBLICATION 500, THE BANK HEREBY SPECIFICALLY AGREES TO EFFECT PAYMENT IF THIS CREDIT IS
DRAWN AGAINST WITHIN 30 DAYS AFTER THE RESUMPTION OF BUSINESS.
SILICON VALLEY BANK,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AUTHORIZED SIGNATURE
|
|
|
|
AUTHORIZED SIGNATURE
|
|
|
Exhibit E Page 2
EXHIBIT A
DATE:
TO: SILICON VALLEY BANK
3003 TASMAN DRIVE
SANTA CLARA, CA 95054
ATTN: GLOBAL FINANCIAL SERVICES
RE: SILICON VALLEY BANK, SANTA CLARA , CALIFORNIA
IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF___
DATED
___, 20___AMOUNT: US$___.
GENTLEMEN:
FOR VALUE RECEIVED, THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO:
_______________________________________________________________________________
(NAME OF TRANSFEREE)
________________________________________________________________________________
(ADDRESS)
ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT UP TO ITS
AVAILABLE AMOUNT AS SHOWN ABOVE AS OF THE DATE OF THIS TRANSFER.
BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE
TRANSFERRED TO THE TRANSFEREE. TRANSFEREE SHALL HAVE THE SOLE RIGHTS AS BENEFICIARY THEREOF,
INCLUDING SOLE RIGHTS RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER
AMENDMENTS, AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED DIRECT TO
THE TRANSFEREE WITHOUT NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY.
THE ORIGINAL OF SUCH LETTER OF CREDIT IS RETURNED HEREWITH, AND WE ASK YOU TO ENDORSE THE TRANSFER
ON THE REVERSE THEREOF, AND FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF
TRANSFER.
SINCERELY,
METROPOLITAN LIFE INSURANCE COMPANY
__________________________
(SIGNATURE OF BENEFICIARY)**
** THIS TRANSFER FORM, EXHIBIT A, MUST BE NOTARIZED BY A NOTARY PUBLIC
Exhibit E Page 3
EXHIBIT F
FAIR MARKET RENTAL RATE
1.
Definition of Fair Market Rental Rate
. Fair Market Rental Rate shall mean the
Monthly Base Rent equal to the monthly base rental per rentable square foot which a tenant would
pay and which a willing landlord would accept for space comparable to the Premises in the Building
and in other buildings of class A standards in Seaport Centre and along the Highway 101 corridor in
Redwood City, Redwood Shores, San Carlos and Belmont (Applicable Market) for the period for which
such rental is to be paid and for a lease on terms substantially similar to those of the Lease
(including, without limitation, those applicable to Taxes, Operating Expenses and exclusions, but
also considering so-called net and triple net leases, and leases utilizing operating expense stops
or base years, and making appropriate adjustment between such leases and this Lease, as described
below), based on prevailing market conditions in the Building and in other buildings of class A
standards in the Applicable Market at the time such determination is made (Comparable
Transactions). Without limiting the generality of the foregoing, Comparable Transactions shall be
for a term similar to the term of tenancy and for space comparable in use, floor levels, square
footage and location within the Building and in other buildings of class A standards in the
Applicable Market as the transaction for which Fair Market Rental Rate is being determined;
however, leases of unusual or odd shaped spaces shall not be considered. In any determination of
Fair Market Rental Rate, the stated or contract monthly net or base rental in Comparable
Transactions shall be appropriately adjusted to take into account the different terms and
conditions prevailing in such transactions and those present in the Lease, including, without
limitation: (a) the extent to which average annual expenses and taxes per rentable square foot
payable by tenants in Comparable Transactions vary from those payable by Tenant under the Lease,
and so, for example, if the Lease provides for payment of Rent Adjustments and/or certain Operating
Expenses on the basis of increases over a base year, then the rate of Monthly Base Rent under the
Lease shall be based upon a step-up to change the calendar year which serves as the base year for
calculation of the base for such Operating Expenses for the Option Term to be the full calendar
year in which the Option Term commences, and such step-up shall be considered in the determination
of the Fair Market Rental Rate; (b) tenant improvements, value of existing tenant improvements, the
concessions, if any, being given by landlords in Comparable Transactions, such as parking charge
abatement, free rent or rental abatement applicable after substantial completion of any tenant
improvements (and no adjustment shall be made for any free or abated rent during any construction
periods), loans at below-market interest rates, moving allowances, space planning allowances, lease
takeover payments and work allowances, as compared to any tenant improvement, refurbishment or
repainting allowance given to Tenant under the Lease for the space for which Fair Market Rental
Rate is being determined; (c) the brokerage commissions, fees and bonuses payable by landlords in
Comparable Transactions (whether to tenants agent, such landlord or any person or entity
affiliated with such landlord), as compared to any such amounts payable by Landlord to the
broker(s) identified with respect to the transaction for which Fair Market Rental Rate is being
determined; (d) the time value of money; (e) any material difference between the definition of
rentable area and the ratio of project rentable to useable square feet in Comparable Transactions,
as compared to such figures applicable to the space for which Fair Market Rental Rate is being
determined; and (f) the extent to which charges for parking by tenants in Comparable Transactions
vary from those payable by Tenant under the Lease.
2.
Sealed Estimates
. In the event the Lease requires Fair Market Rental Rate to be
determined in accordance with this Exhibit, Landlord and Tenant shall meet within ten (10) business
days thereafter and each simultaneously submit to the other in a sealed envelope its good faith
estimate of Fair Market Rental Rate (the Estimates). If the higher Estimate is not more than one
hundred five percent (105%) of the lower Estimate, then Fair Market Rental Rate shall be the
average of the two Estimates. If such simultaneous submission of Estimates does not occur within
such ten (10) business day period, then either party may by notice to the other designate any
reasonable time within five (5) business days thereafter and any reasonable place at or near the
Building for such meeting to take place. In the event only one party submits an Estimate at that
meeting, such Estimate shall be Fair Market Rental. In the event neither party submits an Estimate
at that meeting, the transaction for which Fair Market Rental Rate is being determined shall be
deemed cancelled and of no further force or effect.
3.
Selection of Arbitrators
. If the higher Estimate is more than one hundred five
percent (105%) of the lower Estimate, then either Landlord or Tenant may, by written notice to the
other within five (5) business days after delivery of Estimates at the meeting, require that the
disagreement be resolved by arbitration. In the event neither party gives such notice, the
transaction for which Fair Market Rental Rate is being determined shall be deemed cancelled and of
no further force or effect. Within five (5) business days after such notice, the parties shall
select as arbitrators three (3) mutually acceptable independent MAI appraisers with experience in
real estate activities, including at least five (5) years experience in appraising comparable space
in the Applicable Market (Qualified Appraisers). If the parties cannot timely agree on such
arbitrators, then within the following five (5) business days, each shall select and inform the
other party of one (1) Qualified Appraiser and within a third period of five (5) business days, the
two appraisers (or if only one (1) has been duly selected, such single appraiser) shall select as
arbitrators a panel of three additional Qualified Appraisers, which three arbitrators shall proceed
to determine Fair Market Rental Rate pursuant to Section 4 of this Exhibit. Both Landlord and
Tenant shall be entitled to present evidence supporting their respective positions to the panel of
three arbitrators.
4.
Arbitration Procedure
. Once a panel of arbitrators has been selected as provided
above, then as soon thereafter as practicable each arbitrator shall select one of the two Estimates
as the one which, in its opinion, is closer to Fair Market Rental Rate. Upon an Estimates
selection by two (2) of the arbitrators, it shall be the applicable Fair Market Rental Rate and
such selection shall be binding upon Landlord and Tenant. If the arbitrators collectively
determine that expert advice is reasonably necessary to assist them in determining Fair Market
Rental Rate, then they may retain one or more qualified persons, including but not limited to legal
counsel, brokers, architects or engineers, to provide such expert advice. The party whose Estimate
is not chosen by the arbitrators shall pay the costs of the arbitrators and any experts retained by
the arbitrators. Any fees of any counsel or expert engaged directly by Landlord or Tenant,
however, shall be borne by the party retaining such counsel or expert.
Exhibit F Page 1
5.
Rent Pending Determination of Fair Market Rental Rate
. In the event that the
determination of Fair Market Rental Rate has not been concluded prior to commencement of the
applicable rental period for the applicable space for which the Fair Market Rental Rate is being
determined, Tenant shall pay Landlord Monthly Base Rent and Rent Adjustment Deposits as would apply
under Landlords Estimate pursuant to Section 2 of this Exhibit until the Fair Market Rental Rate
is determined. In the event that the Fair Market Rental Rate subsequently determined is different
from the amount paid for the applicable period, then within thirty (30) days after such
determination, Tenant shall pay Landlord any greater amounts due and Landlord shall credit Tenant
(against the next Monthly Base Rent installments due) for any reduction in the amounts due.
Exhibit F Page 2
EXHIBIT G
TENANTS PERSONAL PROPERTY
Tenants Personal Property shall mean the following items belonging to Tenant, it being
acknowledged that if any of the following are affixed to the Premises in the normal manner for such
item, it shall still be deemed to be Tenants Personal Property:
1.
|
|
Water deionization/purification systems;
|
|
2.
|
|
Facility vacuum system;
|
|
3.
|
|
Facility clean dry air system;
|
|
4.
|
|
Telecommunications systems;
|
|
5.
|
|
Computer network systems;
|
|
6.
|
|
Waste neutralization and monitoring systems;
|
|
7.
|
|
Trash compactor system;
|
|
8.
|
|
Satellite and/or radio frequency signal receivers/transmitters;
|
|
9.
|
|
Compressed gas distribution system;
|
|
10.
|
|
Audio-visual equipment;
|
|
11.
|
|
Electronic security and monitoring systems;
|
|
12.
|
|
Back-up and emergency electrical power equipment;
|
|
13.
|
|
Laboratory casework including fume hoods;
|
|
14.
|
|
Moveable benches and tables;
|
|
15.
|
|
Office furniture and equipment;
|
|
16.
|
|
Bicycle lockers;
|
|
17.
|
|
Shower room lockers;
|
|
18.
|
|
Laboratory equipment including autoclaves, glass washers, ice makers, cage washers, dryers,
environmental chambers;
|
|
19.
|
|
Servery equipment (
i.e.
, equipment used in food service, in the break area or kitchen
area)
|
|
20.
|
|
Fermentation system equipment;
|
|
21.
|
|
Such other items installed in the Premises by Tenant at Tenants expense during the term of
the Lease as are agreed to in writing by Tenant and Landlord to be Tenants Personal Property.
|
Exhibit G Page 1
EXHIBIT H
FORM OF LETTER OF CREDIT
FOR INTERNAL IDENTIFICATION PURPOSES ONLY
Our No. __________ Other __________
Applicant ___________________________
|
|
|
TO:
|
|
Metropolitan Life Insurance Company
|
|
|
[Address]
|
|
|
Attention: Director, EIM
|
IRREVOCABLE LETTER OF CREDIT NO. ___________
We hereby establish this irrevocable Letter of Credit in favor of the aforesaid addressee
(Beneficiary) for drawings up to United States $500,000.00 effective immediately. This Letter of
Credit is issued, presentable and payable at our office at
[issuing banks address in either
San Francisco or San Jose]
and expires with our close of business on ___, 20___.
The term Beneficiary includes any successor by operation of law of the named Beneficiary
including, without limitation, any liquidator, rehabilitator, receiver or conservator.
We hereby undertake to promptly honor your sight draft(s) drawn on us, indicating our Credit
No. ___, for all or any part of this Credit if presented at our office specified in paragraph
one on or before the expiry date or any automatically extended expiry date.
Except as expressly stated herein, this undertaking is not subject to any agreement, condition
or qualification. The obligation of
[issuing bank]
under this Letter of Credit is the
individual obligation of
[issuing bank]
, and is in no way contingent upon reimbursement
with respect thereto.
It is a condition of this Letter of Credit that it is deemed to be automatically extended
without amendment for one year from the expiry date hereof, or any future expiration date, unless
at least thirty (30) days prior to an expiration date we notify you by registered mail that we
elect not to consider this Letter of Credit renewed for any such additional period.
This Letter of Credit is transferable by the Beneficiary and by any successive transferees at
no charge or cost to Beneficiary or any transferee. Transfers of this Letter of Credit are subject
to receipt of Beneficiarys (and subsequently, transferees) instructions in the form attached
hereto as Schedule 1 accompanied by the original Letter of Credit and amendments(s) if any.
This Letter of Credit is subject to and governed by the Laws of the State of New York and the
1993 revision of the Uniform Customs and Practice for Documentary Credits of the International
Chamber of Commerce (Publication 500) and, in the event of any conflict, the Laws of the State of
New York will control. If this Credit expires during an interruption of business as described in
article 17 of said Publication 500, the bank hereby specifically agrees to effect payment if this
Credit is drawn against within 30 days after the resumption of business.
|
|
|
|
|
|
|
Very truly yours,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[issuing bank]
|
|
|
Exhibit H Page 1
Schedule 1 to Letter of Credit
[Bank
then current issuer of Letter of Credit]
Re: Irrevocable Letter of Credit No. ________________
Ladies & Gentlemen:
The undersigned acknowledges receipt of your advice No. ___of a credit issued
in our favor, the terms of which are satisfactory. We now irrevocably transfer the said credit and
all amendments and extensions thereof, if any, to:
[Name of Transferee]
[Address]
You are to inform the transferee of this transfer and such transferee shall have sole rights
as beneficiary under the credit, including any amendments, extension or increases thereof, without
notice to or further assent from us.
This transfer is at no charge or cost to Beneficiary or the transferee.
|
|
|
|
|
|
|
|
|
Yours very truly,
|
|
|
|
|
|
|
|
|
|
|
|
Beneficiary
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit H Page 2
RIDER 1
COMMENCEMENT DATE AGREEMENT
Metropolitan Life Insurance Company, a New York corporation (Landlord), and Genomic Health, Inc.,
a Delaware corporation (Tenant), have entered into a
certain Lease dated as of
, 2005 (the Lease).
WHEREAS, Landlord and Tenant wish to confirm and memorialize the Commencement Date and Expiration
Date of the Lease as provided for in Section 2.02(b) of the Lease;
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein and in
the Lease, Landlord and Tenant agree as follows:
1. Unless otherwise defined herein, all capitalized terms shall have the same meaning ascribed
to them in the Lease.
2. The Initial Premises Commencement Date of the Term of the Lease is
.
3. The Expiration Date of the Term of the Lease is
.
4. Tenant hereby confirms the following:
|
(a)
|
|
That it has accepted possession of the premises pursuant to the
terms of the Lease;
|
|
|
(b)
|
|
That the Landlord Work, if any, is Substantially Complete; and
|
|
|
(c)
|
|
That the Lease is in full force and effect.
|
5. Except as expressly modified hereby, all terms and provisions of the Lease are hereby
ratified and confirmed and shall remain in full force and effect and binding on the parties hereto.
6. The Lease and this Commencement Date Agreement contain all of the terms, covenants,
conditions and agreements between the Landlord and the Tenant relating to the subject matter
herein. No prior other agreements or understandings pertaining to such matters are valid or of any
force and effect.
IN WITNESS WHEREOF, Landlord and Tenant have executed this Commencement Date Agreement and
such execution and delivery have been duly authorized.
|
|
|
|
|
|
|
|
|
|
|
TENANT:
|
|
|
|
LANDLORD:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Genomic Health, Inc.,
|
|
|
|
Metropolitan Life Insurance Company,
|
|
|
a Delaware corporation
|
|
|
|
a New York corporation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By
|
|
|
|
|
|
By
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Print name
|
|
|
|
|
|
Print name
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Its
|
|
|
|
|
|
Its
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Chairman of Board, President or Vice
President)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Print name
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Its
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Secretary, Assistant Secretary, CFO or Assistant Treasurer)
|
|
|
|
|
|
|
|
|
Rider 1 Page 1
RIDER 2
ADDITIONAL PROVISIONS
This Rider 2 (Rider) is attached to and a part of a certain Lease by and between
Metropolitan Life Insurance Company, a New York corporation, as Landlord, and Genomic Health, Inc.,
a Delaware corporation (for purposes of this Rider, Genomic), as Tenant, for the Premises as
described therein (the Lease).
SECTION 1. DEFINED TERMS; FORCE AND EFFECT
Capitalized terms used in this Rider shall have the same meanings set forth in the Lease except as
otherwise specified herein and except for terms capitalized in the ordinary course of punctuation.
This Rider forms a part of the Lease. Should any inconsistency arise between this Rider and any
other provision of the Lease as to the specific matters which are the subject of this Rider, the
terms and conditions of this Rider shall control.
SECTION 2. PREMISES; CONDITION; DELIVERY; CONSTRUCTION PERIOD; COMMENCEMENT DATE
2.1.
Premises Consisting of Initial Premises & of Expansion Premises.
The Premises is
classified in two parts, namely the Initial Premises and Expansion Premises, for purposes of
determining and providing separately as to each part for the Delivery Date, respective Commencement
Dates and certain other rights and obligations of the parties, as more particularly provided in
this Rider 2, the Workletter and other provisions of this Lease.
2.2
AS-IS Condition
. Tenant acknowledges that it presently occupies all of the
Expansion Premises as subtenant under the Prior Sublease described in Section 2.4 below and that
prior to the Execution Date Tenant has inspected the Initial Premises. Tenant hereby leases and
Landlord shall deliver the Premises to Tenant in its AS IS condition, without any express or
implied representations or warranties of any kind by Landlord, its brokers, manager or agents, or
the employees of any of them regarding the Premises; and Landlord shall not have any obligation to
construct or install any tenant improvements or alterations or to pay for any such construction or
installation except to the extent of the Allowance, all as specifically provided in the Workletter.
Any Tenant Work and Landlord Work, if any, shall be subject to and governed by the Workletter and
other applicable provisions of this Lease.
2.3.
Initial Premises: Projected Delivery Date; Delivery Date; Commencement Date;
Tenants Obligations During Construction Period
.
(a) Landlord shall tender to Tenant possession of the Initial Premises in its AS IS condition
described in Section 2.2 (but free of all prior occupants and their personal property) no later
than 2 business days after execution of this Lease (the Projected Delivery Date). On the date
Landlord actually tenders to Tenant possession of the Initial Premises (the Delivery Date), the
Premises shall be subject to, and Tenant shall observe and perform, all the conditions and
covenants applicable to Tenant under this Lease, except as otherwise expressly provided in this
Rider. During the period (the Construction Period) from the Delivery Date until the Initial
Premises Commencement Date, in recognition of Tenants construction and installations in, and
preparation of, the Premises for the use and occupancy permitted by this Lease, Tenant shall not be
obligated to pay Monthly Base Rent, Rent Adjustment Deposits or Rent Adjustments. The Term of this
Lease shall be as shown in Section 1.01(5) of the Basic Lease Provisions and the Initial Premises
Commencement Date of the Term shall be the date which is the earlier to occur of (i) the date
Tenant commences its business operations in the Initial Premises beyond operations in the Temporary
Space (described below), or (ii) five (5) months after the Delivery Date. To the extent permitted
by Law and that Tenant obtains any and all necessary approvals and permits for such use, during the
Construction Period Tenant may use part of the Initial Premises for the conduct of business by up
to twenty (20) employees of Tenant without obligation to pay Monthly Base Rent for the space so
used (Temporary Space), but Tenant shall be obligated to pay its pro rata share of Rent
Adjustment Deposits and Rent Adjustment with respect to the Temporary Space based upon the number
of square feet of Rentable Area of the Temporary Space to the Rentable Area of the Building, Phase
and Project.
(b) Within thirty (30) days following the occurrence of the Initial Premises Commencement
Date, upon request by Landlord, Tenant and Landlord shall enter into an agreement (which is
attached to this Lease as Rider 1) confirming the Initial Premises Commencement Date and the
Expiration Date. If Tenant fails to enter into such agreement, then the Initial Premises
Commencement Date and the Expiration Date shall be the dates designated by Landlord in such
agreement.
(c) If Landlord shall be unable to give possession of the Initial Premises on the Projected
Delivery Date by reason of the following: (i) the holding over or retention of possession of any
tenant, tenants or occupants, or (ii) for any other reason beyond Landlords reasonable control,
then Landlord shall not be subject to any liability for the failure to give possession on said
date. Under such circumstances, by operation of Subsection (a) above, the Delivery Date and
Initial Premises Commencement Date are automatically adjusted and determined in relation to the
date Landlord actually tenders possession of the Initial Premises to Tenant. No such failure to
deliver possession on the originally scheduled Projected Delivery Date shall affect the validity of
this Lease or the obligations of the Tenant hereunder.
2.4.
Expansion Premises: Prior Sublease; Certain Restoration Obligations; Delivery;
Commencement Date
. Tenant and Landlord acknowledge that (i) Tenant presently occupies all of
the Expansion Premises as Subtenant pursuant to a Sublease from Corixa Corporation, a Delaware
corporation (Corixa) as Sublandlord, dated as of June 1, 2001, to which Landlord consented by
that certain Consent Letter dated as of June 12, 2001 by and between Landlord, Tenant and Corixa,
as such Sublease was amended by the Amendment to Sublease dated as of October 29, 2003, to which
Landlord consented by that certain Consent Letter by and between Landlord, Tenant and Corixa, as
such Sublease was further amended by the Second
Rider 2 Page 1
Amendment to Sublease dated as of January 31, 2005, to which Landlord consented by that certain
Consent Letter by and between Landlord, Tenant and Corixa dated as of February, 2005 (the Sublease,
as amended, is referred to as the Prior Sublease); and (ii) the term of the Prior Sublease and of
the underlying prime lease between Corixa and Landlord will terminate February 28, 2006. Upon such
termination, Landlord shall not require Tenant or Corixa to remove any of the existing improvements
or alterations installed pursuant to the Prior Sublease and Corixa lease in the Premises and to
restore the Premises to its condition prior to such installation, provided however that upon the
expiration or earlier termination of this Lease, Landlord reserves the right to require Tenant to
remove any fixtures or equipment installed by Corixa or Tenant which contain Hazardous Material,
and to repair any damage caused by such removal. The Expansion Premises is leased and accepted by
Tenant in its AS IS condition described in Section 2.2. Possession of the Expansion Premises for
purposes of this Lease is hereby acknowledged and agreed to be delivered to Tenant by Landlord as
of the date of March 1, 2006. Immediately after February 28, 2006, Tenant shall continue in
occupancy of the Expansion Premises hereunder. The Expansion Premises Commencement Date shall be
March 1, 2006, and the Term of the lease of the Expansion Premises shall continue through the
Expiration Date, as defined in Section 1.03 at the beginning of this Lease.
SECTION 3. MONUMENT SIGNAGE.
(a)
Grant of Right
. Notwithstanding any provision of Section 6.06 of the Lease to the
contrary, Tenant shall have the right to place Tenant identification on one line of the existing,
exterior monument sign for the Building in which the Premises are located, subject to the terms and
conditions set forth in this Section (Exterior Sign Right).
(b)
General Conditions & Requirements
. The size, type, style, materials, color,
method of installation and exact location of the sign, and the contractor for and all work in
connection with the sign, contemplated by this Section shall (i) be subject to Tenants compliance
with all applicable laws, regulations and ordinances and with any covenants, conditions and
restrictions of record which affect the Property; (ii) be subject to Tenants compliance with all
requirements of Landlords current Project signage criteria at the time of installation; (iii) be
consistent with the design of the Building and the Project; (iv) be further subject to Landlords
prior written consent. Tenant shall, at its sole cost and expense, procure, install, maintain in
first class appearance and condition, and remove such sign.
(c)
Removal & Restoration
. Upon the expiration or termination of the Exterior Sign
Right, but in no event later than the expiration of the Term or earlier termination of the Lease,
Tenant shall, at its sole cost and expense, remove such sign and shall repair and restore the area
in which the sign was located to its condition prior to installation of such sign.
(d)
Right Personal
. The Exterior Sign Right under this Section is personal to Genomic
Health, Inc., and may not be used by, and shall not be transferable or assignable (voluntarily or
involuntarily) to any person or entity.
SECTION 4. OPTION TO EXTEND.
(a) Landlord hereby grants Tenant a single option to extend the Term of the Lease for an
additional period of five (5) years (such period may be referred to as the Option Term), as to
the entire Premises as it then exists, upon and subject to the terms and conditions of this Section
(the Option To Extend), and provided that at the time of exercise of such option (and each
Option, if more than one Option is granted): (i) Tenant or a Permitted Transferee which has
satisfied the requirements of Sections 10.01 and 10.05 of the Lease must be conducting regular,
active, ongoing business in, and be in occupancy (and occupancy by a subtenant, licensee or other
party permitted or suffered by Tenant shall not satisfy such condition) of the entire Premises; and
(ii) there has been no material adverse change in Tenants financial position from such position as
of the date of execution of the Lease, as certified by Tenants independent certified public
accountants, and as supported by Tenants certified financial statements, copies of which shall be
delivered to Landlord with Tenants written notice exercising its right hereunder. Without
limiting the generality of the foregoing, Landlord may reasonably conclude there has been a
material adverse change if Tenants independent certified public accountants do not certify there
has been no such change.
(b) Tenants election (the Election Notice) to exercise the Option To Extend must be given
to Landlord in writing no earlier than the date which is twelve (12) months prior to the Expiration
Date and no later than the date which is nine (9) months prior to the Expiration Date. If Tenant
either fails or elects not to exercise the Option to Extend by not timely giving its Election
Notice, then the Option to Extend shall be null and void, including, if more than one Option is
granted, the then applicable Option to Extend and all further Options to Extend.
(c) The Option Term (and each Option Term, if more than one Option is granted) shall commence
immediately after the expiration of the preceding Term of the Lease. Tenants leasing of the
Premises during the Option Term shall be upon and subject to the same terms and conditions
contained in the Lease except that (i) Tenant shall pay the Option Term Rent, defined and
determined in the manner set forth in the immediately following Subsection; (ii) the Security shall
be increased to an amount that is the same percentage or proportion of Option Term Rent as the
prior amount of Security was in relation to Rent for the Term prior to the Option Term, but in no
event shall the Security be decreased; and (iii) Tenant shall accept the Premises in its as is
condition without any obligation of Landlord to repaint, remodel, repair, improve or alter the
Premises or to provide Tenant any allowance therefor, except to the extent tenants leasing space in
Comparable Transactions receive an allowance pursuant to the definition of Fair Market Rental Rate
defined in
Exhibit F
hereto, provided, however, Landlord by notice given to Tenant within
thirty (30) days after final determination of the Fair Market Rental Rate, may elect to provide, in
lieu of such allowance for alterations to the Offer Space, a rent credit equal to the amount of the
allowance that would have otherwise been given, credited toward the rents applicable only to the
Offer Space and due starting after such rent obligation commences. If Tenant timely and properly
Rider 2 Page 2
exercises the Option To Extend, references in the Lease to the Term shall be deemed to mean the
preceding Term as extended by the Option Term unless the context clearly requires otherwise.
(d) The Option Term Rent shall mean the sum of the Monthly Base Rent at the Fair Market Rental
Rate (as defined in
Exhibit F
) plus Rent Adjustments and/or certain Operating Expenses (if
applicable, based upon a step-up to change the base year or base amount for calculation of
Operating Expenses in connection with determination of the Fair Market Rental Rate) plus other
charges pursuant to the Lease payable to Landlord. The determination of Fair Market Rental Rate
and Option Term Rent shall be made by Landlord, in the good faith exercise of Landlords business
judgment. Within forty-five (45) days after Tenants exercise of the Option To Extend, Landlord
shall notify Tenant of Landlords determination of the Fair Market Rental Rate and Option Term Rent
for the Premises. Tenant may, within fifteen (15) days after receipt thereof, deliver to Landlord
a written notice either: (i) accepting Landlords determination, in which case the extension shall
be effective and binding (subject to Subsection (f) below) at the accepted rate; or (ii) setting
forth Tenants good faith estimate, in which case Landlord and Tenant will promptly confer and
attempt to agree upon the Fair Market Rental Rate and Option Term Rent. Tenants failure to timely
deliver such notice within such fifteen (15) day period shall be deemed its cancellation of the
Option. In the event Tenant has delivered notice setting forth Tenants different estimate, but no
agreement in writing between Tenant and Landlord on Fair Market Rental Rate and Option Term Rent is
reached within thirty (30) days after Landlords receipt of Tenants estimate, the Fair Market
Rental Rate shall be determined in accordance with the terms of
Exhibit F
. Notwithstanding
any of the foregoing to the contrary, at no time during the Option Term shall the Option Term Rent
be less than the Preceding Rent (defined below). The Preceding Rent shall mean the sum of the
Monthly Base Rent payable by Tenant under this Lease calculated at the rate applicable for the last
full month of the Term preceding the Option Term plus the Rent Adjustments payable by Tenant under
the Lease (if applicable, using the base year for calculation of Base Operating Expenses applicable
for the last full month of the Term preceding the Option Term), plus other charges pursuant to the
Lease payable to Landlord. To the extent that Tenant pays directly the utility or service provider
for utilities or services which Tenant is to obtain directly pursuant to the Lease, Tenant shall
continue to pay such amounts, but such amounts shall not be counted as part of the Preceding Rent
or the Fair Market Rental Rate as used herein. Further, in the event that Landlord notifies Tenant
that the Option Term Rent shall equal the Preceding Rent, such determination shall be conclusive
and binding to set the Preceding Rent as the Option Term Rent for the Option Term, Tenant shall not
be entitled to dispute or contest such determination, and the extension shall be effective and
binding (subject to Subsection (f) below).
(e) Promptly after final determination of the Fair Market Rental Rate, Landlord shall prepare
a memorandum confirming the specific dates, amounts and terms of the extension for the Option Term
in accordance with the terms and conditions of this Option to Extend, in the form of an amendment
to the Lease, and Tenant shall execute such amendment within five (5) business days after Landlord
and Tenant agree to the form of the proposed amendment and Landlord shall execute it promptly after
Tenant. Notwithstanding any of the foregoing to the contrary, the failure of Landlord to prepare
such amendment or of either party to execute an amendment shall not affect the validity and
effectiveness of the extension for the Option Term in accordance with the terms and conditions of
this Option to Extend.
(f) Upon the occurrence of any of the following events, Landlord shall have the option,
exercisable at any time prior to commencement of the Option Term, to terminate all of the
provisions of this Section with respect to the Option to Extend, whereupon any prior or subsequent
exercise of this Option to Extend shall be of no force or effect:
(i) Tenants failure to timely exercise or timely to perform the Option to Extend in
strict accordance with the provisions of this Section.
(ii) The existence at the time Tenant exercises the Option to Extend or at the
commencement of the Option Term of a Default on the part of Tenant under the Lease or of any
state of facts which with the passage of time or the giving of notice, or both, would
constitute such a Default.
(iii) Tenants third Default under the Lease prior to the commencement of the Option
Term, notwithstanding that all such Defaults may subsequently be cured.
(g) Without limiting the generality of any provision of the Lease, time shall be of the
essence with respect to all of the provisions of this Section.
(h) This Option to Extend is personal to Genomic Health and may not be used by, and shall not
be transferable or assignable (voluntarily or involuntarily) to any person or entity other than a
Permitted Transferee which is an assignee of the Lease and which has satisfied the requirements of
Sections 10.01 and 10.05 of this Lease, and such Permitted Transferee may exercise the right
without Tenant joining in or consenting to such exercise, and notwithstanding anything to the
contrary, Tenant shall remain liable for all obligations under the Lease, including those resulting
from any such exercise with the same force and effect as if Tenant had joined in such exercise.
Rider 2 Page 3